{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "NLP.ipynb",
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "accelerator": "GPU"
  },
  "cells": [
    {
      "cell_type": "code",
      "metadata": {
        "id": "VfmfChrDJv5o"
      },
      "source": [
        "import numpy as np \n",
        "import pandas as pd \n",
        "from pathlib import Path\n",
        "from fastai.text import *"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "zt3hfF9NJxth",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 121
        },
        "outputId": "d48bf5f1-6400-4f02-b6d0-a1085e543d5e"
      },
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/gdrive')"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Go to this URL in a browser: https://accounts.google.com/o/oauth2/auth?client_id=947318989803-6bn6qk8qdgf4n4g3pfee6491hc0brc4i.apps.googleusercontent.com&redirect_uri=urn%3aietf%3awg%3aoauth%3a2.0%3aoob&response_type=code&scope=email%20https%3a%2f%2fwww.googleapis.com%2fauth%2fdocs.test%20https%3a%2f%2fwww.googleapis.com%2fauth%2fdrive%20https%3a%2f%2fwww.googleapis.com%2fauth%2fdrive.photos.readonly%20https%3a%2f%2fwww.googleapis.com%2fauth%2fpeopleapi.readonly\n",
            "\n",
            "Enter your authorization code:\n",
            "··········\n",
            "Mounted at /content/gdrive\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "UTSodnH8KBcp"
      },
      "source": [
        "path=Path('/content/gdrive/My Drive/covidnlp')"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "OUwA7tomKyiE"
      },
      "source": [
        "df= pd.read_csv(path/'train.csv', encoding='utf-8')"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "osD7tCEJNnIN",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "60f6f5dc-cf4f-42f8-b753-ffb4b4b5bd26"
      },
      "source": [
        "import os\n",
        "for dirname, _, filenames in os.walk('/content/gdrive/My Drive/covidnlp'):\n",
        "    for filename in filenames:\n",
        "        print(os.path.join(dirname, filename))\n"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "/content/gdrive/My Drive/covidnlp/train.csv\n",
            "/content/gdrive/My Drive/covidnlp/test-sample.csv\n",
            "/content/gdrive/My Drive/covidnlp/databunch.pkl\n",
            "/content/gdrive/My Drive/covidnlp/filename.pth.pth\n",
            "/content/gdrive/My Drive/covidnlp/filename2.pth.pth\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00070/00070-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00070/00070-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00070/00070-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00071/00071-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00071/00071-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00063/00063-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00063/00063-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00063/00063-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00063/00063-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00103/00103-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00103/00103-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00103/00103-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00103/00103-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00128/00128-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00128/00128-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00109/00109-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00109/00109-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00109/00109-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00127/00127-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00127/00127-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00127/00127-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-38.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-42.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-45.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-44.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-55.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-54.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-69.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-42.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-82.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-96.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-97.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-83.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-81.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-68.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-80.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-90.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-93.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-137.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-51.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-108.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-45.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-50.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-95.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-87.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-130.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-109.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-118.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-57.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-133.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-125.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-52.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-53.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-121.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-132.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-91.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-136.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-85.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-84.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-47.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-43.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-92.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-131.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-134.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-46.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-94.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-123.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-135.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-119.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-127.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-122.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-120.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-86.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-44.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-124.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-111.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-114.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-128.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-116.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-103.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-63.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-61.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-102.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-98.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-74.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-49.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-73.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-101.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-89.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-100.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-59.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-104.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-99.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-110.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-129.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-117.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-88.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-66.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-112.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-62.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-67.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-48.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-115.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-113.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-107.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-105.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-72.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-106.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-70.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-71.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-64.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-58.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-65.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-51.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-80.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-42.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-78.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-43.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-83.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-50.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-82.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-68.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-57.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-45.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-69.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-54.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-55.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-81.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-44.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-52.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-47.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-90.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-85.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-38.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-86.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-79.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-53.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-84.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-61.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-65.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-72.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-75.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-77.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-74.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-59.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-76.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-62.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-70.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-58.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-89.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-48.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-67.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-88.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-73.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-71.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-60.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-66.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-63.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-64.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00455/00455-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00193/00193-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/models/tmp.pth\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "3GuHqy0BLlUi"
      },
      "source": [
        "texts = []\n",
        "for i in range(len(df['Filename'])):\n",
        "    fn = df['Filename'][i]\n",
        "    folder = fn.split(\"-\")[0]\n",
        "    f = open('/content/gdrive/My Drive/covidnlp/train-data/'+folder+'/'+fn, \"r\")\n",
        "    texts.append(f.read())\n",
        "\n",
        "df['text'] = texts"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "pj1EnEa1OCHZ",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 402
        },
        "outputId": "dc882b6e-cd30-4d1e-cdbc-6b27f678976f"
      },
      "source": [
        "df"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Filename</th>\n",
              "      <th>Blinding of intervention</th>\n",
              "      <th>Blinding of Outcome assessment</th>\n",
              "      <th>Classes</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00060-02.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>A Multicomponent Intervention To Prevent Major...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00060-03.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>Original article\\nSelf-management versus conve...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00060-04.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>Original Research\\nHome Management of Oral Ant...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00060-05.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>For personal use only. Not to be reproduced wi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00060-06.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>© 2016 Pozzi et al. This work is published and...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>623</th>\n",
              "      <td>00458-20.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>﻿Effect of daily versus twice weekly long-term...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>624</th>\n",
              "      <td>00458-21.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>﻿Eur J Nutr 39 : 263–269 (2000)\\n© Steinkopff ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>625</th>\n",
              "      <td>00458-22.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>﻿ARTICLE\\n \\n\\n \\nWeekly vs Daily Iron and Fol...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>626</th>\n",
              "      <td>00458-24.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>﻿Symposium: Improving Adolescent Iron Status\\n...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>627</th>\n",
              "      <td>00458-25.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>﻿Effectiveness of weekly vitamin A (10 000 IU)...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>628 rows × 5 columns</p>\n",
              "</div>"
            ],
            "text/plain": [
              "         Filename  ...                                               text\n",
              "0    00060-02.txt  ...  A Multicomponent Intervention To Prevent Major...\n",
              "1    00060-03.txt  ...  Original article\\nSelf-management versus conve...\n",
              "2    00060-04.txt  ...  Original Research\\nHome Management of Oral Ant...\n",
              "3    00060-05.txt  ...  For personal use only. Not to be reproduced wi...\n",
              "4    00060-06.txt  ...  © 2016 Pozzi et al. This work is published and...\n",
              "..            ...  ...                                                ...\n",
              "623  00458-20.txt  ...  ﻿Effect of daily versus twice weekly long-term...\n",
              "624  00458-21.txt  ...  ﻿Eur J Nutr 39 : 263–269 (2000)\\n© Steinkopff ...\n",
              "625  00458-22.txt  ...  ﻿ARTICLE\\n \\n\\n \\nWeekly vs Daily Iron and Fol...\n",
              "626  00458-24.txt  ...  ﻿Symposium: Improving Adolescent Iron Status\\n...\n",
              "627  00458-25.txt  ...  ﻿Effectiveness of weekly vitamin A (10 000 IU)...\n",
              "\n",
              "[628 rows x 5 columns]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "dHG7ejH3FP0H"
      },
      "source": [
        "from functools import partial\n",
        "import io\n",
        "import os\n",
        "\n",
        "df['text'] = df['text'].str.replace(\"[^a-zA-Z]\", \" \")"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "ZRqJSuvSFj1P",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 50
        },
        "outputId": "ed29909b-1319-4228-d0c2-3c7c4d6891c6"
      },
      "source": [
        "import nltk\n",
        "nltk.download('stopwords')\n",
        "\n",
        "from nltk.corpus import stopwords \n",
        "stop_words = stopwords.words('english')"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Unzipping corpora/stopwords.zip.\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "YMZLBF8oFupW"
      },
      "source": [
        "# tokenization \n",
        "tokenized_doc = df['text'].apply(lambda x: x.split())\n",
        "\n",
        "# remove stop-words \n",
        "tokenized_doc = tokenized_doc.apply(lambda x: [item for item in x if item not in stop_words])\n",
        "\n",
        "# de-tokenization \n",
        "detokenized_doc = [] \n",
        "for i in range(len(df)): \n",
        "    t = ' '.join(tokenized_doc[i]) \n",
        "    detokenized_doc.append(t) \n",
        "\n",
        "df['text'] = detokenized_doc"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "v-zvdDWIF5_g",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 402
        },
        "outputId": "ae5cf25c-6a06-4aa1-bf46-340aa65672b4"
      },
      "source": [
        "df"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Filename</th>\n",
              "      <th>Blinding of intervention</th>\n",
              "      <th>Blinding of Outcome assessment</th>\n",
              "      <th>Classes</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00060-02.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>A Multicomponent Intervention To Prevent Major...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00060-03.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>Original article Self management versus conven...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00060-04.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>Original Research Home Management Oral Anticoa...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00060-05.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>For personal use Not reproduced without permis...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00060-06.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>Pozzi et al This work published licensed Dove ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>623</th>\n",
              "      <td>00458-20.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>Effect daily versus twice weekly long term iro...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>624</th>\n",
              "      <td>00458-21.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>Eur J Nutr Steinkopff Verlag Summary Backgroun...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>625</th>\n",
              "      <td>00458-22.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>ARTICLE Weekly vs Daily Iron Folic Acid Supple...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>626</th>\n",
              "      <td>00458-24.txt</td>\n",
              "      <td>N</td>\n",
              "      <td>N</td>\n",
              "      <td>NN</td>\n",
              "      <td>Symposium Improving Adolescent Iron Status Chi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>627</th>\n",
              "      <td>00458-25.txt</td>\n",
              "      <td>P</td>\n",
              "      <td>P</td>\n",
              "      <td>PP</td>\n",
              "      <td>Effectiveness weekly vitamin A IU iron mg supp...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>628 rows × 5 columns</p>\n",
              "</div>"
            ],
            "text/plain": [
              "         Filename  ...                                               text\n",
              "0    00060-02.txt  ...  A Multicomponent Intervention To Prevent Major...\n",
              "1    00060-03.txt  ...  Original article Self management versus conven...\n",
              "2    00060-04.txt  ...  Original Research Home Management Oral Anticoa...\n",
              "3    00060-05.txt  ...  For personal use Not reproduced without permis...\n",
              "4    00060-06.txt  ...  Pozzi et al This work published licensed Dove ...\n",
              "..            ...  ...                                                ...\n",
              "623  00458-20.txt  ...  Effect daily versus twice weekly long term iro...\n",
              "624  00458-21.txt  ...  Eur J Nutr Steinkopff Verlag Summary Backgroun...\n",
              "625  00458-22.txt  ...  ARTICLE Weekly vs Daily Iron Folic Acid Supple...\n",
              "626  00458-24.txt  ...  Symposium Improving Adolescent Iron Status Chi...\n",
              "627  00458-25.txt  ...  Effectiveness weekly vitamin A IU iron mg supp...\n",
              "\n",
              "[628 rows x 5 columns]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 11
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "FDIDz6BXOjGI"
      },
      "source": [
        "df = df.iloc[np.random.permutation(len(df))]\n",
        "cut1 = int(0.8 * len(df)) + 1\n",
        "df_train, df_valid = df[:cut1], df[cut1:]"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "oeDSqZ0SQb3q",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "2a171147-f2fb-4b1c-eaff-63034334643d"
      },
      "source": [
        "data_lm = TextLMDataBunch.from_df(path=path,\n",
        " train_df=df_train,\n",
        " valid_df=df_valid, \n",
        " label_cols='Blinding of intervention', \n",
        " text_cols='text',\n",
        " bs=16)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              ""
            ],
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ]
          },
          "metadata": {
            "tags": []
          }
        },
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              ""
            ],
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ]
          },
          "metadata": {
            "tags": []
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "MoPaw4JRQynu"
      },
      "source": [
        "#data_lm.save('/content/gdrive/My Drive/covidnlp/','databunch.pkl')"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "X1NyNsHfRJkq",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 34
        },
        "outputId": "8745a797-1266-4a9c-ddf8-9b66a6534850"
      },
      "source": [
        "lm = language_model_learner(data_lm, AWD_LSTM, drop_mult=0.3)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Downloading https://s3.amazonaws.com/fast-ai-modelzoo/wt103-fwd.tgz\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              ""
            ],
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ]
          },
          "metadata": {
            "tags": []
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "y34NJXk1Y9ng"
      },
      "source": [
        "#lm.lr_find()"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "ozH6iqEYY-SH"
      },
      "source": [
        "#lm.recorder.plot(suggestion=True)"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "jWMMApuUZwDJ",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 77
        },
        "outputId": "24c224db-2c44-42aa-c48c-6eafc9afabd9"
      },
      "source": [
        "lm.fit_one_cycle(1)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: left;\">\n",
              "      <th>epoch</th>\n",
              "      <th>train_loss</th>\n",
              "      <th>valid_loss</th>\n",
              "      <th>accuracy</th>\n",
              "      <th>time</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <td>0</td>\n",
              "      <td>5.318124</td>\n",
              "      <td>4.960936</td>\n",
              "      <td>0.273988</td>\n",
              "      <td>02:12</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>"
            ],
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ]
          },
          "metadata": {
            "tags": []
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "7rRL8-A3Si6c"
      },
      "source": [
        "lm.save_encoder(path/'filename.pth')"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "J1h50CpEStv9",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "5398dc0d-90be-435a-d037-b25cb5040d25"
      },
      "source": [
        "data_clas=TextClasDataBunch.from_df(path=path,train_df=df_train, \n",
        "                                    valid_df=df_valid, \n",
        "                                    vocab=data_lm.train_ds.vocab, \n",
        "                                    label_cols='Blinding of intervention', \n",
        "                                    text_cols='text',\n",
        "                                    bs=64)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              ""
            ],
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ]
          },
          "metadata": {
            "tags": []
          }
        },
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              ""
            ],
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ]
          },
          "metadata": {
            "tags": []
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "v-i4WJiuS4s8"
      },
      "source": [
        "clas = text_classifier_learner(data_clas,AWD_LSTM,drop_mult=0.7)"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "eBi7cUsATEvr",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "c0009ec7-c543-4f66-fe58-303d14b3ebf7"
      },
      "source": [
        "clas.load_encoder(path/'filename.pth')"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "RNNLearner(data=TextClasDataBunch;\n",
              "\n",
              "Train: LabelList (503 items)\n",
              "x: TextList\n",
              "xxbos xxmaj original research article xxmaj two randomized controlled trials comparing xxmaj hulka xxmaj filshie xxmaj clips tubal sterilization xxmaj xxunk xxmaj xxunk xxmaj deborah xxmaj xxunk xxmaj david xxmaj xxunk xxmaj milton xxmaj xxunk xxmaj jorge xxmaj lasso de la xxmaj xxunk xxmaj arturo xxmaj remes xxmaj xxunk xxmaj john xxmaj xxunk xxmaj david xxmaj limb xxmaj serge xxmaj xxunk xxmaj roberto xxmaj santiso xxmaj xxunk xxmaj luis xxmaj xxunk xxmaj itic xxmaj xxunk xxmaj family xxmaj health xxmaj international xxmaj research xxmaj triangle xxmaj park xxup nc xxup usa b xxmaj the xxmaj clinical xxmaj investigator xxmaj team xxmaj received xxmaj june accepted xxmaj september xxmaj abstract xxmaj to compare effectiveness safety xxmaj filshie xxmaj clip xxmaj system xxmaj hulka xxmaj clip xxmaj system applied via minilaparotomy laparoscopy conducted multicenter randomized controlled trials women minilaparotomy study laparoscopy study received either xxmaj filshie xxmaj hulka xxmaj clip a physician operator evaluated patients postoperatively months surgery xxmaj we compared cumulative incidence pregnancy frequency safety related events device groups xxmaj twenty four month follow planned subset women laparoscopy study xxmaj one woman received xxmaj filshie xxmaj clip women received xxmaj hulka xxmaj clip became pregnant within one year xxmaj the month life table pregnancy probability per women xxmaj filshie xxmaj clip group per women xxmaj hulka xxmaj clip group xxmaj the difference risk pregnancy months device groups neared statistical significance p xxmaj among extended follow subset month cumulative pregnancy probabilities per women xxmaj filshie xxmaj clip group per women xxmaj hulka xxmaj clip group p comparison months xxmaj both xxmaj filshie xxmaj hulka xxmaj clips effective safe use tubal occlusion xxmaj elsevier xxmaj science xxmaj inc xxmaj all rights reserved xxmaj keywords xxmaj tubal occlusion devices xxmaj female sterilization xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj introduction xxmaj in xxup us xxmaj food xxmaj drug xxmaj administration approved xxmaj filshie xxmaj clip tubal sterilization xxmaj the xxmaj filshie xxmaj hulka clips vary slightly mechanism action xxmaj while xxmaj hulka xxmaj clip spring mechanism holds clip closed fallopian tube xxmaj filshie xxmaj clip uses pressure exerted applicator close clip around fallopian tube flatten xxunk upper jaw clip xxmaj this action causes upper jaw leading edge extend lip lower jaw locking position simultaneously trapping occluding fallopian tube xxmaj published reports failure rates clips varied widely xxmaj this may reflect several factors including level experience surgeon timing surgery postpartum interval procedure used method used calculate failure rates characteristics study population a randomized trial women found xxmaj filshie xxmaj clip performed better xxmaj hulka xxmaj clip respect ease application perioperative pain xxmaj to evaluate clinically relative effectiveness safety methods conducted randomized controlled trials xxmaj filshie xxmaj hulka clips used interval sterilization one applied via minilaparotomy applied via laparoscopy xxmaj materials methods xxmaj except type surgical approach used laparoscopy minilaparotomy two study protocols identical xxmaj the lead investigator site required xxmaj corresponding author xxmaj tel fax e mail address xxunk fhi org r xxmaj dominik xxmaj contraception see front matter xxmaj elsevier xxmaj science xxmaj inc xxmaj all rights reserved xxup pii s experienced surgeon sites served operator another experienced surgeon served evaluator xxmaj family xxmaj health xxmaj international xxup fhi institutional review board xxup irb approved two protocols xxmaj november xxmaj in addition study center obtained approval conduct study xxup irb prior study initiation xxmaj if local xxup irb available xxup fhi xxup irb acted lieu local xxup irb xxmaj women least years age legally able consent sterilization normal physical pelvic examination results eligible participate studies xxmaj we enroll women undergone pregnancy termination within past days pre existing clinically important abnormal condition diabetes renal cardiac disease xxmaj we enroll women already pregnant women undergoing surgery routine curettage xxup iud removal concurrent sterilization xxmaj for example woman eligible coming induced abortion sterilization procedure xxmaj nor enroll women required sterilization reasons voluntarily limiting size family xxmaj after participant signed informed consent agreement randomized receive one two tubal occlusion devices using computer generated randomization scheme stratified center xxmaj her group assignment revealed operator opening sealed sequentially numbered opaque envelope provided site study initiation xxup fhi xxmaj minilaparotomy used access view fallopian tubes one study performed five centers laparoscopy used study performed four centers xxmaj prior surgery took medical history conducted physical examination including pelvic examination xxmaj the operator recorded type anesthetic surgical approach reason change assigned tubal occlusion method applicable xxmaj before women discharged another physician informed type clip women received assessed complications involving surgical incision pelvic pain infection complications complaints a surgeon operator evaluated participants months sterilization xxmaj at selected sites month evaluation planned subset laparoscopy participants xxmaj at early month follow visit evaluated women complications associated surgical procedure xxmaj at later visits gave participants physical examination including pelvic examination clinical assessment pelvic infection asked questions menstrual patterns including intermenstrual bleeding pain xxmaj at follow visits recorded pregnancies adverse events abdominal pelvic surgery clinic admissions occurred since surgery xxmaj we diagnosed pregnancies urine pregnancy test pelvic examination clinical evaluation routinely administer chemical pregnancy test month visits a total five centers four countries included minilaparotomy study four centers four countries included laparoscopy study xxmaj field work completed xxmaj february xxmaj we defined three different subject populations analyzed individual trial results xxmaj the intent treat population included women assigned receive xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj the treated population included women least one fallopian tube occluded either xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj the efficacy population included women fallopian tubes occluded assigned device except inclusion criteria violations might interfere evaluation effectiveness xxmaj prior initiation primary analysis either trial determined treated population primary analysis population interest focus individual trial pooled trial results presented xxmaj the effectiveness outcome interest pregnancy xxmaj we calculated month gross cumulative life table pregnancy probabilities device type combining data collected studies device type within study xxmaj we calculated standard errors using method described xxmaj peto et al xxmaj we used log rank test test differences pregnancy curves device group xxmaj we also calculated gross cumulative life table pregnancy probabilities months subgroup participants extended follow planned xxmaj we excluded women effectiveness analysis treated population later determined pregnant time tubes occluded e women luteal phase pregnancies xxmaj in event hysterectomy surgical intervention would alter risk pregnancy women censored life table analysis xxmaj participants reported pregnant censored life table analysis date last visit xxmaj for pregnancies date conception estimated using algorithm based last menstrual period gestational age termination pregnancy confirmation xxmaj we calculated percentage surgical injuries primary incision complications infections major complications early follow device received within strata defined surgical approach xxmaj within surgical approach stratum used xxmaj fisher exact test test differences device groups number women type event xxmaj we combine early safety results surgical approaches differences characteristics procedures xxmaj we summarized reports hospital readmission abdominal pelvic surgery follow r xxmaj dominik et al xxmaj contraception xxmaj results xxmaj unless otherwise stated present results treated population device received a total women minilaparotomy study laparoscopy study comprised entire intent treat population xxmaj figs xxmaj of assigned xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj we identified major violations inclusion exclusion criteria women minilaparotomy study laparoscopy study xxmaj of received xxmaj filshie xxmaj clip received xxmaj hulka xxmaj clip xxmaj almost half protocol violations women whose last pregnancy terminated less weeks surgery xxmaj the violations women variety pre existing conditions women pre existing pelvic pathology xxmaj table shows number participants analysis population surgical approach country xxmaj the women device groups mean age years given birth average children xxmaj about half women device groups pregnant within months prior sterilization slightly half used form contraceptive method months prior sterilization xxmaj about one third women device group reported menses months prior enrollment xxmaj the likelihood amenorrhea baseline considerably higher among women delivered within months preceding study enrollment among women presumably due breast feeding xxmaj in device groups reported previous intraperitoneal surgery previously pelvic inflammatory disease xxmaj operators experienced type surgical difficulty operating women received xxmaj filshie xxmaj clip women received xxmaj hulka xxmaj clip xxmaj the three common difficulties minilaparotomy study grasping tubes xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases entering peritoneum xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases visualizing tubes xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases xxmaj the three common difficulties laparoscopy study visualizing tubes xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases occluding tubes xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases entering peritoneum xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases xxmaj operators dropped one clips abdominal cavity women received xxmaj filshie xxmaj clip xxmaj the operator find dropped clip one cases presumably still xxmaj an operator noted xxmaj hulka clip came apart abdominal cavity one woman retrieved parts xxmaj these four surgical difficulties occurred laparoscopy study xxmaj operators failed apply assigned device fallopian tubes total women xxmaj in cases assigned xxmaj filshie xxmaj clip one assigned xxmaj hulka xxmaj clip operators provided explanation xxunk xxmaj participant flow chart minilaparotomy study xxmaj fig xxmaj participant flow chart laparoscopy study xxmaj includes one participant received xxmaj hulka clips stop one tube bleeding transected xxmaj filshie clip xxmaj this participant excluded subsequent counts r xxmaj dominik et al xxmaj contraception xxunk occurrence appeared unintentional error xxmaj in women assigned xxmaj filshie xxmaj clip assigned xxmaj hulka xxmaj clip problems encountered surgery prevented application assigned device tubes xxmaj problems encountered surgery included need repair surgical injury cases discovery ovarian fimbrial cysts cases thick fallopian tubes one case xxmaj when surgeon unable apply assigned clip used alternate method e g xxmaj pomeroy technique xxmaj in one cases cysts encountered sterilization procedure applied tube xxmaj in one xxmaj filshie xxmaj clip group participant surgeon used pair xxmaj hulka xxmaj clips stop one tube bleeding transected xxmaj filshie xxmaj clip xxmaj the surgeon placed one xxmaj hulka xxmaj clip end transected tube xxmaj in immediate postoperative period participant noted moderate pelvic pain treated oral analgesics xxmaj she followed one year evaluator noted difficulties complications xxmaj this woman enrolled laparoscopy study assigned receive xxmaj filshie xxmaj clip woman excluded treated population xxmaj within trial days discharge vary device xxmaj over women laparoscopy study discharged clinic day surgery minilaparotomy study discharged day surgery discharged following day xxmaj the percentage women returning follow visits similar two groups declined time xxmaj although women device groups returned early follow evaluation group completed month visit returned month later visit xxmaj among subset laparoscopy participants month follow planned women xxmaj filshie xxmaj clip group women xxmaj hulka xxmaj clip group group returned days surgery xxmaj table shows month cumulative life table pregnancy probabilities xxmaj there pregnancies xxmaj hulka xxmaj clip group one pregnancy xxmaj filshie xxmaj clip group xxmaj all reported pregnancies intrauterine xxmaj the difference risk pregnancy device groups xxmaj table xxmaj number participants analysis population device group xxmaj analysis xxmaj population xxmaj study xxmaj country xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj intent treat populationa xxmaj minilaparotomy study xxmaj xxunk xxmaj panama xxmaj dominican xxmaj republic xxmaj mexico xxmaj laparoscopy study xxmaj xxunk xxmaj guatemala xxmaj mexico xxmaj haiti xxmaj treated populationc xxmaj minilaparotomy study xxmaj laparoscopy study xxmaj efficacy populationc e f xxmaj minilaparotomy study xxmaj laparoscopy study xxmaj by assigned device b xxmaj there two centers xxmaj malaysia one closed participants enrolled c xxmaj by device received xxmaj excludes woman intent treat population received study devices one tube xxmaj filshie xxmaj clip tube e xxmaj this group subset treated population excluding women women violations inclusion exclusion criteria women luteal phase pregnancies woman random allocation error women receive assigned device tubes due technical failures f xxmaj this group subset treated population excluding women women violations inclusion exclusion criteria women luteal phase pregnancies women random allocation errors women receive assigned device tubes due technical failures xxmaj table xxmaj six month gross cumulative life table pregnancy probabilities per women approach device group treated population xxmaj approach xxmaj month xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxunk xxmaj number riska xxmaj cumulative probability pregnancyb xxmaj standard error xxmaj number riska xxmaj cumulative probability pregnancyb xxmaj standard error xxmaj both approaches combined xxmaj laparoscopy xxmaj minilaparotomy xxmaj number women remaining trial beginning month b xxmaj per women c xxmaj log rank test comparison month pregnancy curves r xxmaj dominik et al xxmaj contraception neared statistical significance p xxmaj given final sample size observed discontinuation rate study provided power detect difference true annual pregnancy probabilities per women per women pooled analysis xxmaj the numbers risk month xxmaj table somewhat less numbers non pregnant women xxmaj figs made month visits especially minilaparotomy study xxmaj these differences reflect use slightly different definitions a month visit defined visit days surgery xxmaj however life table analysis women risk pregnancy month visit day later e first day th month surgery xxmaj in subset laparoscopy study participants followed months additional pregnancies intrauterine xxmaj one pregnancies xxmaj filshie xxmaj clip group xxmaj hulka xxmaj clip group xxmaj among subset month cumulative pregnancy probabilities per women xxmaj filshie xxmaj clip group per women xxmaj hulka xxmaj clip group p comparison months xxmaj thus total pregnancies occurred scheduled follow period intrauterine xxmaj filshie xxmaj clip group xxmaj hulka xxmaj clip group xxmaj the pregnancies identified study luteal phase pregnancies defined conception occurring date sterilization procedure xxmaj filshie xxmaj clip group xxmaj hulka xxmaj clip group xxmaj the women luteal phase pregnancies excluded efficacy analysis xxmaj table shows within study number participants surgical injuries primary incision complications early follow infections early follow complications early follow similar two device groups xxmaj during scheduled month follow period sterilization women xxmaj filshie xxmaj clip group xxmaj table xxmaj surgical injuries safety events reported early follow treated population xxmaj safety xxmaj event xxmaj minilaparotomy xxmaj laparoscopy xxmaj filshie xxmaj hulka xxmaj filshie xxmaj hulka xxwrep 4 n xxmaj surgical injuries xxmaj none xxmaj cervical laceration xxmaj uterine perforation xxmaj tubal mesosalpingeal injury xxmaj other xxmaj total p valuea xxmaj primary incision complications early follow xxmaj none xxmaj serious discharge xxmaj inflammation xxmaj abscess xxmaj bleeding xxmaj hematoma xxmaj other xxmaj total p valuea xxmaj infections early follow xxmaj none xxmaj in uterus xxmaj in adnexa xxmaj other xxmaj total p valuea xxmaj other complications early follow xxunk xxmaj none xxmaj at least one xxmaj total p valuea xxmaj by xxmaj fisher exact test complication event versus event b xxmaj specifically urinary tract infection vaginal bleeding menses lochia respiratory cardiovascular gastrointestinal drug allergy xxunk responses provided major complication section early follow visit data collection form r xxmaj dominik et al xxmaj contraception women xxmaj hulka xxmaj clip group hospitalized underwent abdominal pelvic surgery xxmaj we found clinically significant difference two groups various reasons surgery hospitalization xxmaj in addition one participant xxmaj filshie xxmaj clip group minilaparotomy study appeared experienced granuloma formation related sterilization led surgery performed scheduled follow period xxmaj four months sterilization presented right iliac pain left adnexal mass xxmaj at months underwent pelvic ultrasound flat plate abdominal x ray diagnostic laparoscopy xxmaj these examinations revealed left ovarian cyst abdominal wall mass right bilateral adhesions xxmaj fifteen months sterilization surgeon removed left clip left adnexa found right clip lodged granuloma xxunk muscular abdominal wall xxmaj he left right clip place concern muscles would damaged removal xxmaj discussion xxmaj our estimate probability pregnancy first year sterilization xxmaj hulka xxmaj clip per lower probability per observed xxmaj center xxmaj disease xxmaj control xxmaj prevention xxunk xxup us xxmaj collaborative xxmaj review xxmaj sterilization xxup crest xxmaj in trials sterilization procedures performed small number investigators selected surgical expertise experience xxmaj in xxup crest study resident physicians teaching centers performed sterilization procedures xxmaj our lower pregnancy probabilities may due choice experienced investigators operators xxmaj alternatively differences estimates risk pregnancy may due differences underlying fecundity study populations incomplete follow chance xxmaj although slightly higher percentage women spring clip group xxup cdc study xxmaj hulka xxmaj clip group study less years age studies similar proportion women years age xxmaj clip recipients studies included women desiring interval sterilization xxmaj our study include substantial proportion women reported amenorrheic since previous delivery presumably due breast feeding comparable data provided xxup cdc study xxmaj censoring participants date last visit would expected slightly underestimate month pregnancy probabilities since pregnancies yet clinically evident could missed xxmaj we performed additional analysis censored women become pregnant days prior last visit xxmaj the impact point estimate pregnancy probabilities small xxmaj for xxmaj filshie xxmaj clip group estimate went per women per women xxmaj for xxmaj hulka xxmaj clip group estimate went per women per women xxmaj although follow high respect short term safety outcomes long term follow rate somewhat disappointing xxmaj however age distributions participants complete month later visit studies quite similar distributions women complete month later visit nearly participants included studies previous live births xxmaj less educated women women rural areas less likely complete month later visit participants pattern loss similar device groups within study data shown xxmaj the two devices appear similar safety profiles serious adverse experiences related sterilization either device rare xxmaj all primary incision complications observed complications might expected surgery xxmaj the choice surgical approach appear affect overall efficacy safety xxmaj clip related adverse events expulsion migration abscess granuloma formation uncommon xxmaj no participants reported clip xxunk study xxmaj however events reported comparative trials xxmaj filshie xxmaj clip tubal ring xxmaj acknowledgments xxmaj funding xxup us xxmaj agency xxmaj international xxmaj development xxup usaid cooperative agreements xxup aid xxup dpe c xxup aid xxup dpe a xxup aid xxup dpe a xxup aid xxup xxunk a supported studies analyses xxmaj however views expressed article necessarily reflect xxup usaid xxmaj femcare xxmaj limited manufacturer xxmaj filshie xxmaj clip xxmaj system supplied xxmaj filshie xxmaj clips applicators cost xxmaj family xxmaj health xxmaj international xxup fhi receives xxunk xxmaj femcare xxmaj ltd clips sold xxunk institutions xxmaj united xxmaj states xxmaj this paper prepared funding xxmaj femcare xxmaj ltd xxup usaid xxmaj the minilaparotomy study conducted xxmaj milton xxmaj xxunk xxup md xxup xxunk xxmaj santo xxmaj xxunk xxmaj dominican xxmaj republic xxmaj jorge xxmaj lasso de la xxmaj vega xxup md xxmaj complejo xxmaj xxunk xxmaj xxunk xxmaj panama xxmaj city xxmaj panama xxmaj arturo xxmaj remes xxmaj ruiz xxmaj hospital xxmaj general de xxmaj veracruz xxmaj veracruz xxmaj mexico xxmaj john xxmaj xxunk xxup md xxmaj kuala xxmaj lumpur xxmaj maternity xxmaj hospital xxmaj kuala xxmaj lumpur xxmaj malaysia xxmaj david xxmaj lim xxup md xxup xxunk xxmaj national xxmaj population xxmaj family xxmaj development xxmaj board xxmaj kuala xxmaj lumpur xxmaj malaysia xxmaj the laparoscopy study conducted xxmaj serge xxmaj xxunk xxup md xxmaj re gion xxmaj xxunk du xxmaj xxunk xxmaj le xxmaj xxunk xxmaj haiti xxmaj roberto xxmaj santiso xxmaj xxunk xxup md xxup xxunk xxmaj guatamala xxmaj city xxmaj guatamala xxmaj luis xxmaj uribe xxup md xxmaj hospital xxmaj gineco xxmaj obstetrica xxmaj xxunk xxmaj mexico xxmaj itic xxmaj xxunk xxup md xxmaj maternidad xxmaj concepcio n xxmaj palacios xxmaj xxunk xxmaj xxunk r xxmaj dominik et al xxmaj contraception xxmaj references xxmaj richard xxmaj wolf xxmaj medical xxmaj instruments xxmaj corporation xxmaj laparoscopic sterilization spring clips xxmaj xxunk xxmaj il xxmaj filshie xxup gm xxmaj the development titanium silicone rubber clip female sterilization xxmaj thesis submitted xxmaj university xxmaj nottingham xxmaj degree xxmaj doctor xxmaj medicine xxmaj october xxmaj xxunk xxup ma xxmaj pattison xxup ns xxmaj wilson p xxmaj female xxmaj sterilization xxmaj national xxmaj women xxmaj hospital xxup nz xxmaj med j xxmaj stovall xxup tg xxmaj ling xxup fw xxmaj henry xxup gm xxmaj ryan xxup gm xxmaj jr xxmaj method failures laparoscopic tubal sterilization residency training program a comparison tubal ring spring loaded clip j xxmaj reprod xxmaj med xxmaj chi xxup ic xxmaj gates d xxmaj xxunk s et al xxmaj timing postpartum tubal sterilization using xxmaj filshie clips analysis data two developing country centers xxmaj contraception xxmaj xxunk xxup vj xxmaj female sterilization vaginal route positive reassessment comparison tubal occlusion methods xxmaj aust xxup nz j xxmaj obstet xxmaj gynaecol xxmaj chi i xxmaj xxunk xxup le xxmaj gardner xxup sd et al xxmaj an epidemiologic study risk factors associated pregnancy following female sterilization xxmaj am j xxmaj obstet xxmaj gynecol xxmaj peterson xxup hb xxmaj xia z xxmaj hughes j xxmaj wilcox xxup ls xxmaj tylor xxup lr xxmaj trussell j xxmaj the risk pregnancy tubal sterilization findings u s xxmaj collaborative xxmaj review xxmaj sterilization xxmaj am j xxmaj obstet xxmaj gynecol xxmaj sokal d xxmaj gates d xxmaj amatya r xxmaj dominik r xxmaj clinical xxmaj investigator xxmaj team xxmaj two randomized controlled trials comparing tubal ring xxmaj filshie clip tubal sterilization xxmaj fertil xxmaj steril xxmaj davies xxup gc xxmaj letchworth xxup at xxmaj diamond i a comparison xxmaj filshie xxmaj hulka xxmaj clemens clips used sterilisation operations j xxmaj obstet xxmaj gynaecol xxmaj potter xxup rg xxmaj jr xxmaj use effectiveness intrauterine contraception problem competing risks xxmaj in xxmaj freedman r xxmaj xxunk xxup jy editors xxmaj family xxmaj planning xxmaj taiwan xxmaj new xxmaj jersey xxmaj princeton xxmaj university xxmaj press p xxmaj peto r xxmaj pike xxup mc xxmaj armitage p et al xxmaj design analysis randomized clinical trials requiring prolonged observation patient xxup ii xxmaj analysis examples xxmaj br j xxmaj cancer xxmaj xxunk xxup jd xxmaj prentice xxup rl xxmaj the xxmaj statistical xxmaj analysis xxmaj failure xxmaj time xxmaj data xxmaj new xxmaj york xxmaj john xxmaj wiley xxmaj sons xxmaj inc xxmaj lachin xxup jm xxmaj xxunk xxup ma xxmaj evaluation sample size power analyses survival allowance xxunk patient entry losses follow noncompliance stratification xxmaj biometrics r xxmaj dominik et al xxmaj contraception,xxbos xxmaj anemia prophylaxis adolescent school girls weekly daily iron folate supplementation xxmaj agarwal xxup kn xxmaj gomber s xxmaj bisht h xxmaj som m xxmaj author information xxmaj department xxmaj pediatrics xxmaj university xxmaj college xxmaj medical xxmaj sciences xxup gtb xxmaj hospital xxmaj delhi xxmaj india xxmaj xxunk hotmail com xxmaj abstract xxup objective xxmaj to examine benefits anemia prophylaxis adolescent school girls weekly daily iron folate supplementation xxup design xxmaj prospective study xxup setting xxmaj government girl schools northeast xxmaj delhi xxup subjects subjects hemoglobin greater g dl including daily weekly iron folate administration girls served controls xxup results xxmaj about girls iron deficient anemic xxmaj weekly administration took longer time raise hemoglobin effective well practical xxmaj plasma ferritin estimation girls showed rise level treated groups xxup conclusion xxmaj weekly administration iron folate practical effective strategy anemia prophylaxis adolescent school girls,xxbos xxmaj this article downloaded xxmaj university xxmaj liverpool xxmaj on xxmaj december xxmaj at xxmaj publisher xxmaj routledge xxmaj informa xxmaj ltd xxmaj registered xxmaj england xxmaj wales xxmaj registered xxmaj number xxmaj registered office xxmaj mortimer xxmaj house xxmaj mortimer xxmaj street xxmaj london w t xxup jh xxup uk xxmaj journal xxmaj dual xxmaj diagnosis xxmaj publication details including instructions authors subscription information http www tandfonline com loi wjdd a xxmaj randomized xxmaj trial xxmaj clozapine xxmaj versus xxmaj other xxmaj antipsychotics xxmaj cannabis xxmaj use xxmaj disorder xxmaj patients xxmaj with xxmaj schizophrenia xxmaj mary f xxmaj brunette xxup md xxmaj ree xxmaj dawson phd b xxmaj christopher d o xxmaj keefe xxup ma c xxmaj meera xxmaj narasimhan xxup md xxmaj douglas l xxmaj noordsy xxup md c xxmaj joanne xxmaj wojcik phd e xxmaj alan i xxmaj green xxup md c xxmaj dartmouth xxmaj psychiatric xxmaj research xxmaj center xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj lebanon xxmaj new xxmaj hampshire xxup usa b xxmaj frontier xxmaj science xxmaj research xxmaj technology xxmaj boston xxmaj massachusetts xxup usa c xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj lebanon xxmaj new xxmaj hampshire xxup usa xxmaj department xxmaj psychiatry xxmaj university xxmaj south xxmaj carolina xxmaj columbia xxmaj south xxmaj carolina xxup usa e xxmaj department xxmaj psychiatry xxmaj beth xxmaj israel xxmaj deaconess xxmaj medical xxmaj center xxmaj harvard xxmaj medical xxmaj school xxmaj boston xxmaj massachusetts xxup usa xxmaj published online xxmaj may xxmaj to cite article xxmaj mary f xxmaj brunette xxup md xxmaj ree xxmaj dawson phd xxmaj christopher d o xxmaj keefe xxup ma xxmaj meera xxmaj narasimhan xxup md xxmaj douglas l xxmaj noordsy xxup md xxmaj joanne xxmaj wojcik phd xxmaj alan i xxmaj green xxup md a xxmaj randomized xxmaj trial xxmaj clozapine xxmaj versus xxmaj other xxmaj antipsychotics xxmaj cannabis xxmaj use xxmaj disorder xxmaj patients xxmaj with xxmaj schizophrenia xxmaj journal xxmaj dual xxmaj diagnosis xxmaj to link article http dx doi org xxup please xxup scroll xxup down xxup for xxup article xxmaj taylor xxmaj francis makes every effort ensure accuracy information xxmaj content contained publications platform xxmaj however xxmaj taylor xxmaj francis agents licensors make representations warranties whatsoever accuracy completeness suitability purpose xxmaj content xxmaj any opinions views expressed publication opinions views authors views endorsed xxmaj taylor xxmaj francis xxmaj the accuracy xxmaj content relied upon independently verified primary sources information xxmaj taylor xxmaj francis shall liable losses actions claims proceedings demands costs expenses damages liabilities whatsoever howsoever caused arising directly indirectly connection relation arising use xxmaj content xxmaj this article may used research teaching private study purposes xxmaj any substantial systematic reproduction redistribution reselling loan sub licensing systematic supply distribution form anyone expressly forbidden xxmaj terms xxmaj conditions access use found http www tandfonline com page termsand conditions xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxup journal xxup of xxup dual xxup diagnosis xxmaj copyright c xxmaj taylor xxmaj francis xxmaj group xxup llc xxup issn print online xxup doi xxup psychopharmacology xxup neurobiology a xxmaj randomized xxmaj trial xxmaj clozapine xxmaj versus xxmaj other xxmaj antipsychotics xxmaj cannabis xxmaj use xxmaj disorder xxmaj patients xxmaj with xxmaj schizophrenia xxmaj mary f xxmaj brunette xxup md xxmaj ree xxmaj dawson phd xxmaj christopher d o xxmaj keefe xxup ma xxmaj meera xxmaj narasimhan xxup md xxmaj douglas l xxmaj noordsy xxup md xxmaj joanne xxmaj wojcik phd xxmaj alan i xxmaj green xxup md xxmaj objective xxmaj cannabis use disorder common co occurring drug use disorder people schizophrenia associated poor outcomes xxmaj the authors launched randomized controlled trial assess impact clozapine compared treatment usual cannabis use patients schizophrenia co occurring cannabis use disorder xxmaj methods xxmaj thirty one patients schizophrenia co occurring cannabis use disorder randomly assigned switch clozapine stay current antipsychotic followed weekly weeks xxmaj blinded raters assessed participants weekly xxmaj timeline xxmaj followback substance use expanded xxmaj brief xxmaj psychiatric xxmaj rating xxmaj scale symptoms xxmaj longitudinal random effects models used investigate time varying differences cannabis use outcomes treatment usual clozapine groups xxmaj results xxmaj the two groups differed average intensity cannabis use approximately joints week lesser use clozapine group df p effect size xxmaj symptoms functioning different two groups xxmaj conclusions xxmaj clozapine may reduce cannabis use among patients schizophrenia co occurring cannabis use disorder xxmaj further controlled trials warranted xxmaj journal xxmaj dual xxmaj diagnosis xxmaj keywords schizophrenia cannabis substance use disorder clozapine treatment co occurring xxmaj dartmouth xxmaj psychiatric xxmaj research xxmaj center xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj lebanon xxmaj new xxmaj hampshire xxup usa xxmaj frontier xxmaj science xxmaj research xxmaj technology xxmaj boston xxmaj massachusetts xxup usa xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj lebanon xxmaj new xxmaj hampshire xxup usa xxmaj department xxmaj psychiatry xxmaj university xxmaj south xxmaj carolina xxmaj columbia xxmaj south xxmaj carolina xxup usa xxmaj department xxmaj psychiatry xxmaj beth xxmaj israel xxmaj deaconess xxmaj medical xxmaj center xxmaj harvard xxmaj medical xxmaj school xxmaj boston xxmaj massachusetts xxup usa xxmaj address correspondence xxmaj mary f xxmaj brunette xxup md xxmaj dartmouth xxmaj psychiatric xxmaj research xxmaj center xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj pleasant xxmaj st nd xxmaj floor xxmaj north xxmaj concord xxup nh xxup usa e mail mary f brunette dartmouth edu xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj up people schizophrenia lifetime co occurring substance use disorder xxmaj alterman xxmaj erdlen xxmaj murphy xxmaj ananth et al xxmaj freed xxmaj kessler et al xxmaj kessler et al xxmaj mueser et al xxmaj cannabis use disorder common co occurring drug use disorder individuals xxmaj kessler et al xxmaj mueser et al xxmaj regier et al lifetime rates ranging dequardo xxmaj carpenter xxmaj tandon xxmaj dixon xxmaj haas xxmaj weiden xxmaj sweeney xxmaj frances xxmaj hambrecht xxmaj hafner xxmaj koskinen xxmaj lohonen xxmaj koponen xxmaj isohanni xxmaj miettunen xxmaj mueser xxmaj bennett xxmaj kushner xxmaj peralta xxmaj cuesta fold increase lifetime prevalence general population xxmaj regier et al xxmaj cannabis use disorder associated clinical exacerbations noncompliance treatment poor global functioning increased relapse rehospitalization rates dequardo et al xxmaj knudsen xxmaj vilmar xxmaj linszen xxmaj dingemans xxmaj lenior xxmaj negrete xxmaj knapp xxmaj douglas xxmaj smith xxmaj peralta xxmaj cuesta xxmaj treffert xxmaj it adds greatly financial costs emotional toll schizophrenia places patients families mental health system e g xxmaj dickey xxmaj azeni xxmaj kivlahan xxmaj heiman xxmaj wright xxmaj mundt xxmaj shupe xxmaj comprehensive psychosocial treatment programs integrate treatments schizophrenia substance including cannabis use disorder developed shown effective population xxmaj drake xxmaj mueser xxmaj brunette mchugo xxmaj nevertheless even abstinence relapse common xxmaj xie mchugo xxmaj fox xxmaj drake moreover almost half patients co occurring disorders continue use substances experience negative consequences months psychosocial treatment xxmaj hence continues need better treatments better understanding role pharmacological treatments co occurring cannabis substance use disorders patients schizophrenia xxmaj while typical antipsychotic medications appear limit cannabis substance use patients schizophrenia xxmaj noordsy o xxmaj keefe xxmaj mueser xxmaj xie preliminary data suggest atypical antipsychotic clozapine may helpful treatment psychotic symptoms also limiting cannabis substance abuse xxmaj case reports retrospective studies small open label prospective study reported reduced substance tobacco use treatment clozapine xxmaj albanese xxmaj khantzian xxmaj murphy xxmaj green xxmaj buckley mccarthy xxmaj chapman xxmaj richman xxmaj yamamoto xxmaj george xxmaj sernyak xxmaj ziedonis xxmaj woods xxmaj lee xxmaj marcus xxmaj snyder mcevoy xxmaj freudenreich xxmaj levin xxmaj rose xxmaj yovell xxmaj opler xxmaj zimmet xxmaj strous xxmaj burgess xxmaj kohnstamm xxmaj green a subsequent study group provided evidence potential role clozapine dual diagnosis patients xxmaj this study naturalistic clinical services survey followed patients co occurring psychotic substance use disorders years xxmaj drake xxmaj xie mchugo xxmaj green xxmaj patients taking clozapine higher rates remission cannabis abuse compared treated typical antipsychotics xxmaj similarly remission alcohol abuse higher patients taking clozapine compared treated typical antipsychotics xxmaj moreover continuing assessment patients whose abuse remitted treated clozapine relapsed abuse following months compared treated antipsychotics xxmaj brunette xxmaj drake xxmaj xie mchugo xxmaj green xxmaj given many side effects clozapine led restriction xxmaj food xxmaj drug xxmaj administration approval use patients treatment refractory psychosis many investigators currently assessing whether atypical antipsychotics share clozapine ability limit substance use patients schizophrenia xxmaj unfortunately available data somewhat xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al mixed overly promising xxmaj green xxmaj noordsy xxmaj brunette o xxmaj keefe risperidone xxmaj green xxmaj burgess xxmaj dawson xxmaj zimmet xxmaj strous xxmaj smelson et al xxmaj smelson et al olanzapine xxmaj akerele xxmaj levin xxmaj brunette et al xxmaj noordsy et al xxmaj petrakis xxmaj leslie xxmaj finney xxmaj rosenheck xxmaj smelson et al quetiapine xxmaj brown xxmaj nejtek xxmaj perantie xxmaj rajan xxmaj thomas xxmaj rush xxmaj brunette o xxmaj keefe xxmaj dawson xxmaj buckley xxmaj green xxmaj potvin et al aripiprazole xxmaj beresford et al xxmaj brown xxmaj jeffress xxmaj liggin xxmaj garza xxmaj beard xxmaj warsi xxmaj sattar xxmaj bhatia xxmaj petty xxmaj thus present clozapine remains antipsychotic medication published research provides consistent evidence substantive decrease cannabis substance use xxmaj we presented neurobiological formulation based animal studies suggesting clozapine unusual clinical effects substance abuse patients schizophrenia may relate varied pharmacological actions dopaminergic particularly noradrenergic systems xxmaj specifically proposed clozapine weak dopamine d receptor blockade coupled activation norepinephrine xxup ne system including antagonistic effects xxup ne receptor ability release xxup ne e g xxmaj antelman xxmaj caggiula xxmaj breier et al xxmaj green et al xxmaj lieberman et al xxmaj rice xxmaj smith xxmaj silk xxmaj rosen xxmaj sarafoff xxmaj davis xxmaj ruther xxmaj svensson et al xxmaj thierry xxmaj godbout xxmaj mantz xxmaj glowinski xxmaj van xxmaj kammen et al may ameliorate dysfunction dopamine mediated brain reward system may underlie common use cannabis substances patients schizophrenia xxmaj green xxmaj zimmet xxmaj strous xxmaj schildkraut xxmaj given consistent albeit still preliminary data clozapine ability decrease substance use patients schizophrenia well published rationale basis effect group launched randomized controlled trial clozapine compared treatment usual cannabis use patients schizophrenia co occurring cannabis use disorder xxup methods xxmaj the study month randomized open label investigation blinded assessments efficacy safety clozapine compared continued current antipsychotic treatment e treatment usual outpatients schizophrenia schizoaffective disorder comorbid cannabis use disorder xxmaj after researchers established participants eligibility baseline blinded raters assessed participants weekly substance use symptoms side effects xxmaj unblinded clinicians prescribed adjusted study medications weekly weeks xxmaj the institutional review boards xxmaj dartmouth xxmaj medical xxmaj school xxmaj university xxmaj south xxmaj carolina approved study xxmaj all procedures consistent xxmaj declaration xxmaj helsinki xxmaj good xxmaj clinical xxmaj practice according xxmaj international xxmaj conference xxmaj harmonization guidelines xxmaj there complete thorough discussion study potential participants participants gave written informed consent prior engaging study procedures xxmaj study xxmaj participants xxmaj participants recruited primarily clinician referral two urban study sites one xxmaj new xxmaj hampshire affiliated xxmaj dartmouth second xxmaj south xxmaj carolina affiliated xxmaj university xxmaj south xxmaj carolina xxmaj inclusion criteria follows xxmaj diagnostic xxmaj statistical xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj manual xxup dsm xxup iv diagnosis schizophrenia schizoaffective disorder current cannabis use disorder cannabis use least days weeks prior screening age outpatient status prior randomization current treatment antipsychotic medication clozapine xxmaj patients taking medications possible effects alcohol use e g naltrexone disulfiram topiramate excluded patients active serious medical illness suicidality severe psychiatric instability xxmaj patients clozapine contraindicated e g white blood cell count mm screening history seizure disorder also excluded xxmaj fifty patients screened xxmaj nine meet eligibility criteria seven withdrew consent four lost follow one left area prior baseline xxmaj thirty one patients proceeded baseline study visit randomized treatment group xxmaj study xxmaj procedures xxmaj once patients deemed eligible randomly assigned one two treatment conditions switching treatment clozapine staying current antipsychotic medication xxmaj randomization blocked site xxmaj for patients switched clozapine study physicians increased dose clozapine flexible manner reach daily dose mg end week xxmaj during titration period dose participants initial antipsychotic medication gradually reduced eliminated within weeks xxmaj dose adjustments clozapine allowed based psychosis symptom response side effects maximum allowed dose clozapine mg per day xxmaj those patients randomized continue receiving current antipsychotic kept steady dose although adjustments allowed address newly emerging symptoms psychosis side effects xxmaj the group research physicians principal investigator xxup aig reviewed pharmacological treatment study participants monthly intervals ensure antipsychotic treatment consistent across study xxmaj participants attended weekly study visits weeks xxmaj unblinded study physicians assessed participants psychosis treatment response adverse events xxmaj trained blinded raters assessed participants cannabis alcohol substance use psychiatric symptoms medication side effects xxmaj experienced study raters trained certified prior rating study patients recertified yearly xxmaj psychosocial treatment psychosis substance use measured monthly xxmaj participants reimbursed gift card completion study visit time travel expenses xxmaj measures xxmaj during screening phase raters used xxmaj structured xxmaj clinical xxmaj interview xxup dsm xxup iv xxmaj axis i xxmaj disorders xxmaj patient xxmaj edition xxmaj first xxmaj spitzer xxmaj gibbon xxmaj williams establish participant diagnoses schizophrenia schizoaffective disorder cannabis substance use disorders xxmaj study physicians completed physical examination laboratory assessment complete blood cell count glucose lipid profile establish participants medical stability xxmaj patients randomized clozapine complete blood cell count repeated weekly participants stayed baseline antipsychotic medication blood drawn weekly complete blood cell count assessments xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al xxmaj blinded raters assessed participant substance use xxmaj timeline xxmaj followback procedure l c xxmaj sobell xxmaj sobell m b xxmaj sobell et al screening baseline weekly course study xxmaj in addition visit participants given breathalyzer test alcohol alcohawk xxmaj pro q xxmaj innovations urine screening drugs xxup acon xxmaj panel xxmaj multi line xxmaj test xxmaj device tetra hydro cannabinol ng ml cocaine ng ml xxmaj blinded interviewers conducted xxmaj timeline xxmaj followback procedure using calendars data urine drug screenings breathalyzer tests facilitate recall substance use past week increase validity self report xxmaj participants asked estimate amount cannabis converted average sized joints used day xxmaj information collateral informants also obtained increase validity self report xxmaj baseline level addiction treatment engagement measured point xxmaj substance xxmaj abuse xxmaj treatment xxmaj scale higher scores indicating progress treatment mchugo xxmaj drake xxmaj burton xxmaj ackerson xxmaj motivation stop using cannabis measured single item xxmaj contemplation xxmaj ladder higher level indicating motivation xxmaj amodei xxmaj lamb xxmaj blinded raters assessed participants symptoms weekly expanded xxmaj brief xxmaj psychiatric xxmaj rating xxmaj scales xxup bprs xxmaj lukoff xxmaj liberman xxmaj nuechterlein weekly xxmaj clinical xxmaj global xxmaj inventories xxup cgi xxmaj guy biweekly use xxmaj schedule xxmaj assessment xxmaj negative xxmaj symptoms xxup sans xxmaj andreasen xxmaj the xxup bprs rated symptom items score item present extremely severe xxmaj the xxup cgi used assess general improvement one item scored much improved much worse xxmaj the xxup sans used assess five negative symptom components scale severe xxmaj unblinded clinicians measured neurologic side effects weekly xxmaj simpson xxmaj angus xxmaj scale xxmaj simpson xxmaj angus xxmaj abnormal xxmaj involuntary xxmaj movement xxmaj scale xxmaj lane xxmaj glazer xxmaj hansen xxmaj berman xxmaj kramer xxmaj barnes xxmaj akathisia xxmaj rating xxmaj scale xxmaj barnes xxmaj at baseline monthly thereafter blinded raters assessed amount services patients received address alcohol use disorder substance use treatment services questionnaire xxmaj clark et al xxmaj study physicians recorded medication dose visit xxmaj dose later converted chlorpromazine equivalents xxmaj gardner xxmaj murphy o xxmaj donnell xxmaj centorrino xxmaj baldessarini xxmaj medication adherence measured weekly pill count xxmaj byerly et al xxmaj data xxmaj analysis xxmaj chi square tests tests used assess whether characteristics participants different groups xxmaj for analyzing repeated measures outcomes used longitudinal random effects xxup lre models xxmaj laird xxmaj ware investigate time varying differences cannabis use outcomes treatment usual clozapine groups xxmaj the main outcome measure intensity cannabis use measured number joints per week xxmaj baseline values measure included models adjust possible differences two groups improve efficiency fixed effects included group linear quadratic trends retained significant alpha level group trend interactions xxmaj the covariance structure modeled using random effects intercept significant trends first order autocorrelation residual errors also specified xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj for primary explanatory analyses data clozapine group censored set missing deviations treatment protocol including greater days missed study medication doses early termination study medication xxmaj secondary explanatory analyses cannabis use also involved censoring poor adherence early termination medication groups xxmaj for intent treat analysis weekly data cannabis use censored hospitalization confinement consecutive days control halo effects use due forced abstinence xxmaj there need censor hospitalization incarceration explanatory analyses data participants already censored due poor adherence xxmaj note participants terminated study medication contributed data xxup lre models time censoring due medication termination whereas participants poorly adherent contributed data weeks took medication except week poor adherence censored week week basis xxup results xxmaj the characteristics study participants noted xxmaj table xxmaj overall participants primarily single unemployed xxmaj caucasian males whose average age years xxmaj participants moderately symptomatic hospitalized multiple times xxmaj the group assigned clozapine education fewer lifetime psychiatric hospitalizations xxmaj most participants diagnoses cannabis dependence rather abuse half also alcohol disorder third another drug use disorder xxmaj measures substance use motivation treatment differ groups xxmaj the characteristics study medication use treatment use shown xxmaj table xxmaj most participants remained study medication study entire weeks xxmaj study medication well tolerated many patients reported side effects shown xxmaj table xxmaj the frequent side effects somnolence hypersalivation weight gain xxmaj patients taking clozapine likely report somnolence hypersalivation constipation patients remained treatment usual xxmaj outcomes xxmaj for primary explanatory analysis two groups differed average intensity cannabis use approximately joints per week main effect xxup lre due group lesser use clozapine group significant within group trends study follow see xxmaj figure xxmaj this result suggests clozapine treatment compared continuation current antipsychotic associated decrease cannabis use effect size although differences small sample reach statistical significance df p xxmaj similar results found using intent treat analysis modest attenuation treatment differences df p xxmaj the secondary explanatory analysis data treatment usual group also censored due poor adherence showed little change estimated difference intensity cannabis use increased slightly joints per week increased standard error due fewer observations df p xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al xxup table xxmaj baseline xxmaj characteristics xxmaj total xxmaj group xxmaj clozapine xxup tau n n n n m xxup sd n m xxup sd n m xxup sd xxmaj age xxmaj sex xxmaj race xxmaj white xxmaj education xxmaj employed xxmaj marital single xxmaj diagnosis schiz vs schizaf xxup bprs xxmaj total xxup bprs xxmaj positive xxup bprs xxmaj negative xxup sans total xxmaj lifetime hospitalizations xxmaj cannabis dependence vs abuse xxmaj days use week xxmaj number joints week xxmaj diagnosis alcohol disorder xxmaj diagnosis drug disorder xxup mh counselor sessions week xxup sa counselor sessions week xxup aa meetings week xxmaj contemplation xxmaj ladder xxup sats xxmaj note xxup tau xxmaj treatment usual schiz schizophrenia schizaf schizoaffective disorder xxup mh mental health xxup sa substance abuse xxup aa xxmaj alcoholics xxmaj anonymous xxup sats substance abuse treatment scale p xxup table xxmaj treatment xxmaj characteristics xxmaj total xxmaj group xxmaj clozapine xxup tau n n n n m xxup sd n m xxup sd n m xxup sd xxmaj medication xxmaj weeks study med xxmaj dose chlorpromazine equivalents xxmaj number ending med early xxmaj good adherence xxmaj other treatment xxup mh counselor sessions week xxup sa counselor sessions week xxup aa meetings week xxmaj note xxup tau xxmaj treatment usual xxup mh mental health xxup sa substance abuse xxup aa xxmaj alcoholics xxmaj anonymous xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxup table xxmaj adverse xxmaj events xxmaj among xxmaj patients xxmaj taking xxmaj clozapine xxmaj versus xxmaj other xxmaj antipsychotics xxmaj cannabis xxmaj disorder xxmaj schizophrenia xxmaj total xxmaj group n xxmaj clozapine n xxup tau xxwrep 4 n xxmaj somnolence xxmaj hypersalivation xxmaj weight gain xxmaj dizziness xxmaj vomiting xxmaj constipation xxmaj dry mouth xxmaj hypertension xxmaj akathisia xxmaj depression xxmaj fatigue xxmaj headache xxmaj insomnia xxmaj nausea xxmaj noncardiac chest pain xxmaj increased agitation xxmaj flu like symptoms xxmaj irritability xxmaj libido decreased xxmaj muscle spasms xxmaj nasal congestion xxmaj unusual dream activity xxmaj suicide attempt xxmaj urinary incontinence xxmaj note xxup tau treatment usual p xxmaj secondary outcomes included symptoms negative positive total xxup bprs composite summary total xxup sans xxup sans subscales affective blunting alogia avolition anhedonia disturbance attention functioning xxup cgi xxmaj data censored deviation protocol secondary explanatory analyses data censored hospitalization incarceration either explanatory intent treat analyses xxmaj in cases two groups differ terms symptoms functioning xxmaj negative linear trends indicating improvement time found total positive xxup bprs xxmaj in subsidiary analysis two groups also compared alcohol use measured heavy drinking days per week heavy drinking defined drinks per day xxmaj censoring carried cannabis use case linear quadratic terms included xxup lre models capture nonlinear trends time xxmaj interestingly significant differences explanatory df p intent treat analyses df p greater alcohol use clozapine group due primarily one participant group drank heavily throughout study xxmaj when data participant removed analyses differences longer significant shown xxmaj figure xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al xxup figure xxmaj intensity cannabis use joints per week patients treatment usual xxup tau patients switched clozapine xxup cloz xxmaj explanatory analysis explanatory analysis xxmaj moreover comparison xxmaj figure xxmaj figure showed important contrast cannabis alcohol results near significant results cannabis use reflect systematic differences two treatment groups alcohol use outlying data removed xxmaj additionally correlation longitudinally changes drinking changes cannabis use time based days heavy drinking per week days cannabis use per week xxmaj last floor effect possible clozapine action heavy drinking given drinking levels low throughout study average fewer day per week one heavy drinker omitted xxmaj this clearly demonstrated xxmaj figure data outlying participant removed analysis xxup figure xxmaj mean heavy drinking days per week patients treatment usual xxup tau patients clozapine xxup cloz xxmaj explanatory analysis xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxup discussion xxmaj this study provides first evidence randomized controlled trial clozapine may limit cannabis use continued treatment antipsychotics patients schizophrenia co occurring cannabis use disorders xxmaj clozapine well tolerated group patients noted side effects types expected medication xxmaj interestingly find differences psychiatric symptoms two groups despite welldescribed beneficial effects clozapine people treatment resistant schizophrenia xxmaj this may reflect overall moderate levels psychiatric symptoms group patients without treatment refractory psychosis xxmaj the magnitude effect clozapine effect size decreasing cannabis use moderate suggesting clinically meaningful role medication population xxmaj but small size study sample limits conclusions drawn xxmaj recruitment patients schizophrenia co occurring cannabis use disorders randomized medication trials challenging requires number sites large recruitment team available study xxmaj given relatively tenuous connection patients may treatment reluctance clinicians referring research studies recruitment team needs carefully integrated within treatment systems a limitation study beyond sample size included fact prescribing physicians blinded study medication xxmaj because clozapine causes characteristic side effects blinding prescribers patients type study tends difficult attempted xxmaj ratings symptoms substance use however completed blinded raters xxmaj nonetheless whether expectancy effects contributed apparent efficacy clozapine reducing cannabis use can not ascertained xxmaj in study patients cannabis use disorders finding clozapine associated improvement heavy alcohol use consistent previous research e g xxmaj brunette et al xxmaj drake et al xxmaj nevertheless lack correlation changes alcohol changes cannabis use suggests decrease noted cannabis use related increase alcohol use patients xxmaj moreover noted two groups differ significantly alcohol use treatment data single participant unusually heavy drinking removed analysis xxmaj the undue influence participant reflects small size sample generally low amount drinking among cannabis using patients xxmaj we note design sample recruited level cannabis alcohol use thus would unexpected find outlying heavy drinking participant one treatment groups half participants diagnosed alcohol use disorder xxmaj taken together alcohol data appear support robustness primary finding clozapine effect cannabis use despite failing replicate similar result alcohol use xxmaj in summary small randomized trial clozapine compared antipsychotics suggests clozapine may reduce cannabis use patients schizophrenia cannabis use disorders independent effect symptoms overall functioning xxmaj although effective treatments cannabis use disorder schizophrenia sorely needed present clozapine side effect profile severely restricts use clinics xxmaj given findings promising consistent previous research effect clozapine cannabis use fully powered blinded clinical trial xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al warranted definitively establish whether clozapine effective treatment cannabis use disorders population xxmaj if demonstrated definitively decrease cannabis use patients schizophrenia may appropriate expand routine use clozapine beyond treatment refractory psychosis include stable outpatients co occurring cannabis use disorder xxup acknowledgments xxmaj this study supported grant xxmaj no xxup da xxmaj national xxmaj institute xxmaj drug xxmaj abuse xxmaj the authors would like thank xxmaj draeger xxmaj medical xxmaj systems loaning electrocardiography machine study xxup disclosures xxmaj none authors report financial relationships commercial interest regard present study xxmaj dr xxmaj brunette received funding research xxmaj bristol xxmaj myers xxmaj squibb xxmaj foundation xxmaj dr xxmaj green reports research grant support past three years xxmaj janssen xxmaj eli xxmaj lilly astrazeneca xxmaj forest xxmaj laboratories xxmaj he currently serves data safety monitoring board xxmaj eli xxmaj lilly studies owns shares stock xxmaj johnson xxmaj johnson xxmaj pfizer xxmaj mylan two pending patents treatment substance abuse xxmaj dr xxmaj narasimhan reports research grant support past three years xxmaj national xxmaj institute xxmaj mental xxmaj health xxmaj national xxmaj institute xxmaj drug xxmaj abuse astrazeneca xxmaj bristol xxmaj myers xxmaj squibb xxmaj janssen xxmaj eli xxmaj lilly xxmaj forest xxmaj laboratories xxmaj she served speaker bureau bristolmyers xxmaj squibb astrazeneca xxmaj eli xxmaj lilly xxmaj merck advisory boards xxmaj eli xxmaj lilly astrazeneca xxmaj dr xxmaj noordsy received research funding consulting speaking honoraria following companies make psychotropic medications astrazeneca xxmaj bristol xxmaj myers xxmaj squibb xxmaj janssen xxmaj eli xxmaj lilly xxmaj lundbeck xxmaj novartis xxmaj merck xxmaj sunovion xxup references xxmaj akerele e xxmaj levin f r xxmaj comparison olanzapine risperidone substance abusing individuals schizophrenia xxmaj american xxmaj journal xxmaj addictions xxmaj albanese m j xxmaj khantzian e j xxmaj murphy s l xxmaj green a i xxmaj decreased substance use chronically psychotic patients treated clozapine xxmaj american xxmaj journal xxmaj psychiatry xxmaj alterman a j xxmaj erdlen f r xxmaj murphy e xxmaj alcohol abuse psychiatric hospital population xxmaj addictive xxmaj behaviors xxmaj amodei n xxmaj lamb r j xxmaj convergent concurrent validity xxmaj contemplation xxmaj ladder xxup urica scales xxmaj drug xxmaj alcohol xxmaj dependence xxmaj ananth j xxmaj vandewater s xxmaj kamal m xxmaj brodsky a xxmaj gamal r xxmaj miller m xxmaj missed diagnosis substance abuse psychiatric patients xxmaj hospital xxmaj community xxmaj psychiatry xxmaj andreasen n c xxmaj negative symptoms schizophrenia xxmaj archives xxmaj general xxmaj psychiatry xxmaj antelman s m xxmaj caggiula a r xxmaj norepinephrine dopamine interactions behavior xxmaj science xxmaj barnes t r a rating scale drug induced akathisia xxmaj the xxmaj british xxmaj journal xxmaj psychiatry xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj beresford t p xxmaj clapp l xxmaj martin b xxmaj wiberg j l xxmaj alfers j xxmaj beresford h f xxmaj aripiprazole schizophrenia cocaine dependence a pilot study xxmaj journal xxmaj clinical xxmaj psychiatry xxmaj breier a xxmaj buchanan r w xxmaj waltrip nd r w xxmaj listwak s xxmaj holmes c xxmaj goldstein d s xxmaj the effect clozapine plasma norepinephrine xxmaj relationship clinical efficacy xxmaj neuropsychopharmacology xxmaj brown e s xxmaj jeffress j xxmaj liggin j d m xxmaj garza m xxmaj beard l xxmaj switching outpatients bipolar schizoaffective disorders substance abuse current antipsychotic aripiprazole xxmaj journal xxmaj clinical xxmaj psychiatry xxmaj brown e s xxmaj nejtek v a xxmaj perantie d c xxmaj rajan xxmaj thomas n xxmaj rush a j xxmaj cocaine amphetamine use patients psychiatric illness a randomized trial typical antipsychotic continuation discontinuation xxmaj journal xxmaj clinical xxmaj psychopharmacology xxmaj brunette m f xxmaj drake r e xxmaj xie h mchugo g j xxmaj green a i xxmaj clozapine use relapses substance use disorder among patients co occurring schizophrenia substance use disorders xxmaj schizophrenia xxmaj bulletin xxmaj brunette m f o xxmaj keefe c xxmaj dawson r xxmaj buckley p xxmaj green a i xxmaj an open label study quetiapine patients schizophrenia alcohol disorders xxmaj journal xxmaj mental xxmaj health xxmaj substance xxmaj use xxmaj disorders xxmaj brunette m f o xxmaj keefe c xxmaj zimmet s xxmaj wojcik j d xxmaj dawson r xxmaj green a i xxmaj olanzapine alcohol use disorder patients schizophrenia xxmaj journal xxmaj dual xxmaj diagnosis xxmaj buckley p mccarthy m xxmaj chapman p xxmaj richman c xxmaj yamamoto b xxmaj clozapine treatment comorbid substance abuse patients schizophrenia xxmaj schizophrenia xxmaj research xxmaj byerly m j xxmaj thompson a xxmaj carmody t xxmaj bugno r xxmaj ervin t xxmaj kashner m xxmaj rush a j xxmaj validity electronically monitored medication adherence conventional adherence measures schizophrenia xxmaj psychiatric xxmaj services xxmaj clark r xxmaj teague g xxmaj ricketts s xxmaj bush p xxmaj zubkoff m xxmaj keller a xxmaj measuring resource use economic evaluations xxmaj determining social costs mental illness xxmaj journal xxmaj mental xxmaj health xxmaj administration dequardo j r xxmaj carpenter c f xxmaj tandon r xxmaj patterns substance abuse schizophrenia xxmaj nature significance xxmaj journal xxmaj psychiatric xxmaj research xxmaj dickey b xxmaj azeni h xxmaj persons dual diagnoses substance abuse major mental illness xxmaj their excess costs psychiatric care xxmaj american xxmaj journal xxmaj public xxmaj health xxmaj dixon l xxmaj haas g xxmaj weiden p j xxmaj sweeney j xxmaj frances a j xxmaj drug abuse schizophrenic patients xxmaj clinical correlates reasons use xxmaj american xxmaj journal xxmaj psychiatry xxmaj drake r e xxmaj mueser k t xxmaj brunette m f mchugo g j a review treatment people severe mental illness co occurring substance use disorders xxmaj psychchiatricl xxmaj rehabilitation xxmaj journal xxmaj drake r e xxmaj xie h mchugo g j xxmaj green a i xxmaj the effects clozapine alcohol drug use disorders among patients schizophrenia xxmaj schizophrenia xxmaj bulletin xxmaj first m b xxmaj spitzer r l xxmaj gibbon m xxmaj williams j b w xxmaj structured xxmaj clinical xxmaj interview xxup dsm xxup iv xxmaj axis i xxmaj disorders xxmaj patient xxmaj edition xxup scid i p xxmaj version xxmaj new xxmaj york xxup ny xxmaj biometrics xxmaj research xxmaj department xxmaj freed e x xxmaj alcoholism schizophrenia xxmaj the search perspectives xxmaj journal xxmaj studies xxmaj alcohol xxmaj gardner d m xxmaj murphy a l o xxmaj donnell h xxmaj centorrino f xxmaj baldessarini r j xxmaj international consensus study antipsychotic dosing xxmaj american xxmaj journal xxmaj psychiatry xxmaj george t p xxmaj sernyak m j xxmaj ziedonis d xxmaj woods s m xxmaj effects clozapine smoking chronic schizophrenic outpatients xxmaj journal xxmaj clinical xxmaj psychiatry xxmaj green a i xxmaj alam m y xxmaj sobieraj j t xxmaj pappalardo k m xxmaj waternaux c xxmaj salzman c xxmaj schildkraut j j xxmaj clozapine response plasma catecholamines metabolites xxmaj psychiatry xxmaj research xxmaj green a i xxmaj burgess e s xxmaj dawson r xxmaj zimmet s v xxmaj strous r d xxmaj alcohol cannabis use schizophrenia xxmaj effects clozapine vs risperidone xxmaj schizophrenia xxmaj research xxmaj green a i xxmaj noordsy d l xxmaj brunette m f o xxmaj keefe c xxmaj substance abuse schizophrenia xxmaj pharmacotherapeutic intervention xxmaj journal xxmaj substance xxmaj abuse xxmaj treatment xxmaj green a i xxmaj zimmet s v xxmaj strous r d xxmaj schildkraut j j xxmaj clozapine comorbid substance use disorder schizophrenia xxmaj do patients schizophrenia reward deficiency syndrome ameliorated clozapine xxmaj harvard xxmaj review xxmaj psychiatry xxmaj guy w xxup ecdeu xxmaj assessment xxmaj manual xxmaj psychopharmacology xxmaj rockville xxup md u s xxmaj department xxmaj health xxmaj education xxmaj welfare xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al xxmaj hambrecht m xxmaj hafner h xxmaj substance abuse onset schizophrenia xxmaj biological xxmaj psychiatry xxmaj kessler r c xxmaj birnbaum h xxmaj demler o xxmaj falloon i r h xxmaj gagnon e xxmaj guyer m xxmaj wu e q xxmaj the prevalence correlates nonaffective psychosis xxmaj national xxmaj comorbidity xxmaj survey xxmaj replication xxup ncs r xxmaj biological xxmaj psychiatry xxmaj kessler r c mcgonagle k a xxmaj zhao s xxmaj nelson c b xxmaj hughes m xxmaj eshleman s xxmaj kendler k s xxmaj lifetime month prevalence xxup dsm xxup iii r psychiatric disorders xxmaj united xxmaj states xxmaj results xxmaj national xxmaj comorbidity xxmaj survey xxmaj archives xxmaj general xxmaj psychiatry xxmaj kivlahan d r xxmaj heiman j r xxmaj wright r c xxmaj mundt j w xxmaj shupe j a xxmaj treatment cost rehospitalization rate schizophrenic outpatients history substance abuse xxmaj hospital xxmaj community xxmaj psychiatry xxmaj knudsen p xxmaj vilmar t xxmaj cannabis neuroleptic agents schizophrenia xxmaj acta xxmaj psychiatrica xxmaj scandinavica xxmaj koskinen j xxmaj lohonen j xxmaj koponen h xxmaj isohanni m xxmaj miettunen j xxmaj rate cannabis use disorders clinical samples patients schizophrenia a meta analysis xxmaj schizophrenia xxmaj bulletin xxmaj laird n m xxmaj ware j h xxmaj random effects models longitudinal data xxmaj biometrics xxmaj lane r d xxmaj glazer w m xxmaj hansen t e xxmaj berman w h xxmaj kramer s i xxmaj assessment tardive dyskinesia using xxmaj abnormal xxmaj involuntary xxmaj movement xxmaj scale xxmaj journal xxmaj nervous xxmaj mental xxmaj disease xxmaj lee m l xxmaj clozapine substance abuse patients schizophrenia xxmaj canadian xxmaj journal xxmaj psychiatry xxmaj lieberman j xxmaj johns c xxmaj pollack s xxmaj masiar s xxmaj bookstein p xxmaj cooper t xxmaj kane j xxmaj biochemical effects clozapine cerebrospinal fluid patients schizophrenia xxmaj in c xxmaj tamminga s xxmaj schulz xxmaj eds xxmaj advances neuropsychiatry psychopharmacology vol xxmaj schizophrenia research pp xxmaj new xxmaj york xxup ny xxmaj raven xxmaj press xxmaj linszen d xxmaj dingemans p xxmaj lenior m xxmaj cannabis abuse course recent onset schizophrenic disorders xxmaj archives xxmaj general xxmaj psychiatry xxmaj lukoff k xxmaj liberman r xxmaj nuechterlein k xxmaj symptom monitoring rehabilitation schizophrenic patients xxmaj schizophrenia xxmaj bulletin xxmaj marcus p xxmaj snyder r xxmaj reduction comorbid substance abuse clozapine letter xxmaj american xxmaj journal xxmaj psychiatry mcevoy j p xxmaj freudenreich o xxmaj levin e xxmaj rose j e xxmaj haloperidol increases smoking patients schizophrenia xxmaj psychopharmacology mchugo g j xxmaj drake r e xxmaj burton h l xxmaj ackerson t h a scale assessing stage substance abuse treatment persons severe mental illness xxmaj journal xxmaj nervous xxmaj mental xxmaj disease xxmaj mueser k t xxmaj bennett m xxmaj kushner m g xxmaj epidemiology substance use disorders among persons chronic mental illness xxmaj in a f xxmaj lehman l b xxmaj dixon xxmaj eds xxmaj double jeopardy xxmaj chronic mental illness substance use disorders pp xxmaj new xxmaj york xxup ny xxmaj harwood xxmaj mueser k t xxmaj yarnold p r xxmaj levinson d f xxmaj singh h xxmaj bellack a s xxmaj kee k xxmaj yadalam k g xxmaj prevalence substance abuse schizophrenia xxmaj demographic clinical correlates xxmaj schizophrenia xxmaj bulletin xxmaj negrete j c xxmaj knapp w p xxmaj douglas d e xxmaj smith w b xxmaj cannabis affects severity schizophrenic symptoms xxmaj results clinical survey xxmaj psychology xxmaj medicine xxmaj noordsy d l o xxmaj keefe c xxmaj mueser k t xxmaj xie h xxmaj six month outcomes patients switched olanzapine treatment xxmaj psychiatric xxmaj services xxmaj peralta v xxmaj cuesta m j xxmaj influence cannabis abuse schizophrenic psychopathology xxmaj acta xxmaj psychiatrica xxmaj scandinavica xxmaj petrakis i l xxmaj leslie d xxmaj finney j w xxmaj rosenheck r xxmaj atypical antipsychotic medication substance use related outcomes treatment schizophrenia xxmaj the xxmaj american xxmaj journal xxmaj addictions xxmaj potvin s xxmaj stip e xxmaj lipp o xxmaj elie r xxmaj mancinin xxmaj marie a xxmaj demers m f xxmaj gendron a xxmaj quetiapine patients comorbid schizophrenia spectrum substance use disorders xxmaj an open label trial xxmaj current xxmaj medical xxmaj research xxmaj opinion xxmaj regier d a xxmaj farmer m e xxmaj rae d s xxmaj locke b z xxmaj keith s j xxmaj judd l l xxmaj goodwin f k xxmaj comorbidity mental disorders alcohol drug abuse xxmaj results xxmaj epidemiologic xxmaj catchment xxmaj area xxup eca xxmaj study comment xxmaj journal xxmaj american xxmaj medical xxmaj association xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj rice h e xxmaj smith c b xxmaj silk k r xxmaj rosen j xxmaj platelet alpha adrenergic receptors schizophrenic patients phenothiazine treatment xxmaj psychiatry xxmaj research xxmaj sarafoff m xxmaj davis l xxmaj ruther e xxmaj clozapine induced increase human plasma norepinephrine xxmaj journal xxmaj neural xxmaj transmission xxmaj simpson g n xxmaj angus j w s a rating scale extrapyramidal side effects xxmaj acta xxmaj psychiatrica xxmaj scandinavica suppl xxmaj smelson d a xxmaj losonczy m f xxmaj davis c w xxmaj kaune m xxmaj williams j xxmaj ziedonis d xxmaj risperidone decreases craving relapses individuals schizophrenia cocaine dependence xxmaj canadian xxmaj journal xxmaj psychiatry xxmaj smelson d a xxmaj williams j xxmaj ziedonis d xxmaj sussner b d xxmaj losonczy m f xxmaj engelhart c xxmaj kaune m a double blind placebo controlled pilot study risperidone decreasing cue elicited craving recently withdrawn cocaine dependent patients xxmaj journal xxmaj substance xxmaj abuse xxmaj treatment xxmaj smelson d a xxmaj ziedonis d xxmaj williams j xxmaj losonczy m f xxmaj steinberg m l xxmaj kaune m xxmaj the efficacy olanzapine decreasing cue elicited craving individuals schizophrenia cocaine dependence a preliminary report xxmaj journal xxmaj clinical xxmaj psychopharmacology xxmaj sobell m b xxmaj maisto s a xxmaj sobell l c xxmaj cooper a m xxmaj cooper t xxmaj saungers b xxmaj developing prototype evaluating alcohol treatment effectiveness xxmaj in l c xxmaj sobell m b xxmaj sobell e xxmaj ward xxmaj eds xxmaj evaluating alcohol drug abuse treatment effectiveness xxmaj recent advances pp xxmaj new xxmaj york xxup ny xxmaj pergamon xxmaj sobell l c xxmaj sobell m b xxmaj timeline xxmaj follow xxmaj back a technique assessing self reported alcohol consumption xxmaj in r z xxmaj litten j xxmaj allen xxmaj eds xxmaj measuring alcohol consumption xxmaj psychosocial biological methods pp xxmaj totowa xxup nj xxmaj humana xxmaj press xxmaj svensson t h xxmaj mathe j m xxmaj andersson j l xxmaj nomikos g g xxmaj hildebrand b e xxmaj marcus m xxmaj mode action atypical neuroleptics relation phencyclidine model schizophrenia xxmaj role xxup ht receptor alpha adrenoceptor antagonism xxmaj journal xxmaj clinical xxmaj psychopharmacology suppl s s xxmaj thierry a m xxmaj godbout r xxmaj mantz j xxmaj glowinski j xxmaj influence ascending monoaminergic systems activity rat prefrontal cortex xxmaj progress xxmaj brain xxmaj research discussion xxmaj treffert d a xxmaj marijuana use schizophrenia a clear hazard xxmaj american xxmaj journal xxmaj psychiatry xxmaj van xxmaj kammen d p xxmaj peters j l xxmaj van xxmaj kammen w b xxmaj neylan t xxmaj yao j k xxmaj shaw d xxmaj doherty g xxmaj noradrenaline state dependency relapse prediction schizophrenia xxmaj in m xxmaj weller xxmaj ed xxmaj international perspectives schizophrenia pp xxmaj london xxmaj england xxmaj john xxmaj libbey xxmaj warsi m xxmaj sattar s p xxmaj bhatia s c xxmaj petty f xxmaj aripiprazole reduces alcohol use xxmaj canadian xxmaj journal xxmaj psychiatry xxmaj xie h mchugo g j xxmaj fox m xxmaj drake r e xxmaj substance abuse relapses year prospective follow clients co occurring severe mental illness substance use disorders xxmaj psychiatric xxmaj services xxmaj yovell y xxmaj opler l a xxmaj clozapine reverses cocaine craving treatment resistant mentally ill chemical abuser a case report hypothesis xxmaj journal xxmaj nervous xxmaj mental xxmaj disorders xxmaj zimmet s v xxmaj strous r d xxmaj burgess e s xxmaj kohnstamm s xxmaj green a i xxmaj effects clozapine substance use patients schizophrenia schizoaffective disorder a retrospective survey xxmaj journal xxmaj clinical xxmaj psychopharmacology xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december,xxbos xxmaj use sublingual buprenorphine pain relief office hysteroscopy xxmaj yu xxmaj hung xxmaj lin xxup md xxmaj jiann xxmaj loung xxmaj hwang xxup md xxmaj lee xxmaj wen xxmaj huang xxup md xxmaj xxunk xxmaj ju xxmaj chen xxup md xxmaj from xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj shin xxmaj kong xxmaj wu xxmaj ho xxmaj su xxmaj memorial xxmaj hospital xxmaj taipei xxmaj taiwan xxmaj all authors xxmaj college xxmaj medicine xxmaj fu xxmaj jen xxmaj catholic xxmaj university xxmaj taipei xxmaj taiwan xxmaj drs xxmaj lin xxmaj huang xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj taipei xxmaj medical xxmaj university xxmaj taipei xxmaj taiwan xxmaj dr xxmaj huang xxmaj abstract xxup study xxup objective xxmaj to assess efficacy sublingual buprenorphine relief pain associated office hysteroscopy xxup design xxmaj prospective randomized study xxmaj canadian xxmaj task xxmaj force classification i xxup setting xxmaj tertiary medical center xxup patients xxmaj one hundred sixty four women referred office hysteroscopy xxmaj september xxmaj march xxup intervention xxmaj before hysteroscopy women received tablet buprenorphine group a women received placebo group b xxmaj their pain sensations evaluated cm visual analog scale asked adverse reactions level satisfaction following day xxup measurements xxup and xxup main xxup results xxmaj the pain score group a similar group b xxmaj the pain scores subgroups women also similar within group two groups xxmaj thirty one women group a reported adverse reactions including nausea vomiting drowsiness none group b reported adverse reactions xxup conclusion xxmaj office hysteroscopy mm flexible hysteroscope well tolerated procedure xxmaj sublingual buprenorphine helpful relieving pain associated hysteroscopy associated significant adverse reactions xxup aagl xxmaj all rights reserved xxup key xxup words xxmaj buprenorphine xxmaj hysteroscope xxmaj analgesia xxmaj hysteroscopy allows direct visualization uterine cavity directed biopsy regarded gold standard investigation intrauterine abnormalities xxmaj although generally well tolerated associated certain degree pain possible vasovagal reaction xxmaj actually pain common reason failure complete procedure xxmaj in outpatient hysteroscopies reported required local anesthesia failed due excessive discomfort xxmaj various methods analgesia proposed suppress pain associated hysteroscopy general anesthesia paracervical block intracervical injection lidocaine spray intrauterine instillation lignocaine xxmaj however results controversial established guidelines use analgesia office hysteroscopy xxmaj buprenorphine potent safe opioid analgesic xxmaj corresponding author xxmaj jiann xxmaj loung xxmaj hwang xxup md xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj shin xxmaj kong xxmaj wu xxmaj ho xxmaj su xxmaj memorial xxmaj hospital xxmaj no xxmaj wen xxmaj chang xxmaj road xxmaj shih xxmaj lin xxmaj district xxmaj taipei xxmaj taiwan e mail ms xxunk org tw xxmaj submitted xxmaj december xxmaj accepted xxmaj march see front matter xxup aagl xxmaj all rights reserved doi j jmig xxmaj journal xxmaj minimally xxmaj invasive xxmaj gynecology partial agonist antagonist actions xxmaj as analgesic buprenorphine used relief moderate severe pain xxmaj compared morphine buprenorphine provides adequate postoperative analgesia longer duration analgesic potency parenteral buprenorphine times parenteral morphine xxmaj in series patients receiving buprenorphine immediate postoperative period patients good adequate pain relief xxmaj buprenorphine also used provide preoperative sedation analgesia adjunct surgical anesthesia xxmaj its anxiolytic sedative properties make suitable preoperative medication xxmaj buprenorphine given xxunk well parenterally xxmaj it readily absorbed following sublingual administration xxmaj although maximal effect reached later sublingual administration provides longer duration action cause discomfort administered parenteral routes xxmaj in order assess efficacy sublingual buprenorphine relief pain hysteroscopy conducted prospective randomized study double blind conditions xxmaj materials methods xxmaj from xxmaj september xxmaj march women referred office hysteroscopy included study xxmaj the study approved medical ethics committee hospital xxmaj the patients randomized computergenerated numbers receive buprenorphine xxmaj xxunk xxmaj xxunk xxmaj xxunk xxmaj hull xxup uk group a placebo group b xxmaj every woman put tablet buprenorphine mg placebo tongue minutes procedure xxmaj indications hysteroscopy included abnormal uterine bleeding suspected intracavitary lesion uterine synechiae endometrial hyperplasia endometrial polyp submucosal myoma infertility xxmaj all procedures performed physician xxup xxunk using flexible hysteroscope mm outer diameter bending section degrees xxmaj olympus xxup xxunk xxmaj type xxup xp xxmaj tokyo xxmaj japan xxmaj the uterine cavity distended dextrose solution hung cm operating table xxmaj illumination provided w high intensity cold light source xxmaj no tenaculum cervical dilatation used procedures xxmaj during procedure patients observed pain sensations evaluated nurse using cm visual analog scale xxup vas xxmaj for patient worst expression whole procedure recorded pain score xxmaj on day procedure patients asked evaluate level satisfaction satisfied little satisfied satisfied xxmaj all results expressed mean xxup sd unless otherwise stated xxmaj statistical significance assessed independent test xxmaj fisher exact test test appropriate xxup spss software xxmaj statistical xxmaj package xxmaj social xxmaj science xxmaj windows version xxup spss xxmaj inc xxmaj chicago xxup il used statistical analysis a p value considered statistically significant xxmaj results xxmaj from xxmaj september xxmaj march women underwent office hysteroscopy hospital xxmaj the procedure failed women cervical stenosis xxmaj these women underwent repeat hysteroscopy general anesthesia xxmaj none procedures discontinued intolerable pain xxmaj therefore enrolled women study xxmaj thirty seven postmenopausal xxmaj the indications hysteroscopy abnormal uterine bleeding infertility intracavitary tumor lesion myoma polyp others xxmaj among women women received buprenorphine group a received placebo group b xxmaj as shown xxmaj table significant differences patients characteristics including mean age number nulliparous multiparous postmenopausal women xxmaj the xxup vas pain scores shown xxmaj table xxmaj the mean pain score group a similar group b xxmaj the pain scores various subgroups women including postmenopausal nulliparous multiparous women also similar within group two groups xxmaj for patients worst discomfort related insertion speculum hysteroscopy per se xxmaj in group a women reported adverse reactions associated procedure xxmaj among reported nausea vomiting reported drowsiness reported xxmaj none women group b reported discomfort adverse effects xxmaj no woman experienced vagal reactions xxmaj table shows levels satisfaction xxmaj women group b satisfied procedure xxmaj thirty women group a satisfied procedure adverse effects xxmaj table xxmaj patient characteristics xxmaj with buprenorphine n xxmaj without buprenorphine n p xxmaj mean age yrs xxup ns xxmaj no premenopausal xxup ns xxmaj nulliparous xxup ns xxmaj multiparous xxup ns xxmaj no postmenopausal xxup ns xxup ns significant independent test test xxmaj journal xxmaj minimally xxmaj invasive xxmaj gynecology xxmaj vol xxmaj no xxmaj july xxmaj august xxmaj discussion xxmaj pain associated hysteroscopy occurs insertion speculum dilatation cervix insertion hysteroscope distention uterine cavity distention medium direct stimulation uterine wall hysteroscope xxmaj also use tenaculum biopsy may also cause pain xxmaj office hysteroscopy may painful even performed experienced surgeon nontraumatic technique xxmaj in fact single common reason failure hysteroscopy pain xxmaj the effect local analgesia office hysteroscopy inconclusive xxmaj although studies demonstrated paracervical block reduced pain others reveal beneficial effect xxmaj in addition paracervical block carries potential complications infection bleeding toxicity intravasation systemic absorption sacral plexus trauma xxmaj one study showed intracervical injection helpful women found injection painful part procedure xxmaj the afferent innervations upper lower parts uterus differ course source xxmaj afferent fibers conducting pain impulses fundus body follow sympathetic fibers t t afferent fibers cervix follow parasympathetic fibers s s xxmaj therefore injection local analgesic around cervix blocks pain arising cervix block pain originating uterine cavity xxmaj we speculated systemic administration analgesics might effective local analgesics relieving pain associated hysteroscopy xxmaj buprenorphine narcotic analgesic given sublingual route easier patients physicians cause discomfort associated local injection xxmaj in study however found buprenorphine benefit reducing pain associated hysteroscopy xxmaj the mean xxup vas pain scores similar group a group b xxmaj the mean pain scores subgroups also similar within group groups a b xxmaj this indicates flexible hysteroscopy well tolerated procedure even without analgesia taking buprenorphine beforehand beneficial effect xxmaj in study performed researchers using mm flexible hysteroscope without anesthesia women experienced little pain a study using mm flexible hysteroscope also found procedure well tolerated xxmaj in study mean pain score higher postmenopausal women xxmaj however study mean pain scores similar premenopausal postmenopausal women either without buprenorphine xxmaj the adverse effects buprenorphine similar morphine meperidine xxmaj in large series xxmaj caucasian patients receiving mg buprenorphine postoperatively nausea developed vomiting developed xxmaj however xxmaj chinese patients seem sensitive buprenorphine xxmaj in study women reported nausea vomiting taking buprenorphine xxmaj sedation including drowsiness common adverse effect parenteral buprenorphine occurring approximately two thirds patients xxmaj in study women developed drowsiness xxmaj the high incidence adverse reactions associated buprenorphine reflected high level dissatisfaction patients group a xxmaj conclusion xxmaj office hysteroscopy mm flexible hysteroscope well tolerated procedure xxmaj nearly patients found procedure acceptable even without analgesia xxmaj buprenorphine beneficial relieving pain associated high adverse effects lower level satisfaction xxmaj references xxmaj nagele f xxmaj connor xxup ho xxmaj davies a et al outpatient diagnostic hysteroscopies xxmaj obstet xxmaj gynecol xxmaj lau xxup wc xxmaj lo xxup wk xxmaj tam xxup wh et al xxmaj paracervical anaesthesia outpatient hysteroscopy randomized double blind placebo controlled trial xxmaj br j xxmaj obstet xxmaj gynaecol xxmaj cicinelli e xxmaj didonna t xxmaj schonauer xxup lm et al xxmaj paracervical anesthesia hysteroscopy endometrial biopsy post menopausal women j xxmaj reprod xxmaj med xxmaj broadbent xxup jam xxmaj hill xxup ncw xxmaj molnar xxup bg et al xxmaj randomized placebo controlled trial assess role intracervical lignocaine outpatient hysteroscopy xxmaj br j xxmaj obstet xxmaj gynaecol xxmaj table xxmaj pain scores xxup vas according subgroups xxmaj with buprenorphine n xxmaj without buprenorphine n p xxmaj whole group xxup ns xxmaj premenopausal xxup ns xxmaj nulliparous xxup ns xxmaj multiparous xxup ns xxmaj postmenopausal xxup ns xxup ns significant independent test xxup vas visual analog scale xxmaj table xxmaj level satisfaction xxmaj with buprenorphine xxmaj no n xxmaj without buprenorphine xxmaj no n xxmaj not satisfied a little satisfied xxmaj very satisfied p xxmaj fisher exact test xxmaj lin et al xxmaj use buprenorphine office hysteroscopy xxmaj davis a xxmaj richardson xxup mb o xxmaj connor h et al xxmaj lidocaine aerosol spray outpatient hysteroscopy randomized double blind placebo controlled trial xxmaj fertil xxmaj steril xxmaj soriano d xxmaj ajaj s xxmaj chuong t et al xxmaj lidocaine spray outpatient hysteroscopy randomized placebo controlled trial xxmaj obstet xxmaj gynecol xxmaj lau xxup wc xxmaj tam xxup wh xxmaj lo xxup wk et al a randomised double blind placebocontrolled trial transcervical intrauterine local anaesthesia xxunk hysteroscopy xxmaj br j xxmaj obstet xxmaj gynecol xxmaj yang j xxmaj vollenhoven b xxmaj pain control outpatient hysteroscopy xxmaj obstet xxmaj gynecol xxmaj surv xxmaj heel xxup rc xxmaj brogden xxup rn xxmaj speight xxup tm et al xxmaj buprenorphine review pharmacological properties therapeutic efficacy xxmaj drugs xxmaj xxunk xxup ah xxmaj ward xxup ae xxmaj smith xxup dw xxmaj buprenorphine postoperative pain results patients xxmaj anaesthesia xxmaj sear xxup jw xxmaj alexander xxup ji xxmaj comparison buprenorphine hyoscine papaveretum hyoscine xxunk gynaecological surgery xxmaj br j xxmaj anaesth xxmaj edge xxup wg xxmaj cooper xxup gm xxmaj morgan m xxmaj analgesic effects sublingual buprenorphine xxmaj anaesthesia xxmaj de xxmaj iaco p xxmaj marabini a xxmaj stefanetti m xxmaj acceptability pain outpatient hysteroscopy j xxmaj am xxmaj assoc xxmaj gynecol xxmaj laparosc xxmaj nagele f xxmaj lockwood g xxmaj magos xxup al xxmaj randomized placebo controlled trial mefenamic acid premedication outpatient hysteroscopy pilot study xxmaj brit j xxmaj obstet xxmaj gynaecol xxmaj vercellini p xxmaj colombo a xxmaj mauro f et al xxmaj paracervical anesthesia outpatient hysteroscopy xxmaj fertil xxmaj steril xxmaj anatomy reproductive tract women xxmaj in xxmaj cunningham xxup fg xxmaj xxunk xxup nf xxmaj xxunk xxup kj et al eds xxmaj williams xxmaj obstetrics st ed xxmaj new xxmaj york xxup ny mcgraw xxmaj hill xxmaj kremer c xxmaj xxunk s xxmaj duffy s xxmaj flexible outpatient hysteroscopy without anesthesia safe successful well tolerated procedure xxmaj br j xxmaj obstet xxmaj gynaecol xxmaj agostini a xxmaj bretelle f xxmaj cravello l et al xxmaj acceptance outpatient flexible hysteroscopy premenopausal postmenopausal women j xxmaj reprod xxmaj med xxmaj paul xxmaj walsh xxmaj physicians xxmaj desk xxmaj reference th ed xxmaj montvale xxup nj xxmaj medical xxmaj economics xxmaj company xxmaj inc xxmaj journal xxmaj minimally xxmaj invasive xxmaj gynecology xxmaj vol xxmaj no xxmaj july xxmaj august,xxbos xxmaj evidence xxmaj suggesting xxmaj that xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program xxmaj can xxmaj improve xxmaj health xxmaj status xxmaj while xxmaj reducing xxmaj hospitalization a xxmaj randomized xxmaj trial xxmaj author xxmaj kate r xxmaj lorig xxmaj david s xxmaj sobel xxmaj anita l xxmaj stewart xxmaj byron xxmaj william xxmaj brown xxmaj jr xxmaj albert xxmaj bandura xxmaj philip xxmaj ritter xxmaj virginia m xxmaj gonzalez xxmaj diana d xxmaj laurent xxmaj halsted r xxmaj holman xxmaj reviewed work xxmaj source xxmaj medical xxmaj care xxmaj vol xxmaj no xxmaj jan pp xxmaj published xxmaj lippincott xxmaj williams xxmaj wilkins xxmaj stable xxup url http www jstor org stable xxmaj accessed xxmaj your use xxup jstor archive indicates acceptance xxmaj terms xxmaj conditions xxmaj use available http www jstor org page info policies terms jsp xxup jstor profit service helps scholars researchers students discover use build upon wide range content trusted digital archive xxmaj we use information technology tools increase productivity facilitate new forms scholarship xxmaj for information xxup jstor please contact support jstor org xxmaj lippincott xxmaj williams xxmaj wilkins collaborating xxup jstor digitize preserve extend access xxmaj medical xxmaj care http www jstor org xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup medical xxup care xxmaj volume xxmaj number pp xxmaj lippincott xxmaj williams xxmaj wilkins xxmaj evidence xxmaj suggesting xxmaj that xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program xxmaj can xxmaj improve xxmaj health xxmaj status xxmaj while xxmaj reducing xxmaj hospitalization a xxmaj randomized xxmaj trial xxup kate r xxup lorig xxup rn xxup xxunk xxup david s xxup sobel xxup md xxup mph xxup anita l xxup stewart xxup phd xxup byron xxup william xxup brown xxup jr xxup phd xxup albert xxup bandura xxup phd xxup philip xxup ritter xxup phd xxup virginia m xxup gonzalez xxup mph xxup diana d xxup laurent xxup mph xxup and xxup halsted r xxup holman xxup md xxup objectives xxmaj this study evaluated effectiveness changes health behaviors health status health service utilization self management program chronic disease designed use heterogeneous group chronic disease patients xxmaj it also explored differential effectiveness intervention subjects specific diseases comorbidities xxup methods xxmaj the study six month randomized controlled trial communitybased sites comparing treatment subjects wait list control subjects xxmaj participants patients years age older physician confirmed diagnosis heart disease lung disease stroke arthritis xxmaj health behaviors health status health service utilization determined mailed self administered questionnaires measured xxup results xxmaj treatment subjects compared control subjects demonstrated xxmaj as average age population increases prevalence chronic disease xxmaj it estimated people aged years older average chronic conditions xxmaj chronic disease responsible almost health care expenditures xxmaj from xxmaj stanford xxmaj university xxmaj school xxmaj medicine xxmaj stanford xxmaj california tfrom xxmaj kaiser xxmaj permanente xxmaj northern xxmaj california xxmaj region xxmaj xxunk xxmaj california tfrom xxmaj university xxmaj california xxmaj san xxmaj francisco xxmaj institute xxmaj health xxmaj aging xxmaj san xxmaj francisco xxmaj california xxmaj from xxmaj department xxmaj psychology xxmaj stanford xxmaj university xxmaj stanford xxmaj california improvements months weekly minutes exercise frequency cognitive symptom management communication physicians self reported health health distress fatigue disability social role activities limitations xxmaj they also fewer hospitalizations days hospital xxmaj no differences found pain physical discomfort shortness breath psychological well xxup conclusions xxmaj an intervention designed specifically meet needs heterogeneous group chronic disease patients including comorbid conditions feasible beneficial beyond usual care terms improved health behaviors health status xxmaj it also resulted fewer hospitalizations days hospitalization xxmaj key words chronic disease self management patient education cost utilization xxmaj med xxmaj care xxmaj there many examples patient education programs specific chronic conditions increased healthful behaviors improved health status decreased health care costs participants xxmaj an excellent bibliography patient education studies xxmaj supported xxmaj university xxmaj xxunk xxmaj tobacco xxmaj related xxmaj disease xxmaj research xxmaj program grant xxup tr xxup ahcpr grant r xxup hs xxmaj address correspondence xxmaj dr xxmaj kate xxmaj lorig xxmaj stanford xxmaj patient xxmaj education xxmaj research xxmaj center xxmaj welch xxmaj road xxmaj suite xxmaj palo xxmaj alto xxup ca e mail lorig xxunk xxmaj stanford edu xxmaj received xxmaj december initial review completed xxmaj february accepted xxmaj may xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup lorig xxup et xxup al published recently xxmaj to date studies dealt one disease problems comorbidity xxmaj rather patient education intervention disease specific xxmaj with emergence chronic disease largest threat health status largest cause health care expenditures potential role patient self management assumes increased importance xxmaj if benefits shown inexpensive xxunk self management program programs might useful part therapeutic regime xxmaj our study explored possibility xxmaj it differed previous self management studies placed subjects different chronic diseases different combinations comorbid diseases program time utilized randomized controlled design measured outcomes terms behaviors health status health service utilization xxmaj although former patient self management education studies one attributes none three xxmaj the objectives study evaluate effectiveness changes health behaviors health status health service utilization selfmanagement program chronic disease designed use heterogeneous group chronic disease patients explore differential effectiveness intervention subjects specific diseases comorbidities xxmaj the experience months patients heart disease lung disease stroke arthritis reported xxmaj methods xxmaj the xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program xxup cdsmp community based patient self management education course xxmaj three principal assumptions underlie xxup cdsmp patients different chronic diseases similar self management problems disease related tasks patients learn take responsibility day day management disease confident knowledgeable patients practicing self management experience improved health status utilize fewer health care resources xxmaj other assumptions shaped program patient selfmanagement education inexpensive widely available trained lay persons chronic conditions could effectively deliver structured patient education program lay instructors would acceptable patients health professionals xxmaj there research evidence positive role models case lay leaders similar backgrounds disease problems increase patients self efficacy confidence ability manage disease xxmaj needs a xxunk xxmaj the content methodology xxup cdsmp based two needs assessments xxmaj the first literature review existing chronic disease patient education programs xxmaj the purpose review identify common topics taught across chronic disease courses xxmaj in review articles authors found common tasks recognizing acting symptoms using medication correctly managing emergencies maintaining nutrition diet maintaining adequate exercise giving smoking using stress reduction techniques interacting effectively health care providers using community resources adapting work managing relations significant others managing psychological responses illness xxmaj the second needs assessment sought information focus groups xxmaj participants included people older years chronic diseases xxmaj participants invited describe disease thought caused explain feelings beliefs getting older describe physical social emotional impacts chronic disease lives lives families describe coped problems caused disease elaborate fears hopes wishes future xxmaj theme analysis groups responses used shape content xxup cdsmp process instruction xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program xxmaj design xxmaj the topics covered xxup cdsmp included exercise use cognitive symptom management techniques nutrition fatigue sleep management use community resources use medications dealing emotions fear anger depression communication others including health professionals problem solving decision making xxmaj the content course xxup medical xxup care xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup chronic xxup disease xxup self xxup management published xxmaj living xxmaj healthy xxmaj life xxmaj chronic xxmaj conditions xxmaj this book used text course participants xxmaj the process teaching course based xxmaj self xxmaj efficacy xxmaj theory xxmaj it incorporates strategies suggested xxmaj bandura enhance self efficacy xxmaj these include weekly action planning feedback modeling behaviors problem solving participants one another xxunk symptoms giving many possible causes symptom well several different management techniques group problem solving individual decision making xxmaj the leaders act facilitators xxunk xxmaj for example rather prescribing specific behavior changes assist participants making management choices achieving success reaching self selected goals xxmaj the process documented detailed protocol xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj leader xxmaj manual xxmaj each course participants mixed ages diagnoses including family members wished attend xxmaj each course taught pair trained volunteer lay leaders xxmaj the leaders received hours training detailed teaching manual xxmaj they ranged age years older xxmaj seventy one percent leaders one chronic diseases health professionals students xxmaj few previous experience health education xxmaj on average leaders taught courses xxmaj the program given seven weekly hour sessions xxmaj entry xxmaj criteria xxmaj to enter study subjects physician confirm diagnosis chronic lung disease asthma chronic bronchitis emphysema heart disease coronary artery disease congestive heart failure stroke completed cerebrovascular accident neurologic handicap normal mentation chronic arthritis xxmaj in addition least one conditions could conditions xxmaj patients compromised mentation cancer patients received chemotherapy radiation within past year persons younger years age excluded xxmaj subjects physicians hospitals informed study status treatment control xxmaj recruitment xxmaj randomization xxmaj subjects recruited using public service announcements mass media referrals flyers left physicians offices community clinics posters senior xxunk centers announcements health maintenance organization xxup hmo patient newsletters referrals county government employers xxmaj before filling initial questionnaire randomization subjects told would either receive course immediately serving control months xxmaj to assure program would easily accessible patients held multiple community sites four county area xxmaj programs held xxunk senior community centers public libraries health care facilities xxmaj in addition programs planned varied times convenience patients including late mornings early xxunk evenings xxmaj saturday mornings xxmaj the project approved institutional xxmaj committee xxmaj protection xxmaj human xxmaj subjects xxmaj research xxmaj all participants gave written informed consent xxmaj after subject physician supplied diagnosis subject completed consent form baseline questionnaire participants randomized treatment control status xxmaj randomization conducted serially xxmaj after subjects applied specific site typically subjects randomization ratio treatment versus controls determined assure fewer treatment subjects xxmaj thus sites ratio treatment control subjects whereas others xxmaj this randomization method resulted overall ratio xxmaj outcome xxmaj measures xxmaj there three primary classifications outcome variables health behaviors health status health service utilization xxmaj data collected previously tested self administered mailed questionnaires xxmaj to minimize xxunk response data collection completely separate intervention carried persons know subjects treatment status xxmaj measures included self rated health scale used xxmaj national xxmaj health xxmaj interview xxmaj survey modified version xxmaj health xxmaj assessment xxmaj questionnaire xxup xxunk disability scale xxmaj the psychological xxmaj vol xxmaj no xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup medical xxup care well scale also known xxup mhi part xxup sf well xxup sf used xxmaj the pain physical discomfort scale adaptation xxmaj medical xxmaj outcomes xxmaj study xxup mos pain scale modified include physical discomfort xxmaj the energy fatigue scale scale used long form xxup mos health distress scale slightly modified version xxup mos health distress scale xxmaj the remaining measures ie duration exercise use cognitive symptom management communication physicians social role activity limitations shortness breath utilization measures developed tested study xxmaj definitions measures information reliability validity presented elsewhere xxmaj the magnitude correlations among health status scales ranged median xxmaj the highest correlation psychological well health distress xxmaj subjects assessed three types health utilization visits physicians including visits emergency room xxup er visits hospitals past months number nights spent hospital xxmaj for category reported often used health services xxmaj the self reported data subjects xxup hmo members validated automated medical records xxmaj outpatient self reported visits associated medical record visits r xxup er visits r xxmaj we found patients often included urgent care hour visits xxup er visits instead counting outpatient visits xxmaj thus data subjects xxup er visits combined data outpatient physician visits xxmaj when combined self reported data outpatient visits correlated r medical records xxmaj we found errors made patients automated record system xxmaj patients tended xxunk recorded visits approximately xxmaj conversely system sometimes xxunk visits xxmaj for example subject received numerous allergy injections nurse reported system physician visit injection xxmaj for days hospital medical records correlated patient self report r xxmaj analyses xxmaj the primary analysis compared month outcomes treatment control groups outcome variable using analysis covariance endpoint scores controlling baseline value study variable well age sex education marital status xxmaj the endpoint data examined analysis covariance variation among xxup xxunk programs participants taught program variation effects found minimal influence overall conclusions xxmaj therefore treatment control data aggregated across programs instruction xxmaj the secondary analyses determined intervention different outcomes different diseases xxmaj two way analyses variance utilized testing interaction disease treatment status treatment control xxmaj results xxmaj primary xxmaj results xxmaj of subjects entered study ie randomized treatment n control status n completed month study xxmaj of treatment subjects completed months compared control subjects xxmaj treatment subjects completing month data attended average seven program sessions xxmaj of treatment subjects completing month data died ill continue unknown reasons xxmaj for control subjects respective percentages xxmaj comparing baseline data subjects completed month data noncompleters significantly fewer minutes aerobic exercise per week higher levels activity limitation pain physical discomfort fatigue health distress completed months p however statistically significant differences treatment control subjects study entry variable xxmaj table presents demographic disease characteristics study participants completing study xxmaj only marital status significantly different p xxmaj table gives baseline data mean month uncorrected change scores xxup cdsmp treatment subjects control subjects xxmaj as compared controls treatment group demonstrated significant improvement four health behavior variables p number minutes per week stretching strengthening aerobic exercise xxup lorig xxup et xxup al xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup chronic xxup disease xxup self xxup management xxup table xxmaj subject xxmaj characteristics xxmaj treatment xxmaj control n n xxmaj mean age years xxmaj age range xxmaj median xxmaj mode xxmaj female xxmaj mean education years xxwrep 4 yrs xxmaj married xxmaj white xxmaj diseases xxmaj heart disease xxmaj lung disease xxmaj arthritis xxmaj stroke xxmaj mean number diseases xxmaj provider xxmaj covered xxup hmo xxmaj private fee service xxmaj govt xxmaj medicare xxmaj medical xxup xxunk xxup va x p creased practice cognitive symptom management improved communication physician xxmaj they also demonstrated significant improvement five health status variables self rated health disability social role activities limitation energy fatigue health distress p xxmaj no significant differences demonstrated pain physical discomfort shortness breath psychological well xxmaj the treatment group compared control group fewer hospitalizations p spent average fewer nights hospital p xxmaj there significant differences visits physicians p xxmaj an intent treat analysis also conducted included subjects xxmaj baseline entry data used months subjects drop outs complete month data xxmaj the eight treatment four control subjects died excluded xxmaj in analysis probability values remained unchanged although change scores reduced slightly treatment control groups xxmaj for example changes communication physicians treatment subjects compared controls health distress treatment subjects compared controls nights hospital treatment subjects compared controls xxmaj of control subjects completed month randomized study chose take xxup cdsmp xxmaj of provided month post xxup cdsmp endpoint data xxmaj using matched pair tests comparing data starting xxup cdsmp months starting program group increased aerobic exercise use coping strategies p xxmaj they also decreased disability health distress increasing social role activities p xxmaj visits physicians decreased p xxmaj the group fewer visits hospitals fewer days hospital p xxmaj changes study variables listed xxmaj table significant although demonstrated trend toward improvement xxmaj thus appears taking xxup cdsmp control subjects reversed many trends toward worsening health demonstrated month randomized trial xxmaj secondary xxmaj results xxmaj tables present baseline data month change scores treatment control subjects various disease categories whose disease arthritis heart disease lung disease comorbidities xxmaj subjects stroke included analysis small numbers a twoway analysis covariance controlling baseline status examined main treatment effects interactions among four disease categories found significant interactions outcome variables xxmaj examination month change scores confirmed tendency change scores reflect program effects similarly across four diagnostic subgroups xxmaj program costs versus savings also examined xxmaj although treatment group reduced visits physicians slightly control group difference significant xxmaj the decrease number hospitalizations number nights hospitalization significant p xxmaj table xxmaj assuming xxmaj vol xxmaj no xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup medical xxup care xxup table xxmaj baseline xxmaj six xxmaj month xxmaj changes xxmaj treatment xxmaj control xxmaj subjects xxmaj health xxmaj behaviors xxmaj health xxmaj status xxmaj health xxmaj service xxmaj utilization xxmaj baseline xxmaj six xxmaj month xxmaj change xxmaj treatment xxmaj control xxmaj treatment xxmaj control xxmaj mean xxup sd xxmaj mean xxup sd xxmaj mean xxmaj mean n n xxup sd a xxup sd a xxmaj significance p xxmaj health behaviors xxmaj stretching strengthening xxmaj exercise minutes week xxmaj aerobic exercise minutes week xxmaj cognitive symptom xxmaj mgmt t better xxmaj communication w xxup md t better xxmaj health status xxmaj self rated health better xxmaj disability better xxmaj social xxmaj role activities xxmaj limitations better xxmaj pain xxmaj physical discomfort i better xxmaj psychological well t better xxmaj energy xxmaj fatigue t better xxmaj health distress better xxmaj shortness breath better xxmaj health service utilization xxup md xxup er visits times past months xxmaj number hospital stays past months xxmaj nights hospital past months xxmaj analysis covariance month post test scores controlling treatment status age sex education marital status baseline status xxmaj two tailed p values cost per day hospitalization gram treatment subjects completed month health care costs control partici month study calculated per xxunk study greater xxunk xxmaj this includes training leaders xxunk subject xxmaj the costs providing pro xxunk two leaders teach course xxup lorig xxup et xxup al xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup table xxmaj baseline xxmaj scores xxmaj treatment xxmaj control xxmaj subjects xxmaj by xxmaj disease xxmaj health xxmaj behaviors xxmaj health xxmaj status xxmaj health xxmaj service xxmaj utilization xxmaj arthritis xxmaj only xxmaj heart xxmaj disease xxmaj only xxmaj lung xxmaj disease xxmaj only xxmaj comorbid xxmaj conditions xxmaj treatment xxmaj mean xxmaj control xxmaj mean xxmaj treatment xxmaj mean xxmaj control xxmaj mean xxmaj treatment xxmaj mean xxmaj control xxmaj mean xxmaj treatment xxmaj mean xxmaj control xxmaj mean xxup sd n xxup sd n xxup sd n xxup sd n xxup sd n xxup sd n xxup sd n xxup sd n xxmaj health behaviors xxmaj stretching xxmaj strengthening xxmaj exercise minutes week xxmaj aerobic exercise minutes week xxmaj cognitive symptom xxmaj mgmt t better xxmaj communication xxup md better xxmaj health status xxmaj self rated health better xxmaj disability better xxmaj social xxmaj role activities xxmaj limitations better xxmaj pain xxmaj physical discomfort i better xxmaj psychological well better xxmaj energy xxmaj fatigue t better xxmaj health distress better xxmaj shortness breath better xxmaj health service utilization xxup md xxup er visits times past months xxmaj number hospital stays past months xxmaj nights hospital past months z c xxmaj cd xxmaj cl xxmaj cd c xxunk xxunk h r i i dl c r xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup table xxmaj six xxmaj month xxmaj changes xxmaj treatment xxmaj control xxmaj subjects xxmaj by xxmaj disease xxmaj health xxmaj behaviors xxmaj health xxmaj status xxmaj health xxmaj service xxmaj utilization xxmaj arthritis xxmaj only xxmaj heart xxmaj disease xxmaj only xxmaj lung xxmaj disease xxmaj only xxmaj comorbid xxmaj conditions xxmaj treatment xxmaj control xxmaj treatment xxmaj control xxmaj treatment xxmaj control xxmaj treatment xxmaj control xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj health behaviors xxmaj stretching xxmaj strengthening xxmaj exercise minutes week xxmaj aerobic exercise minutes week xxmaj cognitive symptom xxmaj mgmt better xxmaj communication w xxup md better xxmaj health status xxmaj self reported health better xxmaj disability j better xxmaj social xxmaj role activities xxmaj limitations better xxmaj pain xxmaj physical discomfort j better xxmaj psychological well better xxmaj energy xxmaj fatigue t better xxmaj health distress better xxmaj shortness breath better xxmaj health service utilization xxup md xxup er visits times past months xxmaj number hospital stays past months xxmaj nights hospital past months c xxup xxunk h r z cr xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup chronic xxup disease xxup self xxup management leader teaches one course volunteer leader xxunk assuming per leader per course participants course materials book audio tape administrative costs xxmaj this analysis take account cost space donated study indirect costs xxmaj assuming figures reflect current costs health care expenditure savings savings hospital nights minus program costs approximated per participant times cost intervention xxmaj discussion xxmaj this study evaluation self management education intervention persons one different conditions xxmaj the format intervention attributes medium sized classes lay leaders heterogeneity participants terms type severity disease xxmaj overall intervention successful increasing healthful behaviors maintaining improving health status decreasing rates hospitalization xxmaj table xxmaj these results indicate possible educate patients different chronic diseases successfully intervention time xxmaj because chronic disease patient education programs formally evaluated difficult determine heterogeneous educational interventions xxup cdsmp less effective homogeneous single disease oriented programs xxmaj because people years age older average two chronic conditions would seem program focused problems common various comorbidities would reasonable substitute adjunct traditional single disease programs xxmaj one key question concerns generalizability findings xxmaj as nearly studies subjects self selected study may motivated chronic disease patients xxmaj from past arthritis self management studies evidence patients closed xxup hmo rheumatology practice repeatedly offered opportunity participate intervention similar xxup cdsmp chose xxmaj men non xxmaj english speakers less likely attend xxmaj xxunk xxmaj litzelman found similar participation diabetes self management intervention xxmaj studies conducted xxmaj kaiser system xxmaj xxunk offer information generalizability xxup cdsmp xxmaj the subjects study high mean level education xxmaj it noteworthy approximately subjects years education less years xxmaj when education entered analysis covariant outcomes however affect xxmaj because heterogeneous mix patients patients symptoms need change behaviors xxmaj thus results primary analysis specific outcomes may underestimated somewhat individual improvements contained data subjects either target symptom already achieved acceptable levels outcome xxmaj although definitive answer clinical significance activity limitation health distress disability improved xxmaj this suggests xxup cdsmp affected important physical mental aspects participants lives xxmaj tables explore effectiveness intervention various subsets patients xxmaj because secondary analyses can not draw definitive conclusions data xxmaj the findings however may helpful guiding future studies xxmaj although subgroups appear made changes healthful behaviors changes varied group might expected xxmaj for example group heart disease reported aerobic exercise baseline minutes week treatment control groups respectively lung disease group reported least arthritis group intermediate xxmaj table xxmaj the treatment participants arthritis lung disease increased exercise control subjects xxmaj table xxmaj the treatment group heart disease remained control group decreased exercise xxmaj thus patients low baseline activity levels intervention increased activity whereas patients relatively high activity level level maintained xxmaj the results concerning practice cognitive symptom management techniques communication physicians uniform across subgroups xxmaj that intervention differential effects different subsets patients surprising xxmaj although chronic diseases create similar problems problems less salient xxmaj vol xxmaj no xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup lorig xxup et xxup al individual patient different times across diseases xxmaj the xxup cdsmp designed meet challenge aiding patients identify individual needs problems assisting work intensively areas xxmaj in addition designed meet needs many older patients one chronic condition xxmaj it important note participants study volunteers recruited largely word mouth various forms public announcement xxmaj although physicians confirmed diagnoses knew participation linkage xxup cdsmp content individual treatment plans xxmaj the xxup cdsmp alter participants treatment xxmaj therefore benefits achieved additional achieved usual care xxmaj conceivably integration xxup cdsmp usual care perhaps outset chronic disease would enhance benefits xxmaj conclusion xxmaj the xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program program designed specifically meet needs heterogeneous group chronic disease patients including comorbid conditions xxmaj the results study suggest intervention feasible beneficial beyond usual care terms improved health status decrease hospitalization potential substantial savings health care costs xxmaj if replicated similar studies program xxup cdsmp deserves place treatment regime patients chronic disease xxmaj references xxmaj rothenberg xxup rb xxmaj xxunk xxup jp xxmaj chronic disease xxmaj annu xxmaj rev xxmaj public xxmaj health xxmaj hoffman c xxmaj rice d xxmaj sung h y xxmaj persons chronic conditions xxmaj their prevalence costs j xxmaj am xxmaj med xxmaj assoc xxmaj center xxmaj advancement xxmaj health xxmaj the xxmaj center xxmaj health xxmaj studies xxmaj group xxmaj health xxmaj cooperative xxmaj puget xxmaj sound xxmaj an indexed bibliography selfmanagement people chronic disease st ed xxmaj washington xxup dc xxmaj center xxmaj advancement xxmaj health xxmaj bandura a xxmaj self efficacy mechanism physiological activation health promoting behavior xxmaj in xxmaj madden xxup ji xxmaj xxunk s xxmaj xxunk j eds xxmaj adaptation learning affect xxmaj new xxmaj york xxmaj raven xxmaj press xxmaj clark n xxmaj becker m xxmaj janz n xxmaj lorig k xxmaj xxunk w xxmaj anderson l xxmaj self management chronic disease older adults a review questions research j xxmaj aging xxmaj health xxmaj lorig k xxmaj stewart a xxmaj ritter p xxmaj gonzalez v xxmaj laurent d xxmaj lynch j xxmaj outcome measures health education health care interventions xxmaj thousand xxmaj oaks xxup ca xxmaj sage xxmaj publications xxmaj lorig k xxmaj holman h xxmaj sobel d xxmaj laurent d xxmaj gonzalez v xxmaj minor m xxmaj living healthy life chronic conditions xxmaj palo xxmaj alto xxup ca xxmaj bull xxmaj publishing xxmaj company xxmaj bandura a xxmaj self efficacy xxmaj toward unifying theory behavioral change xxmaj psychol xxmaj rev xxmaj stanford xxmaj patient xxmaj education xxmaj research xxmaj center xxmaj chronic disease self management leader manual xxmaj palo xxmaj alto xxup ca xxmaj stanford xxmaj patient xxmaj education xxmaj research xxmaj center xxup us xxmaj department xxmaj commerce xxmaj national xxmaj health xxmaj interview xxmaj survey xxmaj bureau xxmaj census xxmaj xxunk d xxmaj fries j xxmaj singh g xxmaj the xxmaj health xxmaj assessment xxmaj questionnaire xxmaj status review xxmaj in xxmaj spilker b ed xxmaj pharmacoeconomics quality life clinical trials xxmaj philadelphia xxup pa xxmaj lippincott xxmaj raven xxmaj ware xxup je xxmaj sherbourne xxup cd xxmaj the xxup mos item short form health survey xxup sf xxmaj med xxmaj care xxmaj stewart a xxmaj hays r xxmaj ware j xxmaj the xxup mos shortform general health survey xxmaj reliability validity patient population xxmaj med xxmaj care xxmaj sherbourne xxup cd xxmaj pain measures xxmaj in xxmaj stewart xxup al xxmaj ware xxup je eds xxmaj measuring functioning well xxmaj the medical outcomes study approach xxmaj durham xxup nc xxmaj duke xxmaj university xxmaj press xxmaj stewart xxup al xxmaj hays xxup rd xxmaj ware xxup je xxmaj health perceptions energy fatigue health distress measures xxmaj in xxmaj stewart xxup al xxmaj ware xxup je eds xxmaj measuring functioning well xxmaj the medical outcomes study approach xxmaj durham xxup nc xxmaj duke xxmaj university xxmaj press xxmaj lorig k xxmaj holman h xxmaj patient education xxmaj accepted highly motivated generalizable treatment xxmaj presented xxmaj american xxmaj college xxmaj rheumatology th xxmaj annual xxmaj meeting xxmaj glasgow r xxmaj chance xxup pl xxmaj toobert d xxmaj brown j xxmaj hampson s xxmaj riddle m xxmaj long term effects costs brief behavioral dietary intervention patients diabetes delivered medical office xxmaj patient xxmaj edu xxmaj xxunk xxmaj litzelman d xxmaj xxunk c xxmaj xxunk c et al xxmaj reduction lower extremity clinical abnormalities patients non insulin dependent diabetes mellitus a randomized controlled trial xxmaj ann xxmaj intern xxmaj med xxup medical xxup care xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions\n",
              "y: CategoryList\n",
              "P,Q,N,Q,P\n",
              "Path: /content/gdrive/My Drive/covidnlp;\n",
              "\n",
              "Valid: LabelList (125 items)\n",
              "x: TextList\n",
              "xxbos e xxmaj mail karger karger com xxmaj original xxmaj article xxmaj gynecol xxmaj obstet xxmaj invest xxup doi xxmaj the xxmaj effect xxmaj intrauterine xxmaj lidocaine xxmaj rectal xxmaj indomethacin xxmaj pain xxmaj office xxmaj vaginoscopic xxmaj hysteroscopy xxmaj randomized xxmaj double xxmaj blind xxmaj controlled xxmaj study xxmaj xxunk xxmaj xxunk xxmaj xxunk xxmaj hakan xxmaj xxunk b b lent xxmaj xxunk lu b xxmaj xxunk xxmaj ya ar b xxmaj xxunk xxmaj xxunk xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj xxunk xxmaj xxunk xxmaj gynecologic xxmaj pediatric xxmaj training xxmaj research xxmaj hospital b xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj xxunk xxmaj dr xxmaj xxunk xxmaj xxunk xxmaj teaching xxmaj research xxmaj hospital xxmaj istanbul xxmaj turkey plied vaginoscopic technique useful hysteroscopy xxmaj however intrauterine anesthesia effective reducing pain s xxmaj karger xxup ag xxmaj basel xxmaj introduction xxmaj diagnostic hysteroscopy gold standard modality visualization uterine cavity minimally invasive procedure allows surgical procedures easily applied office conditions xxmaj although diagnostic hysteroscopy easily tolerated sometimes painful xxmaj several patient technique associated factors cause pain xxmaj in addition tenaculum speculum diameter hysteroscope duration procedure additional procedures performed time e g endometrial biopsy affect pain xxmaj these factors may prevent accurate evaluation pain caused hysteroscope passing uterine cavity xxmaj lower levels pain reported diagnostic hysteroscopy applied vaginoscopy touch technique compared conventional hysteroscopy using speculum xxmaj key xxmaj words xxmaj analog xxmaj pain xxmaj scale xxmaj anesthesia xxmaj hysteroscopy xxmaj abstract xxmaj backgrounds xxmaj aims xxmaj the aim study investigate effect rectal intrauterine anesthesia vaginoscopic hysteroscopy xxmaj methods xxmaj this randomized double blind placebo controlled study xxmaj patients randomized rectal indomethacin intrauterine lidocaine placebo groups xxmaj patients conditions could cause contribute pelvic pain excluded xxmaj pain evaluated xxmaj visual xxmaj analog xxmaj scale cervical canal passed within cavity min procedure xxmaj the xxmaj analog xxmaj pain xxmaj scale scores groups compared xxmaj kruskal xxmaj wallis way analysis variance test a value p accepted statistically significant xxmaj results xxmaj the study included total patients xxmaj no difference seen groups respect indication age xxunk duration procedure xxmaj while anesthesia determined superior placebo reducing pain stages p intrauterine lidocaine determined effective rectal indomethacin reducing pain within cavity min procedure p xxmaj conclusion xxmaj rectal intrauterine anesthesia ap xxmaj received xxmaj june xxmaj accepted xxmaj october xxmaj published online xxmaj november xxmaj xxunk xxmaj xxunk xxmaj xxunk xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj xxunk xxmaj xxunk xxmaj gynecologic xxmaj pediatric xxmaj training xxmaj research xxmaj hospital xxmaj xxunk xxmaj dr xxmaj xxunk xxmaj xxunk xxmaj cad xxmaj no xxmaj xxunk xxmaj istanbul xxmaj turkey e xxmaj mail dr xxunk gmail com s xxmaj karger xxup ag xxmaj basel www karger com goi xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm xxmaj pain xxmaj diagnostic xxmaj hysteroscopy xxmaj gynecol xxmaj obstet xxmaj invest xxup doi tenaculum xxmaj in vaginoscopic technique pain effect anesthesia used accurately evaluated xxmaj to best knowledge prospective studies evaluated benefit anesthesia hysteroscopy applied diagnostic purposes alone xxunk factors could cause pain e g use tenaculum speculum independent procedure xxmaj in prospective study compared intrauterine lidocaine rectal indomethacin placebo hysteroscopy applied vaginoscopic method xxmaj material xxmaj method xxmaj this randomized double blind study conducted xxmaj xxunk xxmaj dr xxmaj xxunk xxmaj xxunk xxmaj training xxmaj research xxmaj hospital xxmaj july xxmaj march xxmaj approval study granted xxmaj local xxmaj ethics xxmaj committee decision xxmaj the study included patients suspected endometrial polyp abnormal uterine bleeding diagnosis myoma infertility xxmaj patients conditions could cause contribute pelvic pain excluded xxmaj these factors evaluated dysmenorrhea dyspareunia history uterine surgery chronic pelvic pain previous caesarean section cervical canal surgery xxmaj in addition pregnant patients gastro oesophageal diseases could inhibit use rectal non steroid using medication allergies excluded study xxmaj informed consent obtained participants xxmaj patients selected according random numbers table separated groups xxmaj the control group administered ml distention medium containing ml serum physiologic per ml rectal placebo xxmaj the second group administered ml distention medium containing ml lidocaine per ml xxunk ampoule mg xxmaj xxunk xxmaj xxunk xxmaj turkey rectal placebo xxmaj the third group administered rectal indomethacin xxunk xxmaj xxunk mg supp xxmaj xxunk xxmaj istanbul xxmaj turkey min procedure ml distention medium containing ml serum physiologic per ml xxmaj the medications administered patients nurse xxmaj the xxunk patient blind xxmaj diagnostic hysteroscopy applied rigid endoscope mm single current shaft mm telescope xxmaj karl xxmaj storz xxmaj tuttlingen xxmaj germany xxmaj saline solution sodium chloride room temperature used distention medium xxmaj intrauterine pressure mm xxmaj hg provided pump xxmaj wolf xxmaj illinois xxup usa xxmaj the procedure applied single physician xxup xxunk experienced hysteroscopy xxmaj all patients evaluated days end menstrual bleeding xxmaj the procedure applied vaginoscopic technique without using tenaculum speculum xxmaj the hysteroscope inserted vagina without xxunk xxunk posterior fornix reached observation without xxunk vaginal walls xxmaj then xxunk back xxunk lower lip cervix external cervical os seen xxmaj the time entry external os passing cavity entering cavity end observation recorded separately pain levels points xxmaj ten min end procedure patients evaluated respect pain a xxmaj visual xxmaj analog xxmaj scale xxup vas used evaluation pain xxmaj in scale points different pictures faces patients asked indicate pain felt pictures appropriate points scored xxmaj statistical evaluation data made xxup spss xxmaj windows version software xxmaj the chi square test used comparisons groups indications menopause status nulliparity xxunk duration compared way analysis variance xxup anova test pain age parity xxunk abortion curettage ectopic pregnancies compared xxmaj kruskal xxmaj wallis way xxup anova tests a value p accepted statistically significant xxmaj results xxmaj the total patients comprised placebo group lidocaine group indomethacin group xxmaj no statistically significant difference determined groups terms age xxunk parity abortion curettage menopause status history systemic disease p xxmaj the common indication diagnostic hysteroscopy suspected endometrial polyps significant difference determined groups respect indication types p table xxmaj the time passing cervical canal observation period cavity similar groups p xxmaj when pain evaluated pain scores placebo group cervix cavity min procedure statistically significantly higher groups p xxmaj there differences rectal indomethacin placebo regard pain cavity min procedure table xxmaj while difference observed lidocaine indomethacin groups cervix pain scores p scores cavity min procedure determined statistically significantly higher indomethacin group intrauterine lidocaine group p table xxmaj there vasovagal side effects patients placebo patients lidocaine patients indomethacin groups xxmaj discussion xxmaj the results study showed use intrauterine lidocaine rectal indomethacin hysteroscopy applied vaginoscopic technique effective placebo reducing pain procedure xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm xxmaj gynecol xxmaj obstet xxmaj invest xxmaj xxunk xxmaj xxunk xxmaj xxunk lu xxmaj ya ar xxmaj xxunk xxup doi p xxmaj in addition use intrauterine lidocaine determined effective rectal indomethacin administered procedure reducing pain cavity min procedure p xxmaj to able reduce make accurate evaluation pain associated procedure necessary minimize factors except associated cervix uterine cavity xxmaj experienced physician using small diameter hysteroscope reaching cavity quickly xxunk minimal trauma reduce pain a majority studies related pain control office hysteroscopy based application conventional technique together procedures endometrial biopsy xxmaj however relatively studies related necessity anesthesia diagnostic hysteroscopy alone xxmaj zupi et al reported pain reduced ml mepivacaine xxmaj endometrial biopsy applied study pain diagnostic hysteroscopy recorded endometrial biopsy xxmaj no information given respect whether procedure applied conventional methods xxunk technique xxmaj lau et al reported lignocaine applied cavity superiority xxmaj table xxmaj the character patients indications hysteroscopy xxmaj placebo n xxmaj lidocaine n xxmaj indomethacin n p value xxmaj age mean xxup sd xxmaj xxunk median xxup iqr b xxmaj parity median xxup iqr b xxmaj abortion median xxup iqr b xxmaj dilatation curettage median xxup iqr b xxmaj ectopic pregnancy n xxmaj hypertension n xxmaj diabetes mellitus n xxmaj another n xxmaj menopause n c xxmaj nulliparous n c xxmaj xxunk multiparous n xxmaj xxunk n c xxmaj polyp xxmaj abnormal uterine bleeding xxmaj xxunk xxmaj infertility xxmaj one way xxup anova b xxmaj kruskal xxmaj wallis way xxup anova c xxmaj chi square test xxup iqr xxmaj interquartile range xxmaj table xxmaj time pain scores groups xxmaj placebo n xxmaj lidocaine n xxmaj indomethacin n p value xxmaj time pass cervical canal mean xxup sd xxmaj observation period uterine cavity mean xxup sd xxmaj pain passing cervical canal median xxup iqr x b xxmaj pain observation uterine cavity median xxup iqr x z b xxmaj pain min procedure median xxup iqr x z b xxmaj one way xxup anova b xxmaj kruskal xxmaj wallis way xxup anova xxup iqr xxmaj interquartile range x xxmaj indicates statistical significance placebo lidocaine groups statistically significant placebo indomethacin groups z indicates statistical significance lidocaine indomethacin groups xxmaj bold xxunk character demonstrate statistically significant changes xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm xxmaj pain xxmaj diagnostic xxmaj hysteroscopy xxmaj gynecol xxmaj obstet xxmaj invest xxup doi placebo xxmaj in study pain evaluated hysteroscopy biopsy applied xxmaj after administering anesthesia mean xxup vas score placebo group hysteroscopy determined anesthesia group mean score xxmaj the mean pain score higher patients score xxmaj however procedure applied using speculum tenaculum could contributed pain xxmaj in current study used instrument speculum tenaculum make accurate pain related hysteroscope shown intrauterine lidocaine rectal indomethacin effective placebo respect pain control xxmaj in study xxmaj xxunk et al vaginoscopic technique used patients reported rectal indomethacin vaginal misoprostol effective reducing pain placebo xxmaj in study patients infertile mm hysteroscope used xxmaj conversely current study rectal indomethacin found effective placebo xxmaj this disparity findings study xxmaj xxunk et al may due low number nulliparity patients current study patient group xxmaj the uterus xxunk innervated organ xxmaj parasympathetic innervation corpus cervix provided nerve fibers coming xxmaj xxunk plexus s sympathetic innervation provided nerve fibers coming ovarian plexus nerve fibers terminated densely sub endometrial region xxmaj pain caused administration distention medium cavity direct effects manipulation nerve ends increased prostaglandin xxmaj by reaching nerve fibers quickly intrauterine anesthesia provides effective pain control indomethacin reduces pain inhibiting prostaglandin xxmaj but significant component pain felt hysteroscopy probably xxunk cervical canal xxmaj factors arising cervical canal e g xxunk also diameter hysteroscope increase pain passing cervical canal xxmaj in study cases cervical xxunk degree would require dilatation cases xxunk included xxmaj in addition premedication administered cervical preparation xxmaj our study demonstrated pain passing cervical canal placebo group groups xxmaj but cavity examination min significant difference placebo rectal indomethacin groups lidocaine effective xxmaj as explained earlier lidocaine administered cavity directly reaches nerve fibers sub endometrial region effective analgesia may provided route xxmaj this result also support need anesthesia office diagnostic hysteroscopy cervical canal xxmaj compared previous reports literature duration procedure current study seen short xxmaj however procedure considered started visualization internal cervical os xxmaj furthermore procedures short may reduced pain xxmaj this study considered significant examined hysteroscopy procedure alone minimizing instrument patient related factors could cause pain xxmaj therefore comparison benefit anesthesia medications used considered objective xxmaj to best knowledge previous report literature placebo controlled study rectal indomethacin intra xxunk lidocaine applied hysteroscopy vaginoscopic technique xxmaj however low number cases groups evaluated limitation current study xxmaj in conclusion anesthesia applied diagnostic hysteroscopy made vaginoscopic technique office conditions significantly reduces pain xxmaj in addition intra xxunk anesthesia seen superior rectal indomethacin xxmaj to able say whether anesthesia necessary hysteroscopy applied vaginoscopic approach need randomized controlled studies review studies xxmaj disclosure xxmaj statement xxmaj the authors declared conflict interest xxmaj acknowledgment xxmaj language edited native xxmaj english speaker xxmaj caroline xxmaj walker xxmaj references van xxmaj dongen h de xxmaj kroon xxup cd xxmaj jacobi xxup ce xxmaj trimbos xxup jb xxmaj jansen xxup fw xxmaj diagnostic hysteroscopy abnormal uterine bleeding systematic review meta analysis xxup bjog xxmaj xxunk xxup rm xxmaj xxunk g xxmaj del xxmaj xxunk n xxmaj xxunk a xxmaj xxunk xxup ma xxmaj xxunk g xxmaj sforza r xxmaj xxunk xxup af xxmaj xxunk i xxmaj xxunk v xxmaj hysteroscopy valid tool endometrial pathology patients postmenopausal bleeding asymptomatic patients thickened endometrium hysteroscopic histological results xxmaj gynecol xxmaj obstet xxmaj invest xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm xxmaj gynecol xxmaj obstet xxmaj invest xxmaj xxunk xxmaj xxunk xxmaj xxunk lu xxmaj ya ar xxmaj xxunk xxup doi xxmaj teran xxmaj alonso xxup mj xxmaj de xxmaj santiago j xxmaj usandizaga r xxmaj zapardiel i xxmaj evaluation pain office hysteroscopy prior analgesic medication prospective randomized study xxmaj eur j xxmaj obstet xxmaj gynecol xxmaj reprod xxmaj biol xxmaj xxunk d xxmaj xxunk e xxmaj anesthetic xxmaj implications xxmaj hysteroscopy xxmaj st xxmaj louis xxup cv xxmaj mosby xxmaj co xxmaj cicinelli e xxmaj hysteroscopy without anesthesia review recent literature j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj diniz xxup db xxmaj xxunk xxmaj xxunk b xxmaj pereira xxup am xxmaj david xxup sd xxmaj xxunk xxup ug xxmaj baracat xxup ff xxmaj lopes xxup rg xxmaj pain evaluation office hysteroscopy comparison two techniques xxmaj rev xxmaj xxunk xxmaj xxunk xxmaj obstet xxmaj xxunk r xxmaj xxunk o xxmaj xxunk m xxmaj xxunk m xxmaj schechter e xxmaj golan a a new approach office hysteroscopy compared traditional hysteroscopy randomized controlled trial xxmaj obstet xxmaj gynecol xxmaj cooper xxup na xxmaj khan xxup ks xxmaj clark xxup tj xxmaj local anaesthesia pain control outpatient hysteroscopy systematic review meta analysis xxup bmj c xxmaj cooper xxup na xxmaj smith p xxmaj khan xxup ks xxmaj clark xxup tj xxmaj vaginoscopic approach outpatient hysteroscopy systematic review effect pain xxup bjog xxmaj campbell f xxmaj xxunk xxup bj xxmaj chronic pelvic pain xxmaj br j xxmaj anaesth xxmaj cicinelli e xxmaj rossi xxup ac xxmaj xxunk m xxmaj matteo m xxmaj xxunk n xxmaj tinelli r xxmaj predictive factors pain experienced office fluid minihysteroscopy j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj kabli n xxmaj tulandi t a randomized trial outpatient hysteroscopy without intrauterine anesthesia j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj xxunk h xxmaj xxunk y xxmaj xxunk t xxmaj xxunk k xxmaj effectiveness vaginal misoprostol rectal nonsteroidal anti inflammatory drug vaginoscopic diagnostic outpatient hysteroscopy primarily infertile women double blind randomized controlled trial j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj xxunk a xxmaj oliveira xxup ma xxmaj xxunk xxup cp xxmaj xxunk xxup mf xxmaj xxunk xxup ts xxmaj santos xxup lc xxmaj diagnostic hysteroscopy using liquid distention medium comparison pain xxunk saline solution vs room temperature saline solution j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj jensen xxup mp xxmaj chen c xxmaj xxunk xxup am xxmaj postsurgical pain outcome assessment xxmaj pain t r k p xxmaj major t xxmaj evaluating level pain office hysteroscopy according menopausal status parity size instrument xxmaj arch xxmaj gynecol xxmaj obstet xxmaj van den xxmaj bosch t xxmaj xxunk j xxmaj daemen a xxmaj xxunk o xxmaj domali e xxmaj xxunk f xxmaj vandenbroucke v xxmaj de xxmaj moor b xxmaj deprest j xxmaj timmerman d xxmaj pain experienced transvaginal ultrasound saline contrast sonohysterography hysteroscopy office sampling comparative study xxmaj ultrasound xxmaj obstet xxmaj gynecol xxmaj campo r xxmaj molinas xxup cr xxmaj rombauts l xxmaj xxunk g xxmaj lauwers m xxmaj xxunk p xxmaj brosens i xxmaj van xxmaj belle y xxmaj xxunk s xxmaj prospective multicentre randomized controlled trial evaluate factors influencing success rate office diagnostic hysteroscopy xxmaj hum xxmaj reprod de xxmaj xxunk xxmaj fonseca m xxmaj xxunk xxup xxunk xxmaj xxunk xxup ja xxmaj jr xxmaj xxunk xxup cg xxmaj xxunk xxup cm xxmaj jr xxmaj xxunk xxup cp xxmaj identifying predictors unacceptable pain office hysteroscopy j xxmaj minim xxmaj invasive xxmaj gynecol van xxmaj dongen h de xxmaj kroon xxup cd van den xxmaj xxunk xxup sa xxmaj xxunk xxup la xxmaj trimbos xxmaj xxunk xxup gc xxmaj jansen xxup fw a randomised comparison vaginoscopic office hysteroscopy saline infusion sonography patient compliance study xxup bjog xxmaj zupi e xxmaj luciano xxup aa xxmaj valli e xxmaj marconi d xxmaj maneschi f xxmaj romanini c xxmaj the use topical anesthesia diagnostic hysteroscopy endometrial biopsy xxmaj fertil xxmaj steril xxmaj lau xxup wc xxmaj tam xxup wh xxmaj lo xxup wk xxmaj yuen xxup pm a randomised double blind placebo controlled trial transcervical intrauterine local anaesthesia outpatient hysteroscopy xxup bjog xxmaj xxunk xxup rj xxmaj xxunk xxup ml xxmaj intrauterine anesthesia gynecologic procedures systematic review xxmaj obstet xxmaj gynecol xxmaj waller xxup dg xxmaj xxunk xxup ag xxmaj xxunk k xxmaj medical xxmaj pharmacology xxmaj therapeutics ed xxmaj london xxmaj elsevier xxmaj saunders xxmaj xxunk i xxmaj xxunk a xxmaj xxunk s xxmaj xxunk m xxmaj di xxmaj xxunk xxup gc xxmaj xxunk e xxmaj xxunk v xxmaj xxunk s xxmaj pain diagnostic hysteroscopy role cervical canal a pilot study xxmaj eur j xxmaj obstet xxmaj gynecol xxmaj reprod xxmaj biol xxmaj xxunk i xxmaj xxunk a xxmaj xxunk m xxmaj xxunk s xxmaj xxunk v xxmaj di xxmaj xxunk xxup gc xxmaj xxunk s xxmaj pain diagnostic hysteroscopy multivariate analysis randomized controlled trial xxmaj fertil xxmaj steril xxmaj di xxmaj spiezio xxmaj sardo a xxmaj taylor a xxmaj xxunk p xxmaj xxunk g xxmaj sharma m xxmaj magos a xxmaj hysteroscopy technique xxmaj analysis outpatient hysteroscopies xxmaj fertil xxmaj steril xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm,xxbos xxmaj pulmonary xxmaj perspective xxmaj an xxmaj appraisal xxmaj evidence xxmaj underlying xxmaj performance xxmaj measures xxmaj community acquired xxmaj pneumonia xxmaj kevin c xxmaj wilson xxmaj holger j xxmaj schu nemann xxmaj department xxmaj medicine xxmaj boston xxmaj university xxmaj school xxmaj medicine xxmaj boston xxmaj massachusetts xxmaj department xxmaj clinical xxmaj epidemiology xxmaj biostatistics xxmaj medicine mcmaster xxmaj university xxmaj hamilton xxmaj ontario xxmaj canada xxmaj numerous organizations use performance measures monitor quality care provided variety clinical conditions xxmaj an appraisal evidence underlying performance measures never reported xxmaj our objective estimate effects interventions recommended performance measures determine quality evidence estimates derive using xxmaj joint xxmaj commission xxmaj centers xxmaj medicare xxmaj medicaid xxmaj services performance measures community acquired pneumonia xxup cap examples xxmaj we performed systematic reviews literature identify evidence related performance measures xxup cap xxmaj metaanalyses performed estimate absolute relative effects interventions recommended performance measures xxmaj the xxmaj grading xxmaj recommendations xxmaj assessment xxmaj development xxmaj evaluation system used determine quality evidence xxmaj the estimated effects favored interventions recommended five six performance measures xxmaj these included pneumococcal vaccination incidence pneumococcal pneumonia relative risk xxup rr confidence interval xxup ci blood cultures antibiotic administration within hours use guideline compliant antibiotic regimen influenza vaccination incidence symptomatic influenza xxup rr xxup ci xxmaj however among performance measures influenza vaccination supported high quality evidence xxmaj one step smoking cessation counseling xxunk moderate quality evidence smoking quit rate xxup rr xxup ci xxmaj the evidence supporting performance measures frequently high quality occasionally contradictory xxmaj keywords pneumococcal vaccines blood specimen collection smoking cessation xxunk agents influenza vaccines xxmaj performance measures developed many organizations monitor quality care rendered variety clinical conditions xxmaj the goal performance measures provide incentive clinicians healthcare organizations improve quality care deliver a performance measure considered recommendation use intervention specific patient population xxmaj the decision recommend intervention influenced several factors including balance desirable undesirable consequences quality evidence patient values preferences related intervention outcomes resource use xxmaj when consideration factors indicates implementation recommendation lead greater benefit xxunk strong recommendation warranted xxmaj this requires reasonable degree certainty desirable undesirable effects intervention xxmaj performance measures primarily based strong recommendations rather weak recommendations xxmaj performance measures related weak recommendations e alternative actions reasonable decision making process accounts reasons alternative action require substantially debate development implementation either less certainty balance desirable undesirable effects intervention patient values preferences exert greater influence decisions xxmaj certainty balance desirable undesirable consequences intervention directly influenced quality evidence xxmaj the greatest certainty exists estimated effects derived high quality evidence whereas less certainty exists estimated effects derived lower quality evidence xxmaj thus performance measures supported highest possible level clinical evidence transparent descriptions factors led selection performance measures patient values preferences resource considerations xxmaj although latter three factors may routinely adequately considered development performance measures reasonable assume develop performance measures routinely evaluate quality evidence balance benefits harms xxmaj performance measures evidence supporting well studied xxmaj the purpose study estimate effects interventions recommended performance measures determine quality evidence estimates derived xxmaj we chose xxmaj joint xxmaj commission xxmaj centers xxmaj medicare xxmaj medicaid xxmaj services performance measures e xxmaj national xxmaj hospital xxmaj quality xxmaj measures community acquired pneumonia xxup cap illustrative set performance measures xxup methods xxmaj performance xxmaj measures xxmaj we identified updated versions major performance measures patients admitted xxup cap version xxmaj specification xxmaj manual xxmaj national xxmaj hospital xxmaj quality xxmaj measures xxmaj they included recommendations pneumococcal vaccination blood cultures xxunk smoking cessation counseling antibiotics within hours use guideline compliant antibiotics influenza vaccination xxmaj each described detail xxup results section xxmaj data xxmaj sources xxmaj searches xxmaj systematic reviews performed performance measure using two step approach xxmaj the first step consisted one investigators searching xxmaj medline via pubmed xxmaj cochrane xxmaj central xxmaj register xxmaj controlled xxmaj trials xxmaj cochrane xxmaj database xxmaj systematic xxmaj received original form xxmaj september accepted final form xxmaj january xxmaj correspondence requests reprints addressed xxmaj kevin c xxmaj wilson m d xxmaj sawyer xxmaj road xxmaj waltham xxup ma e mail xxunk uptodate com xxmaj this article online supplement accessible issue table contents www atsjournals org xxmaj am j xxmaj respir xxmaj crit xxmaj care xxmaj med xxmaj vol pp xxmaj originally xxmaj published xxmaj press xxup doi xxunk xxup pp xxmaj january xxmaj internet address www atsjournals org xxmaj reviews xxmaj google xxmaj scholar randomized trials see xxmaj table e online supplement xxmaj if eligible randomized trials identified second step used virtually identical first except observational studies e cohort studies case control studies sought xxmaj table e xxmaj in addition electronic database searches bibliographies published metaanalyses selected studies xxmaj specification xxmaj manual xxmaj national xxmaj hospital xxmaj quality xxmaj measures reviewed potentially eligible studies xxmaj the electronic database searches included dates beginning database xxmaj april xxmaj study xxmaj selection xxmaj for performance measures recommending pneumococcal vaccination smoking cessation counseling influenza vaccination studies selected compared intervention either placebo intervention measured patient important outcomes xxmaj for performance measures recommending blood cultures antibiotics within hours guideline compliant antibiotics selection criteria used patients hospitalized xxup cap xxmaj data xxmaj extraction xxmaj quality xxmaj assessment xxmaj for selected study one investigators extracted data published article regarding study design participant characteristics outcome measures frequency events xxmaj occasionally event data could extracted either study could located study report event data xxmaj when occurred attempt made extract event data published metaanalyses included study xxmaj when secondary approach also failed identify event data could calculate estimated effects instead relied effects reported original studies inform judgments xxmaj data xxmaj synthesis xxmaj analysis xxmaj for performance measure whose systematic review identified multiple relevant studies one investigator performed metaanalyses estimate absolute relative effects recommended intervention xxmaj metaanalyses conducted xxmaj review xxmaj manager revman using random effects model relative risk measure effect xxmaj once estimated effects recommended intervention calculated two investigators appraised quality evidence using xxmaj grading xxmaj assessment xxmaj development xxmaj evaluation xxup grade approach xxmaj randomized trials began assumption high quality evidence whereas well done observational studies began assumption low quality evidence xxmaj the quality evidence downgraded upgraded according criteria shown xxmaj table e xxmaj discussion consensus used arrive final quality assessment xxmaj evidence tables constructed using gradepro xxup results xxmaj pneumococcal xxmaj vaccination xxmaj the pneumococcal vaccination performance measure determines proportion patients aged years older hospitalized xxup cap screened pneumococcal vaccine status vaccinated discharge indicated xxmaj our systematic review identified randomized trials met inclusion criteria e compared pneumococcal vaccination either placebo vaccination measured patient important outcomes xxmaj figure e xxmaj metaanalyses randomized trials found pneumococcal vaccination decreased incidence pneumococcal pneumonia relative risk xxup rr confidence interval xxup ci incidence invasive pneumococcal disease xxup rr xxup ci mortality due pneumonia xxup rr xxup ci although third outcome statistically significant xxmaj table xxmaj the absolute effects small outcomes due low baseline risks xxmaj prior metaanalyses similarly found either small absolute benefits pneumococcal vaccination xxmaj the quality evidence supporting performance measure recommendation pneumococcal vaccination low outcomes xxmaj there multiple randomized trials results inconsistent trials detected relative benefit several found effect harm populations indirectly related performance measure target population xxmaj sources indirectness included clinical context trials include patients recovering infection performance measure targets adults recovering xxup cap age trials included adults ages performance measure targets adults years old comorbidity evidence patients without significant comorbidities performance measure also intended patients comorbidities xxmaj table xxmaj this indirectness may important data suggest pneumococcal vaccination may less effective among elderly patients recently infected patients comorbidities xxmaj blood xxmaj cultures xxmaj this performance measure determines proportion adult xxup icu patients transferred admitted xxup icu within hours hospital arrival xxup cap blood cultures performed within hours hospital arrival xxmaj our systematic review identified two retrospective cohort studies met inclusion criteria e enrolled patients hospitalized xxup cap compared blood cultures performed measured patient important outcomes xxmaj figure e xxmaj metaanalyses performed studies report event data xxmaj blood cultures associated increased likelihood clinically stable hours study looked outcome adjusted odds ratio xxup or xxup ci xxmaj the studies also found reduction relative risk mortality among patients blood cultures performed adjusted xxup or xxup ci adjusted xxup or xxup ci although failed achieve statistical significance xxmaj the quality evidence supporting performance measure recommendation blood cultures low outcomes xxmaj for clinical stability hours observational study population indirectly related performance measure target population study included many non xxup icu patients target population xxup icu patients xxmaj for mortality two observational studies estimates imprecise risk bias confounding indication populations indirectly related performance measure target population one study included elderly patients studies included non xxup icu patients xxmaj smoking xxmaj cessation xxmaj the smoking cessation performance measure determines proportion adult patients xxup cap history smoking cigarettes time prior year given smoking cessation advice counseling hospitalization xxmaj our systematic review identified randomized trials met inclusion criteria e compared inpatient smoking cessation advice smoking cessation intervention measured patient important outcomes xxmaj figure e a metaanalysis trials found inpatient smoking cessation advice without outpatient follow improve xxmaj pulmonary xxmaj perspective smoking quit rate xxup rr xxup ci contradicting performance measure recommendation inpatient smoking cessation advice xxmaj the quality evidence moderate multiple randomized trials estimates effect imprecise xxmaj table xxmaj our results similar prior metaanalysis included many studies xxmaj antibiotics within xxmaj hours xxmaj the antibiotic timing performance measure determines proportion adult patients xxup cap received first dose antibiotics within hours hospital arrival a threshold hours used previous versions performance measure threshold changed hours xxunk reports increased misdiagnosis inappropriate antibiotic use implementation hour threshold xxmaj we reviewed evidence underlying prior performance measure antibiotics within hours response reviewers found estimated effects inconsistent xxmaj two observational studies found initiation antibiotics within hours associated reduced mortality one observational study reported possible benefit e mortality decreased hour threshold one bundle interventions study analyze xxup table xxup evidence xxup table xxup for xxup the xxup pneumococcal xxup vaccination xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no xxmaj studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other xxmaj considerations xxmaj mortality due pneumonia xxmaj randomized trials xxmaj no serious limitations xxmaj serious xxmaj very serious xxmaj no serious imprecision xxmaj none xxmaj pneumococcal pneumonia xxmaj randomized trials xxmaj no serious limitations xxmaj xxunk xxmaj very serious xxmaj no serious imprecision xxmaj none xxmaj invasive pneumococcal disease xxmaj randomized trials xxmaj no serious limitations xxmaj xxunk xxmaj very serious xxmaj no serious imprecision xxmaj none xxmaj summary findings xxmaj no xxmaj patients xxmaj effect xxmaj pneumococcal xxmaj vaccination xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj mortality due pneumonia xxup rr fewer per fewer xxup oo xxmaj very low xxmaj critical xxmaj pneumococcal pneumonia xxup rr fewer per fewer fewer xxup oo xxmaj very low xxmaj important xxmaj invasive pneumococcal disease xxup rr fewer per fewer fewer xxup oo xxmaj very low xxmaj important xxmaj definition abbreviations xxup ci confidence interval xxup rr relative risk xxmaj comparison xxmaj pneumococcal vaccination versus pneumococcal vaccination xxmaj data xxmaj references xxmaj inconsistency xxmaj we downgraded inconsistency metaanalysis randomized trials found severe amount heterogeneity i p xxmaj in addition visual inspection relative risks xxmaj forrest plot metaanalysis revealed five studies relative benefit four studies little relative benefit one study relative harm xxmaj indirectness xxmaj the performance measure intended patients aged years older recovering community acquired pneumonia evidence presented adults ages recovering infection xxmaj we downgraded indirectness population data suggest pneumococcal vaccine may less effective among elderly patients comorbidity patients currently recently infected xxmaj imprecision xxmaj we downgrade imprecision already downgraded inconsistency partially related wide xxup ci relative effect xxmaj we also note absolute effects small compatible small benefit absolute risk reduction upper limit confidence interval x xxmaj inconsistency xxmaj visual inspection xxmaj forrest plot metaanalysis revealed seven studies relative benefit five studies little relative benefit two studies relative harm xxmaj in addition found large amount heterogeneity i p k xxmaj inconsistency xxmaj we downgraded inconsistency metaanalysis randomized trials found moderate amount heterogeneity i p xxmaj in addition visual inspection relative risks xxmaj forrest plot metaanalysis revealed six studies relative benefit three studies little relative benefit three studies relative harm xxup table xxup evidence xxup table xxup for xxup the xxup smoking xxup cessation xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other considerations xxmaj quit rate xxmaj randomized trials xxmaj no serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj serious xxmaj none xxmaj summary xxmaj findings xxmaj no xxmaj patients xxmaj effect xxmaj smoking cessation advice xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj quit rate xxup rr per fewer o xxmaj moderate xxmaj critical xxmaj for definition abbreviations see xxmaj table xxmaj comparator xxmaj inpatient smoking cessation counseling versus counseling xxmaj data xxmaj references xxmaj the quit rate surrogate many patient important outcomes xxmaj however well established reliable surrogate xxmaj therefore evidence downgraded indirectness comparator xxmaj slight imprecision xxmaj assuming absolute risk reduction quit rate would prompt clinicians provide smoking cessation counseling threshold number needed treat upper lower limits cis indicate opposite clinical decisions xxup american xxup journal xxup of xxup respiratory xxup and xxup critical xxup care xxup medicine xxup vol intervention separately three observational studies found improvement clinical outcomes xxmaj our systematic review targeted evidence related current performance measure antibiotics within hours xxmaj the review identify studies met inclusion criteria e enrolled patients xxup cap compared initial antibiotic dose within hours later antibiotic dose measured patient important outcomes therefore extracted data studies described relationship outcome duration initial antibiotic dose range durations xxmaj we identified three retrospective cohort studies xxmaj figure e xxmaj metaanalyses performed studies report event data xxmaj however studies found administration initial antibiotic dose within hours associated lower likelihood prolonged hospital stay xxup rr xxup ci xxmaj table xxmaj it also associated decreased mortality adjusted xxup or xxup ci adjusted xxup or xxup ci although latter study statistically significant xxmaj the quality evidence supporting performance measure recommendation begin antibiotics within hours depended upon outcome xxmaj table xxmaj for mortality low quality evidence two observational studies dose response gradient serious risk bias imprecise estimates xxmaj for incidence prolonged hospital stay low quality evidence observational study large effect serious risk bias xxmaj guideline xxmaj compliant xxmaj antibiotics xxmaj the antibiotic selection performance measure determines proportion adult patients xxup cap received initial antibiotic regimen consistent current guidelines first hours hospitalization xxmaj acceptable regimens listed xxmaj specification xxmaj manual xxmaj national xxmaj hospital xxmaj quality xxmaj measures consistent xxmaj infectious xxmaj disease xxmaj society xxmaj america xxup idsa xxmaj american xxmaj thoracic xxmaj society xxup ats guidelines xxup cap xxmaj our systematic review identified two retrospective cohort studies met inclusion criteria e enrolled patients xxup cap compared antibiotic regimens consistent xxup idsa xxup ats guidelines regimens measured patient important outcomes xxmaj given paucity data fact xxup idsa xxup ats guidelines xxup ats guidelines recommend similar antibiotic regimens xxunk selection criteria repeated systematic review xxmaj we selected studies compared antibiotic regimens consistent either xxup idsa xxup ats guidelines xxup ats guidelines regimens xxmaj our repeat systematic review identified six observational studies xxmaj figure e xxmaj metaanalyses performed several studies report event data xxmaj however studies consistently found guideline compliant antibiotic regimen associated decreased mortality xxup rr xxup ci adjusted xxup or xxup ci adjusted xxup or xxup ci adjusted xxup or xxup ci adjusted xxup rr p adjusted xxup or xxup ci xxmaj table xxmaj the quality evidence supporting performance measure recommendation use guideline consistent antibiotic regimen moderate xxmaj table xxmaj there multiple observational studies strengthened large effect xxmaj influenza xxmaj vaccination xxmaj the influenza vaccination performance measure determines proportion patients aged years older hospitalized xxup cap months xxmaj october xxmaj march xxup table xxup evidence xxup tables xxup for xxup the xxup antibiotic xxup timing xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no xxmaj studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other xxmaj considerations xxmaj mortality xxmaj observational studies xxmaj serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj serious xxmaj dose response xxunk xxmaj incidence prolonged length stay xxmaj observational studies xxmaj serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj no serious imprecision xxmaj strong association xxmaj summary xxmaj findings xxmaj no xxmaj patients xxmaj effect xxmaj intervention xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj mortality k k xxmaj not pooled xxmaj not pooled o xxmaj very low xxmaj critical xxmaj incidence prolonged length stay xxup rr fewer per fewer fewer xxup oo xxmaj low xxmaj important xxmaj definition abbreviations xxup ci confidence interval xxup or odds ratio xxup rr relative risk xxmaj comparison xxmaj antibiotics initiated within hours versus antibiotics initiated later xxmaj data xxmaj references xxmaj early antibiotic therapy may marker aggressive approach initial care xxmaj thus cointerventions rather antibiotics within hours may responsible effects measured xxmaj indirectness xxmaj the performance measure adults studies primarily conducted patients years old xxmaj nevertheless downgrade quality evidence indirectness could think reason advanced age would xxunk us true impact early antibiotic therapy xxmaj imprecision xxmaj assuming absolute risk reduction mortality would prompt clinicians administer first antibiotic dose within hours threshold number needed treat upper lower limits cis studies indicate opposite clinical decisions x xxmaj dose response gradient xxmaj both studies found earlier antibiotic administration associated lower mortality range approximately hours k xxmaj only one studies reported event data shown a metaanalysis conducted event data reported one studies xxmaj the relative effects individual studies included adjusted xxup or xxup ci adjusted xxup or xxup ci xxmaj the incidence prolonged length stay antibiotics administered within hours less half incidence antibiotics administered later xxmaj pulmonary xxmaj perspective screened influenza vaccine status vaccinated discharge indicated xxmaj our systematic review identified randomized trials met inclusion criteria e compared influenza vaccination influenza measured patient important outcomes xxmaj figure e xxmaj metaanalyses trials found influenza vaccination decreased incidence laboratory confirmed cases symptomatic influenza xxup rr xxup ci influenza like illnesses xxup rr xxup ci xxmaj table xxmaj our findings consistent previous metaanalyses xxmaj the quality evidence supporting performance measure recommendation influenza vaccination varied according outcome xxmaj table xxmaj for laboratory confirmed cases symptomatic influenza quality evidence high numerous randomized trials large effect xxmaj for influenza like illnesses quality evidence moderate randomized trials inconsistent results trials found benefit several found effect xxup discussion xxmaj the purpose study systematically evaluate evidence underlying performance measures xxmaj our results suggest estimated effect usually favors intervention xxup table xxup evidence xxup table xxup for xxup the xxup guideline xxup compliant xxup antibiotic xxup regimen xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no xxmaj studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other xxmaj considerations xxmaj mortality xxmaj observational studies xxmaj no serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj no serious imprecision xxmaj strong association xxmaj summary xxmaj findings xxmaj no xxmaj patients xxmaj effect xxmaj guideline xxmaj compliant xxmaj antibiotics xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj mortality xxmaj not pooledx xxmaj not pooledx xxmaj not pooledx xxmaj not pooledx o xxmaj moderate xxmaj critical xxmaj for definition abbreviations see xxmaj table xxmaj comparison xxmaj guideline compliant antibiotic regimen versus non guideline compliant antibiotic regimen xxmaj data references xxmaj the performance measure intended adults community acquired pneumonia xxmaj however one studies looked elderly patients xxmaj we downgrade indirectness population results similar among studies suggesting age population little impact results xxmaj only one six studies imprecision therefore downgrade imprecision xxmaj five six studies estimated guideline compliant antimicrobial therapy associated adjusted mortality less half associated noncompliant therapy therefore upgraded large magnitude effect x a metaanalysis performed event data reported several studies xxmaj the relative effects individual studies included xxup rr xxup ci adjusted xxup or xxup ci adjusted xxup or xxup ci adjusted xxup or xxup ci adjusted xxup rr p adjusted xxup or xxup ci xxup table xxup evidence xxup table xxup for xxup the xxup influenza xxup vaccination xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other xxmaj considerations xxmaj laboratory confirmed cases symptomatic influenza xxmaj randomized trials xxmaj no serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj no serious imprecision xxmaj strong association xxmaj influenza like illness xxmaj randomized trials xxmaj no serious limitations xxmaj serious xxmaj no serious indirectness xxmaj no serious imprecision xxmaj none xxmaj summary xxmaj findings xxmaj no xxmaj patients xxmaj effect xxmaj influenzae xxmaj vaccination xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj laboratory confirmed cases symptomatic influenza xxup rr fewer per fewer fewer xxmaj high xxmaj critical xxmaj influenza like illness xxup rr fewer per fewer fewer o xxmaj moderate xxmaj important xxmaj for definition abbreviations see xxmaj table xxmaj question xxmaj influenzae vaccination versus either influenza vaccination placebo xxmaj data xxmaj references xxmaj the performance measure intended patients aged years older evidence presented adults ages xxmaj we downgrade indirectness population metaanalyses randomized trials demonstrated effectiveness influenza vaccination among elderly patients xxmaj large effect xxmaj our metaanalysis randomized trials found incidence influenza less half among patients received influenza vaccine compared xxmaj inconsistency xxmaj visual inspection relative risks xxmaj forrest plot metaanalysis revealed trials relative benefit trials little relative benefit xxmaj in addition metaanalysis randomized trials found large amount heterogeneity i p xxup american xxup journal xxup of xxup respiratory xxup and xxup critical xxup care xxup medicine xxup vol recommended performance measure evidence frequently high quality xxmaj this implies uncertainty balance desirable undesirable effects intervention xxmaj we believe uncertainty exists compelling factors favor intervention going recommended performance measure xxmaj these factors may include patient values preferences pertain intervention outcomes well resource use xxmaj it possible factors implicitly influence development performance measures suggest stated explicitly xxunk evaluated basis performance measures xxmaj we chose xxmaj joint xxmaj commission xxmaj centers xxmaj medicaid xxmaj medicare xxmaj services performance measures xxup cap illustrative set performance measures xxmaj we believe recommendations influenza vaccination guideline compliant antibiotics reasonable performance measures xxmaj influenza vaccination large effect supported high quality evidence xxmaj table whereas use guideline compliant antibiotic regimen also large effect supported moderate quality evidence xxmaj table xxmaj although would ideal guideline compliant antibiotic performance measure supported high quality evidence uncertainty exists ratio desirable undesirable effects seems superseded potential major patient important benefits implicit distribution values preferences limited resource requirements xxmaj specifically potential desirable effects administering guideline compliant antibiotics decrease mortality far exceeds potential undesirable effects antibiotic side effects resource requirements cost antibiotic administered appropriate patients xxmaj thus likely patients would choose receive guideline compliant antibiotics xxmaj in contrast recommendations influenza vaccination guideline compliant antibiotics believe rationale recommendations pneumococcal vaccination antibiotics within hours blood cultures one step inpatient smoking cessation counseling elusive either reconsideration description sponsoring organizations warranted xxmaj with respect recommendation pneumococcal vaccination finding pneumococcal vaccination decreases pneumococcal pneumonia invasive pneumococcal disease supported low quality evidence suggesting uncertainty presence magnitude estimated effect xxmaj even pneumococcal vaccination beneficial magnitude pneumococcal vaccination decreases pneumococcal pneumonia invasive pneumococcal disease probably extremely small due low baseline risk xxmaj based randomized trials absolute risk reduction may low xxmaj table xxmaj patients clinicians healthcare organizations may reasonably decide small benefits pneumococcal vaccination outweigh burdens costs xxmaj it argued benefits may larger among elderly patients performance measure intended highest risk complications pneumococcal infection xxmaj however assumes pneumococcal vaccination effective elderly patients recovering xxup cap can not confirmed due conflicting data xxmaj with respect recommendation antibiotics within hours hospital arrival relevant evidence low low quality depending outcome meaning little confidence direction magnitude estimated effects xxmaj thus balance potential desirable effects decreased mortality decreased likelihood prolonged hospital stay undesirable effects increased misdiagnosis inappropriate antibiotic use uncertain xxmaj it seems likely early antibiotics beneficial patients e g patients sepsis due xxup cap others e g patients whose diagnosis uncertain xxmaj this argues use antibiotics within hours performance measure interventions recommended performance measures routinely benefit vast majority patients performance measure intended xxmaj with respect recommendation draw blood cultures patients admitted xxup icu evidence performing blood cultures patients xxup cap low quality xxmaj this means uncertainty presence magnitude estimated benefits blood cultures xxmaj it may argued blood cultures performed positive blood cultures frequently affect empiric therapy xxmaj however citing impact positive blood cultures xxunk importance performing blood culture relatively blood cultures positive even among xxup icu patients xxmaj it also assumes changes empiric therapy represent optimization therapy may incorrect xxmaj the possibility clinical benefits associated performing blood cultures benefits due optimization antimicrobial therapy suggests performing blood cultures merely surrogate interventions improve outcomes e g aggressive protocol guided care xxmaj with respect recommendation inpatient smoking cessation counseling found moderate quality evidence suggesting inpatient smoking cessation counseling alone improve smoking quit rate xxmaj table xxmaj however high quality evidence reported indicates inpatient smoking cessation counseling improves smoking quit rate followed least month outpatient smoking cessation therapy xxmaj we recognize importance smoking cessation believe performance measure may improved making recommendation inpatient smoking cessation counseling followed outpatient therapy least documentation intention continue counseling outpatient xxmaj it argued inpatient counseling prerequisite outpatient intervention therefore xxunk performance measure sine xxunk non argument weakened lack evidence enough patients complete outpatient counseling make inpatient efforts worthwhile xxmaj our study following strengths xxmaj we selected updated list performance measures conducted systematic reviews evidence used xxup grade strategy appraise evidence xxup grade approach focuses transparency evaluation quality evidence considers factors influence appropriateness performance measure based widely validated factors lead systematic errors factors used evaluate cause effect relationship xxmaj there also limitations study xxmaj we use multidisciplinary approach rigorous guideline development process evaluate performance measures xxmaj however believe methods transparent findings reproducible xxmaj in addition selected performance measures related xxup cap performance measures xxmaj given paucity attention paid importance developing performance measures supported high quality evidence presence lower quality evidence supported compelling factors favor intervention study probably representative would remain important even issues identified study less prevalent among performance measures diseases xxmaj pulmonary xxmaj perspective xxmaj in summary study suggests evidence supporting performance measures frequently high quality xxmaj this implies uncertainty balance desirable undesirable consequences interventions recommended performance measures xxmaj with respect illustrative performance measures xxup cap xxmaj joint xxmaj commission xxmaj centers xxmaj medicare xxmaj medicaid xxmaj services believe two performance measures recommendations influenza vaccination guideline compliant antibiotics reasonable performance measures four recommendations pneumococcal vaccination antibiotics within hours blood cultures one step smoking cessation counseling require explanation reconsideration xxmaj author xxmaj disclosure k c w full time employee uptodate xxmaj wolters xxmaj kluwer h s financial relationship commercial entity interest subject manuscript xxmaj references xxmaj specification xxmaj manual xxmaj national xxmaj hospital xxmaj quality xxmaj measures xxmaj version accessed xxmaj sept xxmaj available http www jointcommission org specifications manual national hospital inpatient quality measures xxmaj principles xxmaj xxunk xxmaj joint xxmaj commission xxmaj core xxmaj performance xxmaj measurement xxmaj activities accessed xxmaj sept xxmaj available http www jointcommission org assets xxmaj attach a xxmaj principles xxmaj review pdf xxmaj guyatt xxup gh xxmaj oxman xxup ad xxmaj kunz r xxmaj vist xxup ge xxmaj falck xxmaj ytter y xxmaj schunemann xxup hj xxmaj rating quality evidence strength recommendations quality evidence important clinicians xxup bmj xxmaj schunemann xxup hj xxmaj hill xxup sr xxmaj xxunk m xxmaj bellamy r xxmaj uyeki xxup tm xxmaj hayden xxup fg xxmaj yazdanpanah y xxmaj xxunk j xxmaj chotpitayasunondh t xxmaj del xxmaj mar c et al xxup who rapid advice guidelines pharmacological management sporadic infection avian influenza a h n virus xxmaj lancet xxmaj infect xxmaj dis xxmaj review xxmaj manager revman xxmaj computer program xxmaj version xxmaj copenhagen xxmaj the xxmaj nordic xxmaj cochrane xxmaj centre xxmaj the xxmaj cochrane xxmaj collaboration xxmaj schunemann xxup hj xxmaj vist xxup ge xxmaj jaeschke r xxmaj kunz r xxmaj cook xxup dj xxmaj guyatt xxup gh xxmaj grading recommendations xxmaj in xxmaj guyatt g xxmaj xxunk d xxmaj meade xxup mo xxmaj cook xxup dj editors xxmaj users guides medical literature nd ed xxmaj new xxmaj york mcgraw xxmaj hill pp gradepro xxmaj computer program xxmaj version xxmaj windows xxmaj jan xxmaj brozek xxmaj andrew xxmaj oxman xxmaj holger xxmaj schu nemann xxmaj xxunk s xxmaj holden j xxmaj xxunk xxup dp xxmaj andrews xxup rm xxmaj vaccines preventing pneumococcal infection adults xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj xxunk a xxmaj scott p xxmaj stuck xxup ae xxmaj xxunk c xxmaj egger m xxmaj efficacy pneumococcal vaccination adults meta analysis xxup cmaj xxmaj fine xxup mj xxmaj smith xxup ma xxmaj carson xxup ca xxmaj xxunk f xxmaj xxunk xxup ss xxmaj xxunk xxup la xxmaj detsky xxup as xxmaj kapoor xxup wn xxmaj efficacy pneumococcal vaccination adults meta analysis randomized controlled trials xxmaj arch xxmaj intern xxmaj med xxmaj cornu c xxmaj xxunk d xxmaj leophonte p xxmaj gaillat j xxmaj boissel xxup jp xxmaj xxunk m xxmaj efficacy pneumococcal polysaccharide vaccine immunocompetent adults meta analysis randomized trials xxmaj vaccine xxmaj moore xxup ra xxmaj wiffen xxup pj xxmaj lipsky xxup ba xxmaj are pneumococcal polysaccharide vaccines effective xxmaj meta analysis prospective trials xxup bmc xxmaj fam xxmaj pract xxmaj hutchison xxup bg xxmaj oxman xxup ad xxmaj shannon xxup hs xxmaj lloyd s xxmaj xxunk xxup ca xxmaj thomas k xxmaj clinical effectiveness pneumococcal vaccine metaanalysis xxmaj can xxmaj fam xxmaj physician xxmaj xxunk s xxmaj watson l xxmaj xxunk j xxmaj xxunk n xxmaj the effectiveness pneumococcal polysaccharide vaccines adults systematic review observational studies comparison results randomized controlled trials xxmaj vaccine xxmaj honkanen xxup po xxmaj xxunk t xxmaj xxunk l xxmaj herva e xxmaj sankilampi u xxmaj laara e xxmaj leinonen m xxmaj kivela xxup sl xxmaj makela xxup ph xxmaj incremental effectiveness pneumococcal vaccine simultaneously administered influenza vaccine preventing pneumonia pneumococcal pneumonia among persons aged years older xxmaj vaccine xxmaj xxunk xxup gc xxmaj xxunk m xxmaj makela h xxmaj greenwood xxup bm xxmaj response pneumococcal vaccination normal post infected xxmaj xxunk j xxmaj infect xxmaj xxunk j xxmaj singer xxup de xxmaj chang y xxmaj moore m xxmaj atlas xxup sj xxmaj processes care illness severity outcomes management communityacquired pneumonia academic hospitals xxmaj arch xxmaj intern xxmaj med xxmaj meehan xxup tp xxmaj fine xxup mj xxmaj xxunk xxup hm xxmaj xxunk xxup jd xxmaj xxunk xxup dh xxmaj xxunk xxup jt xxmaj weber xxup gf xxmaj xxunk xxup mk xxmaj houck xxup pm xxmaj fine xxup jm xxmaj quality care process outcomes elderly patients pneumonia xxup jama xxmaj xxunk n xxmaj xxunk xxup mr xxmaj stead xxup lf xxmaj interventions smoking cessation hospitalized patients xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj barlow g xxmaj xxunk d xxmaj williams f xxmaj xxunk s xxmaj winter j xxmaj jones m xxmaj xxunk p xxmaj myers e xxmaj sullivan f xxmaj stevens n et al xxmaj reducing door antibiotic time community acquired pneumonia controlled evaluation cost effectiveness analysis xxmaj thorax xxmaj xxunk m xxmaj xxunk n xxmaj khatib r xxmaj xxunk xxup mg xxmaj misdiagnosis community acquired pneumonia inappropriate utilization antibiotics side effects h antibiotic administration rule xxmaj chest xxmaj metersky xxup ml xxmaj sweeney xxup ta xxmaj xxunk xxup mb xxmaj siddiqui f xxmaj nsa w xxmaj bratzler xxup dw xxmaj antibiotic timing diagnostic uncertainty xxmaj medicare patients pneumonia reasonable expect patients receive antibiotics within hours xxmaj chest xxmaj xxunk xxup rm xxmaj flanders xxup sa xxmaj fee c xxmaj xxunk xxup pj xxmaj public reporting antibiotic timing patients pneumonia lessons flawed performance measure xxmaj ann xxmaj intern xxmaj med xxmaj welker xxup ja xxmaj huston m xxunk xxup jd xxmaj antibiotic timing errors diagnosing pneumonia xxmaj arch xxmaj intern xxmaj med xxmaj pines xxup jm xxmaj hollander xxup je xxmaj lee h xxmaj xxunk xxup ww xxmaj xxunk xxmaj pines l xxmaj xxunk xxup jp xxmaj emergency department operational changes response xxunk performance antibiotic timing pneumonia xxmaj acad xxmaj emerg xxmaj med xxmaj drake xxup de xxmaj cohen a xxmaj cohn j xxmaj national hospital antibiotic timing measures pneumonia antibiotic overuse xxmaj qual xxmaj manag xxmaj health xxmaj care xxmaj xxunk xxup ba xxmaj xxunk xxup de xxmaj xxunk xxup mt xxmaj the xxmaj centers xxmaj medicare xxmaj medicaid xxmaj services xxup xxunk community acquired pneumonia core measures lead unnecessary antibiotic administration emergency physicians xxmaj acad xxmaj emerg xxmaj med xxmaj xxunk xxup gw xxmaj kessler xxup la xxmaj wunderink xxup rg xxmaj delayed administration antibiotics atypical presentation community acquired pneumonia xxmaj chest xxmaj houck xxup pm xxmaj bratzler xxup dw xxmaj niederman m xxmaj bartlett xxup jg xxmaj pneumonia treatment process quality xxmaj arch xxmaj intern xxmaj med mcgarvey xxup rn xxmaj harper xxup jj xxmaj pneumonia mortality reduction quality improvement community hospital xxup xxunk xxmaj qual xxmaj rev xxmaj bull xxmaj bruns xxup ah xxmaj xxunk xxup jj xxmaj xxunk xxup wn xxmaj xxunk xxup ca xxmaj xxunk e xxmaj hoepelman xxup ai xxmaj time first antibiotic dose predictive early clinical failure moderate severe community acquired pneumonia xxmaj eur j xxmaj clin xxmaj microbiol xxmaj infect xxmaj dis xxmaj xxunk xxup ds xxmaj callahan m xxmaj thaler xxup ht xxmaj rapid antibiotic delivery appropriate antibiotic selection reduce length hospital stay patients community acquired pneumonia link quality care resource utilization xxmaj arch xxmaj intern xxmaj med xxmaj houck xxup pm xxmaj bratzler xxup dw xxmaj nsa w xxmaj ma a xxmaj bartlett xxup jg xxmaj timing antibiotic administration outcomes xxmaj medicare patients hospitalized community acquired pneumonia xxmaj arch xxmaj intern xxmaj med xxmaj mandell xxup la xxmaj wunderink xxup rg xxmaj xxunk a xxmaj bartlett xxup jg xxmaj campbell xxup gd xxmaj dean xxup nc xxmaj dowell xxup sf xxmaj file xxup tm xxmaj jr xxmaj xxunk xxup dm xxmaj niederman xxup ms et al xxmaj infectious xxmaj diseases xxmaj society xxmaj america xxmaj american xxmaj thoracic xxmaj society consensus guidelines management community acquired pneumonia adults xxmaj clin xxmaj infect xxmaj dis s s xxmaj niederman xxup ms xxmaj mandell xxup la xxmaj anzueto a xxmaj bass xxup jb xxmaj broughton xxup wa xxmaj campbell xxup gd xxmaj dean n xxmaj file t xxmaj fine xxup mj xxmaj gross xxup pa et al xxmaj guidelines management adults community acquired pneumonia xxmaj am j xxmaj respir xxmaj crit xxmaj care xxmaj med xxmaj arnold xxup fw xxunk xxup as xxmaj brock xxup gn xxmaj xxunk p xxmaj xxunk j xxmaj menendez r xxmaj xxunk g xxmaj torres a xxmaj rossi p xxmaj ramirez xxup ja xxmaj improving outcomes elderly patients community acquired pneumonia adhering national guidelines community acquired pneumonia organization international cohort study results xxmaj arch xxmaj intern xxmaj med mccabe c xxmaj kirschner c xxmaj zhang h xxmaj xxunk j xxmaj fisman xxup dn xxmaj guidelineconcordant therapy reduced mortality length stay xxup american xxup journal xxup of xxup respiratory xxup and xxup critical xxup care xxup medicine xxup vol adults community acquired pneumonia playing rules xxmaj arch xxmaj intern xxmaj med xxmaj xxunk xxup pg xxmaj torres a xxmaj valles x xxmaj mensa j xxmaj xxunk xxup ma xxmaj xxunk g xxmaj xxunk m xxmaj estruch r xxmaj sanchez m xxmaj menendez r et al xxmaj adherence guidelines empirical antibiotic recommendations communityacquired pneumonia outcome xxmaj eur xxmaj respir j xxmaj mortensen xxup em xxmaj restrepo xxup mi xxmaj anzueto a xxmaj pugh xxup ja xxmaj antibiotic therapy hour mortality patients pneumonia xxmaj am j xxmaj med xxmaj xxunk xxup cr xxmaj restrepo xxup mi xxmaj mortensen xxup em xxmaj burgess xxup ds xxmaj impact guideline concordant empiric antibiotic therapy communityacquired pneumonia xxmaj am j xxmaj med xxmaj mortensen xxup em xxmaj restrepo m xxmaj anzueto a xxmaj pugh j xxmaj effects guidelineconcordant antimicrobial therapy mortality among patients community acquired pneumonia xxmaj am j xxmaj med xxmaj villari p xxmaj xxunk l xxmaj xxunk a xxmaj methodological quality studies patient age major sources variation efficacy estimates influenza vaccination healthy adults meta analysis xxmaj vaccine xxmaj jefferson xxup to xxmaj rivetti d xxmaj di xxmaj pietrantonj c xxmaj rivetti a xxmaj demicheli v xxmaj vaccines preventing influenza healthy adults xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj rivetti d xxmaj jefferson t xxmaj thomas r xxmaj rudin m xxmaj rivetti a xxmaj di xxmaj pietrantonj c xxmaj demicheli v xxmaj vaccines preventing influenza elderly xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj schunemann xxup hj xxmaj jaeschke r xxmaj cook xxup dj xxmaj xxunk xxup wf xxmaj el xxmaj xxunk xxup aa xxmaj ernst a xxmaj xxunk xxup bf xxmaj gould xxup mk xxmaj horan xxup kl xxmaj xxunk xxup ja xxmaj an official xxup ats statement grading quality evidence strength recommendations xxup ats guidelines recommendations xxmaj am j xxmaj respir xxmaj crit xxmaj care xxmaj med xxmaj metersky xxup ml xxmaj ma a xxmaj bratzler xxup dw xxmaj houck xxup pm xxmaj predicting bacteremia patients community acquired pneumonia xxmaj am j xxmaj respir xxmaj crit xxmaj care xxmaj med xxmaj campbell xxup sg xxmaj xxunk xxup tj xxmaj xxunk r xxmaj dickinson g xxmaj xxunk xxmaj xxunk s xxmaj the contribution blood cultures clinical management adult patients admitted hospital community acquired pneumonia prospective observational study xxmaj chest xxmaj atkins d xxmaj best d xxmaj xxunk xxup pa xxmaj eccles m xxmaj falck xxmaj ytter y xxmaj xxunk s xxmaj guyatt xxup gh xxmaj harbour xxup rt xxmaj haugh xxup mc xxmaj henry d et al xxmaj grading quality evidence strength recommendations xxup bmj xxmaj ward xxup ac xxmaj the role causal criteria causal inferences xxunk aspects association xxmaj epidemiol xxmaj perspect xxmaj xxunk xxmaj xxunk i xxmaj xxunk r xxmaj reyes n xxmaj munoz j xxmaj fernandez a xxmaj hernandez m xxmaj merino m xxmaj perez j xxmaj lima j xxmaj clinical efficacy anti pneumococcal vaccination patients xxup copd xxmaj thorax xxmaj austrian r xxmaj surveillance pneumococcal infection field trials polyvalent pneumococcal vaccines xxmaj bethesda xxup md xxmaj national xxmaj institute xxmaj allergy xxmaj infectious xxmaj diseases pp xxmaj austrian r xxmaj douglas xxup rm xxmaj schiffman g xxmaj coetzee xxup am xxmaj koornhof xxup hj xxmaj hayden xxmaj smith s xxmaj reid xxup rd xxmaj prevention pneumococcal pneumonia vaccination xxmaj trans xxmaj assoc xxmaj am xxmaj physicians xxmaj davis xxup al xxmaj aranda xxup cp xxmaj schiffman g xxmaj xxunk xxup lc xxmaj pneumococcal infection immunologic response pneumococcal vaccine chronic obstructive pulmonary disease pilot study xxmaj chest xxmaj french n xxmaj xxunk j xxmaj carpenter xxup lm xxmaj xxunk e xxmaj xxunk c xxmaj moi k xxmaj moore m xxmaj xxunk d xxmaj mulder d xxmaj xxunk xxup en et al valent pneumococcal polysaccharide vaccine xxup hiv infected xxmaj xxunk adults double blind randomised placebo controlled trial xxmaj lancet xxmaj gaillat j xxmaj xxunk d xxmaj xxunk xxup mr xxmaj xxunk d xxmaj xxunk xxup jp xxmaj stahl xxup jp xxmaj xxunk p xxmaj xxunk m xxmaj clinical trial xxunk vaccine elderly subjects living institutions xxmaj rev xxmaj epidemiol xxmaj sante xxmaj xxunk xxmaj honkanen xxup po xxmaj xxunk t xxmaj miettinen l xxmaj herva e xxmaj sankilampi u xxmaj laara e xxmaj leinonen m xxmaj kivela xxup sl xxmaj makela xxup ph xxmaj incremental effectiveness pneumococcal vaccine simultaneously administered influenza vaccine preventing pneumonia pneumococcal pneumonia among persons aged years older xxmaj vaccine xxmaj kaufman p xxmaj pneumonia old age active immunization pneumonia pneumococcal polysaccharide results six year study xxmaj arch xxmaj intern xxmaj med xxmaj klastersky j xxmaj xxunk p xxmaj xxunk f xxmaj xxunk a xxmaj placebo controlled pneumococcal immunization patients bronchogenic carcinoma xxmaj eur j xxmaj cancer xxmaj clin xxmaj oncol xxmaj xxunk i xxmaj xxunk m xxmaj leinonen m xxmaj makela xxup ph xxmaj clinical efficacy pneumococcal vaccine elderly randomized single blind population based trial xxmaj am j xxmaj med xxmaj leech xxup ja xxmaj xxunk a xxmaj ruben xxup fl xxmaj efficacy pneumococcal vaccine severe chronic obstructive pulmonary disease xxup cmaj xxmaj xxunk a xxmaj hedlund j xxmaj xxunk xxup la xxmaj xxunk e xxmaj hofer m xxmaj leinonen m xxmaj lindblad i xxmaj xxunk b xxmaj xxunk m xxmaj randomized trial valent pneumococcal xxunk polysaccharide vaccine prevention pneumonia middle aged elderly people xxmaj swedish xxmaj pneumococcal xxmaj vaccination xxmaj study xxmaj group xxmaj lancet xxmaj riley xxup id xxmaj xxunk xxup pi xxmaj andrews m xxmaj pfeiffer m xxmaj howard r xxmaj xxunk p xxmaj xxunk g xxmaj immunization polyvalent pneumococcal vaccine reduction adult respiratory mortality xxmaj new xxmaj guinea xxmaj highlands community xxmaj lancet xxmaj xxunk xxup ms xxmaj cross xxup ap xxmaj al xxmaj ibrahim m xxmaj xxunk xxup al xxmaj xxunk xxup ph xxmaj nadler j xxmaj richmond xxup as xxmaj smith xxup rp xxmaj schiffman g xxmaj shepard xxup ds et al xxmaj efficacy pneumococcal vaccine high risk patients results xxmaj veterans xxmaj administration xxmaj cooperative xxmaj study n xxmaj engl j xxmaj med xxmaj smit p xxmaj xxunk d xxmaj hayden xxmaj smith s xxmaj koornhof xxup hj xxmaj hilleman xxup mr xxmaj protective efficacy pneumococcal polysaccharide vaccines xxup jama xxmaj xxunk j xxmaj xxunk xxup hb xxmaj xxunk j xxmaj xxunk g xxmaj andersen xxup jr xxmaj response pneumococcal vaccine chronic obstructive lung xxunk effect ongoing systematic steroid treatment xxmaj vaccine xxmaj xxunk xxup sd xxmaj xxunk xxup vd xxmaj xxunk xxup va xxmaj mel xxunk xxup pi xxmaj xxunk xxup pi xxmaj efficacy pneumococcal vaccine military units xxmaj zh xxmaj xxunk xxmaj epidemiol xxmaj xxunk xxmaj xxunk c de xxmaj vries h van xxmaj breukelen g a minimal contact intervention cardiac inpatients long term effects smoking cessation xxmaj prev xxmaj med xxmaj chouinard xxup mc xxmaj xxunk xxmaj xxunk s xxmaj the effectiveness nursing inpatient smoking cessation program individuals cardiovascular disease xxmaj nurs xxmaj res xxmaj croghan xxup ga xxmaj croghan xxup it xxmaj frost xxup ma xxmaj sloan xxup ja xxmaj novotny xxup pj xxmaj nelson xxup ma xxmaj smoking cessation interventions post operative outcomes xxunk lung cancer patients xxmaj society xxmaj research xxmaj nicotine xxmaj tobacco th xxmaj annual xxmaj meeting xxmaj march xxmaj prague xxmaj czech xxmaj republic xxmaj xxunk p xxmaj taylor xxup tz xxmaj mills p xxmaj brief intervention hospital admission help patients give smoking myocardial infarction bypass surgery randomized controlled trial xxup bmj xxmaj xxunk xxup dj xxmaj xxunk xxup ha mccarty xxup mc xxmaj xxunk d xxmaj xxunk n xxmaj xxunk xxup ja xxmaj xxunk s xxmaj xxunk xxup pr xxmaj pine d xxmaj sullivan s et al xxmaj the xxup team project effectiveness smoking cessation intervention hospital patients xxmaj prev xxmaj med xxmaj molyneux a xxmaj lewis s xxmaj xxunk u xxmaj xxunk a xxmaj xxunk m xxmaj xxunk a xxmaj nilsson f xxunk a xxmaj west r xxmaj xxunk j et al xxmaj clinical trial comparing nicotine replacement therapy xxup xxunk plus brief counseling alone minimal intervention smoking cessation hospital patients xxmaj thorax xxmaj xxunk xxup al xxmaj hensley xxup mj xxmaj schofield xxup mj xxmaj xxunk xxup aj a randomized controlled trial evaluate efficacy nurse provided intervention hospitalized smokers xxmaj aust n z j xxmaj public xxmaj health xxmaj pelletier xxup jg xxmaj moisan xxup jt xxmaj smoking cessation hospitalized patients quasi experimental study xxmaj quebec xxmaj can j xxmaj public xxmaj health xxmaj pederson xxup ll xxmaj xxunk xxup jm xxmaj xxunk xxup nm xxmaj the effects counseling smoking cessation among patients hospitalized chronic obstructive pulmonary disease randomized clinical trial xxmaj int j xxmaj addict xxmaj xxunk b xxmaj xxunk xxup me xxmaj baker xxup ca xxmaj the effectiveness xxunk minimal smoking cessation intervention among hospitalized patients cancer xxmaj oncol xxmaj nurs xxmaj forum xxmaj bridges xxup cb xxmaj thompson xxup ww xxmaj meltzer xxup mi xxmaj reeve xxup gr xxmaj talamonti xxup wj xxmaj cox xxup nj xxmaj xxunk xxup ha xxmaj hall h xxmaj klimov a xxmaj xxunk k xxmaj effectiveness cost benefit influenza vaccination healthy working adults randomized controlled trial xxup jama xxmaj couch xxup rb xxmaj quarles xxup jm xxmaj cate xxup tr xxmaj zahradnik xxmaj clinical trials live cold xxunk influenza virus vaccines xxmaj in xxmaj kendal xxup ap xxmaj patriarca xxup pa editors xxmaj options control influenza xxmaj proceedings xxmaj viratek xxup ucla symposium xxmaj xxunk xxup co xxup ucla xxunk xxmaj perspective sia molecular cellular biology xxmaj new xxmaj york xxmaj alan r xxmaj liss pp xxmaj eddy xxup ts xxmaj davies xxup na xxmaj the effect vaccine close epidemic xxmaj hong xxmaj kong influenza s xxmaj afr xxmaj med j xxmaj edmondson xxup kw xxmaj graham xxup ds xxmaj warburton xxup mf a clinical trial influenza vaccine xxmaj canberra xxmaj med j xxmaj aust xxmaj edwards xxup km xxmaj dupont xxup wd xxmaj westrich xxup mk xxmaj plummer xxup wd xxmaj jr xxmaj palmer xxup ps xxmaj wright xxup pf a randomized controlled trial cold adapted inactivated vaccines prevention influenza a disease j xxmaj infect xxmaj dis xxmaj hammond xxup ml xxmaj ferris xxup aa xxmaj faine s mcavan t xxmaj effective protection influenza vaccination subunit vaccine xxmaj med j xxmaj aust xxmaj hoskins xxup tw xxmaj davies xxup jr xxmaj allchin a xxmaj miller xxup cl xxmaj pollock xxup tm xxmaj controlled trial inactivated influenza vaccine containing xxmaj hong xxmaj kong strain outbreak influenza due xxmaj england strain xxmaj lancet xxmaj keitel xxup wa xxmaj cate xxup tr xxmaj couch xxup rb xxmaj huggins xxup ll xxmaj hess xxup kr xxmaj efficacy repeated annual immunization inactivated influenza virus vaccines five year period xxmaj vaccine xxmaj leibovitz a xxmaj xxunk xxup rl xxmaj kilbourne xxup ed xxmaj xxunk xxup lj xxmaj smith xxup cd xxmaj chin j xxmaj schulman xxup jl xxmaj correlated studies recombinant influenza virus vaccine xxup iv xxmaj protection naturally occurring influenza military trainees j xxmaj infect xxmaj dis xxmaj mair xxup hj xxmaj xxunk xxup da xxmaj tillett xxup he a controlled trial inactivated monovalent influenza a vaccines general practice j xxmaj hyg xxmaj lond xxmaj maynard xxup je xxmaj dull xxup hb xxmaj hanson xxup ml xxmaj feltz xxup et xxmaj berger r xxmaj xxunk l xxmaj evaluation monovalent polyvalent influenza vaccines epidemic type a b influenza xxmaj am j xxmaj epidemiol xxmaj xxunk xxup ma xxmaj vespa xxup gn xxmaj forleo xxmaj neto e xxmaj xxunk xxmaj neto j xxmaj alves xxup pm xxmaj impact influenza vaccination civilian xxunk illness absenteeism xxmaj xxunk xxmaj space xxmaj environ xxmaj med xxmaj mogabgab xxup wj xxmaj leiderman e xxmaj immunogenicity polyvalent xxmaj hong xxmaj kong influenza vaccines xxup jama xxmaj monto xxup as xxmaj miller xxup fd xxmaj maassab xxup hf xxmaj evaluation attenuated coldrecombinant influenza b virus vaccine j xxmaj infect xxmaj dis xxmaj nichol xxup kl xxmaj lind a xxmaj margolis xxup kl xxmaj murdoch m mcfadden r xxmaj hauge m xxmaj xxunk s xxmaj drake m xxmaj the effectiveness vaccination influenza healthy working adults n xxmaj engl j xxmaj med xxmaj nichol xxup kl xxmaj mendelman xxup pm xxmaj mallon xxup kp xxmaj jackson xxup la xxmaj gorse xxup gj xxmaj belshe xxup rb xxmaj glezen xxup wp xxmaj wittes j xxmaj effectiveness live attenuated intranasal influenza virus vaccine healthy working adults randomized controlled trial xxup jama xxmaj powers xxup dc xxmaj smith xxup ge xxmaj anderson xxup el xxmaj kennedy xxup dj xxmaj hackett xxup cs xxmaj wilkinson xxup be xxmaj volvovitz f xxmaj belshe xxup rb xxmaj treanor xxup jj xxmaj influenza a virus vaccines containing purified recombinant h hemagglutinin well tolerated induce protective immune responses healthy adults j xxmaj infect xxmaj dis xxmaj rytel xxup mw xxmaj jackson xxup lj xxmaj niebojewski xxup ra xxmaj haagensen xxup jl xxmaj rosenkranz xxup ma xxmaj field trial live attenuated influenza a b xxmaj alice r vaccine xxmaj am j xxmaj epidemiol xxmaj slepuskin xxup an xxmaj bobyleva xxup tk xxmaj russina xxup ae xxmaj vitkina xxup bs xxmaj xxunk xxup ns xxmaj xxunk xxup vm xxmaj evaluation effectiveness large scale vaccination influenza xxup ussr xxmaj bull xxmaj world xxmaj health xxmaj organ xxmaj tannock xxup ga xxmaj bryce xxup da xxmaj hensley xxup mj xxmaj saunders xxup na xxmaj gillett xxup rs xxmaj kennedy xxup ws xxmaj responses one two deoxycholate subunit influenza vaccine primed population xxmaj vaccine xxmaj waldman xxup rh xxmaj coggins xxup wj xxmaj influenza immunization field trial university campus j xxmaj infect xxmaj dis xxmaj waldman xxup rh xxmaj bond xxup jo xxmaj levitt xxup lp xxmaj hartwig xxup ed xxmaj prather xxup ec xxmaj baratta xxup rl xxmaj neill xxup js xxmaj small xxup pa xxmaj jr xxmaj an evaluation influenza immunization influence route administration vaccine strain xxmaj bull xxmaj world xxmaj health xxmaj organ xxmaj waldman xxup rh xxmaj mann xxup jj xxmaj small xxup pa xxmaj jr xxmaj immunization influenza prevention illness man aerosolized inactivated vaccine xxup jama xxmaj weingarten s xxmaj staniloff h xxmaj ault m xxmaj miles p xxmaj bamberger m xxmaj xxunk xxup rd xxmaj do hospital employees benefit influenza vaccine a placebocontrolled clinical trial j xxmaj gen xxmaj intern xxmaj med xxmaj wilde xxup ja mcmillan xxup ja xxmaj serwint j xxmaj butta j o xxmaj riordan xxup ma xxmaj steinhoff xxup mc xxmaj effectiveness influenza vaccine health care professionals randomized trial xxup jama xxmaj williams xxup mc xxmaj xxunk l mcdonald xxup jc xxmaj xxunk xxup pv xxmaj xxunk a xxmaj clayton xxup aj xxmaj trials aqueous killed influenza vaccine xxmaj canada xxmaj bull xxmaj world xxmaj health xxmaj organ xxup american xxup journal xxup of xxup respiratory xxup and xxup critical xxup care xxup medicine xxup vol,xxbos xxmaj arch xxmaj gynecol xxmaj obstet xxup doi xxup reproductive xxup medicine xxmaj letrozole versus laparoscopic ovarian diathermy ovulation induction clomiphene resistant women polycystic ovary syndrome randomized controlled trial xxmaj hatem xxmaj abu xxmaj hashim xxmaj abdel xxmaj xxunk xxmaj xxunk xxmaj ahmed xxmaj badawy xxmaj received xxmaj february xxmaj accepted xxmaj june xxmaj published online xxmaj june xxmaj springer xxmaj verlag xxmaj abstract xxmaj purpose xxmaj to compare xxunk letrozole laparoscopic ovarian diathermy xxup lod ovulation induction clomiphene citrate xxup cc resistant women polycystic ovary syndrome xxup pcos xxmaj methods xxmaj two hundred sixty anovulatory women xxup cc resistant xxup pcos selected randomized controlled trial xxmaj group a n received mg letrozole daily days six cycles xxmaj group b n underwent xxup lod months follow xxmaj outcome measures ovulation rate midcycle endometrial thickness pregnancy miscarriage live birth rates xxmaj results xxmaj ovulation occurred cycles letrozole group cycles xxup lod group without xxunk xxunk groups xxmaj resumption regular menstruation similar treatment groups a xxunk increase midcycle endometrial thickness observed letrozole group mm vs mm p xxmaj pregnancy rate similar groups vs xxmaj there statistical xxunk xxunk regards miscarriage live birth rates groups xxmaj no multiple pregnancy ovarian hyperstimulation occurred either group xxmaj conclusion xxmaj letrozole xxup lod equally xxunk inducing ovulation achieving pregnancy xxup cc resistant xxup pcos patients xxmaj keywords xxmaj polycystic ovary syndrome xxmaj clomiphene resistance xxmaj laparoscopic ovarian diathermy xxmaj letrozole xxmaj ovulation induction xxmaj introduction xxmaj polycystic ovary syndrome xxup pcos common cause infertility associated chronic anovulation hyperandrogenemia xxmaj it xxunk reproductive age women xxmaj clomiphene citrate xxup cc still holding place xxmaj xxunk line therapy ovulation induction patients xxmaj however use xxup cc may associated poor cervical mucous endometrial xxunk patients due prolonged xxunk depletion endometrium possibly cervix xxmaj furthermore clomiphene resistance e failure ovulate receiving mg day common occurs approximately women xxup pcos xxmaj although treatment gonadotropins often successful patients yet expensive risk ovarian hyperstimulation xxup ohss multiple pregnancy xxmaj laparoscopic ovarian diathermy xxup lod currently accepted successful second line treatment ovulation induction xxup cc resistant xxup pcos xxmaj bayram et al randomized trial compared xxup lod recombinant xxup fsh xxup cc resistant xxup pcos women xxmaj they reported ovulation rate per cycle pregnancy live birth rates patients respectively following xxup lod xxup fsh therapy xxmaj nevertheless xxup lod costly requires hospital treatment general anesthesia carries risk post operative adhesions premature ovarian failure xxunk hands h xxmaj abu xxmaj hashim a xxmaj xxunk a xxmaj badawy xxmaj departments xxmaj obstetrics xxmaj gynecology xxmaj mansoura xxmaj faculty xxmaj medicine xxmaj mansoura xxmaj university xxmaj mansoura xxmaj egypt e mail hatem ah hotmail com xxmaj arch xxmaj gynecol xxmaj obstet xxmaj letrozole aromatase inhibitor xxup ai attracted attention long time oral ovulatory agent reported ovulation rate pregnancy rate per cycle xxmaj moreover use xxup cc resistant xxup pcos patients achieve ovulation patients xxmaj to knowledge studies yet compared xxunk letrozole therapy xxup lod xxup cc resistant xxup pcos patients xxmaj the aim prospective randomized trial compare xxunk letrozole administration six cycles xxup lod ovulation induction xxup cc resistant infertile xxup pcos women xxmaj materials methods xxmaj patient population xxmaj the study comprised women xxup cc resistant xxup pcos among attending xxmaj outpatient xxmaj clinic xxmaj mansoura xxmaj university xxmaj hospitals private practice setting period xxmaj august xxmaj march xxmaj diagnosis xxup pcos based revised consensus diagnostic criteria long term health risks related xxup pcos xxmaj all women previously treated mg xxup cc daily days per cycle least three cycles persistent anovulation e xxup cc resistant xxmaj they patent xxmaj fallopian tubes proved hysterosalpingography normal semen analysis partners according xxunk criteria xxmaj world xxmaj health xxmaj organization xxmaj at study entry patients basal hormonal assays day progesterone induced menstruation overnight fast consisting xxup fsh xxup lh thyroid stimulating hormone xxup tsh prolactin xxunk xxup xxunk total testosterone sex xxunk globulin xxup shbg xxmaj fasting serum insulin glucose levels also performed xxmaj all patients normal serum prolactin xxup tsh xxup xxunk xxmaj exclusion criteria causes infertility age years xxup bmi contraindication general anesthetic previous history xxup lod women received metformin gonadotrophin oral contraceptives hormonal drugs preceding months xxmaj women intended start diet xxunk program physical activity also excluded xxmaj all women instructed maintain usual lifestyle eating habits study xxmaj the study approved xxmaj mansoura xxmaj university xxmaj hospital xxmaj research xxmaj ethics xxmaj committee participants gave informed consent inclusion trial xxmaj randomization xxmaj women randomized according computer generated random numeric table prepared independent statistician concealment treatment allocation use sealed opaque envelopes given third party nurse assigned patients study arms group a letrozole b xxup lod xxmaj once allocated treatment revealed investigator patient xxmaj however radiologist performed transvaginal ultrasound follow assessment blinded treatment groups xxmaj protocol treatment xxmaj in letrozole group group a treatment continued six cycles xxmaj initially withdrawal bleeding achieved using mg dydrogesterone tablets days stimulation using mg letrozole oral tablets xxmaj xxunk xxmaj novartis xxmaj pharma xxmaj services xxmaj switzerland daily day menses days xxmaj all patients monitored transvaginal ultrasound mean follicular diameter endometrial thickness days cycle xxmaj serum p ng ml measured days cycle xxup ria using antibody coated tube method xxmaj coat a xxmaj count xxmaj diagnostic xxmaj product xxmaj corporation xxmaj los xxmaj angeles xxup ca xxup usa xxmaj actually ovulate following three successive cycles letrozole dose considered responsive counseled lines treatment hcg total xxup iu xxup im xxmaj choriomon xxup ibsa xxmaj switzerland given one follicle measured least mm found xxmaj patients advised intercourse h hcg injection xxmaj in xxup lod group group b laparoscopy performed using three puncture technique xxmaj each ovary cauterized four points w depth mm mixed current using monopolar electrosurgical needle xxmaj karl xxmaj storz xxup nd xxmaj germany xxmaj the pelvis irrigated using xxmaj ringer lactated solution xxmaj the total duration procedure recorded intra operative post operative complications reported xxmaj follow continued months procedure xxmaj if menstruation occurred within weeks surgery blood sample would taken day cycle measurement serum concentration progesterone xxmaj ovulation diagnosed xxmaj serum p level ng ml xxmaj subsequent cycles monitored ovulation transvaginal ultrasound mean follicular diameter endometrial thickness days cycle serum progesterone day cycle xxmaj all patients showed ovulation advised natural intercourse xxmaj on hand anovulation persisted xxup lod evidenced low progesterone levels lack menstruation patient became anovulatory counseled lines treatment xxmaj in either group biochemical pregnancy considered serum hcg miu ml absence menstruation meanwhile sonographic evidence xxmaj arch xxmaj gynecol xxmaj obstet intrauterine gestational sac weeks gestation considered criteria xxunk clinical pregnancy xxmaj all pregnant women followed obtain miscarriage live birth rates xxmaj clinical miscarriage xxunk xxunk clinical pregnancy subsequently lost weeks gestation meanwhile biochemical miscarriage considered xxunk biochemical pregnancy subsequently lost without evidence intrauterine pregnancy demonstrated ultrasound xxmaj sample size xxmaj the primary outcome measure ovulation rate xxmaj secondary outcome measures included midcycle endometrial thickness mm biochemical pregnancy miscarriage live birth rates xxmaj sample size calculated based fact expected rate ovulation xxup lod group needed women show absolute increase ovulation rate letrozole group power xxunk interval using two tailed chi square test xxunk level type error xxmaj statistical analysis xxmaj data obtained statistically analyzed using xxmaj statistical xxmaj package xxmaj social xxmaj sciences xxup spss xxmaj chicago xxup usa software version xxmaj windows xxmaj analysis performed intention treat basis xxmaj means compared using unpaired student test proportions compared using chi square test p value less considered statistically xxunk xxmaj results a total patients studied women cycles women cycles groups a b respectively xxmaj fig xxmaj there statistical xxunk xxunk two groups regards age duration infertility anthropometric variables clinical manifestations hormonal xxunk ultrasound xxmaj xxunk xxup pcos xxmaj table xxmaj the duration xxup lod min intra operative post operative complications occurred xxmaj clinical reproductive outcomes presented xxmaj table xxmaj ovulation occurred cycles group a cycles group b without xxunk xxunk groups xxmaj resumption regular menstruation similar two treatment groups xxmaj there statistically xxunk xxunk pretreatment endometrial thickness two groups a xxunk increase mid cycle endometrial thickness observed group a mm vs mm p xxmaj biochemical pregnancy occurred cycles group a cycles group b xxmaj fig xxmaj flow chart participants trial xxmaj assessed eligibility n xxmaj excluded n xxmaj not meeting inclusion criteria n xxmaj refused participate n xxmaj randomized n xxmaj allocated xxup lod n xxmaj received allocated intervention n xxmaj did receive allocated intervention give reasons n xxmaj lost follow n xxmaj discontinued intervention n xxmaj analysed n xxmaj excluded analysis n xxmaj allocated letrozole n xxmaj received allocated intervention n xxmaj did receive allocated intervention give reasons n xxmaj lost follow n xxmaj discontinued intervention n xxmaj analysed n xxmaj excluded analysis n xxmaj enrolment xxmaj allocation xxmaj follow xxmaj analysis xxmaj table xxmaj patients characteristics xxmaj variable xxmaj group a letrozole n xxmaj group b xxup lod n xxmaj age years xxmaj parity xxmaj nulliparous xxmaj multiparous xxmaj duration infertility years xxup bmi kg xxmaj waist hip ratio xxmaj menstrual cycle xxmaj oligomenorrhoea xxmaj amenorrhoea xxmaj hyperandrogenism xxup lh miu ml xxup fsh miu ml xxup lh xxup fsh ratio xxmaj fasting glucose mg dl xxmaj fasting insulin u ml xxmaj fasting glucose insulin ratio xxmaj ovarian volume ml xxmaj arch xxmaj gynecol xxmaj obstet xxunk statistically xxunk xxmaj there statistically xxunk xxunk regarding clinical pregnancy rate two groups vs group a b respectively xxmaj no twin higher order pregnancies cases xxup ohss occurred either group xxmaj miscarriage either biochemical clinical live birth rates similar groups xxmaj discussion xxmaj in randomized controlled trial xxmaj xxunk time evaluated xxunk letrozole administration six cycles method ovulation induction xxup cc resistant infertile xxup pcos women comparison xxup lod xxmaj letrozole third generation aromatase inhibitor xxmaj its early administration follicular phase induces ovulation releasing hypothalamic pituitary axis e negative feedback thus increasing xxup fsh secretion stimulating ovarian follicular development xxmaj in addition increases follicular sensitivity xxup fsh accumulation intraovarian androgens xxmaj in study ovulation occurred cycles group a comparable reported two recent randomized trials xxmaj bayer et al xxmaj badawy et al ovulatory rates letrozole cycles respectively xxmaj in trials xxmaj xxunk xxmaj casper ovulatory rate xxmaj al xxmaj xxunk et al ovulatory rate xxmaj xxunk et al reported ovulation rate xxmaj this may explained small sample size trials xxmaj pregnancy achieved cycles group a comparable reported xxmaj badawy et al however less reported others xxmaj the miscarriage live birth rates similar groups a recent large randomized trial xxmaj xxunk et al compared xxunk letrozole rfsh xxup cc rfsh ovarian stimulation xxup iui cycles xxup pcos women xxup cc failure xxmaj they reported ovulation rate letrozole group versus groups respectively pregnancy rate letrozole group versus groups respectively xxmaj however included xxup cc resistant xxup pcos patients also failed conceive mg day xxup cc six cycles despite ovulating showed poor endometrial development e endometrial thickness mm day hcg administration xxmaj monofollicular growth seen advantage xxup lod ais xxup lod resume physiological monofollicular ovulation reducing risk xxup ohss multiple pregnancy ais rapidly eliminated body due relatively shorter half life days xxup cc month xxmaj so contrast use xxup cc hypothalamus able respond estrogen mediated negative feedback mechanism xxmaj this modulate excessive xxup fsh discharge thus likely result monofollicular ovulation moderate estrogen concentrations xxmaj also view absence regulation hypothalamic pituitary estrogen receptors late follicular phase adverse xxunk peripheral organs endometrium cervix considerably less xxmaj in study xxunk increase mid cycle endometrial thickness observed letrozole group xxmaj xxunk xxmaj casper showed letrozole associated xxunk endometrium compared xxup cc xxmaj this might due improved xxunk reported recent xxmaj doppler study xxmaj the safety letrozole xxunk xxunk discussion xxmaj preliminary data xxmaj xxunk et al suggested increased risk congenital anomalies letrozole treated babies whereas recent data retrospective prospective trials xxunk initial xxmaj xxunk supported safety letrozole compared traditional ovulation induction treatment xxmaj the cost treatment another issue xxmaj the cost letrozole per cycle much lower compared hospital charges needed xxup lod vs xxmaj egyptian xxmaj table xxmaj clinical reproductive outcomes letrozole xxup lod groups xxmaj group a letrozole n xxmaj group b xxup lod n p value xxmaj number cycles xxmaj regular menstruation xxup ns xxmaj ovulation cycle xxup ns xxmaj pretreatment endometrial thickness mm xxup ns xxmaj mid cycle endometrial thickness mm xxmaj biochemical pregnancy cycle xxup ns xxmaj clinical pregnancy patient xxup ns xxmaj biochemical miscarriage patient xxup ns xxmaj clinical miscarriage patient xxup ns xxmaj live birth rate xxup ns xxup ns xxunk xxmaj statistically xxunk xxmaj arch xxmaj gynecol xxmaj obstet pounds respectively xxmaj on hand xxup lod may cost xxunk one treatment principle results several ovulatory cycles whereas one course letrozole therapy yields single ovulatory cycle xxmaj in conclusion trial suggested six cycles letrozole xxup lod month follow period equally xxunk inducing ovulation achieving pregnancy patients xxup cc resistant xxup pcos xxmaj in view invasiveness cost surgery seems plausible letrozole therapy tried xxmaj xxunk women shifting xxup lod xxmaj acknowledgments xxmaj the authors would like thank xxmaj dr m xxmaj el xxmaj xxunk senior lecturer consultant xxmaj diagnostic xxmaj radiology xxmaj mansoura xxmaj university xxmaj hospitals xxunk xxunk transvaginal ultrasound assessment follow patients enabling completion trial report xxunk interest statement xxmaj we declare xxunk interest xxmaj references xxmaj azziz r xxmaj woods xxup ks xxmaj xxunk r xxmaj key xxup tj xxmaj knochenhauer xxup es xxmaj yildiz xxup bo xxmaj the prevalence features polycystic ovary syndrome unselected population j xxmaj clin xxmaj endocrinol xxmaj metab doi jc xxmaj brown j xxmaj farquhar c xxmaj beck j xxmaj boothroyd c xxmaj hughes e xxmaj clomiphene anti oestrogens ovulation induction xxup pcos xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj thessaloniki xxup eshre xxup asrm xxmaj sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group xxmaj consensus infertility treatment related polycystic ovary syndrome xxmaj fertil xxmaj steril doi j fertnstert xxmaj randall xxup jm xxmaj templeton a xxmaj cervical mucus score vitro sperm mucus interaction spontaneous xxup cc citrate cycles xxmaj fertil xxmaj steril xxmaj xxunk xxup ms xxmaj robins xxup ed o xxmaj connor xxup dm xxmaj scott xxup rt xxmaj fritz xxup ma xxmaj characteristics gonadotropin response follicular development endometrial growth maturation across consecutive cycles clomiphene citrate treatment xxmaj fertil xxmaj steril xxmaj nakamura y xxmaj xxunk m xxmaj yoshida y xxmaj sugino n xxmaj ueda k xxmaj kato h xxunk xxup cc endometrial thickness xxunk pattern endometrium xxmaj fertil xxmaj steril doi s xxmaj national xxmaj collaborating xxmaj centre xxmaj women xxmaj children xxmaj health xxmaj national xxmaj institue xxmaj clinical xxmaj excellence xxmaj fertility assessment treatment people fertility problems xxmaj clinical xxmaj guideline xxmaj no xxup rcog xxmaj press xxmaj london http www nice org uk xxunk pdf xxup cg xxunk pdf xxmaj farquhar xxup cm xxmaj williamson k xxmaj gudex g xxmaj johnson xxup np xxmaj garland j xxmaj sadler l a randomized controlled trial laparoscopic ovarian diathermy versus gonadotropin therapy women clomiphene citrate resistant polycystic ovary syndrome xxmaj fertil xxmaj steril doi s xxmaj farquhar c xxmaj lilford xxup rj xxmaj marjoribanks j xxmaj vandekerckhove p xxmaj laparoscopic drilling diathermy laser ovulation induction anovulatory polycystic ovary syndrome xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj bayram n van xxmaj wely m xxmaj kaaijk xxup em xxmaj bossuyt xxup pm van der xxmaj veen f xxmaj using electrocautery strategy recombinant follicle stimulating hormone induce ovulation polycystic ovary syndrome randomised controlled trial xxup bmj doi bmj xxmaj felemban a xxmaj lin xxmaj tan s xxmaj tulandi t xxmaj laparoscopic treatment polycystic ovaries insulated needle cautery reappraisal xxmaj fertil xxmaj steril doi s xxmaj holzer h xxmaj casper r xxmaj tulandi t a new era ovulation induction xxmaj fertil xxmaj steril doi j fertnstert xxmaj xxunk a xxmaj fouad h xxmaj xxunk m xxmaj xxunk n xxmaj letrozole induction ovulation women clomiphene citrate resistant polycystic ovary syndrome may depend period infertility body mass index luteinizing hormone xxunk hormone ratio xxmaj fertil xxmaj steril doi j fertnstert xxmaj xxunk xxup fm xxmaj casper xxup rf xxmaj use aromatase inhibitor induction ovulation patients inadequate response clomiphene citrate xxmaj fertil xxmaj steril doi s xxmaj al xxmaj xxunk xxup wr xxmaj xxunk w xxmaj al xxmaj xxunk n xxmaj comparison two aromatase inhibitors women clomiphene resistant polycystic ovary syndrome xxmaj int j xxmaj gynaecol xxmaj obstet doi j ijgo xxmaj rotterdam xxup eshre xxup asrm xxmaj sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group xxmaj revised consensus diagnostic criteria long term health risks related polycystic ovary syndrome xxmaj fertil xxmaj steril doi j fertnstert xxmaj organization xxmaj world xxmaj health xxup who laboratory manual examination human semen sperm cervical mucus interactions th edn xxmaj cambridge xxmaj university xxmaj press xxmaj cambridge xxmaj casper xxup rf xxmaj xxunk xxup mf xxmaj review aromatase inhibitors ovulation induction j xxmaj clin xxmaj endocrinol xxmaj metab doi jc xxmaj homburg r xxmaj oral agents ovulation induction clomiphene citrate versus aromatase inhibitors xxmaj hum xxmaj fertil xxmaj camb doi xxmaj xxunk u xxmaj xxunk m xxmaj xxunk s xxmaj xxunk a xxmaj xxunk s xxmaj use aromatase inhibitor patients polycystic ovary syndrome prospective randomized trial xxmaj fertil xxmaj steril doi j fertnstert xxmaj badawy a xxmaj xxunk a xxmaj xxunk m xxmaj xxunk letrozole ovulation induction clomiphene resistant women polycystic ovarian syndrome prospective randomized trial xxmaj fertil xxmaj steril doi j fertnstert xxmaj xxunk a xxmaj goswami xxup sk xxmaj xxunk r xxmaj xxunk k xxmaj xxunk b xxmaj comparison letrozole continuous gonadotropins clomiphene gonadotropin combination ovulation induction xxup pcos women clomiphene citrate failure randomized prospective clinical trial j xxmaj assist xxmaj reprod xxmaj genet doi xxmaj baruah j xxmaj roy xxup kk xxmaj rahman xxup sm xxmaj kumar s xxmaj sharma xxup jb xxmaj xxunk d xxmaj endometrial xxunk letrozole clomiphene citrate women polycystic ovary syndrome using spiral artery xxmaj doppler xxmaj arch xxmaj gynecol xxmaj obstet doi xxmaj xxunk xxup mm xxmaj xxunk r xxmaj xxunk n xxmaj the outcome babies following treatment letrozole letrozole gonadotropins xxmaj fertil xxmaj steril xxmaj supplement doi j fertnstert xxmaj tulandi t xxmaj martin j xxmaj al xxmaj xxunk r xxmaj kabli n xxmaj forman r xxmaj xxunk j xxmaj xxunk c xxmaj greenblatt e xxmaj casper xxup rf xxmaj congenital malformations among newborns conceived infertility treatment letrozole clomiphene citrate xxmaj fertil xxmaj steril doi j fertnstert xxmaj badawy a xxmaj xxunk a xxmaj xxunk xxup af xxmaj xxunk h xxmaj pregnancy outcome ovulation induction aromatase inhibitors clomiphene citrate unexplained infertility xxmaj acta xxmaj obstet xxmaj gynecol xxmaj scand doi,xxbos xxmaj abstract a double blind randomized placebo controlled cross multi center study conducted evaluate efficacy safety gabapentin treatment neuropathic pain caused traumatic postsurgical peripheral nerve injury using doses mg day xxmaj the study comprised run period two weeks two treatment periods five weeks separated three weeks washout period xxmaj the primary efficacy variable change mean pain intensity score baseline last week treatment xxmaj other variables included pain relief health related quality life xxup sf interference sleep pain xxmaj clinician xxmaj patient xxmaj global xxmaj impression xxmaj change adverse effects xxmaj nine centers randomized total patients withdrew xxmaj there statistically significant difference treatments primary outcome efficacy variable xxmaj however gabapentin provided significantly better pain relief p compared placebo xxmaj more patients least pain reduction gabapentin compared placebo p pain interfered significantly less sleep gabapentin treatment compared placebo p xxmaj both xxmaj patient p xxmaj clinician p xxmaj global xxmaj impression xxmaj change indicated better response gabapentin compared placebo xxmaj gabapentin well tolerated xxmaj the common adverse effects dizziness tiredness,xxbos xxup clinical xxup article xxmaj metformin versus laparoscopic ovarian drilling clomiphene insulin resistant women polycystic ovary syndrome xxmaj hossam o xxmaj hamed xxmaj xxunk f xxmaj hasan b xxmaj xxunk g xxmaj ahmed b xxmaj xxunk a xxmaj ahmed b xxmaj women xxmaj health xxmaj university xxmaj center xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj faculty xxmaj medicine xxmaj assiut xxmaj university xxmaj assiut xxmaj egypt b xxmaj department xxmaj physiology xxmaj faculty xxmaj medicine xxmaj assiut xxmaj university xxmaj assiut xxmaj egypt article info abstract xxmaj article history xxmaj received xxmaj may xxmaj received revised form xxmaj august xxmaj accepted xxmaj september xxmaj keywords xxmaj clomiphene resistance xxmaj insulin resistance xxmaj laparoscopic ovarian drilling xxmaj metformin xxmaj polycystic ovary syndrome xxmaj objective xxmaj to compare hormonal metabolic profiles reproductive outcomes clomiphene resistant patients polycystic ovary syndrome insulin resistance women receiving metformin undergoing laparoscopic ovarian drilling xxmaj methods a total eligible participants randomly allocated diagnostic laparoscopy plus metformin therapy group n laparoscopic ovarian drilling group n xxmaj the test used mean comparisons hormonal metabolic parameters xxup ogtt values treatment xxmaj the test used comparisons ovulation pregnancy abortion rates xxmaj results xxmaj groups showed significant decline testosterone insulin like growth factor xxmaj pb vs xxmaj pb luteinizing hormone xxmaj pb vs xxmaj pb glucose insulin ratio significantly increased xxmaj pb vs xxmaj pb compared baseline xxmaj group patients regular cycles higher rates ovulation pregnancy compared group vs xxmaj pb vs xxmaj pb vs xxmaj pb respectively xxmaj the difference early abortion rate groups statistically significant xxmaj conclusion xxmaj although metformin results better attenuation insulin resistance laparoscopic ovarian drilling associated higher rates ovulation pregnancy xxmaj international xxmaj federation xxmaj gynecology xxmaj obstetrics xxmaj published xxmaj elsevier xxmaj ireland xxmaj ltd xxmaj all rights reserved xxmaj introduction xxmaj polycystic ovary syndrome xxup pcos common endocrine metabolic disorder affecting women reproductive age xxmaj insulin resistance found approximately obese xxup pcos patients increased risk associated glucose intolerance development type diabetes xxmaj insulin resistance obesity result hyperinsulinemia considered key factor pathogenesis anovulation hyperandrogenism xxmaj weight reduction clomiphene citrate xxup cc considered first line medical approach improve fertility women xxup pcos xxmaj when xxup cc fails second line treatments attempted include laparoscopic ovarian drilling xxup lod gonadotropins xxup lod associated ovulation rate comparable gonadotropins advantages lower complications less need ongoing monitoring xxmaj in last years metformin used improve ovulation conflicting results xxmaj in previous studies metformin seen effective achieving ovulation improving clinical biochemical features xxup pcos xxmaj however recently xxmaj thessaloniki xxup eshre xxup asrm sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group recommended treatment metformin restricted women glucose intolerance xxmaj this recommendation based randomized trials concluded routine use metformin primary line treatment associated improvement rates ovulation live birth xxmaj two studies literature compared metformin xxup lod xxup cc resistant patients without considering insulin resistance prerequisite results conflicting xxmaj in first study significant difference found ovulation pregnancy rates patients received metformin xxup lod however second study reported higher pregnancy rate metformin group xxmaj with background mind hypothesized metformin used xxup pcos patients insulin resistance ovulation pregnancy rates might comparable obtained patients underwent xxup lod xxmaj the aim present study compare hormonal metabolic profile reproductive outcomes xxup cc resistant xxup pcos patients insulin resistance received metformin underwent xxup lod xxmaj materials methods xxmaj the study conducted xxmaj women xxmaj health xxmaj center cooperation xxmaj physiology xxmaj department xxmaj assiut xxmaj university xxmaj egypt xxmaj all xxup pcos patients attending infertility clinic previous xxup cc failure years age counseled xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics xxmaj corresponding author xxmaj tel fax e mail address xxmaj hossam omar yahoo com h o xxmaj hamed see front matter xxmaj international xxmaj federation xxmaj gynecology xxmaj obstetrics xxmaj published xxmaj elsevier xxmaj ireland xxmaj ltd xxmaj all rights reserved doi j ijgo xxmaj contents lists available sciencedirect xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics j u r n l h om e p g e www e l ev e r c om l c e j g participate study period xxmaj may xxmaj september xxmaj the study approved xxmaj assiut xxmaj medical xxmaj school xxmaj ethical xxmaj review board xxmaj written informed consent obtained participant information sheet provided xxmaj all women met criteria diagnosis xxup pcos according xxmaj rotterdam xxmaj consensus xxmaj group xxmaj the inclusion criteria included patients xxup cc resistance xxmaj the male partner couple normal result semen analysis patent tubes woman shown hysterosalpingography xxmaj all recruited patients insulin resistance based fasting glucose insulin ratio g i using cut less xxmaj this test done recruited patients randomization xxmaj exclusion criteria included women years patients received gonadotropins hormonal contraception months prior study xxmaj patients hyperprolactinemia morning plasma prolactin ng ml endocrine hepatic renal disorders also excluded patients organic pelvic mass previous abdominal surgery suggesting pelvic factor infertility xxmaj randomization performed using computer generated random numbers table xxmaj allocation concealment done using serially numbered opaque envelopes xxmaj the patient allocation changed opening envelope xxmaj group underwent diagnostic laparoscopy followed mg metformin orally twice daily beginning day laparoscopic procedure xxmaj group underwent xxup lod using punctures according size ovary seconds insulated needle monopolar diathermy adjusted watts xxmaj all laparoscopic procedures performed general anesthesia xxmaj at enrollment study eligible patients examined physically body mass index xxup bmi calculated weight kilograms divided height meters squared recorded a blood sample baseline biochemical assays taken day prior laparoscopy groups a standard oral glucose tolerance test xxup ogtt performed using xxunk enzymatic method xxunk quantitation xxmaj glucose xxup hk xxmaj assay xxmaj kit xxunk xxmaj st xxmaj louis xxup mo xxup usa assessed according international standards xxmaj the fasting blood samples used measuring total testosterone xxup elisa kit xxmaj biosource xxmaj europe xxmaj belgium luteinizing hormone xxup drg xxmaj diagnostics xxmaj marburg xxmaj germany insulin like growth factor xxup igf xxup elisa method xxmaj xxunk xxmaj systems xxmaj limited xxmaj xxunk xxup uk xxmaj serum samples separated stored c assayed a second blood sample taken first postoperative menstrual period excluding patients achieved pregnancy first cycle xxmaj all surgical interventions biochemical assays done early proliferative phase spontaneous menstrual cycle progestin withdrawal bleeding xxmaj the patients treated followed cycles weeks whichever occurred first xxmaj they asked report length menstrual cycles bleeding days xxmaj throughout study patients asked follow usual diet physical activity report adverse effects poor compliance metformin xxmaj patients returned month visits measure xxup bmi confirm ovulation xxmaj the baseline xxup bmi compared xxup bmi obtained last visit pregnancy end study xxmaj ovulation confirmed either presence mature ovarian follicle mm day serum progesterone ng ml xxmaj the couples advised sexual intercourse every day mature follicle seen vaginal ultrasound xxmaj the patients asked contact clinic evaluation soon missed period n week positive urinary pregnancy test xxmaj once clinical pregnancy proved appearance intrauterine gestational sac patients xxmaj fig xxmaj participant flow trial h o xxmaj hamed et al xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics group instructed stop taking metformin xxmaj the pregnancy followed weeks gestation xxmaj the primary outcome ovulation rate xxmaj the secondary outcomes clinical pregnancy first trimester b weeks abortion rates patients xxunk regular cycles g i ratio a patient considered menstruating regularly cycles follow days duration xxmaj the sample size calculated according ovulation rate primary outcome study xxmaj in multiple previous reports xxup lod associated average ovulation rate range xxmaj on assumption difference ovulation rate metformin would clinically relevant needed patients arm demonstrate difference statistical significance type i error probability type xxup ii error power xxmaj data analyzed using xxup spss version xxup spss xxmaj chicago xxup il xxup usa expressed mean xxup se percentages xxmaj the test used mean comparisons hormonal metabolic parameters xxup ogtt values treatment xxmaj the test used comparisons ovulation pregnancy abortion rates p considered statistically significant xxmaj results xxmaj of patients assessed eligibility met inclusion criteria randomly allocated either receive metformin diagnostic laparoscopy group n undergo xxup lod group n xxmaj participant flow trial shown xxmaj fig xxmaj the patients demographic data baseline shown xxmaj table xxmaj there significant differences groups age duration infertility previous pregnancies xxup bmi biochemical assays testosterone luteinizing hormone xxup igf xxmaj throughout study metformin generally well tolerated xxmaj in group women treated metformin reported dizziness nausea flatulence first month treatment symptoms self limiting affect treatment continuation xxmaj laparoscopies completed successfully without intraoperative postoperative complications xxmaj in groups laparoscopy revealed patent healthy tubes pelvic masses adhesions endometriosis xxmaj the postoperative biochemical assays performed mean period days starting metformin group compared days undergoing xxup lod group xxmaj one patient group two patients group achieved pregnancy within first month treatment consequently excluded biochemical assays xxmaj both groups significant decreases levels testosterone xxup igf luteinizing hormone treatment compared baseline xxmaj table xxmaj however obvious increase g i ratio group vs xxmaj pb compared group vs xxmaj pb xxup bmi significantly decreased group xxmaj regarding xxup ogtt total number patients impaired fasting glucose baseline vs mg dl groups respectively xxmaj fig shows treatment significant decrease blood glucose minutes compared baseline groups xxmaj pb vs b xxmaj the patients observed total cycles groups respectively xxmaj as shown xxmaj table ovulation rate per cycle significantly higher group compared group odds ratio xxup ci xxmaj pb xxmaj women group xxmaj table xxmaj comparison baseline clinical hormonal metabolic characteristics study groups xxmaj characteristics xxmaj metformin xxup lod p value group group n n xxmaj age xxmaj period infertility mo xxmaj previous pregnancy xxmaj live birth xxmaj abortions xxmaj regular cycles xxup bmi xxmaj fasting glucose insulin ratio xxmaj fasting blood glucose mg dl xxmaj total testosterone ng dl xxmaj luteinizing hormone xxup iu l xxmaj insulin like growth factor ug l xxmaj abbreviation xxup bmi body mass index calculated weight kilograms divided height meters squared xxup lod laparoscopic ovarian drilling xxmaj values given mean xxup se range number percentage xxmaj table xxmaj body mass index biochemical assay results treatment xxmaj metformin group xxup lod group xxmaj before xxmaj after b p value xxmaj before xxmaj after b p value xxwrep 4 n xxup bmi xxmaj fasting g i ratio xxmaj testosterone ng dl xxmaj luteinizing hormone xxup iu l xxup igf ug l xxmaj abbreviations g i glucose insulin ratio xxup igf insulin like growth factor xxup bmi body mass index calculated weight kilograms divided height meters squared xxmaj values given mean xxup se unless otherwise indicated b xxmaj one patient group two patients group excluded assays conceived first month treatment xxmaj fig xxmaj oral glucose tolerance test xxup ogtt results metformin group laparoscopic ovarian drilling xxup lod group groups treatment h o xxmaj hamed et al xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics significantly increased pregnancy rate per cycle xxup or xxup ci cumulative pregnancy rate xxup or xxup ci number regular cycles xxup or xxup ci compared women group xxmaj although first trimester abortion rate higher group compared group difference statistically significant p xxmaj discussion xxmaj insulin resistance diagnosed using g i ratio less equal measured randomization xxmaj obesity documented current study high xxup bmi exacerbate insulin resistance increase risk type diabetes proven impairment fasting blood glucose patients xxmaj both insulin resistance obesity lead development hyperinsulinemia stimulation ovarian theca cell androgen production either direct action ovary binding insulin xxup igf receptors stimulating release luteinizing hormone xxmaj hyperinsulinemia could enhance bioavailability androgen decreasing biosynthesis sex hormone binding xxunk xxup shbg xxmaj perhaps convincing evidence linking insulin resistance reproductive metabolic abnormalities data trials metformin women xxup pcos xxmaj in agreement reports metformin current study showed significant decrease levels luteinizing hormone testosterone xxup igf xxmaj metformin possibly exerts effects part increasing xxup shbg modulation adrenal androgen production decreasing intraovarian androgen production either generalized improvement insulin metabolism modulation ovarian steroidogenesis localized attenuation insulin sensitivity ovary xxmaj in present study patients treated xxup lod also showed significant decrease levels luteinizing hormone testosterone xxup igf agreement previous reports xxmaj these changes could explained reduction ovarian theca cell mass consequently androgen production xxmaj converting androgenic intrafollicular environment estrogenic one corrects disturbances ovarian pituitary feedback resulting decrease luteinizing hormone pulse xxunk recruitment ovarian follicles xxmaj the significant improvement g i ratio treatment groups agreement several studies xxmaj however effect obvious metformin group xxup lod group xxmaj this could explained metabolic actions metformin xxmaj it inhibits hepatic glucose output improves peripheral insulin sensitivity increase glucose utilization skeletal muscles xxmaj on hand underlying mechanism xxup lod affects g i ratio fully understood xxmaj the attenuation ovarian androgen production ovarian cautery suggested possible mechanism xxmaj the improvement g i ratio seen xxup lod present study xxunk studies reported little change insulin sensitivity xxup lod however studies distinguish women hyperinsulinemia normal xxunk xxmaj in present study although metformin resulted greater improvement insulin resistance metabolic effect translated higher reproductive outcomes compared xxup lod xxmaj this could explained ovarian theca cell mass destruction together greater reduction luteinizing hormone seen xxup lod important role xxunk normal intraovarian xxunk xxunk decreasing local androgen production xxmaj these could greater effect achieving ovulation general metabolic effect metformin reducing insulin resistance xxmaj the higher rates ovulation pregnancy seen xxup lod present study inconsistent two previous studies compared metformin xxup lod xxup cc resistant patients xxmaj the first study prospective included patients xxup cc added treatment groups spontaneous ovulation achieved within months laparoscopy performed metformin group a significant improvement regularity menstrual cycles noted significant difference found ovulation pregnancy rates vs vs respectively xxmaj the second study carried overweight xxup pcos patients double blind placebo controlled randomized trial xxmaj diagnostic laparoscopy carried metformin group xxmaj although ovulation rate significantly different treatment groups cycles vs cumulative pregnancy live birth rates higher metformin group vs vs respectively xxmaj although present study showed significantly higher rates ovulation pregnancy xxup lod possibility benefit metformin can not excluded xxmaj the ovulation cumulative pregnancy rates metformin seen present study respectively relatively higher obtained multicenter randomized trial patients randomized xxup cc metformin combination xxmaj the study reported ovulation pregnancy rates respectively metformin group xxmaj this difference could explained targeting selected population high xxup bmi insulin resistance glucose intolerance hence metformin optimal metabolic reproductive effects xxmaj another possible explanation substantial decrease xxup bmi noted metformin additional factor could affect fertility independently xxmaj in present study ovulation pregnancy rates patients managed xxup lod respectively agreement studies reported rates respectively depending follow period xxmaj this variation regarding reproductive outcomes mostly due heterogeneity samples studied different techniques used xxmaj the first trimester abortion rate present study comparable groups xxmaj these results inconsistent xxmaj palomba et al reported significantly lower abortion rates metformin compared xxup lod vs respectively xxmaj table xxmaj reproductive clinical outcomes study groups xxmaj clinical outcomes xxmaj metformin group xxup lod group xxmaj relative risk p value n n xxmaj odds ratio xxup ci xxmaj total ovulation rate per cycle b xxmaj first cycle xxmaj second cycle xxmaj third cycle xxmaj fourth cycle xxmaj fifth cycle xxmaj sixth cycle xxmaj never ovulating patients xxmaj pregnancy rate per cycle c xxmaj cumulative pregnancy rate xxmaj first trimester abortion rate e xxmaj regular cycles f xxmaj values given number percentages unless otherwise indicated b xxmaj calculated number ovulatory cycles divided number cycles c xxmaj calculated number pregnancies divided number cycles xxmaj calculated number pregnancies divided number patients e xxmaj calculated number abortions divided number pregnancies f xxmaj patient considered regularly menstruating observed cycles days duration h o xxmaj hamed et al xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics xxmaj however study adequately powered detect difference needs research xxmaj in conclusion although metformin better attenuated insulin resistance xxup lod associated greater regulation menstrual cycles higher rates ovulation pregnancy obese xxup pcos patients insulin resistance xxup cc failure xxmaj conflict interest xxmaj the authors conflicts interest xxmaj references xxmaj homburg r xxmaj polycystic ovary syndrome xxmaj best xxmaj pract xxmaj res xxmaj clin xxmaj obstet xxmaj gynaecol xxmaj hart r xxmaj norman r xxmaj polycystic ovarian syndrome prognosis outcomes xxmaj best xxmaj pract xxmaj res xxmaj clin xxmaj obstet xxmaj gynaecol xxmaj palomba s xxmaj orio f xxmaj zullo f xxmaj ovulation induction women polycystic ovary syndrome xxmaj fertil xxmaj steril xxmaj suppl s xxmaj seow xxup km xxmaj juan xxup cc xxmaj hwang xxup jl xxmaj ho xxup lt xxmaj laparoscopic surgery polycystic ovary syndrome reproductive metabolic effects xxmaj semin xxmaj reprod xxmaj med xxmaj xxunk xxup jm xxmaj flight xxup ih xxmaj norman xxup rj xxmaj insulin sensitizing drugs metformin xxunk xxunk xxunk d xxunk xxunk polycystic ovary syndrome xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj norman xxup rj xxmaj editorial xxmaj metformin comparison therapies ovulation induction polycystic ovary syndrome j xxmaj clin xxmaj endocrinol xxmaj metab xxmaj de xxmaj leo v xxmaj la xxmaj xxunk a xxmaj xxunk f xxmaj insulin lowering agents management polycystic ovary syndrome xxmaj endocr xxmaj rev xxmaj thessaloniki xxup eshre xxup asrm xxmaj sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group xxmaj consensus infertility treatment related polycystic ovary syndrome xxmaj hum xxmaj reprod xxmaj moll e xxmaj bossuyt xxup pm xxmaj xxunk xxup jc xxmaj lambalk xxup cb van der xxmaj veen f xxmaj effect clomifene citrate plus metformin clomifene citrate plus placebo induction ovulation women newly diagnosed polycystic ovary syndrome randomised double blind clinical trial xxup bmj xxmaj legro xxup rs xxmaj barnhart xxup xxunk xxmaj xxunk xxup wd xxmaj carr xxup br xxmaj diamond xxup mp xxmaj carson xxup sa et al xxmaj clomiphene metformin infertility polycystic ovary syndrome n xxmaj engl j xxmaj med xxmaj malkawi xxup hy xxmaj qublan xxup hs xxmaj hamaideh xxup ah xxmaj medical vs surgical treatment clomiphene citrate resistant women polycystic ovary syndrome j xxmaj obstet xxmaj gynaecol xxmaj palomba s xxmaj orio f xxmaj nardo xxup lg xxmaj falbo a xxmaj russo t xxmaj corea d et al xxmaj metformin xxmaj administration xxmaj versus xxmaj laparoscopic xxmaj ovarian xxmaj diathermy xxmaj clomiphene citrateresistant xxmaj women xxmaj polycystic xxmaj ovary xxmaj syndrome a xxmaj prospective xxmaj parallel xxmaj randomized xxmaj double xxmaj blind xxmaj placebo xxmaj controlled xxmaj trial j xxmaj clin xxmaj endocrinol xxmaj metab xxmaj rotterdam xxup eshre xxup asrm xxmaj sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group xxmaj revised consensus diagnostic criteria long term health risks related polycystic ovary syndrome xxmaj fertil xxmaj steril xxmaj xxunk a xxmaj xxunk h xxmaj xxunk lane r xxmaj xxunk e xxmaj xxunk xxup fz xxmaj xxunk xxup rj xxmaj acute effects metformin therapy include improvement insulin resistance ovarian morphology xxmaj fertil xxmaj steril xxmaj tulandi t xxmaj saleh a xxmaj payne n xxmaj jacobs h xxmaj tan xxup sl xxmaj effects laparoscopic ovarian drilling serum vascular endothelial growth factor insulin responses oral glucose tolerance test women polycystic ovarian syndrome xxmaj fertil xxmaj steril xxmaj xxunk xxup mm xxmaj hanson xxup rl xxmaj xxunk d xxmaj xxunk g xxmaj xxunk j xxmaj bennett xxup ph et al xxmaj the xxmaj american xxmaj diabetes xxmaj association xxmaj world xxmaj health xxmaj organization criteria hyperglycemia diagnosis prediction diabetes xxmaj diabetes xxmaj care xxmaj tang t xxmaj xxunk j xxmaj hayden xxup cj xxmaj combined lifestyle modification metformin obese patients polycystic ovary syndrome a randomized placebo controlled double blind multicentre study xxmaj hum xxmaj reprod xxmaj tan s xxmaj hahn s xxmaj xxunk b xxmaj xxunk d xxmaj xxunk l xxmaj lars xxup cm et al xxmaj metformin improves polycystic ovary syndrome symptoms irrespective pre treatment insulin resistance xxmaj eur j xxmaj endocrinol xxmaj palomba s xxmaj orio f xxmaj falbo a xxmaj xxunk f xxmaj russo t xxmaj xxunk t et al xxmaj prospective parallel randomized double blind double dummy controlled clinical trial comparing clomiphene citrate metformin first line treatment ovulation induction nonobese anovulatory women polycystic ovary syndrome j xxmaj clin xxmaj endocrinol xxmaj metab xxmaj xxunk xxup ir xxmaj tulandi t xxmaj laparoscopic treatment polycystic ovaries time xxunk procedure xxmaj fertil xxmaj steril xxmaj xxunk xxup ir xxmaj yates xxup rw xxmaj cameron xxup it xxmaj fleming r xxmaj effects insulin sensitizing drug metformin ovarian function follicular growth ovulation rate obese women oligomenorrhoea xxmaj hum xxmaj reprod xxmaj youssef h xxmaj atallah xxup mm xxmaj unilateral ovarian drilling polycystic ovarian syndrome prospective randomized study xxmaj reprod xxmaj biomed xxmaj online xxmaj farquhar xxup cm xxmaj the role ovarian surgery polycystic ovary syndrome xxmaj best xxmaj pract xxmaj res xxmaj clin xxmaj obstet xxmaj gynaecol xxmaj saleh a xxmaj morris d xxmaj tan xxup ls xxmaj tulandi t xxmaj effects laparoscopic ovarian drilling adrenal steroids polycystic ovary syndrome patients without hyperinsulinemia xxmaj fertil xxmaj steril xxmaj api m xxmaj xxunk h xxmaj xxunk a xxmaj laparoscopic ovarian drilling polycystic ovary syndrome xxmaj eur j xxmaj obstet xxmaj gynecol xxmaj reprod xxmaj biol h o xxmaj hamed et al xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics\n",
              "y: CategoryList\n",
              "P,Q,N,P,N\n",
              "Path: /content/gdrive/My Drive/covidnlp;\n",
              "\n",
              "Test: None, model=SequentialRNN(\n",
              "  (0): MultiBatchEncoder(\n",
              "    (module): AWD_LSTM(\n",
              "      (encoder): Embedding(31040, 400, padding_idx=1)\n",
              "      (encoder_dp): EmbeddingDropout(\n",
              "        (emb): Embedding(31040, 400, padding_idx=1)\n",
              "      )\n",
              "      (rnns): ModuleList(\n",
              "        (0): WeightDropout(\n",
              "          (module): LSTM(400, 1152, batch_first=True)\n",
              "        )\n",
              "        (1): WeightDropout(\n",
              "          (module): LSTM(1152, 1152, batch_first=True)\n",
              "        )\n",
              "        (2): WeightDropout(\n",
              "          (module): LSTM(1152, 400, batch_first=True)\n",
              "        )\n",
              "      )\n",
              "      (input_dp): RNNDropout()\n",
              "      (hidden_dps): ModuleList(\n",
              "        (0): RNNDropout()\n",
              "        (1): RNNDropout()\n",
              "        (2): RNNDropout()\n",
              "      )\n",
              "    )\n",
              "  )\n",
              "  (1): PoolingLinearClassifier(\n",
              "    (layers): Sequential(\n",
              "      (0): BatchNorm1d(1200, eps=1e-05, momentum=0.1, affine=True, track_running_stats=True)\n",
              "      (1): Dropout(p=0.27999999999999997, inplace=False)\n",
              "      (2): Linear(in_features=1200, out_features=50, bias=True)\n",
              "      (3): ReLU(inplace=True)\n",
              "      (4): BatchNorm1d(50, eps=1e-05, momentum=0.1, affine=True, track_running_stats=True)\n",
              "      (5): Dropout(p=0.1, inplace=False)\n",
              "      (6): Linear(in_features=50, out_features=3, bias=True)\n",
              "    )\n",
              "  )\n",
              "), opt_func=functools.partial(<class 'torch.optim.adam.Adam'>, betas=(0.9, 0.99)), loss_func=FlattenedLoss of CrossEntropyLoss(), metrics=[<function accuracy at 0x7f7d11556840>], true_wd=True, bn_wd=True, wd=0.01, train_bn=True, path=PosixPath('/content/gdrive/My Drive/covidnlp'), model_dir='models', callback_fns=[functools.partial(<class 'fastai.basic_train.Recorder'>, add_time=True, silent=False)], callbacks=[RNNTrainer\n",
              "learn: RNNLearner(data=TextClasDataBunch;\n",
              "\n",
              "Train: LabelList (503 items)\n",
              "x: TextList\n",
              "xxbos xxmaj original research article xxmaj two randomized controlled trials comparing xxmaj hulka xxmaj filshie xxmaj clips tubal sterilization xxmaj xxunk xxmaj xxunk xxmaj deborah xxmaj xxunk xxmaj david xxmaj xxunk xxmaj milton xxmaj xxunk xxmaj jorge xxmaj lasso de la xxmaj xxunk xxmaj arturo xxmaj remes xxmaj xxunk xxmaj john xxmaj xxunk xxmaj david xxmaj limb xxmaj serge xxmaj xxunk xxmaj roberto xxmaj santiso xxmaj xxunk xxmaj luis xxmaj xxunk xxmaj itic xxmaj xxunk xxmaj family xxmaj health xxmaj international xxmaj research xxmaj triangle xxmaj park xxup nc xxup usa b xxmaj the xxmaj clinical xxmaj investigator xxmaj team xxmaj received xxmaj june accepted xxmaj september xxmaj abstract xxmaj to compare effectiveness safety xxmaj filshie xxmaj clip xxmaj system xxmaj hulka xxmaj clip xxmaj system applied via minilaparotomy laparoscopy conducted multicenter randomized controlled trials women minilaparotomy study laparoscopy study received either xxmaj filshie xxmaj hulka xxmaj clip a physician operator evaluated patients postoperatively months surgery xxmaj we compared cumulative incidence pregnancy frequency safety related events device groups xxmaj twenty four month follow planned subset women laparoscopy study xxmaj one woman received xxmaj filshie xxmaj clip women received xxmaj hulka xxmaj clip became pregnant within one year xxmaj the month life table pregnancy probability per women xxmaj filshie xxmaj clip group per women xxmaj hulka xxmaj clip group xxmaj the difference risk pregnancy months device groups neared statistical significance p xxmaj among extended follow subset month cumulative pregnancy probabilities per women xxmaj filshie xxmaj clip group per women xxmaj hulka xxmaj clip group p comparison months xxmaj both xxmaj filshie xxmaj hulka xxmaj clips effective safe use tubal occlusion xxmaj elsevier xxmaj science xxmaj inc xxmaj all rights reserved xxmaj keywords xxmaj tubal occlusion devices xxmaj female sterilization xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj introduction xxmaj in xxup us xxmaj food xxmaj drug xxmaj administration approved xxmaj filshie xxmaj clip tubal sterilization xxmaj the xxmaj filshie xxmaj hulka clips vary slightly mechanism action xxmaj while xxmaj hulka xxmaj clip spring mechanism holds clip closed fallopian tube xxmaj filshie xxmaj clip uses pressure exerted applicator close clip around fallopian tube flatten xxunk upper jaw clip xxmaj this action causes upper jaw leading edge extend lip lower jaw locking position simultaneously trapping occluding fallopian tube xxmaj published reports failure rates clips varied widely xxmaj this may reflect several factors including level experience surgeon timing surgery postpartum interval procedure used method used calculate failure rates characteristics study population a randomized trial women found xxmaj filshie xxmaj clip performed better xxmaj hulka xxmaj clip respect ease application perioperative pain xxmaj to evaluate clinically relative effectiveness safety methods conducted randomized controlled trials xxmaj filshie xxmaj hulka clips used interval sterilization one applied via minilaparotomy applied via laparoscopy xxmaj materials methods xxmaj except type surgical approach used laparoscopy minilaparotomy two study protocols identical xxmaj the lead investigator site required xxmaj corresponding author xxmaj tel fax e mail address xxunk fhi org r xxmaj dominik xxmaj contraception see front matter xxmaj elsevier xxmaj science xxmaj inc xxmaj all rights reserved xxup pii s experienced surgeon sites served operator another experienced surgeon served evaluator xxmaj family xxmaj health xxmaj international xxup fhi institutional review board xxup irb approved two protocols xxmaj november xxmaj in addition study center obtained approval conduct study xxup irb prior study initiation xxmaj if local xxup irb available xxup fhi xxup irb acted lieu local xxup irb xxmaj women least years age legally able consent sterilization normal physical pelvic examination results eligible participate studies xxmaj we enroll women undergone pregnancy termination within past days pre existing clinically important abnormal condition diabetes renal cardiac disease xxmaj we enroll women already pregnant women undergoing surgery routine curettage xxup iud removal concurrent sterilization xxmaj for example woman eligible coming induced abortion sterilization procedure xxmaj nor enroll women required sterilization reasons voluntarily limiting size family xxmaj after participant signed informed consent agreement randomized receive one two tubal occlusion devices using computer generated randomization scheme stratified center xxmaj her group assignment revealed operator opening sealed sequentially numbered opaque envelope provided site study initiation xxup fhi xxmaj minilaparotomy used access view fallopian tubes one study performed five centers laparoscopy used study performed four centers xxmaj prior surgery took medical history conducted physical examination including pelvic examination xxmaj the operator recorded type anesthetic surgical approach reason change assigned tubal occlusion method applicable xxmaj before women discharged another physician informed type clip women received assessed complications involving surgical incision pelvic pain infection complications complaints a surgeon operator evaluated participants months sterilization xxmaj at selected sites month evaluation planned subset laparoscopy participants xxmaj at early month follow visit evaluated women complications associated surgical procedure xxmaj at later visits gave participants physical examination including pelvic examination clinical assessment pelvic infection asked questions menstrual patterns including intermenstrual bleeding pain xxmaj at follow visits recorded pregnancies adverse events abdominal pelvic surgery clinic admissions occurred since surgery xxmaj we diagnosed pregnancies urine pregnancy test pelvic examination clinical evaluation routinely administer chemical pregnancy test month visits a total five centers four countries included minilaparotomy study four centers four countries included laparoscopy study xxmaj field work completed xxmaj february xxmaj we defined three different subject populations analyzed individual trial results xxmaj the intent treat population included women assigned receive xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj the treated population included women least one fallopian tube occluded either xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj the efficacy population included women fallopian tubes occluded assigned device except inclusion criteria violations might interfere evaluation effectiveness xxmaj prior initiation primary analysis either trial determined treated population primary analysis population interest focus individual trial pooled trial results presented xxmaj the effectiveness outcome interest pregnancy xxmaj we calculated month gross cumulative life table pregnancy probabilities device type combining data collected studies device type within study xxmaj we calculated standard errors using method described xxmaj peto et al xxmaj we used log rank test test differences pregnancy curves device group xxmaj we also calculated gross cumulative life table pregnancy probabilities months subgroup participants extended follow planned xxmaj we excluded women effectiveness analysis treated population later determined pregnant time tubes occluded e women luteal phase pregnancies xxmaj in event hysterectomy surgical intervention would alter risk pregnancy women censored life table analysis xxmaj participants reported pregnant censored life table analysis date last visit xxmaj for pregnancies date conception estimated using algorithm based last menstrual period gestational age termination pregnancy confirmation xxmaj we calculated percentage surgical injuries primary incision complications infections major complications early follow device received within strata defined surgical approach xxmaj within surgical approach stratum used xxmaj fisher exact test test differences device groups number women type event xxmaj we combine early safety results surgical approaches differences characteristics procedures xxmaj we summarized reports hospital readmission abdominal pelvic surgery follow r xxmaj dominik et al xxmaj contraception xxmaj results xxmaj unless otherwise stated present results treated population device received a total women minilaparotomy study laparoscopy study comprised entire intent treat population xxmaj figs xxmaj of assigned xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj we identified major violations inclusion exclusion criteria women minilaparotomy study laparoscopy study xxmaj of received xxmaj filshie xxmaj clip received xxmaj hulka xxmaj clip xxmaj almost half protocol violations women whose last pregnancy terminated less weeks surgery xxmaj the violations women variety pre existing conditions women pre existing pelvic pathology xxmaj table shows number participants analysis population surgical approach country xxmaj the women device groups mean age years given birth average children xxmaj about half women device groups pregnant within months prior sterilization slightly half used form contraceptive method months prior sterilization xxmaj about one third women device group reported menses months prior enrollment xxmaj the likelihood amenorrhea baseline considerably higher among women delivered within months preceding study enrollment among women presumably due breast feeding xxmaj in device groups reported previous intraperitoneal surgery previously pelvic inflammatory disease xxmaj operators experienced type surgical difficulty operating women received xxmaj filshie xxmaj clip women received xxmaj hulka xxmaj clip xxmaj the three common difficulties minilaparotomy study grasping tubes xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases entering peritoneum xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases visualizing tubes xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases xxmaj the three common difficulties laparoscopy study visualizing tubes xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases occluding tubes xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases entering peritoneum xxmaj filshie xxmaj clip cases xxmaj hulka xxmaj clip cases xxmaj operators dropped one clips abdominal cavity women received xxmaj filshie xxmaj clip xxmaj the operator find dropped clip one cases presumably still xxmaj an operator noted xxmaj hulka clip came apart abdominal cavity one woman retrieved parts xxmaj these four surgical difficulties occurred laparoscopy study xxmaj operators failed apply assigned device fallopian tubes total women xxmaj in cases assigned xxmaj filshie xxmaj clip one assigned xxmaj hulka xxmaj clip operators provided explanation xxunk xxmaj participant flow chart minilaparotomy study xxmaj fig xxmaj participant flow chart laparoscopy study xxmaj includes one participant received xxmaj hulka clips stop one tube bleeding transected xxmaj filshie clip xxmaj this participant excluded subsequent counts r xxmaj dominik et al xxmaj contraception xxunk occurrence appeared unintentional error xxmaj in women assigned xxmaj filshie xxmaj clip assigned xxmaj hulka xxmaj clip problems encountered surgery prevented application assigned device tubes xxmaj problems encountered surgery included need repair surgical injury cases discovery ovarian fimbrial cysts cases thick fallopian tubes one case xxmaj when surgeon unable apply assigned clip used alternate method e g xxmaj pomeroy technique xxmaj in one cases cysts encountered sterilization procedure applied tube xxmaj in one xxmaj filshie xxmaj clip group participant surgeon used pair xxmaj hulka xxmaj clips stop one tube bleeding transected xxmaj filshie xxmaj clip xxmaj the surgeon placed one xxmaj hulka xxmaj clip end transected tube xxmaj in immediate postoperative period participant noted moderate pelvic pain treated oral analgesics xxmaj she followed one year evaluator noted difficulties complications xxmaj this woman enrolled laparoscopy study assigned receive xxmaj filshie xxmaj clip woman excluded treated population xxmaj within trial days discharge vary device xxmaj over women laparoscopy study discharged clinic day surgery minilaparotomy study discharged day surgery discharged following day xxmaj the percentage women returning follow visits similar two groups declined time xxmaj although women device groups returned early follow evaluation group completed month visit returned month later visit xxmaj among subset laparoscopy participants month follow planned women xxmaj filshie xxmaj clip group women xxmaj hulka xxmaj clip group group returned days surgery xxmaj table shows month cumulative life table pregnancy probabilities xxmaj there pregnancies xxmaj hulka xxmaj clip group one pregnancy xxmaj filshie xxmaj clip group xxmaj all reported pregnancies intrauterine xxmaj the difference risk pregnancy device groups xxmaj table xxmaj number participants analysis population device group xxmaj analysis xxmaj population xxmaj study xxmaj country xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxmaj intent treat populationa xxmaj minilaparotomy study xxmaj xxunk xxmaj panama xxmaj dominican xxmaj republic xxmaj mexico xxmaj laparoscopy study xxmaj xxunk xxmaj guatemala xxmaj mexico xxmaj haiti xxmaj treated populationc xxmaj minilaparotomy study xxmaj laparoscopy study xxmaj efficacy populationc e f xxmaj minilaparotomy study xxmaj laparoscopy study xxmaj by assigned device b xxmaj there two centers xxmaj malaysia one closed participants enrolled c xxmaj by device received xxmaj excludes woman intent treat population received study devices one tube xxmaj filshie xxmaj clip tube e xxmaj this group subset treated population excluding women women violations inclusion exclusion criteria women luteal phase pregnancies woman random allocation error women receive assigned device tubes due technical failures f xxmaj this group subset treated population excluding women women violations inclusion exclusion criteria women luteal phase pregnancies women random allocation errors women receive assigned device tubes due technical failures xxmaj table xxmaj six month gross cumulative life table pregnancy probabilities per women approach device group treated population xxmaj approach xxmaj month xxmaj filshie xxmaj clip xxmaj hulka xxmaj clip xxunk xxmaj number riska xxmaj cumulative probability pregnancyb xxmaj standard error xxmaj number riska xxmaj cumulative probability pregnancyb xxmaj standard error xxmaj both approaches combined xxmaj laparoscopy xxmaj minilaparotomy xxmaj number women remaining trial beginning month b xxmaj per women c xxmaj log rank test comparison month pregnancy curves r xxmaj dominik et al xxmaj contraception neared statistical significance p xxmaj given final sample size observed discontinuation rate study provided power detect difference true annual pregnancy probabilities per women per women pooled analysis xxmaj the numbers risk month xxmaj table somewhat less numbers non pregnant women xxmaj figs made month visits especially minilaparotomy study xxmaj these differences reflect use slightly different definitions a month visit defined visit days surgery xxmaj however life table analysis women risk pregnancy month visit day later e first day th month surgery xxmaj in subset laparoscopy study participants followed months additional pregnancies intrauterine xxmaj one pregnancies xxmaj filshie xxmaj clip group xxmaj hulka xxmaj clip group xxmaj among subset month cumulative pregnancy probabilities per women xxmaj filshie xxmaj clip group per women xxmaj hulka xxmaj clip group p comparison months xxmaj thus total pregnancies occurred scheduled follow period intrauterine xxmaj filshie xxmaj clip group xxmaj hulka xxmaj clip group xxmaj the pregnancies identified study luteal phase pregnancies defined conception occurring date sterilization procedure xxmaj filshie xxmaj clip group xxmaj hulka xxmaj clip group xxmaj the women luteal phase pregnancies excluded efficacy analysis xxmaj table shows within study number participants surgical injuries primary incision complications early follow infections early follow complications early follow similar two device groups xxmaj during scheduled month follow period sterilization women xxmaj filshie xxmaj clip group xxmaj table xxmaj surgical injuries safety events reported early follow treated population xxmaj safety xxmaj event xxmaj minilaparotomy xxmaj laparoscopy xxmaj filshie xxmaj hulka xxmaj filshie xxmaj hulka xxwrep 4 n xxmaj surgical injuries xxmaj none xxmaj cervical laceration xxmaj uterine perforation xxmaj tubal mesosalpingeal injury xxmaj other xxmaj total p valuea xxmaj primary incision complications early follow xxmaj none xxmaj serious discharge xxmaj inflammation xxmaj abscess xxmaj bleeding xxmaj hematoma xxmaj other xxmaj total p valuea xxmaj infections early follow xxmaj none xxmaj in uterus xxmaj in adnexa xxmaj other xxmaj total p valuea xxmaj other complications early follow xxunk xxmaj none xxmaj at least one xxmaj total p valuea xxmaj by xxmaj fisher exact test complication event versus event b xxmaj specifically urinary tract infection vaginal bleeding menses lochia respiratory cardiovascular gastrointestinal drug allergy xxunk responses provided major complication section early follow visit data collection form r xxmaj dominik et al xxmaj contraception women xxmaj hulka xxmaj clip group hospitalized underwent abdominal pelvic surgery xxmaj we found clinically significant difference two groups various reasons surgery hospitalization xxmaj in addition one participant xxmaj filshie xxmaj clip group minilaparotomy study appeared experienced granuloma formation related sterilization led surgery performed scheduled follow period xxmaj four months sterilization presented right iliac pain left adnexal mass xxmaj at months underwent pelvic ultrasound flat plate abdominal x ray diagnostic laparoscopy xxmaj these examinations revealed left ovarian cyst abdominal wall mass right bilateral adhesions xxmaj fifteen months sterilization surgeon removed left clip left adnexa found right clip lodged granuloma xxunk muscular abdominal wall xxmaj he left right clip place concern muscles would damaged removal xxmaj discussion xxmaj our estimate probability pregnancy first year sterilization xxmaj hulka xxmaj clip per lower probability per observed xxmaj center xxmaj disease xxmaj control xxmaj prevention xxunk xxup us xxmaj collaborative xxmaj review xxmaj sterilization xxup crest xxmaj in trials sterilization procedures performed small number investigators selected surgical expertise experience xxmaj in xxup crest study resident physicians teaching centers performed sterilization procedures xxmaj our lower pregnancy probabilities may due choice experienced investigators operators xxmaj alternatively differences estimates risk pregnancy may due differences underlying fecundity study populations incomplete follow chance xxmaj although slightly higher percentage women spring clip group xxup cdc study xxmaj hulka xxmaj clip group study less years age studies similar proportion women years age xxmaj clip recipients studies included women desiring interval sterilization xxmaj our study include substantial proportion women reported amenorrheic since previous delivery presumably due breast feeding comparable data provided xxup cdc study xxmaj censoring participants date last visit would expected slightly underestimate month pregnancy probabilities since pregnancies yet clinically evident could missed xxmaj we performed additional analysis censored women become pregnant days prior last visit xxmaj the impact point estimate pregnancy probabilities small xxmaj for xxmaj filshie xxmaj clip group estimate went per women per women xxmaj for xxmaj hulka xxmaj clip group estimate went per women per women xxmaj although follow high respect short term safety outcomes long term follow rate somewhat disappointing xxmaj however age distributions participants complete month later visit studies quite similar distributions women complete month later visit nearly participants included studies previous live births xxmaj less educated women women rural areas less likely complete month later visit participants pattern loss similar device groups within study data shown xxmaj the two devices appear similar safety profiles serious adverse experiences related sterilization either device rare xxmaj all primary incision complications observed complications might expected surgery xxmaj the choice surgical approach appear affect overall efficacy safety xxmaj clip related adverse events expulsion migration abscess granuloma formation uncommon xxmaj no participants reported clip xxunk study xxmaj however events reported comparative trials xxmaj filshie xxmaj clip tubal ring xxmaj acknowledgments xxmaj funding xxup us xxmaj agency xxmaj international xxmaj development xxup usaid cooperative agreements xxup aid xxup dpe c xxup aid xxup dpe a xxup aid xxup dpe a xxup aid xxup xxunk a supported studies analyses xxmaj however views expressed article necessarily reflect xxup usaid xxmaj femcare xxmaj limited manufacturer xxmaj filshie xxmaj clip xxmaj system supplied xxmaj filshie xxmaj clips applicators cost xxmaj family xxmaj health xxmaj international xxup fhi receives xxunk xxmaj femcare xxmaj ltd clips sold xxunk institutions xxmaj united xxmaj states xxmaj this paper prepared funding xxmaj femcare xxmaj ltd xxup usaid xxmaj the minilaparotomy study conducted xxmaj milton xxmaj xxunk xxup md xxup xxunk xxmaj santo xxmaj xxunk xxmaj dominican xxmaj republic xxmaj jorge xxmaj lasso de la xxmaj vega xxup md xxmaj complejo xxmaj xxunk xxmaj xxunk xxmaj panama xxmaj city xxmaj panama xxmaj arturo xxmaj remes xxmaj ruiz xxmaj hospital xxmaj general de xxmaj veracruz xxmaj veracruz xxmaj mexico xxmaj john xxmaj xxunk xxup md xxmaj kuala xxmaj lumpur xxmaj maternity xxmaj hospital xxmaj kuala xxmaj lumpur xxmaj malaysia xxmaj david xxmaj lim xxup md xxup xxunk xxmaj national xxmaj population xxmaj family xxmaj development xxmaj board xxmaj kuala xxmaj lumpur xxmaj malaysia xxmaj the laparoscopy study conducted xxmaj serge xxmaj xxunk xxup md xxmaj re gion xxmaj xxunk du xxmaj xxunk xxmaj le xxmaj xxunk xxmaj haiti xxmaj roberto xxmaj santiso xxmaj xxunk xxup md xxup xxunk xxmaj guatamala xxmaj city xxmaj guatamala xxmaj luis xxmaj uribe xxup md xxmaj hospital xxmaj gineco xxmaj obstetrica xxmaj xxunk xxmaj mexico xxmaj itic xxmaj xxunk xxup md xxmaj maternidad xxmaj concepcio n xxmaj palacios xxmaj xxunk xxmaj xxunk r xxmaj dominik et al xxmaj contraception xxmaj references xxmaj richard xxmaj wolf xxmaj medical xxmaj instruments xxmaj corporation xxmaj laparoscopic sterilization spring clips xxmaj xxunk xxmaj il xxmaj filshie xxup gm xxmaj the development titanium silicone rubber clip female sterilization xxmaj thesis submitted xxmaj university xxmaj nottingham xxmaj degree xxmaj doctor xxmaj medicine xxmaj october xxmaj xxunk xxup ma xxmaj pattison xxup ns xxmaj wilson p xxmaj female xxmaj sterilization xxmaj national xxmaj women xxmaj hospital xxup nz xxmaj med j xxmaj stovall xxup tg xxmaj ling xxup fw xxmaj henry xxup gm xxmaj ryan xxup gm xxmaj jr xxmaj method failures laparoscopic tubal sterilization residency training program a comparison tubal ring spring loaded clip j xxmaj reprod xxmaj med xxmaj chi xxup ic xxmaj gates d xxmaj xxunk s et al xxmaj timing postpartum tubal sterilization using xxmaj filshie clips analysis data two developing country centers xxmaj contraception xxmaj xxunk xxup vj xxmaj female sterilization vaginal route positive reassessment comparison tubal occlusion methods xxmaj aust xxup nz j xxmaj obstet xxmaj gynaecol xxmaj chi i xxmaj xxunk xxup le xxmaj gardner xxup sd et al xxmaj an epidemiologic study risk factors associated pregnancy following female sterilization xxmaj am j xxmaj obstet xxmaj gynecol xxmaj peterson xxup hb xxmaj xia z xxmaj hughes j xxmaj wilcox xxup ls xxmaj tylor xxup lr xxmaj trussell j xxmaj the risk pregnancy tubal sterilization findings u s xxmaj collaborative xxmaj review xxmaj sterilization xxmaj am j xxmaj obstet xxmaj gynecol xxmaj sokal d xxmaj gates d xxmaj amatya r xxmaj dominik r xxmaj clinical xxmaj investigator xxmaj team xxmaj two randomized controlled trials comparing tubal ring xxmaj filshie clip tubal sterilization xxmaj fertil xxmaj steril xxmaj davies xxup gc xxmaj letchworth xxup at xxmaj diamond i a comparison xxmaj filshie xxmaj hulka xxmaj clemens clips used sterilisation operations j xxmaj obstet xxmaj gynaecol xxmaj potter xxup rg xxmaj jr xxmaj use effectiveness intrauterine contraception problem competing risks xxmaj in xxmaj freedman r xxmaj xxunk xxup jy editors xxmaj family xxmaj planning xxmaj taiwan xxmaj new xxmaj jersey xxmaj princeton xxmaj university xxmaj press p xxmaj peto r xxmaj pike xxup mc xxmaj armitage p et al xxmaj design analysis randomized clinical trials requiring prolonged observation patient xxup ii xxmaj analysis examples xxmaj br j xxmaj cancer xxmaj xxunk xxup jd xxmaj prentice xxup rl xxmaj the xxmaj statistical xxmaj analysis xxmaj failure xxmaj time xxmaj data xxmaj new xxmaj york xxmaj john xxmaj wiley xxmaj sons xxmaj inc xxmaj lachin xxup jm xxmaj xxunk xxup ma xxmaj evaluation sample size power analyses survival allowance xxunk patient entry losses follow noncompliance stratification xxmaj biometrics r xxmaj dominik et al xxmaj contraception,xxbos xxmaj anemia prophylaxis adolescent school girls weekly daily iron folate supplementation xxmaj agarwal xxup kn xxmaj gomber s xxmaj bisht h xxmaj som m xxmaj author information xxmaj department xxmaj pediatrics xxmaj university xxmaj college xxmaj medical xxmaj sciences xxup gtb xxmaj hospital xxmaj delhi xxmaj india xxmaj xxunk hotmail com xxmaj abstract xxup objective xxmaj to examine benefits anemia prophylaxis adolescent school girls weekly daily iron folate supplementation xxup design xxmaj prospective study xxup setting xxmaj government girl schools northeast xxmaj delhi xxup subjects subjects hemoglobin greater g dl including daily weekly iron folate administration girls served controls xxup results xxmaj about girls iron deficient anemic xxmaj weekly administration took longer time raise hemoglobin effective well practical xxmaj plasma ferritin estimation girls showed rise level treated groups xxup conclusion xxmaj weekly administration iron folate practical effective strategy anemia prophylaxis adolescent school girls,xxbos xxmaj this article downloaded xxmaj university xxmaj liverpool xxmaj on xxmaj december xxmaj at xxmaj publisher xxmaj routledge xxmaj informa xxmaj ltd xxmaj registered xxmaj england xxmaj wales xxmaj registered xxmaj number xxmaj registered office xxmaj mortimer xxmaj house xxmaj mortimer xxmaj street xxmaj london w t xxup jh xxup uk xxmaj journal xxmaj dual xxmaj diagnosis xxmaj publication details including instructions authors subscription information http www tandfonline com loi wjdd a xxmaj randomized xxmaj trial xxmaj clozapine xxmaj versus xxmaj other xxmaj antipsychotics xxmaj cannabis xxmaj use xxmaj disorder xxmaj patients xxmaj with xxmaj schizophrenia xxmaj mary f xxmaj brunette xxup md xxmaj ree xxmaj dawson phd b xxmaj christopher d o xxmaj keefe xxup ma c xxmaj meera xxmaj narasimhan xxup md xxmaj douglas l xxmaj noordsy xxup md c xxmaj joanne xxmaj wojcik phd e xxmaj alan i xxmaj green xxup md c xxmaj dartmouth xxmaj psychiatric xxmaj research xxmaj center xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj lebanon xxmaj new xxmaj hampshire xxup usa b xxmaj frontier xxmaj science xxmaj research xxmaj technology xxmaj boston xxmaj massachusetts xxup usa c xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj lebanon xxmaj new xxmaj hampshire xxup usa xxmaj department xxmaj psychiatry xxmaj university xxmaj south xxmaj carolina xxmaj columbia xxmaj south xxmaj carolina xxup usa e xxmaj department xxmaj psychiatry xxmaj beth xxmaj israel xxmaj deaconess xxmaj medical xxmaj center xxmaj harvard xxmaj medical xxmaj school xxmaj boston xxmaj massachusetts xxup usa xxmaj published online xxmaj may xxmaj to cite article xxmaj mary f xxmaj brunette xxup md xxmaj ree xxmaj dawson phd xxmaj christopher d o xxmaj keefe xxup ma xxmaj meera xxmaj narasimhan xxup md xxmaj douglas l xxmaj noordsy xxup md xxmaj joanne xxmaj wojcik phd xxmaj alan i xxmaj green xxup md a xxmaj randomized xxmaj trial xxmaj clozapine xxmaj versus xxmaj other xxmaj antipsychotics xxmaj cannabis xxmaj use xxmaj disorder xxmaj patients xxmaj with xxmaj schizophrenia xxmaj journal xxmaj dual xxmaj diagnosis xxmaj to link article http dx doi org xxup please xxup scroll xxup down xxup for xxup article xxmaj taylor xxmaj francis makes every effort ensure accuracy information xxmaj content contained publications platform xxmaj however xxmaj taylor xxmaj francis agents licensors make representations warranties whatsoever accuracy completeness suitability purpose xxmaj content xxmaj any opinions views expressed publication opinions views authors views endorsed xxmaj taylor xxmaj francis xxmaj the accuracy xxmaj content relied upon independently verified primary sources information xxmaj taylor xxmaj francis shall liable losses actions claims proceedings demands costs expenses damages liabilities whatsoever howsoever caused arising directly indirectly connection relation arising use xxmaj content xxmaj this article may used research teaching private study purposes xxmaj any substantial systematic reproduction redistribution reselling loan sub licensing systematic supply distribution form anyone expressly forbidden xxmaj terms xxmaj conditions access use found http www tandfonline com page termsand conditions xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxup journal xxup of xxup dual xxup diagnosis xxmaj copyright c xxmaj taylor xxmaj francis xxmaj group xxup llc xxup issn print online xxup doi xxup psychopharmacology xxup neurobiology a xxmaj randomized xxmaj trial xxmaj clozapine xxmaj versus xxmaj other xxmaj antipsychotics xxmaj cannabis xxmaj use xxmaj disorder xxmaj patients xxmaj with xxmaj schizophrenia xxmaj mary f xxmaj brunette xxup md xxmaj ree xxmaj dawson phd xxmaj christopher d o xxmaj keefe xxup ma xxmaj meera xxmaj narasimhan xxup md xxmaj douglas l xxmaj noordsy xxup md xxmaj joanne xxmaj wojcik phd xxmaj alan i xxmaj green xxup md xxmaj objective xxmaj cannabis use disorder common co occurring drug use disorder people schizophrenia associated poor outcomes xxmaj the authors launched randomized controlled trial assess impact clozapine compared treatment usual cannabis use patients schizophrenia co occurring cannabis use disorder xxmaj methods xxmaj thirty one patients schizophrenia co occurring cannabis use disorder randomly assigned switch clozapine stay current antipsychotic followed weekly weeks xxmaj blinded raters assessed participants weekly xxmaj timeline xxmaj followback substance use expanded xxmaj brief xxmaj psychiatric xxmaj rating xxmaj scale symptoms xxmaj longitudinal random effects models used investigate time varying differences cannabis use outcomes treatment usual clozapine groups xxmaj results xxmaj the two groups differed average intensity cannabis use approximately joints week lesser use clozapine group df p effect size xxmaj symptoms functioning different two groups xxmaj conclusions xxmaj clozapine may reduce cannabis use among patients schizophrenia co occurring cannabis use disorder xxmaj further controlled trials warranted xxmaj journal xxmaj dual xxmaj diagnosis xxmaj keywords schizophrenia cannabis substance use disorder clozapine treatment co occurring xxmaj dartmouth xxmaj psychiatric xxmaj research xxmaj center xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj lebanon xxmaj new xxmaj hampshire xxup usa xxmaj frontier xxmaj science xxmaj research xxmaj technology xxmaj boston xxmaj massachusetts xxup usa xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj lebanon xxmaj new xxmaj hampshire xxup usa xxmaj department xxmaj psychiatry xxmaj university xxmaj south xxmaj carolina xxmaj columbia xxmaj south xxmaj carolina xxup usa xxmaj department xxmaj psychiatry xxmaj beth xxmaj israel xxmaj deaconess xxmaj medical xxmaj center xxmaj harvard xxmaj medical xxmaj school xxmaj boston xxmaj massachusetts xxup usa xxmaj address correspondence xxmaj mary f xxmaj brunette xxup md xxmaj dartmouth xxmaj psychiatric xxmaj research xxmaj center xxmaj department xxmaj psychiatry xxmaj dartmouth xxmaj medical xxmaj school xxmaj pleasant xxmaj st nd xxmaj floor xxmaj north xxmaj concord xxup nh xxup usa e mail mary f brunette dartmouth edu xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj up people schizophrenia lifetime co occurring substance use disorder xxmaj alterman xxmaj erdlen xxmaj murphy xxmaj ananth et al xxmaj freed xxmaj kessler et al xxmaj kessler et al xxmaj mueser et al xxmaj cannabis use disorder common co occurring drug use disorder individuals xxmaj kessler et al xxmaj mueser et al xxmaj regier et al lifetime rates ranging dequardo xxmaj carpenter xxmaj tandon xxmaj dixon xxmaj haas xxmaj weiden xxmaj sweeney xxmaj frances xxmaj hambrecht xxmaj hafner xxmaj koskinen xxmaj lohonen xxmaj koponen xxmaj isohanni xxmaj miettunen xxmaj mueser xxmaj bennett xxmaj kushner xxmaj peralta xxmaj cuesta fold increase lifetime prevalence general population xxmaj regier et al xxmaj cannabis use disorder associated clinical exacerbations noncompliance treatment poor global functioning increased relapse rehospitalization rates dequardo et al xxmaj knudsen xxmaj vilmar xxmaj linszen xxmaj dingemans xxmaj lenior xxmaj negrete xxmaj knapp xxmaj douglas xxmaj smith xxmaj peralta xxmaj cuesta xxmaj treffert xxmaj it adds greatly financial costs emotional toll schizophrenia places patients families mental health system e g xxmaj dickey xxmaj azeni xxmaj kivlahan xxmaj heiman xxmaj wright xxmaj mundt xxmaj shupe xxmaj comprehensive psychosocial treatment programs integrate treatments schizophrenia substance including cannabis use disorder developed shown effective population xxmaj drake xxmaj mueser xxmaj brunette mchugo xxmaj nevertheless even abstinence relapse common xxmaj xie mchugo xxmaj fox xxmaj drake moreover almost half patients co occurring disorders continue use substances experience negative consequences months psychosocial treatment xxmaj hence continues need better treatments better understanding role pharmacological treatments co occurring cannabis substance use disorders patients schizophrenia xxmaj while typical antipsychotic medications appear limit cannabis substance use patients schizophrenia xxmaj noordsy o xxmaj keefe xxmaj mueser xxmaj xie preliminary data suggest atypical antipsychotic clozapine may helpful treatment psychotic symptoms also limiting cannabis substance abuse xxmaj case reports retrospective studies small open label prospective study reported reduced substance tobacco use treatment clozapine xxmaj albanese xxmaj khantzian xxmaj murphy xxmaj green xxmaj buckley mccarthy xxmaj chapman xxmaj richman xxmaj yamamoto xxmaj george xxmaj sernyak xxmaj ziedonis xxmaj woods xxmaj lee xxmaj marcus xxmaj snyder mcevoy xxmaj freudenreich xxmaj levin xxmaj rose xxmaj yovell xxmaj opler xxmaj zimmet xxmaj strous xxmaj burgess xxmaj kohnstamm xxmaj green a subsequent study group provided evidence potential role clozapine dual diagnosis patients xxmaj this study naturalistic clinical services survey followed patients co occurring psychotic substance use disorders years xxmaj drake xxmaj xie mchugo xxmaj green xxmaj patients taking clozapine higher rates remission cannabis abuse compared treated typical antipsychotics xxmaj similarly remission alcohol abuse higher patients taking clozapine compared treated typical antipsychotics xxmaj moreover continuing assessment patients whose abuse remitted treated clozapine relapsed abuse following months compared treated antipsychotics xxmaj brunette xxmaj drake xxmaj xie mchugo xxmaj green xxmaj given many side effects clozapine led restriction xxmaj food xxmaj drug xxmaj administration approval use patients treatment refractory psychosis many investigators currently assessing whether atypical antipsychotics share clozapine ability limit substance use patients schizophrenia xxmaj unfortunately available data somewhat xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al mixed overly promising xxmaj green xxmaj noordsy xxmaj brunette o xxmaj keefe risperidone xxmaj green xxmaj burgess xxmaj dawson xxmaj zimmet xxmaj strous xxmaj smelson et al xxmaj smelson et al olanzapine xxmaj akerele xxmaj levin xxmaj brunette et al xxmaj noordsy et al xxmaj petrakis xxmaj leslie xxmaj finney xxmaj rosenheck xxmaj smelson et al quetiapine xxmaj brown xxmaj nejtek xxmaj perantie xxmaj rajan xxmaj thomas xxmaj rush xxmaj brunette o xxmaj keefe xxmaj dawson xxmaj buckley xxmaj green xxmaj potvin et al aripiprazole xxmaj beresford et al xxmaj brown xxmaj jeffress xxmaj liggin xxmaj garza xxmaj beard xxmaj warsi xxmaj sattar xxmaj bhatia xxmaj petty xxmaj thus present clozapine remains antipsychotic medication published research provides consistent evidence substantive decrease cannabis substance use xxmaj we presented neurobiological formulation based animal studies suggesting clozapine unusual clinical effects substance abuse patients schizophrenia may relate varied pharmacological actions dopaminergic particularly noradrenergic systems xxmaj specifically proposed clozapine weak dopamine d receptor blockade coupled activation norepinephrine xxup ne system including antagonistic effects xxup ne receptor ability release xxup ne e g xxmaj antelman xxmaj caggiula xxmaj breier et al xxmaj green et al xxmaj lieberman et al xxmaj rice xxmaj smith xxmaj silk xxmaj rosen xxmaj sarafoff xxmaj davis xxmaj ruther xxmaj svensson et al xxmaj thierry xxmaj godbout xxmaj mantz xxmaj glowinski xxmaj van xxmaj kammen et al may ameliorate dysfunction dopamine mediated brain reward system may underlie common use cannabis substances patients schizophrenia xxmaj green xxmaj zimmet xxmaj strous xxmaj schildkraut xxmaj given consistent albeit still preliminary data clozapine ability decrease substance use patients schizophrenia well published rationale basis effect group launched randomized controlled trial clozapine compared treatment usual cannabis use patients schizophrenia co occurring cannabis use disorder xxup methods xxmaj the study month randomized open label investigation blinded assessments efficacy safety clozapine compared continued current antipsychotic treatment e treatment usual outpatients schizophrenia schizoaffective disorder comorbid cannabis use disorder xxmaj after researchers established participants eligibility baseline blinded raters assessed participants weekly substance use symptoms side effects xxmaj unblinded clinicians prescribed adjusted study medications weekly weeks xxmaj the institutional review boards xxmaj dartmouth xxmaj medical xxmaj school xxmaj university xxmaj south xxmaj carolina approved study xxmaj all procedures consistent xxmaj declaration xxmaj helsinki xxmaj good xxmaj clinical xxmaj practice according xxmaj international xxmaj conference xxmaj harmonization guidelines xxmaj there complete thorough discussion study potential participants participants gave written informed consent prior engaging study procedures xxmaj study xxmaj participants xxmaj participants recruited primarily clinician referral two urban study sites one xxmaj new xxmaj hampshire affiliated xxmaj dartmouth second xxmaj south xxmaj carolina affiliated xxmaj university xxmaj south xxmaj carolina xxmaj inclusion criteria follows xxmaj diagnostic xxmaj statistical xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj manual xxup dsm xxup iv diagnosis schizophrenia schizoaffective disorder current cannabis use disorder cannabis use least days weeks prior screening age outpatient status prior randomization current treatment antipsychotic medication clozapine xxmaj patients taking medications possible effects alcohol use e g naltrexone disulfiram topiramate excluded patients active serious medical illness suicidality severe psychiatric instability xxmaj patients clozapine contraindicated e g white blood cell count mm screening history seizure disorder also excluded xxmaj fifty patients screened xxmaj nine meet eligibility criteria seven withdrew consent four lost follow one left area prior baseline xxmaj thirty one patients proceeded baseline study visit randomized treatment group xxmaj study xxmaj procedures xxmaj once patients deemed eligible randomly assigned one two treatment conditions switching treatment clozapine staying current antipsychotic medication xxmaj randomization blocked site xxmaj for patients switched clozapine study physicians increased dose clozapine flexible manner reach daily dose mg end week xxmaj during titration period dose participants initial antipsychotic medication gradually reduced eliminated within weeks xxmaj dose adjustments clozapine allowed based psychosis symptom response side effects maximum allowed dose clozapine mg per day xxmaj those patients randomized continue receiving current antipsychotic kept steady dose although adjustments allowed address newly emerging symptoms psychosis side effects xxmaj the group research physicians principal investigator xxup aig reviewed pharmacological treatment study participants monthly intervals ensure antipsychotic treatment consistent across study xxmaj participants attended weekly study visits weeks xxmaj unblinded study physicians assessed participants psychosis treatment response adverse events xxmaj trained blinded raters assessed participants cannabis alcohol substance use psychiatric symptoms medication side effects xxmaj experienced study raters trained certified prior rating study patients recertified yearly xxmaj psychosocial treatment psychosis substance use measured monthly xxmaj participants reimbursed gift card completion study visit time travel expenses xxmaj measures xxmaj during screening phase raters used xxmaj structured xxmaj clinical xxmaj interview xxup dsm xxup iv xxmaj axis i xxmaj disorders xxmaj patient xxmaj edition xxmaj first xxmaj spitzer xxmaj gibbon xxmaj williams establish participant diagnoses schizophrenia schizoaffective disorder cannabis substance use disorders xxmaj study physicians completed physical examination laboratory assessment complete blood cell count glucose lipid profile establish participants medical stability xxmaj patients randomized clozapine complete blood cell count repeated weekly participants stayed baseline antipsychotic medication blood drawn weekly complete blood cell count assessments xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al xxmaj blinded raters assessed participant substance use xxmaj timeline xxmaj followback procedure l c xxmaj sobell xxmaj sobell m b xxmaj sobell et al screening baseline weekly course study xxmaj in addition visit participants given breathalyzer test alcohol alcohawk xxmaj pro q xxmaj innovations urine screening drugs xxup acon xxmaj panel xxmaj multi line xxmaj test xxmaj device tetra hydro cannabinol ng ml cocaine ng ml xxmaj blinded interviewers conducted xxmaj timeline xxmaj followback procedure using calendars data urine drug screenings breathalyzer tests facilitate recall substance use past week increase validity self report xxmaj participants asked estimate amount cannabis converted average sized joints used day xxmaj information collateral informants also obtained increase validity self report xxmaj baseline level addiction treatment engagement measured point xxmaj substance xxmaj abuse xxmaj treatment xxmaj scale higher scores indicating progress treatment mchugo xxmaj drake xxmaj burton xxmaj ackerson xxmaj motivation stop using cannabis measured single item xxmaj contemplation xxmaj ladder higher level indicating motivation xxmaj amodei xxmaj lamb xxmaj blinded raters assessed participants symptoms weekly expanded xxmaj brief xxmaj psychiatric xxmaj rating xxmaj scales xxup bprs xxmaj lukoff xxmaj liberman xxmaj nuechterlein weekly xxmaj clinical xxmaj global xxmaj inventories xxup cgi xxmaj guy biweekly use xxmaj schedule xxmaj assessment xxmaj negative xxmaj symptoms xxup sans xxmaj andreasen xxmaj the xxup bprs rated symptom items score item present extremely severe xxmaj the xxup cgi used assess general improvement one item scored much improved much worse xxmaj the xxup sans used assess five negative symptom components scale severe xxmaj unblinded clinicians measured neurologic side effects weekly xxmaj simpson xxmaj angus xxmaj scale xxmaj simpson xxmaj angus xxmaj abnormal xxmaj involuntary xxmaj movement xxmaj scale xxmaj lane xxmaj glazer xxmaj hansen xxmaj berman xxmaj kramer xxmaj barnes xxmaj akathisia xxmaj rating xxmaj scale xxmaj barnes xxmaj at baseline monthly thereafter blinded raters assessed amount services patients received address alcohol use disorder substance use treatment services questionnaire xxmaj clark et al xxmaj study physicians recorded medication dose visit xxmaj dose later converted chlorpromazine equivalents xxmaj gardner xxmaj murphy o xxmaj donnell xxmaj centorrino xxmaj baldessarini xxmaj medication adherence measured weekly pill count xxmaj byerly et al xxmaj data xxmaj analysis xxmaj chi square tests tests used assess whether characteristics participants different groups xxmaj for analyzing repeated measures outcomes used longitudinal random effects xxup lre models xxmaj laird xxmaj ware investigate time varying differences cannabis use outcomes treatment usual clozapine groups xxmaj the main outcome measure intensity cannabis use measured number joints per week xxmaj baseline values measure included models adjust possible differences two groups improve efficiency fixed effects included group linear quadratic trends retained significant alpha level group trend interactions xxmaj the covariance structure modeled using random effects intercept significant trends first order autocorrelation residual errors also specified xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj for primary explanatory analyses data clozapine group censored set missing deviations treatment protocol including greater days missed study medication doses early termination study medication xxmaj secondary explanatory analyses cannabis use also involved censoring poor adherence early termination medication groups xxmaj for intent treat analysis weekly data cannabis use censored hospitalization confinement consecutive days control halo effects use due forced abstinence xxmaj there need censor hospitalization incarceration explanatory analyses data participants already censored due poor adherence xxmaj note participants terminated study medication contributed data xxup lre models time censoring due medication termination whereas participants poorly adherent contributed data weeks took medication except week poor adherence censored week week basis xxup results xxmaj the characteristics study participants noted xxmaj table xxmaj overall participants primarily single unemployed xxmaj caucasian males whose average age years xxmaj participants moderately symptomatic hospitalized multiple times xxmaj the group assigned clozapine education fewer lifetime psychiatric hospitalizations xxmaj most participants diagnoses cannabis dependence rather abuse half also alcohol disorder third another drug use disorder xxmaj measures substance use motivation treatment differ groups xxmaj the characteristics study medication use treatment use shown xxmaj table xxmaj most participants remained study medication study entire weeks xxmaj study medication well tolerated many patients reported side effects shown xxmaj table xxmaj the frequent side effects somnolence hypersalivation weight gain xxmaj patients taking clozapine likely report somnolence hypersalivation constipation patients remained treatment usual xxmaj outcomes xxmaj for primary explanatory analysis two groups differed average intensity cannabis use approximately joints per week main effect xxup lre due group lesser use clozapine group significant within group trends study follow see xxmaj figure xxmaj this result suggests clozapine treatment compared continuation current antipsychotic associated decrease cannabis use effect size although differences small sample reach statistical significance df p xxmaj similar results found using intent treat analysis modest attenuation treatment differences df p xxmaj the secondary explanatory analysis data treatment usual group also censored due poor adherence showed little change estimated difference intensity cannabis use increased slightly joints per week increased standard error due fewer observations df p xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al xxup table xxmaj baseline xxmaj characteristics xxmaj total xxmaj group xxmaj clozapine xxup tau n n n n m xxup sd n m xxup sd n m xxup sd xxmaj age xxmaj sex xxmaj race xxmaj white xxmaj education xxmaj employed xxmaj marital single xxmaj diagnosis schiz vs schizaf xxup bprs xxmaj total xxup bprs xxmaj positive xxup bprs xxmaj negative xxup sans total xxmaj lifetime hospitalizations xxmaj cannabis dependence vs abuse xxmaj days use week xxmaj number joints week xxmaj diagnosis alcohol disorder xxmaj diagnosis drug disorder xxup mh counselor sessions week xxup sa counselor sessions week xxup aa meetings week xxmaj contemplation xxmaj ladder xxup sats xxmaj note xxup tau xxmaj treatment usual schiz schizophrenia schizaf schizoaffective disorder xxup mh mental health xxup sa substance abuse xxup aa xxmaj alcoholics xxmaj anonymous xxup sats substance abuse treatment scale p xxup table xxmaj treatment xxmaj characteristics xxmaj total xxmaj group xxmaj clozapine xxup tau n n n n m xxup sd n m xxup sd n m xxup sd xxmaj medication xxmaj weeks study med xxmaj dose chlorpromazine equivalents xxmaj number ending med early xxmaj good adherence xxmaj other treatment xxup mh counselor sessions week xxup sa counselor sessions week xxup aa meetings week xxmaj note xxup tau xxmaj treatment usual xxup mh mental health xxup sa substance abuse xxup aa xxmaj alcoholics xxmaj anonymous xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxup table xxmaj adverse xxmaj events xxmaj among xxmaj patients xxmaj taking xxmaj clozapine xxmaj versus xxmaj other xxmaj antipsychotics xxmaj cannabis xxmaj disorder xxmaj schizophrenia xxmaj total xxmaj group n xxmaj clozapine n xxup tau xxwrep 4 n xxmaj somnolence xxmaj hypersalivation xxmaj weight gain xxmaj dizziness xxmaj vomiting xxmaj constipation xxmaj dry mouth xxmaj hypertension xxmaj akathisia xxmaj depression xxmaj fatigue xxmaj headache xxmaj insomnia xxmaj nausea xxmaj noncardiac chest pain xxmaj increased agitation xxmaj flu like symptoms xxmaj irritability xxmaj libido decreased xxmaj muscle spasms xxmaj nasal congestion xxmaj unusual dream activity xxmaj suicide attempt xxmaj urinary incontinence xxmaj note xxup tau treatment usual p xxmaj secondary outcomes included symptoms negative positive total xxup bprs composite summary total xxup sans xxup sans subscales affective blunting alogia avolition anhedonia disturbance attention functioning xxup cgi xxmaj data censored deviation protocol secondary explanatory analyses data censored hospitalization incarceration either explanatory intent treat analyses xxmaj in cases two groups differ terms symptoms functioning xxmaj negative linear trends indicating improvement time found total positive xxup bprs xxmaj in subsidiary analysis two groups also compared alcohol use measured heavy drinking days per week heavy drinking defined drinks per day xxmaj censoring carried cannabis use case linear quadratic terms included xxup lre models capture nonlinear trends time xxmaj interestingly significant differences explanatory df p intent treat analyses df p greater alcohol use clozapine group due primarily one participant group drank heavily throughout study xxmaj when data participant removed analyses differences longer significant shown xxmaj figure xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al xxup figure xxmaj intensity cannabis use joints per week patients treatment usual xxup tau patients switched clozapine xxup cloz xxmaj explanatory analysis explanatory analysis xxmaj moreover comparison xxmaj figure xxmaj figure showed important contrast cannabis alcohol results near significant results cannabis use reflect systematic differences two treatment groups alcohol use outlying data removed xxmaj additionally correlation longitudinally changes drinking changes cannabis use time based days heavy drinking per week days cannabis use per week xxmaj last floor effect possible clozapine action heavy drinking given drinking levels low throughout study average fewer day per week one heavy drinker omitted xxmaj this clearly demonstrated xxmaj figure data outlying participant removed analysis xxup figure xxmaj mean heavy drinking days per week patients treatment usual xxup tau patients clozapine xxup cloz xxmaj explanatory analysis xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxup discussion xxmaj this study provides first evidence randomized controlled trial clozapine may limit cannabis use continued treatment antipsychotics patients schizophrenia co occurring cannabis use disorders xxmaj clozapine well tolerated group patients noted side effects types expected medication xxmaj interestingly find differences psychiatric symptoms two groups despite welldescribed beneficial effects clozapine people treatment resistant schizophrenia xxmaj this may reflect overall moderate levels psychiatric symptoms group patients without treatment refractory psychosis xxmaj the magnitude effect clozapine effect size decreasing cannabis use moderate suggesting clinically meaningful role medication population xxmaj but small size study sample limits conclusions drawn xxmaj recruitment patients schizophrenia co occurring cannabis use disorders randomized medication trials challenging requires number sites large recruitment team available study xxmaj given relatively tenuous connection patients may treatment reluctance clinicians referring research studies recruitment team needs carefully integrated within treatment systems a limitation study beyond sample size included fact prescribing physicians blinded study medication xxmaj because clozapine causes characteristic side effects blinding prescribers patients type study tends difficult attempted xxmaj ratings symptoms substance use however completed blinded raters xxmaj nonetheless whether expectancy effects contributed apparent efficacy clozapine reducing cannabis use can not ascertained xxmaj in study patients cannabis use disorders finding clozapine associated improvement heavy alcohol use consistent previous research e g xxmaj brunette et al xxmaj drake et al xxmaj nevertheless lack correlation changes alcohol changes cannabis use suggests decrease noted cannabis use related increase alcohol use patients xxmaj moreover noted two groups differ significantly alcohol use treatment data single participant unusually heavy drinking removed analysis xxmaj the undue influence participant reflects small size sample generally low amount drinking among cannabis using patients xxmaj we note design sample recruited level cannabis alcohol use thus would unexpected find outlying heavy drinking participant one treatment groups half participants diagnosed alcohol use disorder xxmaj taken together alcohol data appear support robustness primary finding clozapine effect cannabis use despite failing replicate similar result alcohol use xxmaj in summary small randomized trial clozapine compared antipsychotics suggests clozapine may reduce cannabis use patients schizophrenia cannabis use disorders independent effect symptoms overall functioning xxmaj although effective treatments cannabis use disorder schizophrenia sorely needed present clozapine side effect profile severely restricts use clinics xxmaj given findings promising consistent previous research effect clozapine cannabis use fully powered blinded clinical trial xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al warranted definitively establish whether clozapine effective treatment cannabis use disorders population xxmaj if demonstrated definitively decrease cannabis use patients schizophrenia may appropriate expand routine use clozapine beyond treatment refractory psychosis include stable outpatients co occurring cannabis use disorder xxup acknowledgments xxmaj this study supported grant xxmaj no xxup da xxmaj national xxmaj institute xxmaj drug xxmaj abuse xxmaj the authors would like thank xxmaj draeger xxmaj medical xxmaj systems loaning electrocardiography machine study xxup disclosures xxmaj none authors report financial relationships commercial interest regard present study xxmaj dr xxmaj brunette received funding research xxmaj bristol xxmaj myers xxmaj squibb xxmaj foundation xxmaj dr xxmaj green reports research grant support past three years xxmaj janssen xxmaj eli xxmaj lilly astrazeneca xxmaj forest xxmaj laboratories xxmaj he currently serves data safety monitoring board xxmaj eli xxmaj lilly studies owns shares stock xxmaj johnson xxmaj johnson xxmaj pfizer xxmaj mylan two pending patents treatment substance abuse xxmaj dr xxmaj narasimhan reports research grant support past three years xxmaj national xxmaj institute xxmaj mental xxmaj health xxmaj national xxmaj institute xxmaj drug xxmaj abuse astrazeneca xxmaj bristol xxmaj myers xxmaj squibb xxmaj janssen xxmaj eli xxmaj lilly xxmaj forest xxmaj laboratories xxmaj she served speaker bureau bristolmyers xxmaj squibb astrazeneca xxmaj eli xxmaj lilly xxmaj merck advisory boards xxmaj eli xxmaj lilly astrazeneca xxmaj dr xxmaj noordsy received research funding consulting speaking honoraria following companies make psychotropic medications astrazeneca xxmaj bristol xxmaj myers xxmaj squibb xxmaj janssen xxmaj eli xxmaj lilly xxmaj lundbeck xxmaj novartis xxmaj merck xxmaj sunovion xxup references xxmaj akerele e xxmaj levin f r xxmaj comparison olanzapine risperidone substance abusing individuals schizophrenia xxmaj american xxmaj journal xxmaj addictions xxmaj albanese m j xxmaj khantzian e j xxmaj murphy s l xxmaj green a i xxmaj decreased substance use chronically psychotic patients treated clozapine xxmaj american xxmaj journal xxmaj psychiatry xxmaj alterman a j xxmaj erdlen f r xxmaj murphy e xxmaj alcohol abuse psychiatric hospital population xxmaj addictive xxmaj behaviors xxmaj amodei n xxmaj lamb r j xxmaj convergent concurrent validity xxmaj contemplation xxmaj ladder xxup urica scales xxmaj drug xxmaj alcohol xxmaj dependence xxmaj ananth j xxmaj vandewater s xxmaj kamal m xxmaj brodsky a xxmaj gamal r xxmaj miller m xxmaj missed diagnosis substance abuse psychiatric patients xxmaj hospital xxmaj community xxmaj psychiatry xxmaj andreasen n c xxmaj negative symptoms schizophrenia xxmaj archives xxmaj general xxmaj psychiatry xxmaj antelman s m xxmaj caggiula a r xxmaj norepinephrine dopamine interactions behavior xxmaj science xxmaj barnes t r a rating scale drug induced akathisia xxmaj the xxmaj british xxmaj journal xxmaj psychiatry xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj beresford t p xxmaj clapp l xxmaj martin b xxmaj wiberg j l xxmaj alfers j xxmaj beresford h f xxmaj aripiprazole schizophrenia cocaine dependence a pilot study xxmaj journal xxmaj clinical xxmaj psychiatry xxmaj breier a xxmaj buchanan r w xxmaj waltrip nd r w xxmaj listwak s xxmaj holmes c xxmaj goldstein d s xxmaj the effect clozapine plasma norepinephrine xxmaj relationship clinical efficacy xxmaj neuropsychopharmacology xxmaj brown e s xxmaj jeffress j xxmaj liggin j d m xxmaj garza m xxmaj beard l xxmaj switching outpatients bipolar schizoaffective disorders substance abuse current antipsychotic aripiprazole xxmaj journal xxmaj clinical xxmaj psychiatry xxmaj brown e s xxmaj nejtek v a xxmaj perantie d c xxmaj rajan xxmaj thomas n xxmaj rush a j xxmaj cocaine amphetamine use patients psychiatric illness a randomized trial typical antipsychotic continuation discontinuation xxmaj journal xxmaj clinical xxmaj psychopharmacology xxmaj brunette m f xxmaj drake r e xxmaj xie h mchugo g j xxmaj green a i xxmaj clozapine use relapses substance use disorder among patients co occurring schizophrenia substance use disorders xxmaj schizophrenia xxmaj bulletin xxmaj brunette m f o xxmaj keefe c xxmaj dawson r xxmaj buckley p xxmaj green a i xxmaj an open label study quetiapine patients schizophrenia alcohol disorders xxmaj journal xxmaj mental xxmaj health xxmaj substance xxmaj use xxmaj disorders xxmaj brunette m f o xxmaj keefe c xxmaj zimmet s xxmaj wojcik j d xxmaj dawson r xxmaj green a i xxmaj olanzapine alcohol use disorder patients schizophrenia xxmaj journal xxmaj dual xxmaj diagnosis xxmaj buckley p mccarthy m xxmaj chapman p xxmaj richman c xxmaj yamamoto b xxmaj clozapine treatment comorbid substance abuse patients schizophrenia xxmaj schizophrenia xxmaj research xxmaj byerly m j xxmaj thompson a xxmaj carmody t xxmaj bugno r xxmaj ervin t xxmaj kashner m xxmaj rush a j xxmaj validity electronically monitored medication adherence conventional adherence measures schizophrenia xxmaj psychiatric xxmaj services xxmaj clark r xxmaj teague g xxmaj ricketts s xxmaj bush p xxmaj zubkoff m xxmaj keller a xxmaj measuring resource use economic evaluations xxmaj determining social costs mental illness xxmaj journal xxmaj mental xxmaj health xxmaj administration dequardo j r xxmaj carpenter c f xxmaj tandon r xxmaj patterns substance abuse schizophrenia xxmaj nature significance xxmaj journal xxmaj psychiatric xxmaj research xxmaj dickey b xxmaj azeni h xxmaj persons dual diagnoses substance abuse major mental illness xxmaj their excess costs psychiatric care xxmaj american xxmaj journal xxmaj public xxmaj health xxmaj dixon l xxmaj haas g xxmaj weiden p j xxmaj sweeney j xxmaj frances a j xxmaj drug abuse schizophrenic patients xxmaj clinical correlates reasons use xxmaj american xxmaj journal xxmaj psychiatry xxmaj drake r e xxmaj mueser k t xxmaj brunette m f mchugo g j a review treatment people severe mental illness co occurring substance use disorders xxmaj psychchiatricl xxmaj rehabilitation xxmaj journal xxmaj drake r e xxmaj xie h mchugo g j xxmaj green a i xxmaj the effects clozapine alcohol drug use disorders among patients schizophrenia xxmaj schizophrenia xxmaj bulletin xxmaj first m b xxmaj spitzer r l xxmaj gibbon m xxmaj williams j b w xxmaj structured xxmaj clinical xxmaj interview xxup dsm xxup iv xxmaj axis i xxmaj disorders xxmaj patient xxmaj edition xxup scid i p xxmaj version xxmaj new xxmaj york xxup ny xxmaj biometrics xxmaj research xxmaj department xxmaj freed e x xxmaj alcoholism schizophrenia xxmaj the search perspectives xxmaj journal xxmaj studies xxmaj alcohol xxmaj gardner d m xxmaj murphy a l o xxmaj donnell h xxmaj centorrino f xxmaj baldessarini r j xxmaj international consensus study antipsychotic dosing xxmaj american xxmaj journal xxmaj psychiatry xxmaj george t p xxmaj sernyak m j xxmaj ziedonis d xxmaj woods s m xxmaj effects clozapine smoking chronic schizophrenic outpatients xxmaj journal xxmaj clinical xxmaj psychiatry xxmaj green a i xxmaj alam m y xxmaj sobieraj j t xxmaj pappalardo k m xxmaj waternaux c xxmaj salzman c xxmaj schildkraut j j xxmaj clozapine response plasma catecholamines metabolites xxmaj psychiatry xxmaj research xxmaj green a i xxmaj burgess e s xxmaj dawson r xxmaj zimmet s v xxmaj strous r d xxmaj alcohol cannabis use schizophrenia xxmaj effects clozapine vs risperidone xxmaj schizophrenia xxmaj research xxmaj green a i xxmaj noordsy d l xxmaj brunette m f o xxmaj keefe c xxmaj substance abuse schizophrenia xxmaj pharmacotherapeutic intervention xxmaj journal xxmaj substance xxmaj abuse xxmaj treatment xxmaj green a i xxmaj zimmet s v xxmaj strous r d xxmaj schildkraut j j xxmaj clozapine comorbid substance use disorder schizophrenia xxmaj do patients schizophrenia reward deficiency syndrome ameliorated clozapine xxmaj harvard xxmaj review xxmaj psychiatry xxmaj guy w xxup ecdeu xxmaj assessment xxmaj manual xxmaj psychopharmacology xxmaj rockville xxup md u s xxmaj department xxmaj health xxmaj education xxmaj welfare xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december m f xxmaj brunette et al xxmaj hambrecht m xxmaj hafner h xxmaj substance abuse onset schizophrenia xxmaj biological xxmaj psychiatry xxmaj kessler r c xxmaj birnbaum h xxmaj demler o xxmaj falloon i r h xxmaj gagnon e xxmaj guyer m xxmaj wu e q xxmaj the prevalence correlates nonaffective psychosis xxmaj national xxmaj comorbidity xxmaj survey xxmaj replication xxup ncs r xxmaj biological xxmaj psychiatry xxmaj kessler r c mcgonagle k a xxmaj zhao s xxmaj nelson c b xxmaj hughes m xxmaj eshleman s xxmaj kendler k s xxmaj lifetime month prevalence xxup dsm xxup iii r psychiatric disorders xxmaj united xxmaj states xxmaj results xxmaj national xxmaj comorbidity xxmaj survey xxmaj archives xxmaj general xxmaj psychiatry xxmaj kivlahan d r xxmaj heiman j r xxmaj wright r c xxmaj mundt j w xxmaj shupe j a xxmaj treatment cost rehospitalization rate schizophrenic outpatients history substance abuse xxmaj hospital xxmaj community xxmaj psychiatry xxmaj knudsen p xxmaj vilmar t xxmaj cannabis neuroleptic agents schizophrenia xxmaj acta xxmaj psychiatrica xxmaj scandinavica xxmaj koskinen j xxmaj lohonen j xxmaj koponen h xxmaj isohanni m xxmaj miettunen j xxmaj rate cannabis use disorders clinical samples patients schizophrenia a meta analysis xxmaj schizophrenia xxmaj bulletin xxmaj laird n m xxmaj ware j h xxmaj random effects models longitudinal data xxmaj biometrics xxmaj lane r d xxmaj glazer w m xxmaj hansen t e xxmaj berman w h xxmaj kramer s i xxmaj assessment tardive dyskinesia using xxmaj abnormal xxmaj involuntary xxmaj movement xxmaj scale xxmaj journal xxmaj nervous xxmaj mental xxmaj disease xxmaj lee m l xxmaj clozapine substance abuse patients schizophrenia xxmaj canadian xxmaj journal xxmaj psychiatry xxmaj lieberman j xxmaj johns c xxmaj pollack s xxmaj masiar s xxmaj bookstein p xxmaj cooper t xxmaj kane j xxmaj biochemical effects clozapine cerebrospinal fluid patients schizophrenia xxmaj in c xxmaj tamminga s xxmaj schulz xxmaj eds xxmaj advances neuropsychiatry psychopharmacology vol xxmaj schizophrenia research pp xxmaj new xxmaj york xxup ny xxmaj raven xxmaj press xxmaj linszen d xxmaj dingemans p xxmaj lenior m xxmaj cannabis abuse course recent onset schizophrenic disorders xxmaj archives xxmaj general xxmaj psychiatry xxmaj lukoff k xxmaj liberman r xxmaj nuechterlein k xxmaj symptom monitoring rehabilitation schizophrenic patients xxmaj schizophrenia xxmaj bulletin xxmaj marcus p xxmaj snyder r xxmaj reduction comorbid substance abuse clozapine letter xxmaj american xxmaj journal xxmaj psychiatry mcevoy j p xxmaj freudenreich o xxmaj levin e xxmaj rose j e xxmaj haloperidol increases smoking patients schizophrenia xxmaj psychopharmacology mchugo g j xxmaj drake r e xxmaj burton h l xxmaj ackerson t h a scale assessing stage substance abuse treatment persons severe mental illness xxmaj journal xxmaj nervous xxmaj mental xxmaj disease xxmaj mueser k t xxmaj bennett m xxmaj kushner m g xxmaj epidemiology substance use disorders among persons chronic mental illness xxmaj in a f xxmaj lehman l b xxmaj dixon xxmaj eds xxmaj double jeopardy xxmaj chronic mental illness substance use disorders pp xxmaj new xxmaj york xxup ny xxmaj harwood xxmaj mueser k t xxmaj yarnold p r xxmaj levinson d f xxmaj singh h xxmaj bellack a s xxmaj kee k xxmaj yadalam k g xxmaj prevalence substance abuse schizophrenia xxmaj demographic clinical correlates xxmaj schizophrenia xxmaj bulletin xxmaj negrete j c xxmaj knapp w p xxmaj douglas d e xxmaj smith w b xxmaj cannabis affects severity schizophrenic symptoms xxmaj results clinical survey xxmaj psychology xxmaj medicine xxmaj noordsy d l o xxmaj keefe c xxmaj mueser k t xxmaj xie h xxmaj six month outcomes patients switched olanzapine treatment xxmaj psychiatric xxmaj services xxmaj peralta v xxmaj cuesta m j xxmaj influence cannabis abuse schizophrenic psychopathology xxmaj acta xxmaj psychiatrica xxmaj scandinavica xxmaj petrakis i l xxmaj leslie d xxmaj finney j w xxmaj rosenheck r xxmaj atypical antipsychotic medication substance use related outcomes treatment schizophrenia xxmaj the xxmaj american xxmaj journal xxmaj addictions xxmaj potvin s xxmaj stip e xxmaj lipp o xxmaj elie r xxmaj mancinin xxmaj marie a xxmaj demers m f xxmaj gendron a xxmaj quetiapine patients comorbid schizophrenia spectrum substance use disorders xxmaj an open label trial xxmaj current xxmaj medical xxmaj research xxmaj opinion xxmaj regier d a xxmaj farmer m e xxmaj rae d s xxmaj locke b z xxmaj keith s j xxmaj judd l l xxmaj goodwin f k xxmaj comorbidity mental disorders alcohol drug abuse xxmaj results xxmaj epidemiologic xxmaj catchment xxmaj area xxup eca xxmaj study comment xxmaj journal xxmaj american xxmaj medical xxmaj association xxmaj journal xxmaj dual xxmaj diagnosis xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december xxmaj clozapine xxmaj cannabis xxmaj use xxmaj patients xxmaj with xxmaj schizophrenia xxmaj rice h e xxmaj smith c b xxmaj silk k r xxmaj rosen j xxmaj platelet alpha adrenergic receptors schizophrenic patients phenothiazine treatment xxmaj psychiatry xxmaj research xxmaj sarafoff m xxmaj davis l xxmaj ruther e xxmaj clozapine induced increase human plasma norepinephrine xxmaj journal xxmaj neural xxmaj transmission xxmaj simpson g n xxmaj angus j w s a rating scale extrapyramidal side effects xxmaj acta xxmaj psychiatrica xxmaj scandinavica suppl xxmaj smelson d a xxmaj losonczy m f xxmaj davis c w xxmaj kaune m xxmaj williams j xxmaj ziedonis d xxmaj risperidone decreases craving relapses individuals schizophrenia cocaine dependence xxmaj canadian xxmaj journal xxmaj psychiatry xxmaj smelson d a xxmaj williams j xxmaj ziedonis d xxmaj sussner b d xxmaj losonczy m f xxmaj engelhart c xxmaj kaune m a double blind placebo controlled pilot study risperidone decreasing cue elicited craving recently withdrawn cocaine dependent patients xxmaj journal xxmaj substance xxmaj abuse xxmaj treatment xxmaj smelson d a xxmaj ziedonis d xxmaj williams j xxmaj losonczy m f xxmaj steinberg m l xxmaj kaune m xxmaj the efficacy olanzapine decreasing cue elicited craving individuals schizophrenia cocaine dependence a preliminary report xxmaj journal xxmaj clinical xxmaj psychopharmacology xxmaj sobell m b xxmaj maisto s a xxmaj sobell l c xxmaj cooper a m xxmaj cooper t xxmaj saungers b xxmaj developing prototype evaluating alcohol treatment effectiveness xxmaj in l c xxmaj sobell m b xxmaj sobell e xxmaj ward xxmaj eds xxmaj evaluating alcohol drug abuse treatment effectiveness xxmaj recent advances pp xxmaj new xxmaj york xxup ny xxmaj pergamon xxmaj sobell l c xxmaj sobell m b xxmaj timeline xxmaj follow xxmaj back a technique assessing self reported alcohol consumption xxmaj in r z xxmaj litten j xxmaj allen xxmaj eds xxmaj measuring alcohol consumption xxmaj psychosocial biological methods pp xxmaj totowa xxup nj xxmaj humana xxmaj press xxmaj svensson t h xxmaj mathe j m xxmaj andersson j l xxmaj nomikos g g xxmaj hildebrand b e xxmaj marcus m xxmaj mode action atypical neuroleptics relation phencyclidine model schizophrenia xxmaj role xxup ht receptor alpha adrenoceptor antagonism xxmaj journal xxmaj clinical xxmaj psychopharmacology suppl s s xxmaj thierry a m xxmaj godbout r xxmaj mantz j xxmaj glowinski j xxmaj influence ascending monoaminergic systems activity rat prefrontal cortex xxmaj progress xxmaj brain xxmaj research discussion xxmaj treffert d a xxmaj marijuana use schizophrenia a clear hazard xxmaj american xxmaj journal xxmaj psychiatry xxmaj van xxmaj kammen d p xxmaj peters j l xxmaj van xxmaj kammen w b xxmaj neylan t xxmaj yao j k xxmaj shaw d xxmaj doherty g xxmaj noradrenaline state dependency relapse prediction schizophrenia xxmaj in m xxmaj weller xxmaj ed xxmaj international perspectives schizophrenia pp xxmaj london xxmaj england xxmaj john xxmaj libbey xxmaj warsi m xxmaj sattar s p xxmaj bhatia s c xxmaj petty f xxmaj aripiprazole reduces alcohol use xxmaj canadian xxmaj journal xxmaj psychiatry xxmaj xie h mchugo g j xxmaj fox m xxmaj drake r e xxmaj substance abuse relapses year prospective follow clients co occurring severe mental illness substance use disorders xxmaj psychiatric xxmaj services xxmaj yovell y xxmaj opler l a xxmaj clozapine reverses cocaine craving treatment resistant mentally ill chemical abuser a case report hypothesis xxmaj journal xxmaj nervous xxmaj mental xxmaj disorders xxmaj zimmet s v xxmaj strous r d xxmaj burgess e s xxmaj kohnstamm s xxmaj green a i xxmaj effects clozapine substance use patients schizophrenia schizoaffective disorder a retrospective survey xxmaj journal xxmaj clinical xxmaj psychopharmacology xxmaj volume xxmaj numbers xxmaj downloaded xxmaj university xxmaj liverpool xxmaj december,xxbos xxmaj use sublingual buprenorphine pain relief office hysteroscopy xxmaj yu xxmaj hung xxmaj lin xxup md xxmaj jiann xxmaj loung xxmaj hwang xxup md xxmaj lee xxmaj wen xxmaj huang xxup md xxmaj xxunk xxmaj ju xxmaj chen xxup md xxmaj from xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj shin xxmaj kong xxmaj wu xxmaj ho xxmaj su xxmaj memorial xxmaj hospital xxmaj taipei xxmaj taiwan xxmaj all authors xxmaj college xxmaj medicine xxmaj fu xxmaj jen xxmaj catholic xxmaj university xxmaj taipei xxmaj taiwan xxmaj drs xxmaj lin xxmaj huang xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj taipei xxmaj medical xxmaj university xxmaj taipei xxmaj taiwan xxmaj dr xxmaj huang xxmaj abstract xxup study xxup objective xxmaj to assess efficacy sublingual buprenorphine relief pain associated office hysteroscopy xxup design xxmaj prospective randomized study xxmaj canadian xxmaj task xxmaj force classification i xxup setting xxmaj tertiary medical center xxup patients xxmaj one hundred sixty four women referred office hysteroscopy xxmaj september xxmaj march xxup intervention xxmaj before hysteroscopy women received tablet buprenorphine group a women received placebo group b xxmaj their pain sensations evaluated cm visual analog scale asked adverse reactions level satisfaction following day xxup measurements xxup and xxup main xxup results xxmaj the pain score group a similar group b xxmaj the pain scores subgroups women also similar within group two groups xxmaj thirty one women group a reported adverse reactions including nausea vomiting drowsiness none group b reported adverse reactions xxup conclusion xxmaj office hysteroscopy mm flexible hysteroscope well tolerated procedure xxmaj sublingual buprenorphine helpful relieving pain associated hysteroscopy associated significant adverse reactions xxup aagl xxmaj all rights reserved xxup key xxup words xxmaj buprenorphine xxmaj hysteroscope xxmaj analgesia xxmaj hysteroscopy allows direct visualization uterine cavity directed biopsy regarded gold standard investigation intrauterine abnormalities xxmaj although generally well tolerated associated certain degree pain possible vasovagal reaction xxmaj actually pain common reason failure complete procedure xxmaj in outpatient hysteroscopies reported required local anesthesia failed due excessive discomfort xxmaj various methods analgesia proposed suppress pain associated hysteroscopy general anesthesia paracervical block intracervical injection lidocaine spray intrauterine instillation lignocaine xxmaj however results controversial established guidelines use analgesia office hysteroscopy xxmaj buprenorphine potent safe opioid analgesic xxmaj corresponding author xxmaj jiann xxmaj loung xxmaj hwang xxup md xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj shin xxmaj kong xxmaj wu xxmaj ho xxmaj su xxmaj memorial xxmaj hospital xxmaj no xxmaj wen xxmaj chang xxmaj road xxmaj shih xxmaj lin xxmaj district xxmaj taipei xxmaj taiwan e mail ms xxunk org tw xxmaj submitted xxmaj december xxmaj accepted xxmaj march see front matter xxup aagl xxmaj all rights reserved doi j jmig xxmaj journal xxmaj minimally xxmaj invasive xxmaj gynecology partial agonist antagonist actions xxmaj as analgesic buprenorphine used relief moderate severe pain xxmaj compared morphine buprenorphine provides adequate postoperative analgesia longer duration analgesic potency parenteral buprenorphine times parenteral morphine xxmaj in series patients receiving buprenorphine immediate postoperative period patients good adequate pain relief xxmaj buprenorphine also used provide preoperative sedation analgesia adjunct surgical anesthesia xxmaj its anxiolytic sedative properties make suitable preoperative medication xxmaj buprenorphine given xxunk well parenterally xxmaj it readily absorbed following sublingual administration xxmaj although maximal effect reached later sublingual administration provides longer duration action cause discomfort administered parenteral routes xxmaj in order assess efficacy sublingual buprenorphine relief pain hysteroscopy conducted prospective randomized study double blind conditions xxmaj materials methods xxmaj from xxmaj september xxmaj march women referred office hysteroscopy included study xxmaj the study approved medical ethics committee hospital xxmaj the patients randomized computergenerated numbers receive buprenorphine xxmaj xxunk xxmaj xxunk xxmaj xxunk xxmaj hull xxup uk group a placebo group b xxmaj every woman put tablet buprenorphine mg placebo tongue minutes procedure xxmaj indications hysteroscopy included abnormal uterine bleeding suspected intracavitary lesion uterine synechiae endometrial hyperplasia endometrial polyp submucosal myoma infertility xxmaj all procedures performed physician xxup xxunk using flexible hysteroscope mm outer diameter bending section degrees xxmaj olympus xxup xxunk xxmaj type xxup xp xxmaj tokyo xxmaj japan xxmaj the uterine cavity distended dextrose solution hung cm operating table xxmaj illumination provided w high intensity cold light source xxmaj no tenaculum cervical dilatation used procedures xxmaj during procedure patients observed pain sensations evaluated nurse using cm visual analog scale xxup vas xxmaj for patient worst expression whole procedure recorded pain score xxmaj on day procedure patients asked evaluate level satisfaction satisfied little satisfied satisfied xxmaj all results expressed mean xxup sd unless otherwise stated xxmaj statistical significance assessed independent test xxmaj fisher exact test test appropriate xxup spss software xxmaj statistical xxmaj package xxmaj social xxmaj science xxmaj windows version xxup spss xxmaj inc xxmaj chicago xxup il used statistical analysis a p value considered statistically significant xxmaj results xxmaj from xxmaj september xxmaj march women underwent office hysteroscopy hospital xxmaj the procedure failed women cervical stenosis xxmaj these women underwent repeat hysteroscopy general anesthesia xxmaj none procedures discontinued intolerable pain xxmaj therefore enrolled women study xxmaj thirty seven postmenopausal xxmaj the indications hysteroscopy abnormal uterine bleeding infertility intracavitary tumor lesion myoma polyp others xxmaj among women women received buprenorphine group a received placebo group b xxmaj as shown xxmaj table significant differences patients characteristics including mean age number nulliparous multiparous postmenopausal women xxmaj the xxup vas pain scores shown xxmaj table xxmaj the mean pain score group a similar group b xxmaj the pain scores various subgroups women including postmenopausal nulliparous multiparous women also similar within group two groups xxmaj for patients worst discomfort related insertion speculum hysteroscopy per se xxmaj in group a women reported adverse reactions associated procedure xxmaj among reported nausea vomiting reported drowsiness reported xxmaj none women group b reported discomfort adverse effects xxmaj no woman experienced vagal reactions xxmaj table shows levels satisfaction xxmaj women group b satisfied procedure xxmaj thirty women group a satisfied procedure adverse effects xxmaj table xxmaj patient characteristics xxmaj with buprenorphine n xxmaj without buprenorphine n p xxmaj mean age yrs xxup ns xxmaj no premenopausal xxup ns xxmaj nulliparous xxup ns xxmaj multiparous xxup ns xxmaj no postmenopausal xxup ns xxup ns significant independent test test xxmaj journal xxmaj minimally xxmaj invasive xxmaj gynecology xxmaj vol xxmaj no xxmaj july xxmaj august xxmaj discussion xxmaj pain associated hysteroscopy occurs insertion speculum dilatation cervix insertion hysteroscope distention uterine cavity distention medium direct stimulation uterine wall hysteroscope xxmaj also use tenaculum biopsy may also cause pain xxmaj office hysteroscopy may painful even performed experienced surgeon nontraumatic technique xxmaj in fact single common reason failure hysteroscopy pain xxmaj the effect local analgesia office hysteroscopy inconclusive xxmaj although studies demonstrated paracervical block reduced pain others reveal beneficial effect xxmaj in addition paracervical block carries potential complications infection bleeding toxicity intravasation systemic absorption sacral plexus trauma xxmaj one study showed intracervical injection helpful women found injection painful part procedure xxmaj the afferent innervations upper lower parts uterus differ course source xxmaj afferent fibers conducting pain impulses fundus body follow sympathetic fibers t t afferent fibers cervix follow parasympathetic fibers s s xxmaj therefore injection local analgesic around cervix blocks pain arising cervix block pain originating uterine cavity xxmaj we speculated systemic administration analgesics might effective local analgesics relieving pain associated hysteroscopy xxmaj buprenorphine narcotic analgesic given sublingual route easier patients physicians cause discomfort associated local injection xxmaj in study however found buprenorphine benefit reducing pain associated hysteroscopy xxmaj the mean xxup vas pain scores similar group a group b xxmaj the mean pain scores subgroups also similar within group groups a b xxmaj this indicates flexible hysteroscopy well tolerated procedure even without analgesia taking buprenorphine beforehand beneficial effect xxmaj in study performed researchers using mm flexible hysteroscope without anesthesia women experienced little pain a study using mm flexible hysteroscope also found procedure well tolerated xxmaj in study mean pain score higher postmenopausal women xxmaj however study mean pain scores similar premenopausal postmenopausal women either without buprenorphine xxmaj the adverse effects buprenorphine similar morphine meperidine xxmaj in large series xxmaj caucasian patients receiving mg buprenorphine postoperatively nausea developed vomiting developed xxmaj however xxmaj chinese patients seem sensitive buprenorphine xxmaj in study women reported nausea vomiting taking buprenorphine xxmaj sedation including drowsiness common adverse effect parenteral buprenorphine occurring approximately two thirds patients xxmaj in study women developed drowsiness xxmaj the high incidence adverse reactions associated buprenorphine reflected high level dissatisfaction patients group a xxmaj conclusion xxmaj office hysteroscopy mm flexible hysteroscope well tolerated procedure xxmaj nearly patients found procedure acceptable even without analgesia xxmaj buprenorphine beneficial relieving pain associated high adverse effects lower level satisfaction xxmaj references xxmaj nagele f xxmaj connor xxup ho xxmaj davies a et al outpatient diagnostic hysteroscopies xxmaj obstet xxmaj gynecol xxmaj lau xxup wc xxmaj lo xxup wk xxmaj tam xxup wh et al xxmaj paracervical anaesthesia outpatient hysteroscopy randomized double blind placebo controlled trial xxmaj br j xxmaj obstet xxmaj gynaecol xxmaj cicinelli e xxmaj didonna t xxmaj schonauer xxup lm et al xxmaj paracervical anesthesia hysteroscopy endometrial biopsy post menopausal women j xxmaj reprod xxmaj med xxmaj broadbent xxup jam xxmaj hill xxup ncw xxmaj molnar xxup bg et al xxmaj randomized placebo controlled trial assess role intracervical lignocaine outpatient hysteroscopy xxmaj br j xxmaj obstet xxmaj gynaecol xxmaj table xxmaj pain scores xxup vas according subgroups xxmaj with buprenorphine n xxmaj without buprenorphine n p xxmaj whole group xxup ns xxmaj premenopausal xxup ns xxmaj nulliparous xxup ns xxmaj multiparous xxup ns xxmaj postmenopausal xxup ns xxup ns significant independent test xxup vas visual analog scale xxmaj table xxmaj level satisfaction xxmaj with buprenorphine xxmaj no n xxmaj without buprenorphine xxmaj no n xxmaj not satisfied a little satisfied xxmaj very satisfied p xxmaj fisher exact test xxmaj lin et al xxmaj use buprenorphine office hysteroscopy xxmaj davis a xxmaj richardson xxup mb o xxmaj connor h et al xxmaj lidocaine aerosol spray outpatient hysteroscopy randomized double blind placebo controlled trial xxmaj fertil xxmaj steril xxmaj soriano d xxmaj ajaj s xxmaj chuong t et al xxmaj lidocaine spray outpatient hysteroscopy randomized placebo controlled trial xxmaj obstet xxmaj gynecol xxmaj lau xxup wc xxmaj tam xxup wh xxmaj lo xxup wk et al a randomised double blind placebocontrolled trial transcervical intrauterine local anaesthesia xxunk hysteroscopy xxmaj br j xxmaj obstet xxmaj gynecol xxmaj yang j xxmaj vollenhoven b xxmaj pain control outpatient hysteroscopy xxmaj obstet xxmaj gynecol xxmaj surv xxmaj heel xxup rc xxmaj brogden xxup rn xxmaj speight xxup tm et al xxmaj buprenorphine review pharmacological properties therapeutic efficacy xxmaj drugs xxmaj xxunk xxup ah xxmaj ward xxup ae xxmaj smith xxup dw xxmaj buprenorphine postoperative pain results patients xxmaj anaesthesia xxmaj sear xxup jw xxmaj alexander xxup ji xxmaj comparison buprenorphine hyoscine papaveretum hyoscine xxunk gynaecological surgery xxmaj br j xxmaj anaesth xxmaj edge xxup wg xxmaj cooper xxup gm xxmaj morgan m xxmaj analgesic effects sublingual buprenorphine xxmaj anaesthesia xxmaj de xxmaj iaco p xxmaj marabini a xxmaj stefanetti m xxmaj acceptability pain outpatient hysteroscopy j xxmaj am xxmaj assoc xxmaj gynecol xxmaj laparosc xxmaj nagele f xxmaj lockwood g xxmaj magos xxup al xxmaj randomized placebo controlled trial mefenamic acid premedication outpatient hysteroscopy pilot study xxmaj brit j xxmaj obstet xxmaj gynaecol xxmaj vercellini p xxmaj colombo a xxmaj mauro f et al xxmaj paracervical anesthesia outpatient hysteroscopy xxmaj fertil xxmaj steril xxmaj anatomy reproductive tract women xxmaj in xxmaj cunningham xxup fg xxmaj xxunk xxup nf xxmaj xxunk xxup kj et al eds xxmaj williams xxmaj obstetrics st ed xxmaj new xxmaj york xxup ny mcgraw xxmaj hill xxmaj kremer c xxmaj xxunk s xxmaj duffy s xxmaj flexible outpatient hysteroscopy without anesthesia safe successful well tolerated procedure xxmaj br j xxmaj obstet xxmaj gynaecol xxmaj agostini a xxmaj bretelle f xxmaj cravello l et al xxmaj acceptance outpatient flexible hysteroscopy premenopausal postmenopausal women j xxmaj reprod xxmaj med xxmaj paul xxmaj walsh xxmaj physicians xxmaj desk xxmaj reference th ed xxmaj montvale xxup nj xxmaj medical xxmaj economics xxmaj company xxmaj inc xxmaj journal xxmaj minimally xxmaj invasive xxmaj gynecology xxmaj vol xxmaj no xxmaj july xxmaj august,xxbos xxmaj evidence xxmaj suggesting xxmaj that xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program xxmaj can xxmaj improve xxmaj health xxmaj status xxmaj while xxmaj reducing xxmaj hospitalization a xxmaj randomized xxmaj trial xxmaj author xxmaj kate r xxmaj lorig xxmaj david s xxmaj sobel xxmaj anita l xxmaj stewart xxmaj byron xxmaj william xxmaj brown xxmaj jr xxmaj albert xxmaj bandura xxmaj philip xxmaj ritter xxmaj virginia m xxmaj gonzalez xxmaj diana d xxmaj laurent xxmaj halsted r xxmaj holman xxmaj reviewed work xxmaj source xxmaj medical xxmaj care xxmaj vol xxmaj no xxmaj jan pp xxmaj published xxmaj lippincott xxmaj williams xxmaj wilkins xxmaj stable xxup url http www jstor org stable xxmaj accessed xxmaj your use xxup jstor archive indicates acceptance xxmaj terms xxmaj conditions xxmaj use available http www jstor org page info policies terms jsp xxup jstor profit service helps scholars researchers students discover use build upon wide range content trusted digital archive xxmaj we use information technology tools increase productivity facilitate new forms scholarship xxmaj for information xxup jstor please contact support jstor org xxmaj lippincott xxmaj williams xxmaj wilkins collaborating xxup jstor digitize preserve extend access xxmaj medical xxmaj care http www jstor org xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup medical xxup care xxmaj volume xxmaj number pp xxmaj lippincott xxmaj williams xxmaj wilkins xxmaj evidence xxmaj suggesting xxmaj that xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program xxmaj can xxmaj improve xxmaj health xxmaj status xxmaj while xxmaj reducing xxmaj hospitalization a xxmaj randomized xxmaj trial xxup kate r xxup lorig xxup rn xxup xxunk xxup david s xxup sobel xxup md xxup mph xxup anita l xxup stewart xxup phd xxup byron xxup william xxup brown xxup jr xxup phd xxup albert xxup bandura xxup phd xxup philip xxup ritter xxup phd xxup virginia m xxup gonzalez xxup mph xxup diana d xxup laurent xxup mph xxup and xxup halsted r xxup holman xxup md xxup objectives xxmaj this study evaluated effectiveness changes health behaviors health status health service utilization self management program chronic disease designed use heterogeneous group chronic disease patients xxmaj it also explored differential effectiveness intervention subjects specific diseases comorbidities xxup methods xxmaj the study six month randomized controlled trial communitybased sites comparing treatment subjects wait list control subjects xxmaj participants patients years age older physician confirmed diagnosis heart disease lung disease stroke arthritis xxmaj health behaviors health status health service utilization determined mailed self administered questionnaires measured xxup results xxmaj treatment subjects compared control subjects demonstrated xxmaj as average age population increases prevalence chronic disease xxmaj it estimated people aged years older average chronic conditions xxmaj chronic disease responsible almost health care expenditures xxmaj from xxmaj stanford xxmaj university xxmaj school xxmaj medicine xxmaj stanford xxmaj california tfrom xxmaj kaiser xxmaj permanente xxmaj northern xxmaj california xxmaj region xxmaj xxunk xxmaj california tfrom xxmaj university xxmaj california xxmaj san xxmaj francisco xxmaj institute xxmaj health xxmaj aging xxmaj san xxmaj francisco xxmaj california xxmaj from xxmaj department xxmaj psychology xxmaj stanford xxmaj university xxmaj stanford xxmaj california improvements months weekly minutes exercise frequency cognitive symptom management communication physicians self reported health health distress fatigue disability social role activities limitations xxmaj they also fewer hospitalizations days hospital xxmaj no differences found pain physical discomfort shortness breath psychological well xxup conclusions xxmaj an intervention designed specifically meet needs heterogeneous group chronic disease patients including comorbid conditions feasible beneficial beyond usual care terms improved health behaviors health status xxmaj it also resulted fewer hospitalizations days hospitalization xxmaj key words chronic disease self management patient education cost utilization xxmaj med xxmaj care xxmaj there many examples patient education programs specific chronic conditions increased healthful behaviors improved health status decreased health care costs participants xxmaj an excellent bibliography patient education studies xxmaj supported xxmaj university xxmaj xxunk xxmaj tobacco xxmaj related xxmaj disease xxmaj research xxmaj program grant xxup tr xxup ahcpr grant r xxup hs xxmaj address correspondence xxmaj dr xxmaj kate xxmaj lorig xxmaj stanford xxmaj patient xxmaj education xxmaj research xxmaj center xxmaj welch xxmaj road xxmaj suite xxmaj palo xxmaj alto xxup ca e mail lorig xxunk xxmaj stanford edu xxmaj received xxmaj december initial review completed xxmaj february accepted xxmaj may xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup lorig xxup et xxup al published recently xxmaj to date studies dealt one disease problems comorbidity xxmaj rather patient education intervention disease specific xxmaj with emergence chronic disease largest threat health status largest cause health care expenditures potential role patient self management assumes increased importance xxmaj if benefits shown inexpensive xxunk self management program programs might useful part therapeutic regime xxmaj our study explored possibility xxmaj it differed previous self management studies placed subjects different chronic diseases different combinations comorbid diseases program time utilized randomized controlled design measured outcomes terms behaviors health status health service utilization xxmaj although former patient self management education studies one attributes none three xxmaj the objectives study evaluate effectiveness changes health behaviors health status health service utilization selfmanagement program chronic disease designed use heterogeneous group chronic disease patients explore differential effectiveness intervention subjects specific diseases comorbidities xxmaj the experience months patients heart disease lung disease stroke arthritis reported xxmaj methods xxmaj the xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program xxup cdsmp community based patient self management education course xxmaj three principal assumptions underlie xxup cdsmp patients different chronic diseases similar self management problems disease related tasks patients learn take responsibility day day management disease confident knowledgeable patients practicing self management experience improved health status utilize fewer health care resources xxmaj other assumptions shaped program patient selfmanagement education inexpensive widely available trained lay persons chronic conditions could effectively deliver structured patient education program lay instructors would acceptable patients health professionals xxmaj there research evidence positive role models case lay leaders similar backgrounds disease problems increase patients self efficacy confidence ability manage disease xxmaj needs a xxunk xxmaj the content methodology xxup cdsmp based two needs assessments xxmaj the first literature review existing chronic disease patient education programs xxmaj the purpose review identify common topics taught across chronic disease courses xxmaj in review articles authors found common tasks recognizing acting symptoms using medication correctly managing emergencies maintaining nutrition diet maintaining adequate exercise giving smoking using stress reduction techniques interacting effectively health care providers using community resources adapting work managing relations significant others managing psychological responses illness xxmaj the second needs assessment sought information focus groups xxmaj participants included people older years chronic diseases xxmaj participants invited describe disease thought caused explain feelings beliefs getting older describe physical social emotional impacts chronic disease lives lives families describe coped problems caused disease elaborate fears hopes wishes future xxmaj theme analysis groups responses used shape content xxup cdsmp process instruction xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program xxmaj design xxmaj the topics covered xxup cdsmp included exercise use cognitive symptom management techniques nutrition fatigue sleep management use community resources use medications dealing emotions fear anger depression communication others including health professionals problem solving decision making xxmaj the content course xxup medical xxup care xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup chronic xxup disease xxup self xxup management published xxmaj living xxmaj healthy xxmaj life xxmaj chronic xxmaj conditions xxmaj this book used text course participants xxmaj the process teaching course based xxmaj self xxmaj efficacy xxmaj theory xxmaj it incorporates strategies suggested xxmaj bandura enhance self efficacy xxmaj these include weekly action planning feedback modeling behaviors problem solving participants one another xxunk symptoms giving many possible causes symptom well several different management techniques group problem solving individual decision making xxmaj the leaders act facilitators xxunk xxmaj for example rather prescribing specific behavior changes assist participants making management choices achieving success reaching self selected goals xxmaj the process documented detailed protocol xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj leader xxmaj manual xxmaj each course participants mixed ages diagnoses including family members wished attend xxmaj each course taught pair trained volunteer lay leaders xxmaj the leaders received hours training detailed teaching manual xxmaj they ranged age years older xxmaj seventy one percent leaders one chronic diseases health professionals students xxmaj few previous experience health education xxmaj on average leaders taught courses xxmaj the program given seven weekly hour sessions xxmaj entry xxmaj criteria xxmaj to enter study subjects physician confirm diagnosis chronic lung disease asthma chronic bronchitis emphysema heart disease coronary artery disease congestive heart failure stroke completed cerebrovascular accident neurologic handicap normal mentation chronic arthritis xxmaj in addition least one conditions could conditions xxmaj patients compromised mentation cancer patients received chemotherapy radiation within past year persons younger years age excluded xxmaj subjects physicians hospitals informed study status treatment control xxmaj recruitment xxmaj randomization xxmaj subjects recruited using public service announcements mass media referrals flyers left physicians offices community clinics posters senior xxunk centers announcements health maintenance organization xxup hmo patient newsletters referrals county government employers xxmaj before filling initial questionnaire randomization subjects told would either receive course immediately serving control months xxmaj to assure program would easily accessible patients held multiple community sites four county area xxmaj programs held xxunk senior community centers public libraries health care facilities xxmaj in addition programs planned varied times convenience patients including late mornings early xxunk evenings xxmaj saturday mornings xxmaj the project approved institutional xxmaj committee xxmaj protection xxmaj human xxmaj subjects xxmaj research xxmaj all participants gave written informed consent xxmaj after subject physician supplied diagnosis subject completed consent form baseline questionnaire participants randomized treatment control status xxmaj randomization conducted serially xxmaj after subjects applied specific site typically subjects randomization ratio treatment versus controls determined assure fewer treatment subjects xxmaj thus sites ratio treatment control subjects whereas others xxmaj this randomization method resulted overall ratio xxmaj outcome xxmaj measures xxmaj there three primary classifications outcome variables health behaviors health status health service utilization xxmaj data collected previously tested self administered mailed questionnaires xxmaj to minimize xxunk response data collection completely separate intervention carried persons know subjects treatment status xxmaj measures included self rated health scale used xxmaj national xxmaj health xxmaj interview xxmaj survey modified version xxmaj health xxmaj assessment xxmaj questionnaire xxup xxunk disability scale xxmaj the psychological xxmaj vol xxmaj no xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup medical xxup care well scale also known xxup mhi part xxup sf well xxup sf used xxmaj the pain physical discomfort scale adaptation xxmaj medical xxmaj outcomes xxmaj study xxup mos pain scale modified include physical discomfort xxmaj the energy fatigue scale scale used long form xxup mos health distress scale slightly modified version xxup mos health distress scale xxmaj the remaining measures ie duration exercise use cognitive symptom management communication physicians social role activity limitations shortness breath utilization measures developed tested study xxmaj definitions measures information reliability validity presented elsewhere xxmaj the magnitude correlations among health status scales ranged median xxmaj the highest correlation psychological well health distress xxmaj subjects assessed three types health utilization visits physicians including visits emergency room xxup er visits hospitals past months number nights spent hospital xxmaj for category reported often used health services xxmaj the self reported data subjects xxup hmo members validated automated medical records xxmaj outpatient self reported visits associated medical record visits r xxup er visits r xxmaj we found patients often included urgent care hour visits xxup er visits instead counting outpatient visits xxmaj thus data subjects xxup er visits combined data outpatient physician visits xxmaj when combined self reported data outpatient visits correlated r medical records xxmaj we found errors made patients automated record system xxmaj patients tended xxunk recorded visits approximately xxmaj conversely system sometimes xxunk visits xxmaj for example subject received numerous allergy injections nurse reported system physician visit injection xxmaj for days hospital medical records correlated patient self report r xxmaj analyses xxmaj the primary analysis compared month outcomes treatment control groups outcome variable using analysis covariance endpoint scores controlling baseline value study variable well age sex education marital status xxmaj the endpoint data examined analysis covariance variation among xxup xxunk programs participants taught program variation effects found minimal influence overall conclusions xxmaj therefore treatment control data aggregated across programs instruction xxmaj the secondary analyses determined intervention different outcomes different diseases xxmaj two way analyses variance utilized testing interaction disease treatment status treatment control xxmaj results xxmaj primary xxmaj results xxmaj of subjects entered study ie randomized treatment n control status n completed month study xxmaj of treatment subjects completed months compared control subjects xxmaj treatment subjects completing month data attended average seven program sessions xxmaj of treatment subjects completing month data died ill continue unknown reasons xxmaj for control subjects respective percentages xxmaj comparing baseline data subjects completed month data noncompleters significantly fewer minutes aerobic exercise per week higher levels activity limitation pain physical discomfort fatigue health distress completed months p however statistically significant differences treatment control subjects study entry variable xxmaj table presents demographic disease characteristics study participants completing study xxmaj only marital status significantly different p xxmaj table gives baseline data mean month uncorrected change scores xxup cdsmp treatment subjects control subjects xxmaj as compared controls treatment group demonstrated significant improvement four health behavior variables p number minutes per week stretching strengthening aerobic exercise xxup lorig xxup et xxup al xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup chronic xxup disease xxup self xxup management xxup table xxmaj subject xxmaj characteristics xxmaj treatment xxmaj control n n xxmaj mean age years xxmaj age range xxmaj median xxmaj mode xxmaj female xxmaj mean education years xxwrep 4 yrs xxmaj married xxmaj white xxmaj diseases xxmaj heart disease xxmaj lung disease xxmaj arthritis xxmaj stroke xxmaj mean number diseases xxmaj provider xxmaj covered xxup hmo xxmaj private fee service xxmaj govt xxmaj medicare xxmaj medical xxup xxunk xxup va x p creased practice cognitive symptom management improved communication physician xxmaj they also demonstrated significant improvement five health status variables self rated health disability social role activities limitation energy fatigue health distress p xxmaj no significant differences demonstrated pain physical discomfort shortness breath psychological well xxmaj the treatment group compared control group fewer hospitalizations p spent average fewer nights hospital p xxmaj there significant differences visits physicians p xxmaj an intent treat analysis also conducted included subjects xxmaj baseline entry data used months subjects drop outs complete month data xxmaj the eight treatment four control subjects died excluded xxmaj in analysis probability values remained unchanged although change scores reduced slightly treatment control groups xxmaj for example changes communication physicians treatment subjects compared controls health distress treatment subjects compared controls nights hospital treatment subjects compared controls xxmaj of control subjects completed month randomized study chose take xxup cdsmp xxmaj of provided month post xxup cdsmp endpoint data xxmaj using matched pair tests comparing data starting xxup cdsmp months starting program group increased aerobic exercise use coping strategies p xxmaj they also decreased disability health distress increasing social role activities p xxmaj visits physicians decreased p xxmaj the group fewer visits hospitals fewer days hospital p xxmaj changes study variables listed xxmaj table significant although demonstrated trend toward improvement xxmaj thus appears taking xxup cdsmp control subjects reversed many trends toward worsening health demonstrated month randomized trial xxmaj secondary xxmaj results xxmaj tables present baseline data month change scores treatment control subjects various disease categories whose disease arthritis heart disease lung disease comorbidities xxmaj subjects stroke included analysis small numbers a twoway analysis covariance controlling baseline status examined main treatment effects interactions among four disease categories found significant interactions outcome variables xxmaj examination month change scores confirmed tendency change scores reflect program effects similarly across four diagnostic subgroups xxmaj program costs versus savings also examined xxmaj although treatment group reduced visits physicians slightly control group difference significant xxmaj the decrease number hospitalizations number nights hospitalization significant p xxmaj table xxmaj assuming xxmaj vol xxmaj no xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup medical xxup care xxup table xxmaj baseline xxmaj six xxmaj month xxmaj changes xxmaj treatment xxmaj control xxmaj subjects xxmaj health xxmaj behaviors xxmaj health xxmaj status xxmaj health xxmaj service xxmaj utilization xxmaj baseline xxmaj six xxmaj month xxmaj change xxmaj treatment xxmaj control xxmaj treatment xxmaj control xxmaj mean xxup sd xxmaj mean xxup sd xxmaj mean xxmaj mean n n xxup sd a xxup sd a xxmaj significance p xxmaj health behaviors xxmaj stretching strengthening xxmaj exercise minutes week xxmaj aerobic exercise minutes week xxmaj cognitive symptom xxmaj mgmt t better xxmaj communication w xxup md t better xxmaj health status xxmaj self rated health better xxmaj disability better xxmaj social xxmaj role activities xxmaj limitations better xxmaj pain xxmaj physical discomfort i better xxmaj psychological well t better xxmaj energy xxmaj fatigue t better xxmaj health distress better xxmaj shortness breath better xxmaj health service utilization xxup md xxup er visits times past months xxmaj number hospital stays past months xxmaj nights hospital past months xxmaj analysis covariance month post test scores controlling treatment status age sex education marital status baseline status xxmaj two tailed p values cost per day hospitalization gram treatment subjects completed month health care costs control partici month study calculated per xxunk study greater xxunk xxmaj this includes training leaders xxunk subject xxmaj the costs providing pro xxunk two leaders teach course xxup lorig xxup et xxup al xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup table xxmaj baseline xxmaj scores xxmaj treatment xxmaj control xxmaj subjects xxmaj by xxmaj disease xxmaj health xxmaj behaviors xxmaj health xxmaj status xxmaj health xxmaj service xxmaj utilization xxmaj arthritis xxmaj only xxmaj heart xxmaj disease xxmaj only xxmaj lung xxmaj disease xxmaj only xxmaj comorbid xxmaj conditions xxmaj treatment xxmaj mean xxmaj control xxmaj mean xxmaj treatment xxmaj mean xxmaj control xxmaj mean xxmaj treatment xxmaj mean xxmaj control xxmaj mean xxmaj treatment xxmaj mean xxmaj control xxmaj mean xxup sd n xxup sd n xxup sd n xxup sd n xxup sd n xxup sd n xxup sd n xxup sd n xxmaj health behaviors xxmaj stretching xxmaj strengthening xxmaj exercise minutes week xxmaj aerobic exercise minutes week xxmaj cognitive symptom xxmaj mgmt t better xxmaj communication xxup md better xxmaj health status xxmaj self rated health better xxmaj disability better xxmaj social xxmaj role activities xxmaj limitations better xxmaj pain xxmaj physical discomfort i better xxmaj psychological well better xxmaj energy xxmaj fatigue t better xxmaj health distress better xxmaj shortness breath better xxmaj health service utilization xxup md xxup er visits times past months xxmaj number hospital stays past months xxmaj nights hospital past months z c xxmaj cd xxmaj cl xxmaj cd c xxunk xxunk h r i i dl c r xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup table xxmaj six xxmaj month xxmaj changes xxmaj treatment xxmaj control xxmaj subjects xxmaj by xxmaj disease xxmaj health xxmaj behaviors xxmaj health xxmaj status xxmaj health xxmaj service xxmaj utilization xxmaj arthritis xxmaj only xxmaj heart xxmaj disease xxmaj only xxmaj lung xxmaj disease xxmaj only xxmaj comorbid xxmaj conditions xxmaj treatment xxmaj control xxmaj treatment xxmaj control xxmaj treatment xxmaj control xxmaj treatment xxmaj control xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj mean a xxup sd xxmaj health behaviors xxmaj stretching xxmaj strengthening xxmaj exercise minutes week xxmaj aerobic exercise minutes week xxmaj cognitive symptom xxmaj mgmt better xxmaj communication w xxup md better xxmaj health status xxmaj self reported health better xxmaj disability j better xxmaj social xxmaj role activities xxmaj limitations better xxmaj pain xxmaj physical discomfort j better xxmaj psychological well better xxmaj energy xxmaj fatigue t better xxmaj health distress better xxmaj shortness breath better xxmaj health service utilization xxup md xxup er visits times past months xxmaj number hospital stays past months xxmaj nights hospital past months c xxup xxunk h r z cr xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup chronic xxup disease xxup self xxup management leader teaches one course volunteer leader xxunk assuming per leader per course participants course materials book audio tape administrative costs xxmaj this analysis take account cost space donated study indirect costs xxmaj assuming figures reflect current costs health care expenditure savings savings hospital nights minus program costs approximated per participant times cost intervention xxmaj discussion xxmaj this study evaluation self management education intervention persons one different conditions xxmaj the format intervention attributes medium sized classes lay leaders heterogeneity participants terms type severity disease xxmaj overall intervention successful increasing healthful behaviors maintaining improving health status decreasing rates hospitalization xxmaj table xxmaj these results indicate possible educate patients different chronic diseases successfully intervention time xxmaj because chronic disease patient education programs formally evaluated difficult determine heterogeneous educational interventions xxup cdsmp less effective homogeneous single disease oriented programs xxmaj because people years age older average two chronic conditions would seem program focused problems common various comorbidities would reasonable substitute adjunct traditional single disease programs xxmaj one key question concerns generalizability findings xxmaj as nearly studies subjects self selected study may motivated chronic disease patients xxmaj from past arthritis self management studies evidence patients closed xxup hmo rheumatology practice repeatedly offered opportunity participate intervention similar xxup cdsmp chose xxmaj men non xxmaj english speakers less likely attend xxmaj xxunk xxmaj litzelman found similar participation diabetes self management intervention xxmaj studies conducted xxmaj kaiser system xxmaj xxunk offer information generalizability xxup cdsmp xxmaj the subjects study high mean level education xxmaj it noteworthy approximately subjects years education less years xxmaj when education entered analysis covariant outcomes however affect xxmaj because heterogeneous mix patients patients symptoms need change behaviors xxmaj thus results primary analysis specific outcomes may underestimated somewhat individual improvements contained data subjects either target symptom already achieved acceptable levels outcome xxmaj although definitive answer clinical significance activity limitation health distress disability improved xxmaj this suggests xxup cdsmp affected important physical mental aspects participants lives xxmaj tables explore effectiveness intervention various subsets patients xxmaj because secondary analyses can not draw definitive conclusions data xxmaj the findings however may helpful guiding future studies xxmaj although subgroups appear made changes healthful behaviors changes varied group might expected xxmaj for example group heart disease reported aerobic exercise baseline minutes week treatment control groups respectively lung disease group reported least arthritis group intermediate xxmaj table xxmaj the treatment participants arthritis lung disease increased exercise control subjects xxmaj table xxmaj the treatment group heart disease remained control group decreased exercise xxmaj thus patients low baseline activity levels intervention increased activity whereas patients relatively high activity level level maintained xxmaj the results concerning practice cognitive symptom management techniques communication physicians uniform across subgroups xxmaj that intervention differential effects different subsets patients surprising xxmaj although chronic diseases create similar problems problems less salient xxmaj vol xxmaj no xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions xxup lorig xxup et xxup al individual patient different times across diseases xxmaj the xxup cdsmp designed meet challenge aiding patients identify individual needs problems assisting work intensively areas xxmaj in addition designed meet needs many older patients one chronic condition xxmaj it important note participants study volunteers recruited largely word mouth various forms public announcement xxmaj although physicians confirmed diagnoses knew participation linkage xxup cdsmp content individual treatment plans xxmaj the xxup cdsmp alter participants treatment xxmaj therefore benefits achieved additional achieved usual care xxmaj conceivably integration xxup cdsmp usual care perhaps outset chronic disease would enhance benefits xxmaj conclusion xxmaj the xxmaj chronic xxmaj disease xxmaj self xxmaj management xxmaj program program designed specifically meet needs heterogeneous group chronic disease patients including comorbid conditions xxmaj the results study suggest intervention feasible beneficial beyond usual care terms improved health status decrease hospitalization potential substantial savings health care costs xxmaj if replicated similar studies program xxup cdsmp deserves place treatment regime patients chronic disease xxmaj references xxmaj rothenberg xxup rb xxmaj xxunk xxup jp xxmaj chronic disease xxmaj annu xxmaj rev xxmaj public xxmaj health xxmaj hoffman c xxmaj rice d xxmaj sung h y xxmaj persons chronic conditions xxmaj their prevalence costs j xxmaj am xxmaj med xxmaj assoc xxmaj center xxmaj advancement xxmaj health xxmaj the xxmaj center xxmaj health xxmaj studies xxmaj group xxmaj health xxmaj cooperative xxmaj puget xxmaj sound xxmaj an indexed bibliography selfmanagement people chronic disease st ed xxmaj washington xxup dc xxmaj center xxmaj advancement xxmaj health xxmaj bandura a xxmaj self efficacy mechanism physiological activation health promoting behavior xxmaj in xxmaj madden xxup ji xxmaj xxunk s xxmaj xxunk j eds xxmaj adaptation learning affect xxmaj new xxmaj york xxmaj raven xxmaj press xxmaj clark n xxmaj becker m xxmaj janz n xxmaj lorig k xxmaj xxunk w xxmaj anderson l xxmaj self management chronic disease older adults a review questions research j xxmaj aging xxmaj health xxmaj lorig k xxmaj stewart a xxmaj ritter p xxmaj gonzalez v xxmaj laurent d xxmaj lynch j xxmaj outcome measures health education health care interventions xxmaj thousand xxmaj oaks xxup ca xxmaj sage xxmaj publications xxmaj lorig k xxmaj holman h xxmaj sobel d xxmaj laurent d xxmaj gonzalez v xxmaj minor m xxmaj living healthy life chronic conditions xxmaj palo xxmaj alto xxup ca xxmaj bull xxmaj publishing xxmaj company xxmaj bandura a xxmaj self efficacy xxmaj toward unifying theory behavioral change xxmaj psychol xxmaj rev xxmaj stanford xxmaj patient xxmaj education xxmaj research xxmaj center xxmaj chronic disease self management leader manual xxmaj palo xxmaj alto xxup ca xxmaj stanford xxmaj patient xxmaj education xxmaj research xxmaj center xxup us xxmaj department xxmaj commerce xxmaj national xxmaj health xxmaj interview xxmaj survey xxmaj bureau xxmaj census xxmaj xxunk d xxmaj fries j xxmaj singh g xxmaj the xxmaj health xxmaj assessment xxmaj questionnaire xxmaj status review xxmaj in xxmaj spilker b ed xxmaj pharmacoeconomics quality life clinical trials xxmaj philadelphia xxup pa xxmaj lippincott xxmaj raven xxmaj ware xxup je xxmaj sherbourne xxup cd xxmaj the xxup mos item short form health survey xxup sf xxmaj med xxmaj care xxmaj stewart a xxmaj hays r xxmaj ware j xxmaj the xxup mos shortform general health survey xxmaj reliability validity patient population xxmaj med xxmaj care xxmaj sherbourne xxup cd xxmaj pain measures xxmaj in xxmaj stewart xxup al xxmaj ware xxup je eds xxmaj measuring functioning well xxmaj the medical outcomes study approach xxmaj durham xxup nc xxmaj duke xxmaj university xxmaj press xxmaj stewart xxup al xxmaj hays xxup rd xxmaj ware xxup je xxmaj health perceptions energy fatigue health distress measures xxmaj in xxmaj stewart xxup al xxmaj ware xxup je eds xxmaj measuring functioning well xxmaj the medical outcomes study approach xxmaj durham xxup nc xxmaj duke xxmaj university xxmaj press xxmaj lorig k xxmaj holman h xxmaj patient education xxmaj accepted highly motivated generalizable treatment xxmaj presented xxmaj american xxmaj college xxmaj rheumatology th xxmaj annual xxmaj meeting xxmaj glasgow r xxmaj chance xxup pl xxmaj toobert d xxmaj brown j xxmaj hampson s xxmaj riddle m xxmaj long term effects costs brief behavioral dietary intervention patients diabetes delivered medical office xxmaj patient xxmaj edu xxmaj xxunk xxmaj litzelman d xxmaj xxunk c xxmaj xxunk c et al xxmaj reduction lower extremity clinical abnormalities patients non insulin dependent diabetes mellitus a randomized controlled trial xxmaj ann xxmaj intern xxmaj med xxup medical xxup care xxmaj this content downloaded xxmaj mon xxmaj jan xxup pm xxmaj all use subject xxup jstor xxmaj terms xxmaj conditions\n",
              "y: CategoryList\n",
              "P,Q,N,Q,P\n",
              "Path: /content/gdrive/My Drive/covidnlp;\n",
              "\n",
              "Valid: LabelList (125 items)\n",
              "x: TextList\n",
              "xxbos e xxmaj mail karger karger com xxmaj original xxmaj article xxmaj gynecol xxmaj obstet xxmaj invest xxup doi xxmaj the xxmaj effect xxmaj intrauterine xxmaj lidocaine xxmaj rectal xxmaj indomethacin xxmaj pain xxmaj office xxmaj vaginoscopic xxmaj hysteroscopy xxmaj randomized xxmaj double xxmaj blind xxmaj controlled xxmaj study xxmaj xxunk xxmaj xxunk xxmaj xxunk xxmaj hakan xxmaj xxunk b b lent xxmaj xxunk lu b xxmaj xxunk xxmaj ya ar b xxmaj xxunk xxmaj xxunk xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj xxunk xxmaj xxunk xxmaj gynecologic xxmaj pediatric xxmaj training xxmaj research xxmaj hospital b xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj xxunk xxmaj dr xxmaj xxunk xxmaj xxunk xxmaj teaching xxmaj research xxmaj hospital xxmaj istanbul xxmaj turkey plied vaginoscopic technique useful hysteroscopy xxmaj however intrauterine anesthesia effective reducing pain s xxmaj karger xxup ag xxmaj basel xxmaj introduction xxmaj diagnostic hysteroscopy gold standard modality visualization uterine cavity minimally invasive procedure allows surgical procedures easily applied office conditions xxmaj although diagnostic hysteroscopy easily tolerated sometimes painful xxmaj several patient technique associated factors cause pain xxmaj in addition tenaculum speculum diameter hysteroscope duration procedure additional procedures performed time e g endometrial biopsy affect pain xxmaj these factors may prevent accurate evaluation pain caused hysteroscope passing uterine cavity xxmaj lower levels pain reported diagnostic hysteroscopy applied vaginoscopy touch technique compared conventional hysteroscopy using speculum xxmaj key xxmaj words xxmaj analog xxmaj pain xxmaj scale xxmaj anesthesia xxmaj hysteroscopy xxmaj abstract xxmaj backgrounds xxmaj aims xxmaj the aim study investigate effect rectal intrauterine anesthesia vaginoscopic hysteroscopy xxmaj methods xxmaj this randomized double blind placebo controlled study xxmaj patients randomized rectal indomethacin intrauterine lidocaine placebo groups xxmaj patients conditions could cause contribute pelvic pain excluded xxmaj pain evaluated xxmaj visual xxmaj analog xxmaj scale cervical canal passed within cavity min procedure xxmaj the xxmaj analog xxmaj pain xxmaj scale scores groups compared xxmaj kruskal xxmaj wallis way analysis variance test a value p accepted statistically significant xxmaj results xxmaj the study included total patients xxmaj no difference seen groups respect indication age xxunk duration procedure xxmaj while anesthesia determined superior placebo reducing pain stages p intrauterine lidocaine determined effective rectal indomethacin reducing pain within cavity min procedure p xxmaj conclusion xxmaj rectal intrauterine anesthesia ap xxmaj received xxmaj june xxmaj accepted xxmaj october xxmaj published online xxmaj november xxmaj xxunk xxmaj xxunk xxmaj xxunk xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj xxunk xxmaj xxunk xxmaj gynecologic xxmaj pediatric xxmaj training xxmaj research xxmaj hospital xxmaj xxunk xxmaj dr xxmaj xxunk xxmaj xxunk xxmaj cad xxmaj no xxmaj xxunk xxmaj istanbul xxmaj turkey e xxmaj mail dr xxunk gmail com s xxmaj karger xxup ag xxmaj basel www karger com goi xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm xxmaj pain xxmaj diagnostic xxmaj hysteroscopy xxmaj gynecol xxmaj obstet xxmaj invest xxup doi tenaculum xxmaj in vaginoscopic technique pain effect anesthesia used accurately evaluated xxmaj to best knowledge prospective studies evaluated benefit anesthesia hysteroscopy applied diagnostic purposes alone xxunk factors could cause pain e g use tenaculum speculum independent procedure xxmaj in prospective study compared intrauterine lidocaine rectal indomethacin placebo hysteroscopy applied vaginoscopic method xxmaj material xxmaj method xxmaj this randomized double blind study conducted xxmaj xxunk xxmaj dr xxmaj xxunk xxmaj xxunk xxmaj training xxmaj research xxmaj hospital xxmaj july xxmaj march xxmaj approval study granted xxmaj local xxmaj ethics xxmaj committee decision xxmaj the study included patients suspected endometrial polyp abnormal uterine bleeding diagnosis myoma infertility xxmaj patients conditions could cause contribute pelvic pain excluded xxmaj these factors evaluated dysmenorrhea dyspareunia history uterine surgery chronic pelvic pain previous caesarean section cervical canal surgery xxmaj in addition pregnant patients gastro oesophageal diseases could inhibit use rectal non steroid using medication allergies excluded study xxmaj informed consent obtained participants xxmaj patients selected according random numbers table separated groups xxmaj the control group administered ml distention medium containing ml serum physiologic per ml rectal placebo xxmaj the second group administered ml distention medium containing ml lidocaine per ml xxunk ampoule mg xxmaj xxunk xxmaj xxunk xxmaj turkey rectal placebo xxmaj the third group administered rectal indomethacin xxunk xxmaj xxunk mg supp xxmaj xxunk xxmaj istanbul xxmaj turkey min procedure ml distention medium containing ml serum physiologic per ml xxmaj the medications administered patients nurse xxmaj the xxunk patient blind xxmaj diagnostic hysteroscopy applied rigid endoscope mm single current shaft mm telescope xxmaj karl xxmaj storz xxmaj tuttlingen xxmaj germany xxmaj saline solution sodium chloride room temperature used distention medium xxmaj intrauterine pressure mm xxmaj hg provided pump xxmaj wolf xxmaj illinois xxup usa xxmaj the procedure applied single physician xxup xxunk experienced hysteroscopy xxmaj all patients evaluated days end menstrual bleeding xxmaj the procedure applied vaginoscopic technique without using tenaculum speculum xxmaj the hysteroscope inserted vagina without xxunk xxunk posterior fornix reached observation without xxunk vaginal walls xxmaj then xxunk back xxunk lower lip cervix external cervical os seen xxmaj the time entry external os passing cavity entering cavity end observation recorded separately pain levels points xxmaj ten min end procedure patients evaluated respect pain a xxmaj visual xxmaj analog xxmaj scale xxup vas used evaluation pain xxmaj in scale points different pictures faces patients asked indicate pain felt pictures appropriate points scored xxmaj statistical evaluation data made xxup spss xxmaj windows version software xxmaj the chi square test used comparisons groups indications menopause status nulliparity xxunk duration compared way analysis variance xxup anova test pain age parity xxunk abortion curettage ectopic pregnancies compared xxmaj kruskal xxmaj wallis way xxup anova tests a value p accepted statistically significant xxmaj results xxmaj the total patients comprised placebo group lidocaine group indomethacin group xxmaj no statistically significant difference determined groups terms age xxunk parity abortion curettage menopause status history systemic disease p xxmaj the common indication diagnostic hysteroscopy suspected endometrial polyps significant difference determined groups respect indication types p table xxmaj the time passing cervical canal observation period cavity similar groups p xxmaj when pain evaluated pain scores placebo group cervix cavity min procedure statistically significantly higher groups p xxmaj there differences rectal indomethacin placebo regard pain cavity min procedure table xxmaj while difference observed lidocaine indomethacin groups cervix pain scores p scores cavity min procedure determined statistically significantly higher indomethacin group intrauterine lidocaine group p table xxmaj there vasovagal side effects patients placebo patients lidocaine patients indomethacin groups xxmaj discussion xxmaj the results study showed use intrauterine lidocaine rectal indomethacin hysteroscopy applied vaginoscopic technique effective placebo reducing pain procedure xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm xxmaj gynecol xxmaj obstet xxmaj invest xxmaj xxunk xxmaj xxunk xxmaj xxunk lu xxmaj ya ar xxmaj xxunk xxup doi p xxmaj in addition use intrauterine lidocaine determined effective rectal indomethacin administered procedure reducing pain cavity min procedure p xxmaj to able reduce make accurate evaluation pain associated procedure necessary minimize factors except associated cervix uterine cavity xxmaj experienced physician using small diameter hysteroscope reaching cavity quickly xxunk minimal trauma reduce pain a majority studies related pain control office hysteroscopy based application conventional technique together procedures endometrial biopsy xxmaj however relatively studies related necessity anesthesia diagnostic hysteroscopy alone xxmaj zupi et al reported pain reduced ml mepivacaine xxmaj endometrial biopsy applied study pain diagnostic hysteroscopy recorded endometrial biopsy xxmaj no information given respect whether procedure applied conventional methods xxunk technique xxmaj lau et al reported lignocaine applied cavity superiority xxmaj table xxmaj the character patients indications hysteroscopy xxmaj placebo n xxmaj lidocaine n xxmaj indomethacin n p value xxmaj age mean xxup sd xxmaj xxunk median xxup iqr b xxmaj parity median xxup iqr b xxmaj abortion median xxup iqr b xxmaj dilatation curettage median xxup iqr b xxmaj ectopic pregnancy n xxmaj hypertension n xxmaj diabetes mellitus n xxmaj another n xxmaj menopause n c xxmaj nulliparous n c xxmaj xxunk multiparous n xxmaj xxunk n c xxmaj polyp xxmaj abnormal uterine bleeding xxmaj xxunk xxmaj infertility xxmaj one way xxup anova b xxmaj kruskal xxmaj wallis way xxup anova c xxmaj chi square test xxup iqr xxmaj interquartile range xxmaj table xxmaj time pain scores groups xxmaj placebo n xxmaj lidocaine n xxmaj indomethacin n p value xxmaj time pass cervical canal mean xxup sd xxmaj observation period uterine cavity mean xxup sd xxmaj pain passing cervical canal median xxup iqr x b xxmaj pain observation uterine cavity median xxup iqr x z b xxmaj pain min procedure median xxup iqr x z b xxmaj one way xxup anova b xxmaj kruskal xxmaj wallis way xxup anova xxup iqr xxmaj interquartile range x xxmaj indicates statistical significance placebo lidocaine groups statistically significant placebo indomethacin groups z indicates statistical significance lidocaine indomethacin groups xxmaj bold xxunk character demonstrate statistically significant changes xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm xxmaj pain xxmaj diagnostic xxmaj hysteroscopy xxmaj gynecol xxmaj obstet xxmaj invest xxup doi placebo xxmaj in study pain evaluated hysteroscopy biopsy applied xxmaj after administering anesthesia mean xxup vas score placebo group hysteroscopy determined anesthesia group mean score xxmaj the mean pain score higher patients score xxmaj however procedure applied using speculum tenaculum could contributed pain xxmaj in current study used instrument speculum tenaculum make accurate pain related hysteroscope shown intrauterine lidocaine rectal indomethacin effective placebo respect pain control xxmaj in study xxmaj xxunk et al vaginoscopic technique used patients reported rectal indomethacin vaginal misoprostol effective reducing pain placebo xxmaj in study patients infertile mm hysteroscope used xxmaj conversely current study rectal indomethacin found effective placebo xxmaj this disparity findings study xxmaj xxunk et al may due low number nulliparity patients current study patient group xxmaj the uterus xxunk innervated organ xxmaj parasympathetic innervation corpus cervix provided nerve fibers coming xxmaj xxunk plexus s sympathetic innervation provided nerve fibers coming ovarian plexus nerve fibers terminated densely sub endometrial region xxmaj pain caused administration distention medium cavity direct effects manipulation nerve ends increased prostaglandin xxmaj by reaching nerve fibers quickly intrauterine anesthesia provides effective pain control indomethacin reduces pain inhibiting prostaglandin xxmaj but significant component pain felt hysteroscopy probably xxunk cervical canal xxmaj factors arising cervical canal e g xxunk also diameter hysteroscope increase pain passing cervical canal xxmaj in study cases cervical xxunk degree would require dilatation cases xxunk included xxmaj in addition premedication administered cervical preparation xxmaj our study demonstrated pain passing cervical canal placebo group groups xxmaj but cavity examination min significant difference placebo rectal indomethacin groups lidocaine effective xxmaj as explained earlier lidocaine administered cavity directly reaches nerve fibers sub endometrial region effective analgesia may provided route xxmaj this result also support need anesthesia office diagnostic hysteroscopy cervical canal xxmaj compared previous reports literature duration procedure current study seen short xxmaj however procedure considered started visualization internal cervical os xxmaj furthermore procedures short may reduced pain xxmaj this study considered significant examined hysteroscopy procedure alone minimizing instrument patient related factors could cause pain xxmaj therefore comparison benefit anesthesia medications used considered objective xxmaj to best knowledge previous report literature placebo controlled study rectal indomethacin intra xxunk lidocaine applied hysteroscopy vaginoscopic technique xxmaj however low number cases groups evaluated limitation current study xxmaj in conclusion anesthesia applied diagnostic hysteroscopy made vaginoscopic technique office conditions significantly reduces pain xxmaj in addition intra xxunk anesthesia seen superior rectal indomethacin xxmaj to able say whether anesthesia necessary hysteroscopy applied vaginoscopic approach need randomized controlled studies review studies xxmaj disclosure xxmaj statement xxmaj the authors declared conflict interest xxmaj acknowledgment xxmaj language edited native xxmaj english speaker xxmaj caroline xxmaj walker xxmaj references van xxmaj dongen h de xxmaj kroon xxup cd xxmaj jacobi xxup ce xxmaj trimbos xxup jb xxmaj jansen xxup fw xxmaj diagnostic hysteroscopy abnormal uterine bleeding systematic review meta analysis xxup bjog xxmaj xxunk xxup rm xxmaj xxunk g xxmaj del xxmaj xxunk n xxmaj xxunk a xxmaj xxunk xxup ma xxmaj xxunk g xxmaj sforza r xxmaj xxunk xxup af xxmaj xxunk i xxmaj xxunk v xxmaj hysteroscopy valid tool endometrial pathology patients postmenopausal bleeding asymptomatic patients thickened endometrium hysteroscopic histological results xxmaj gynecol xxmaj obstet xxmaj invest xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm xxmaj gynecol xxmaj obstet xxmaj invest xxmaj xxunk xxmaj xxunk xxmaj xxunk lu xxmaj ya ar xxmaj xxunk xxup doi xxmaj teran xxmaj alonso xxup mj xxmaj de xxmaj santiago j xxmaj usandizaga r xxmaj zapardiel i xxmaj evaluation pain office hysteroscopy prior analgesic medication prospective randomized study xxmaj eur j xxmaj obstet xxmaj gynecol xxmaj reprod xxmaj biol xxmaj xxunk d xxmaj xxunk e xxmaj anesthetic xxmaj implications xxmaj hysteroscopy xxmaj st xxmaj louis xxup cv xxmaj mosby xxmaj co xxmaj cicinelli e xxmaj hysteroscopy without anesthesia review recent literature j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj diniz xxup db xxmaj xxunk xxmaj xxunk b xxmaj pereira xxup am xxmaj david xxup sd xxmaj xxunk xxup ug xxmaj baracat xxup ff xxmaj lopes xxup rg xxmaj pain evaluation office hysteroscopy comparison two techniques xxmaj rev xxmaj xxunk xxmaj xxunk xxmaj obstet xxmaj xxunk r xxmaj xxunk o xxmaj xxunk m xxmaj xxunk m xxmaj schechter e xxmaj golan a a new approach office hysteroscopy compared traditional hysteroscopy randomized controlled trial xxmaj obstet xxmaj gynecol xxmaj cooper xxup na xxmaj khan xxup ks xxmaj clark xxup tj xxmaj local anaesthesia pain control outpatient hysteroscopy systematic review meta analysis xxup bmj c xxmaj cooper xxup na xxmaj smith p xxmaj khan xxup ks xxmaj clark xxup tj xxmaj vaginoscopic approach outpatient hysteroscopy systematic review effect pain xxup bjog xxmaj campbell f xxmaj xxunk xxup bj xxmaj chronic pelvic pain xxmaj br j xxmaj anaesth xxmaj cicinelli e xxmaj rossi xxup ac xxmaj xxunk m xxmaj matteo m xxmaj xxunk n xxmaj tinelli r xxmaj predictive factors pain experienced office fluid minihysteroscopy j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj kabli n xxmaj tulandi t a randomized trial outpatient hysteroscopy without intrauterine anesthesia j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj xxunk h xxmaj xxunk y xxmaj xxunk t xxmaj xxunk k xxmaj effectiveness vaginal misoprostol rectal nonsteroidal anti inflammatory drug vaginoscopic diagnostic outpatient hysteroscopy primarily infertile women double blind randomized controlled trial j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj xxunk a xxmaj oliveira xxup ma xxmaj xxunk xxup cp xxmaj xxunk xxup mf xxmaj xxunk xxup ts xxmaj santos xxup lc xxmaj diagnostic hysteroscopy using liquid distention medium comparison pain xxunk saline solution vs room temperature saline solution j xxmaj minim xxmaj invasive xxmaj gynecol xxmaj jensen xxup mp xxmaj chen c xxmaj xxunk xxup am xxmaj postsurgical pain outcome assessment xxmaj pain t r k p xxmaj major t xxmaj evaluating level pain office hysteroscopy according menopausal status parity size instrument xxmaj arch xxmaj gynecol xxmaj obstet xxmaj van den xxmaj bosch t xxmaj xxunk j xxmaj daemen a xxmaj xxunk o xxmaj domali e xxmaj xxunk f xxmaj vandenbroucke v xxmaj de xxmaj moor b xxmaj deprest j xxmaj timmerman d xxmaj pain experienced transvaginal ultrasound saline contrast sonohysterography hysteroscopy office sampling comparative study xxmaj ultrasound xxmaj obstet xxmaj gynecol xxmaj campo r xxmaj molinas xxup cr xxmaj rombauts l xxmaj xxunk g xxmaj lauwers m xxmaj xxunk p xxmaj brosens i xxmaj van xxmaj belle y xxmaj xxunk s xxmaj prospective multicentre randomized controlled trial evaluate factors influencing success rate office diagnostic hysteroscopy xxmaj hum xxmaj reprod de xxmaj xxunk xxmaj fonseca m xxmaj xxunk xxup xxunk xxmaj xxunk xxup ja xxmaj jr xxmaj xxunk xxup cg xxmaj xxunk xxup cm xxmaj jr xxmaj xxunk xxup cp xxmaj identifying predictors unacceptable pain office hysteroscopy j xxmaj minim xxmaj invasive xxmaj gynecol van xxmaj dongen h de xxmaj kroon xxup cd van den xxmaj xxunk xxup sa xxmaj xxunk xxup la xxmaj trimbos xxmaj xxunk xxup gc xxmaj jansen xxup fw a randomised comparison vaginoscopic office hysteroscopy saline infusion sonography patient compliance study xxup bjog xxmaj zupi e xxmaj luciano xxup aa xxmaj valli e xxmaj marconi d xxmaj maneschi f xxmaj romanini c xxmaj the use topical anesthesia diagnostic hysteroscopy endometrial biopsy xxmaj fertil xxmaj steril xxmaj lau xxup wc xxmaj tam xxup wh xxmaj lo xxup wk xxmaj yuen xxup pm a randomised double blind placebo controlled trial transcervical intrauterine local anaesthesia outpatient hysteroscopy xxup bjog xxmaj xxunk xxup rj xxmaj xxunk xxup ml xxmaj intrauterine anesthesia gynecologic procedures systematic review xxmaj obstet xxmaj gynecol xxmaj waller xxup dg xxmaj xxunk xxup ag xxmaj xxunk k xxmaj medical xxmaj pharmacology xxmaj therapeutics ed xxmaj london xxmaj elsevier xxmaj saunders xxmaj xxunk i xxmaj xxunk a xxmaj xxunk s xxmaj xxunk m xxmaj di xxmaj xxunk xxup gc xxmaj xxunk e xxmaj xxunk v xxmaj xxunk s xxmaj pain diagnostic hysteroscopy role cervical canal a pilot study xxmaj eur j xxmaj obstet xxmaj gynecol xxmaj reprod xxmaj biol xxmaj xxunk i xxmaj xxunk a xxmaj xxunk m xxmaj xxunk s xxmaj xxunk v xxmaj di xxmaj xxunk xxup gc xxmaj xxunk s xxmaj pain diagnostic hysteroscopy multivariate analysis randomized controlled trial xxmaj fertil xxmaj steril xxmaj di xxmaj spiezio xxmaj sardo a xxmaj taylor a xxmaj xxunk p xxmaj xxunk g xxmaj sharma m xxmaj magos a xxmaj hysteroscopy technique xxmaj analysis outpatient hysteroscopies xxmaj fertil xxmaj steril xxmaj downloaded xxmaj univ xxmaj california xxmaj san xxmaj diego xxup pm,xxbos xxmaj pulmonary xxmaj perspective xxmaj an xxmaj appraisal xxmaj evidence xxmaj underlying xxmaj performance xxmaj measures xxmaj community acquired xxmaj pneumonia xxmaj kevin c xxmaj wilson xxmaj holger j xxmaj schu nemann xxmaj department xxmaj medicine xxmaj boston xxmaj university xxmaj school xxmaj medicine xxmaj boston xxmaj massachusetts xxmaj department xxmaj clinical xxmaj epidemiology xxmaj biostatistics xxmaj medicine mcmaster xxmaj university xxmaj hamilton xxmaj ontario xxmaj canada xxmaj numerous organizations use performance measures monitor quality care provided variety clinical conditions xxmaj an appraisal evidence underlying performance measures never reported xxmaj our objective estimate effects interventions recommended performance measures determine quality evidence estimates derive using xxmaj joint xxmaj commission xxmaj centers xxmaj medicare xxmaj medicaid xxmaj services performance measures community acquired pneumonia xxup cap examples xxmaj we performed systematic reviews literature identify evidence related performance measures xxup cap xxmaj metaanalyses performed estimate absolute relative effects interventions recommended performance measures xxmaj the xxmaj grading xxmaj recommendations xxmaj assessment xxmaj development xxmaj evaluation system used determine quality evidence xxmaj the estimated effects favored interventions recommended five six performance measures xxmaj these included pneumococcal vaccination incidence pneumococcal pneumonia relative risk xxup rr confidence interval xxup ci blood cultures antibiotic administration within hours use guideline compliant antibiotic regimen influenza vaccination incidence symptomatic influenza xxup rr xxup ci xxmaj however among performance measures influenza vaccination supported high quality evidence xxmaj one step smoking cessation counseling xxunk moderate quality evidence smoking quit rate xxup rr xxup ci xxmaj the evidence supporting performance measures frequently high quality occasionally contradictory xxmaj keywords pneumococcal vaccines blood specimen collection smoking cessation xxunk agents influenza vaccines xxmaj performance measures developed many organizations monitor quality care rendered variety clinical conditions xxmaj the goal performance measures provide incentive clinicians healthcare organizations improve quality care deliver a performance measure considered recommendation use intervention specific patient population xxmaj the decision recommend intervention influenced several factors including balance desirable undesirable consequences quality evidence patient values preferences related intervention outcomes resource use xxmaj when consideration factors indicates implementation recommendation lead greater benefit xxunk strong recommendation warranted xxmaj this requires reasonable degree certainty desirable undesirable effects intervention xxmaj performance measures primarily based strong recommendations rather weak recommendations xxmaj performance measures related weak recommendations e alternative actions reasonable decision making process accounts reasons alternative action require substantially debate development implementation either less certainty balance desirable undesirable effects intervention patient values preferences exert greater influence decisions xxmaj certainty balance desirable undesirable consequences intervention directly influenced quality evidence xxmaj the greatest certainty exists estimated effects derived high quality evidence whereas less certainty exists estimated effects derived lower quality evidence xxmaj thus performance measures supported highest possible level clinical evidence transparent descriptions factors led selection performance measures patient values preferences resource considerations xxmaj although latter three factors may routinely adequately considered development performance measures reasonable assume develop performance measures routinely evaluate quality evidence balance benefits harms xxmaj performance measures evidence supporting well studied xxmaj the purpose study estimate effects interventions recommended performance measures determine quality evidence estimates derived xxmaj we chose xxmaj joint xxmaj commission xxmaj centers xxmaj medicare xxmaj medicaid xxmaj services performance measures e xxmaj national xxmaj hospital xxmaj quality xxmaj measures community acquired pneumonia xxup cap illustrative set performance measures xxup methods xxmaj performance xxmaj measures xxmaj we identified updated versions major performance measures patients admitted xxup cap version xxmaj specification xxmaj manual xxmaj national xxmaj hospital xxmaj quality xxmaj measures xxmaj they included recommendations pneumococcal vaccination blood cultures xxunk smoking cessation counseling antibiotics within hours use guideline compliant antibiotics influenza vaccination xxmaj each described detail xxup results section xxmaj data xxmaj sources xxmaj searches xxmaj systematic reviews performed performance measure using two step approach xxmaj the first step consisted one investigators searching xxmaj medline via pubmed xxmaj cochrane xxmaj central xxmaj register xxmaj controlled xxmaj trials xxmaj cochrane xxmaj database xxmaj systematic xxmaj received original form xxmaj september accepted final form xxmaj january xxmaj correspondence requests reprints addressed xxmaj kevin c xxmaj wilson m d xxmaj sawyer xxmaj road xxmaj waltham xxup ma e mail xxunk uptodate com xxmaj this article online supplement accessible issue table contents www atsjournals org xxmaj am j xxmaj respir xxmaj crit xxmaj care xxmaj med xxmaj vol pp xxmaj originally xxmaj published xxmaj press xxup doi xxunk xxup pp xxmaj january xxmaj internet address www atsjournals org xxmaj reviews xxmaj google xxmaj scholar randomized trials see xxmaj table e online supplement xxmaj if eligible randomized trials identified second step used virtually identical first except observational studies e cohort studies case control studies sought xxmaj table e xxmaj in addition electronic database searches bibliographies published metaanalyses selected studies xxmaj specification xxmaj manual xxmaj national xxmaj hospital xxmaj quality xxmaj measures reviewed potentially eligible studies xxmaj the electronic database searches included dates beginning database xxmaj april xxmaj study xxmaj selection xxmaj for performance measures recommending pneumococcal vaccination smoking cessation counseling influenza vaccination studies selected compared intervention either placebo intervention measured patient important outcomes xxmaj for performance measures recommending blood cultures antibiotics within hours guideline compliant antibiotics selection criteria used patients hospitalized xxup cap xxmaj data xxmaj extraction xxmaj quality xxmaj assessment xxmaj for selected study one investigators extracted data published article regarding study design participant characteristics outcome measures frequency events xxmaj occasionally event data could extracted either study could located study report event data xxmaj when occurred attempt made extract event data published metaanalyses included study xxmaj when secondary approach also failed identify event data could calculate estimated effects instead relied effects reported original studies inform judgments xxmaj data xxmaj synthesis xxmaj analysis xxmaj for performance measure whose systematic review identified multiple relevant studies one investigator performed metaanalyses estimate absolute relative effects recommended intervention xxmaj metaanalyses conducted xxmaj review xxmaj manager revman using random effects model relative risk measure effect xxmaj once estimated effects recommended intervention calculated two investigators appraised quality evidence using xxmaj grading xxmaj assessment xxmaj development xxmaj evaluation xxup grade approach xxmaj randomized trials began assumption high quality evidence whereas well done observational studies began assumption low quality evidence xxmaj the quality evidence downgraded upgraded according criteria shown xxmaj table e xxmaj discussion consensus used arrive final quality assessment xxmaj evidence tables constructed using gradepro xxup results xxmaj pneumococcal xxmaj vaccination xxmaj the pneumococcal vaccination performance measure determines proportion patients aged years older hospitalized xxup cap screened pneumococcal vaccine status vaccinated discharge indicated xxmaj our systematic review identified randomized trials met inclusion criteria e compared pneumococcal vaccination either placebo vaccination measured patient important outcomes xxmaj figure e xxmaj metaanalyses randomized trials found pneumococcal vaccination decreased incidence pneumococcal pneumonia relative risk xxup rr confidence interval xxup ci incidence invasive pneumococcal disease xxup rr xxup ci mortality due pneumonia xxup rr xxup ci although third outcome statistically significant xxmaj table xxmaj the absolute effects small outcomes due low baseline risks xxmaj prior metaanalyses similarly found either small absolute benefits pneumococcal vaccination xxmaj the quality evidence supporting performance measure recommendation pneumococcal vaccination low outcomes xxmaj there multiple randomized trials results inconsistent trials detected relative benefit several found effect harm populations indirectly related performance measure target population xxmaj sources indirectness included clinical context trials include patients recovering infection performance measure targets adults recovering xxup cap age trials included adults ages performance measure targets adults years old comorbidity evidence patients without significant comorbidities performance measure also intended patients comorbidities xxmaj table xxmaj this indirectness may important data suggest pneumococcal vaccination may less effective among elderly patients recently infected patients comorbidities xxmaj blood xxmaj cultures xxmaj this performance measure determines proportion adult xxup icu patients transferred admitted xxup icu within hours hospital arrival xxup cap blood cultures performed within hours hospital arrival xxmaj our systematic review identified two retrospective cohort studies met inclusion criteria e enrolled patients hospitalized xxup cap compared blood cultures performed measured patient important outcomes xxmaj figure e xxmaj metaanalyses performed studies report event data xxmaj blood cultures associated increased likelihood clinically stable hours study looked outcome adjusted odds ratio xxup or xxup ci xxmaj the studies also found reduction relative risk mortality among patients blood cultures performed adjusted xxup or xxup ci adjusted xxup or xxup ci although failed achieve statistical significance xxmaj the quality evidence supporting performance measure recommendation blood cultures low outcomes xxmaj for clinical stability hours observational study population indirectly related performance measure target population study included many non xxup icu patients target population xxup icu patients xxmaj for mortality two observational studies estimates imprecise risk bias confounding indication populations indirectly related performance measure target population one study included elderly patients studies included non xxup icu patients xxmaj smoking xxmaj cessation xxmaj the smoking cessation performance measure determines proportion adult patients xxup cap history smoking cigarettes time prior year given smoking cessation advice counseling hospitalization xxmaj our systematic review identified randomized trials met inclusion criteria e compared inpatient smoking cessation advice smoking cessation intervention measured patient important outcomes xxmaj figure e a metaanalysis trials found inpatient smoking cessation advice without outpatient follow improve xxmaj pulmonary xxmaj perspective smoking quit rate xxup rr xxup ci contradicting performance measure recommendation inpatient smoking cessation advice xxmaj the quality evidence moderate multiple randomized trials estimates effect imprecise xxmaj table xxmaj our results similar prior metaanalysis included many studies xxmaj antibiotics within xxmaj hours xxmaj the antibiotic timing performance measure determines proportion adult patients xxup cap received first dose antibiotics within hours hospital arrival a threshold hours used previous versions performance measure threshold changed hours xxunk reports increased misdiagnosis inappropriate antibiotic use implementation hour threshold xxmaj we reviewed evidence underlying prior performance measure antibiotics within hours response reviewers found estimated effects inconsistent xxmaj two observational studies found initiation antibiotics within hours associated reduced mortality one observational study reported possible benefit e mortality decreased hour threshold one bundle interventions study analyze xxup table xxup evidence xxup table xxup for xxup the xxup pneumococcal xxup vaccination xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no xxmaj studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other xxmaj considerations xxmaj mortality due pneumonia xxmaj randomized trials xxmaj no serious limitations xxmaj serious xxmaj very serious xxmaj no serious imprecision xxmaj none xxmaj pneumococcal pneumonia xxmaj randomized trials xxmaj no serious limitations xxmaj xxunk xxmaj very serious xxmaj no serious imprecision xxmaj none xxmaj invasive pneumococcal disease xxmaj randomized trials xxmaj no serious limitations xxmaj xxunk xxmaj very serious xxmaj no serious imprecision xxmaj none xxmaj summary findings xxmaj no xxmaj patients xxmaj effect xxmaj pneumococcal xxmaj vaccination xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj mortality due pneumonia xxup rr fewer per fewer xxup oo xxmaj very low xxmaj critical xxmaj pneumococcal pneumonia xxup rr fewer per fewer fewer xxup oo xxmaj very low xxmaj important xxmaj invasive pneumococcal disease xxup rr fewer per fewer fewer xxup oo xxmaj very low xxmaj important xxmaj definition abbreviations xxup ci confidence interval xxup rr relative risk xxmaj comparison xxmaj pneumococcal vaccination versus pneumococcal vaccination xxmaj data xxmaj references xxmaj inconsistency xxmaj we downgraded inconsistency metaanalysis randomized trials found severe amount heterogeneity i p xxmaj in addition visual inspection relative risks xxmaj forrest plot metaanalysis revealed five studies relative benefit four studies little relative benefit one study relative harm xxmaj indirectness xxmaj the performance measure intended patients aged years older recovering community acquired pneumonia evidence presented adults ages recovering infection xxmaj we downgraded indirectness population data suggest pneumococcal vaccine may less effective among elderly patients comorbidity patients currently recently infected xxmaj imprecision xxmaj we downgrade imprecision already downgraded inconsistency partially related wide xxup ci relative effect xxmaj we also note absolute effects small compatible small benefit absolute risk reduction upper limit confidence interval x xxmaj inconsistency xxmaj visual inspection xxmaj forrest plot metaanalysis revealed seven studies relative benefit five studies little relative benefit two studies relative harm xxmaj in addition found large amount heterogeneity i p k xxmaj inconsistency xxmaj we downgraded inconsistency metaanalysis randomized trials found moderate amount heterogeneity i p xxmaj in addition visual inspection relative risks xxmaj forrest plot metaanalysis revealed six studies relative benefit three studies little relative benefit three studies relative harm xxup table xxup evidence xxup table xxup for xxup the xxup smoking xxup cessation xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other considerations xxmaj quit rate xxmaj randomized trials xxmaj no serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj serious xxmaj none xxmaj summary xxmaj findings xxmaj no xxmaj patients xxmaj effect xxmaj smoking cessation advice xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj quit rate xxup rr per fewer o xxmaj moderate xxmaj critical xxmaj for definition abbreviations see xxmaj table xxmaj comparator xxmaj inpatient smoking cessation counseling versus counseling xxmaj data xxmaj references xxmaj the quit rate surrogate many patient important outcomes xxmaj however well established reliable surrogate xxmaj therefore evidence downgraded indirectness comparator xxmaj slight imprecision xxmaj assuming absolute risk reduction quit rate would prompt clinicians provide smoking cessation counseling threshold number needed treat upper lower limits cis indicate opposite clinical decisions xxup american xxup journal xxup of xxup respiratory xxup and xxup critical xxup care xxup medicine xxup vol intervention separately three observational studies found improvement clinical outcomes xxmaj our systematic review targeted evidence related current performance measure antibiotics within hours xxmaj the review identify studies met inclusion criteria e enrolled patients xxup cap compared initial antibiotic dose within hours later antibiotic dose measured patient important outcomes therefore extracted data studies described relationship outcome duration initial antibiotic dose range durations xxmaj we identified three retrospective cohort studies xxmaj figure e xxmaj metaanalyses performed studies report event data xxmaj however studies found administration initial antibiotic dose within hours associated lower likelihood prolonged hospital stay xxup rr xxup ci xxmaj table xxmaj it also associated decreased mortality adjusted xxup or xxup ci adjusted xxup or xxup ci although latter study statistically significant xxmaj the quality evidence supporting performance measure recommendation begin antibiotics within hours depended upon outcome xxmaj table xxmaj for mortality low quality evidence two observational studies dose response gradient serious risk bias imprecise estimates xxmaj for incidence prolonged hospital stay low quality evidence observational study large effect serious risk bias xxmaj guideline xxmaj compliant xxmaj antibiotics xxmaj the antibiotic selection performance measure determines proportion adult patients xxup cap received initial antibiotic regimen consistent current guidelines first hours hospitalization xxmaj acceptable regimens listed xxmaj specification xxmaj manual xxmaj national xxmaj hospital xxmaj quality xxmaj measures consistent xxmaj infectious xxmaj disease xxmaj society xxmaj america xxup idsa xxmaj american xxmaj thoracic xxmaj society xxup ats guidelines xxup cap xxmaj our systematic review identified two retrospective cohort studies met inclusion criteria e enrolled patients xxup cap compared antibiotic regimens consistent xxup idsa xxup ats guidelines regimens measured patient important outcomes xxmaj given paucity data fact xxup idsa xxup ats guidelines xxup ats guidelines recommend similar antibiotic regimens xxunk selection criteria repeated systematic review xxmaj we selected studies compared antibiotic regimens consistent either xxup idsa xxup ats guidelines xxup ats guidelines regimens xxmaj our repeat systematic review identified six observational studies xxmaj figure e xxmaj metaanalyses performed several studies report event data xxmaj however studies consistently found guideline compliant antibiotic regimen associated decreased mortality xxup rr xxup ci adjusted xxup or xxup ci adjusted xxup or xxup ci adjusted xxup or xxup ci adjusted xxup rr p adjusted xxup or xxup ci xxmaj table xxmaj the quality evidence supporting performance measure recommendation use guideline consistent antibiotic regimen moderate xxmaj table xxmaj there multiple observational studies strengthened large effect xxmaj influenza xxmaj vaccination xxmaj the influenza vaccination performance measure determines proportion patients aged years older hospitalized xxup cap months xxmaj october xxmaj march xxup table xxup evidence xxup tables xxup for xxup the xxup antibiotic xxup timing xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no xxmaj studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other xxmaj considerations xxmaj mortality xxmaj observational studies xxmaj serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj serious xxmaj dose response xxunk xxmaj incidence prolonged length stay xxmaj observational studies xxmaj serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj no serious imprecision xxmaj strong association xxmaj summary xxmaj findings xxmaj no xxmaj patients xxmaj effect xxmaj intervention xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj mortality k k xxmaj not pooled xxmaj not pooled o xxmaj very low xxmaj critical xxmaj incidence prolonged length stay xxup rr fewer per fewer fewer xxup oo xxmaj low xxmaj important xxmaj definition abbreviations xxup ci confidence interval xxup or odds ratio xxup rr relative risk xxmaj comparison xxmaj antibiotics initiated within hours versus antibiotics initiated later xxmaj data xxmaj references xxmaj early antibiotic therapy may marker aggressive approach initial care xxmaj thus cointerventions rather antibiotics within hours may responsible effects measured xxmaj indirectness xxmaj the performance measure adults studies primarily conducted patients years old xxmaj nevertheless downgrade quality evidence indirectness could think reason advanced age would xxunk us true impact early antibiotic therapy xxmaj imprecision xxmaj assuming absolute risk reduction mortality would prompt clinicians administer first antibiotic dose within hours threshold number needed treat upper lower limits cis studies indicate opposite clinical decisions x xxmaj dose response gradient xxmaj both studies found earlier antibiotic administration associated lower mortality range approximately hours k xxmaj only one studies reported event data shown a metaanalysis conducted event data reported one studies xxmaj the relative effects individual studies included adjusted xxup or xxup ci adjusted xxup or xxup ci xxmaj the incidence prolonged length stay antibiotics administered within hours less half incidence antibiotics administered later xxmaj pulmonary xxmaj perspective screened influenza vaccine status vaccinated discharge indicated xxmaj our systematic review identified randomized trials met inclusion criteria e compared influenza vaccination influenza measured patient important outcomes xxmaj figure e xxmaj metaanalyses trials found influenza vaccination decreased incidence laboratory confirmed cases symptomatic influenza xxup rr xxup ci influenza like illnesses xxup rr xxup ci xxmaj table xxmaj our findings consistent previous metaanalyses xxmaj the quality evidence supporting performance measure recommendation influenza vaccination varied according outcome xxmaj table xxmaj for laboratory confirmed cases symptomatic influenza quality evidence high numerous randomized trials large effect xxmaj for influenza like illnesses quality evidence moderate randomized trials inconsistent results trials found benefit several found effect xxup discussion xxmaj the purpose study systematically evaluate evidence underlying performance measures xxmaj our results suggest estimated effect usually favors intervention xxup table xxup evidence xxup table xxup for xxup the xxup guideline xxup compliant xxup antibiotic xxup regimen xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no xxmaj studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other xxmaj considerations xxmaj mortality xxmaj observational studies xxmaj no serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj no serious imprecision xxmaj strong association xxmaj summary xxmaj findings xxmaj no xxmaj patients xxmaj effect xxmaj guideline xxmaj compliant xxmaj antibiotics xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj mortality xxmaj not pooledx xxmaj not pooledx xxmaj not pooledx xxmaj not pooledx o xxmaj moderate xxmaj critical xxmaj for definition abbreviations see xxmaj table xxmaj comparison xxmaj guideline compliant antibiotic regimen versus non guideline compliant antibiotic regimen xxmaj data references xxmaj the performance measure intended adults community acquired pneumonia xxmaj however one studies looked elderly patients xxmaj we downgrade indirectness population results similar among studies suggesting age population little impact results xxmaj only one six studies imprecision therefore downgrade imprecision xxmaj five six studies estimated guideline compliant antimicrobial therapy associated adjusted mortality less half associated noncompliant therapy therefore upgraded large magnitude effect x a metaanalysis performed event data reported several studies xxmaj the relative effects individual studies included xxup rr xxup ci adjusted xxup or xxup ci adjusted xxup or xxup ci adjusted xxup or xxup ci adjusted xxup rr p adjusted xxup or xxup ci xxup table xxup evidence xxup table xxup for xxup the xxup influenza xxup vaccination xxup performance xxup measure xxmaj quality xxmaj assessment xxmaj no studies xxmaj design xxmaj limitations xxmaj inconsistency xxmaj indirectness xxmaj imprecision xxmaj other xxmaj considerations xxmaj laboratory confirmed cases symptomatic influenza xxmaj randomized trials xxmaj no serious limitations xxmaj no serious inconsistency xxmaj no serious indirectness xxmaj no serious imprecision xxmaj strong association xxmaj influenza like illness xxmaj randomized trials xxmaj no serious limitations xxmaj serious xxmaj no serious indirectness xxmaj no serious imprecision xxmaj none xxmaj summary xxmaj findings xxmaj no xxmaj patients xxmaj effect xxmaj influenzae xxmaj vaccination xxmaj control xxmaj relative xxup ci xxmaj absolute xxmaj quality xxmaj importance xxmaj laboratory confirmed cases symptomatic influenza xxup rr fewer per fewer fewer xxmaj high xxmaj critical xxmaj influenza like illness xxup rr fewer per fewer fewer o xxmaj moderate xxmaj important xxmaj for definition abbreviations see xxmaj table xxmaj question xxmaj influenzae vaccination versus either influenza vaccination placebo xxmaj data xxmaj references xxmaj the performance measure intended patients aged years older evidence presented adults ages xxmaj we downgrade indirectness population metaanalyses randomized trials demonstrated effectiveness influenza vaccination among elderly patients xxmaj large effect xxmaj our metaanalysis randomized trials found incidence influenza less half among patients received influenza vaccine compared xxmaj inconsistency xxmaj visual inspection relative risks xxmaj forrest plot metaanalysis revealed trials relative benefit trials little relative benefit xxmaj in addition metaanalysis randomized trials found large amount heterogeneity i p xxup american xxup journal xxup of xxup respiratory xxup and xxup critical xxup care xxup medicine xxup vol recommended performance measure evidence frequently high quality xxmaj this implies uncertainty balance desirable undesirable effects intervention xxmaj we believe uncertainty exists compelling factors favor intervention going recommended performance measure xxmaj these factors may include patient values preferences pertain intervention outcomes well resource use xxmaj it possible factors implicitly influence development performance measures suggest stated explicitly xxunk evaluated basis performance measures xxmaj we chose xxmaj joint xxmaj commission xxmaj centers xxmaj medicaid xxmaj medicare xxmaj services performance measures xxup cap illustrative set performance measures xxmaj we believe recommendations influenza vaccination guideline compliant antibiotics reasonable performance measures xxmaj influenza vaccination large effect supported high quality evidence xxmaj table whereas use guideline compliant antibiotic regimen also large effect supported moderate quality evidence xxmaj table xxmaj although would ideal guideline compliant antibiotic performance measure supported high quality evidence uncertainty exists ratio desirable undesirable effects seems superseded potential major patient important benefits implicit distribution values preferences limited resource requirements xxmaj specifically potential desirable effects administering guideline compliant antibiotics decrease mortality far exceeds potential undesirable effects antibiotic side effects resource requirements cost antibiotic administered appropriate patients xxmaj thus likely patients would choose receive guideline compliant antibiotics xxmaj in contrast recommendations influenza vaccination guideline compliant antibiotics believe rationale recommendations pneumococcal vaccination antibiotics within hours blood cultures one step inpatient smoking cessation counseling elusive either reconsideration description sponsoring organizations warranted xxmaj with respect recommendation pneumococcal vaccination finding pneumococcal vaccination decreases pneumococcal pneumonia invasive pneumococcal disease supported low quality evidence suggesting uncertainty presence magnitude estimated effect xxmaj even pneumococcal vaccination beneficial magnitude pneumococcal vaccination decreases pneumococcal pneumonia invasive pneumococcal disease probably extremely small due low baseline risk xxmaj based randomized trials absolute risk reduction may low xxmaj table xxmaj patients clinicians healthcare organizations may reasonably decide small benefits pneumococcal vaccination outweigh burdens costs xxmaj it argued benefits may larger among elderly patients performance measure intended highest risk complications pneumococcal infection xxmaj however assumes pneumococcal vaccination effective elderly patients recovering xxup cap can not confirmed due conflicting data xxmaj with respect recommendation antibiotics within hours hospital arrival relevant evidence low low quality depending outcome meaning little confidence direction magnitude estimated effects xxmaj thus balance potential desirable effects decreased mortality decreased likelihood prolonged hospital stay undesirable effects increased misdiagnosis inappropriate antibiotic use uncertain xxmaj it seems likely early antibiotics beneficial patients e g patients sepsis due xxup cap others e g patients whose diagnosis uncertain xxmaj this argues use antibiotics within hours performance measure interventions recommended performance measures routinely benefit vast majority patients performance measure intended xxmaj with respect recommendation draw blood cultures patients admitted xxup icu evidence performing blood cultures patients xxup cap low quality xxmaj this means uncertainty presence magnitude estimated benefits blood cultures xxmaj it may argued blood cultures performed positive blood cultures frequently affect empiric therapy xxmaj however citing impact positive blood cultures xxunk importance performing blood culture relatively blood cultures positive even among xxup icu patients xxmaj it also assumes changes empiric therapy represent optimization therapy may incorrect xxmaj the possibility clinical benefits associated performing blood cultures benefits due optimization antimicrobial therapy suggests performing blood cultures merely surrogate interventions improve outcomes e g aggressive protocol guided care xxmaj with respect recommendation inpatient smoking cessation counseling found moderate quality evidence suggesting inpatient smoking cessation counseling alone improve smoking quit rate xxmaj table xxmaj however high quality evidence reported indicates inpatient smoking cessation counseling improves smoking quit rate followed least month outpatient smoking cessation therapy xxmaj we recognize importance smoking cessation believe performance measure may improved making recommendation inpatient smoking cessation counseling followed outpatient therapy least documentation intention continue counseling outpatient xxmaj it argued inpatient counseling prerequisite outpatient intervention therefore xxunk performance measure sine xxunk non argument weakened lack evidence enough patients complete outpatient counseling make inpatient efforts worthwhile xxmaj our study following strengths xxmaj we selected updated list performance measures conducted systematic reviews evidence used xxup grade strategy appraise evidence xxup grade approach focuses transparency evaluation quality evidence considers factors influence appropriateness performance measure based widely validated factors lead systematic errors factors used evaluate cause effect relationship xxmaj there also limitations study xxmaj we use multidisciplinary approach rigorous guideline development process evaluate performance measures xxmaj however believe methods transparent findings reproducible xxmaj in addition selected performance measures related xxup cap performance measures xxmaj given paucity attention paid importance developing performance measures supported high quality evidence presence lower quality evidence supported compelling factors favor intervention study probably representative would remain important even issues identified study less prevalent among performance measures diseases xxmaj pulmonary xxmaj perspective xxmaj in summary study suggests evidence supporting performance measures frequently high quality xxmaj this implies uncertainty balance desirable undesirable consequences interventions recommended performance measures xxmaj with respect illustrative performance measures xxup cap xxmaj joint xxmaj commission xxmaj centers xxmaj medicare xxmaj medicaid xxmaj services believe two performance measures recommendations influenza vaccination guideline compliant antibiotics reasonable performance measures four recommendations pneumococcal vaccination antibiotics within hours blood cultures one step smoking cessation counseling require explanation reconsideration xxmaj author xxmaj disclosure k c w full time employee uptodate xxmaj wolters xxmaj kluwer h s financial relationship commercial entity interest subject manuscript xxmaj references xxmaj specification xxmaj manual xxmaj national xxmaj hospital xxmaj quality xxmaj measures xxmaj version accessed xxmaj sept xxmaj available http www jointcommission org specifications manual national hospital inpatient quality measures xxmaj principles xxmaj xxunk xxmaj joint xxmaj commission xxmaj core xxmaj performance xxmaj measurement xxmaj activities accessed xxmaj sept xxmaj available http www jointcommission org assets xxmaj attach a xxmaj principles xxmaj review pdf xxmaj guyatt xxup gh xxmaj oxman xxup ad xxmaj kunz r xxmaj vist xxup ge xxmaj falck xxmaj ytter y xxmaj schunemann xxup hj xxmaj rating quality evidence strength recommendations quality evidence important clinicians xxup bmj xxmaj schunemann xxup hj xxmaj hill xxup sr xxmaj xxunk m xxmaj bellamy r xxmaj uyeki xxup tm xxmaj hayden xxup fg xxmaj yazdanpanah y xxmaj xxunk j xxmaj chotpitayasunondh t xxmaj del xxmaj mar c et al xxup who rapid advice guidelines pharmacological management sporadic infection avian influenza a h n virus xxmaj lancet xxmaj infect xxmaj dis xxmaj review xxmaj manager revman xxmaj computer program xxmaj version xxmaj copenhagen xxmaj the xxmaj nordic xxmaj cochrane xxmaj centre xxmaj the xxmaj cochrane xxmaj collaboration xxmaj schunemann xxup hj xxmaj vist xxup ge xxmaj jaeschke r xxmaj kunz r xxmaj cook xxup dj xxmaj guyatt xxup gh xxmaj grading recommendations xxmaj in xxmaj guyatt g xxmaj xxunk d xxmaj meade xxup mo xxmaj cook xxup dj editors xxmaj users guides medical literature nd ed xxmaj new xxmaj york mcgraw xxmaj hill pp gradepro xxmaj computer program xxmaj version xxmaj windows xxmaj jan xxmaj brozek xxmaj andrew xxmaj oxman xxmaj holger xxmaj schu nemann xxmaj xxunk s xxmaj holden j xxmaj xxunk xxup dp xxmaj andrews xxup rm xxmaj vaccines preventing pneumococcal infection adults xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj xxunk a xxmaj scott p xxmaj stuck xxup ae xxmaj xxunk c xxmaj egger m xxmaj efficacy pneumococcal vaccination adults meta analysis xxup cmaj xxmaj fine xxup mj xxmaj smith xxup ma xxmaj carson xxup ca xxmaj xxunk f xxmaj xxunk xxup ss xxmaj xxunk xxup la xxmaj detsky xxup as xxmaj kapoor xxup wn xxmaj efficacy pneumococcal vaccination adults meta analysis randomized controlled trials xxmaj arch xxmaj intern xxmaj med xxmaj cornu c xxmaj xxunk d xxmaj leophonte p xxmaj gaillat j xxmaj boissel xxup jp xxmaj xxunk m xxmaj efficacy pneumococcal polysaccharide vaccine immunocompetent adults meta analysis randomized trials xxmaj vaccine xxmaj moore xxup ra xxmaj wiffen xxup pj xxmaj lipsky xxup ba xxmaj are pneumococcal polysaccharide vaccines effective xxmaj meta analysis prospective trials xxup bmc xxmaj fam xxmaj pract xxmaj hutchison xxup bg xxmaj oxman xxup ad xxmaj shannon xxup hs xxmaj lloyd s xxmaj xxunk xxup ca xxmaj thomas k xxmaj clinical effectiveness pneumococcal vaccine metaanalysis xxmaj can xxmaj fam xxmaj physician xxmaj xxunk s xxmaj watson l xxmaj xxunk j xxmaj xxunk n xxmaj the effectiveness pneumococcal polysaccharide vaccines adults systematic review observational studies comparison results randomized controlled trials xxmaj vaccine xxmaj honkanen xxup po xxmaj xxunk t xxmaj xxunk l xxmaj herva e xxmaj sankilampi u xxmaj laara e xxmaj leinonen m xxmaj kivela xxup sl xxmaj makela xxup ph xxmaj incremental effectiveness pneumococcal vaccine simultaneously administered influenza vaccine preventing pneumonia pneumococcal pneumonia among persons aged years older xxmaj vaccine xxmaj xxunk xxup gc xxmaj xxunk m xxmaj makela h xxmaj greenwood xxup bm xxmaj response pneumococcal vaccination normal post infected xxmaj xxunk j xxmaj infect xxmaj xxunk j xxmaj singer xxup de xxmaj chang y xxmaj moore m xxmaj atlas xxup sj xxmaj processes care illness severity outcomes management communityacquired pneumonia academic hospitals xxmaj arch xxmaj intern xxmaj med xxmaj meehan xxup tp xxmaj fine xxup mj xxmaj xxunk xxup hm xxmaj xxunk xxup jd xxmaj xxunk xxup dh xxmaj xxunk xxup jt xxmaj weber xxup gf xxmaj xxunk xxup mk xxmaj houck xxup pm xxmaj fine xxup jm xxmaj quality care process outcomes elderly patients pneumonia xxup jama xxmaj xxunk n xxmaj xxunk xxup mr xxmaj stead xxup lf xxmaj interventions smoking cessation hospitalized patients xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj barlow g xxmaj xxunk d xxmaj williams f xxmaj xxunk s xxmaj winter j xxmaj jones m xxmaj xxunk p xxmaj myers e xxmaj sullivan f xxmaj stevens n et al xxmaj reducing door antibiotic time community acquired pneumonia controlled evaluation cost effectiveness analysis xxmaj thorax xxmaj xxunk m xxmaj xxunk n xxmaj khatib r xxmaj xxunk xxup mg xxmaj misdiagnosis community acquired pneumonia inappropriate utilization antibiotics side effects h antibiotic administration rule xxmaj chest xxmaj metersky xxup ml xxmaj sweeney xxup ta xxmaj xxunk xxup mb xxmaj siddiqui f xxmaj nsa w xxmaj bratzler xxup dw xxmaj antibiotic timing diagnostic uncertainty xxmaj medicare patients pneumonia reasonable expect patients receive antibiotics within hours xxmaj chest xxmaj xxunk xxup rm xxmaj flanders xxup sa xxmaj fee c xxmaj xxunk xxup pj xxmaj public reporting antibiotic timing patients pneumonia lessons flawed performance measure xxmaj ann xxmaj intern xxmaj med xxmaj welker xxup ja xxmaj huston m xxunk xxup jd xxmaj antibiotic timing errors diagnosing pneumonia xxmaj arch xxmaj intern xxmaj med xxmaj pines xxup jm xxmaj hollander xxup je xxmaj lee h xxmaj xxunk xxup ww xxmaj xxunk xxmaj pines l xxmaj xxunk xxup jp xxmaj emergency department operational changes response xxunk performance antibiotic timing pneumonia xxmaj acad xxmaj emerg xxmaj med xxmaj drake xxup de xxmaj cohen a xxmaj cohn j xxmaj national hospital antibiotic timing measures pneumonia antibiotic overuse xxmaj qual xxmaj manag xxmaj health xxmaj care xxmaj xxunk xxup ba xxmaj xxunk xxup de xxmaj xxunk xxup mt xxmaj the xxmaj centers xxmaj medicare xxmaj medicaid xxmaj services xxup xxunk community acquired pneumonia core measures lead unnecessary antibiotic administration emergency physicians xxmaj acad xxmaj emerg xxmaj med xxmaj xxunk xxup gw xxmaj kessler xxup la xxmaj wunderink xxup rg xxmaj delayed administration antibiotics atypical presentation community acquired pneumonia xxmaj chest xxmaj houck xxup pm xxmaj bratzler xxup dw xxmaj niederman m xxmaj bartlett xxup jg xxmaj pneumonia treatment process quality xxmaj arch xxmaj intern xxmaj med mcgarvey xxup rn xxmaj harper xxup jj xxmaj pneumonia mortality reduction quality improvement community hospital xxup xxunk xxmaj qual xxmaj rev xxmaj bull xxmaj bruns xxup ah xxmaj xxunk xxup jj xxmaj xxunk xxup wn xxmaj xxunk xxup ca xxmaj xxunk e xxmaj hoepelman xxup ai xxmaj time first antibiotic dose predictive early clinical failure moderate severe community acquired pneumonia xxmaj eur j xxmaj clin xxmaj microbiol xxmaj infect xxmaj dis xxmaj xxunk xxup ds xxmaj callahan m xxmaj thaler xxup ht xxmaj rapid antibiotic delivery appropriate antibiotic selection reduce length hospital stay patients community acquired pneumonia link quality care resource utilization xxmaj arch xxmaj intern xxmaj med xxmaj houck xxup pm xxmaj bratzler xxup dw xxmaj nsa w xxmaj ma a xxmaj bartlett xxup jg xxmaj timing antibiotic administration outcomes xxmaj medicare patients hospitalized community acquired pneumonia xxmaj arch xxmaj intern xxmaj med xxmaj mandell xxup la xxmaj wunderink xxup rg xxmaj xxunk a xxmaj bartlett xxup jg xxmaj campbell xxup gd xxmaj dean xxup nc xxmaj dowell xxup sf xxmaj file xxup tm xxmaj jr xxmaj xxunk xxup dm xxmaj niederman xxup ms et al xxmaj infectious xxmaj diseases xxmaj society xxmaj america xxmaj american xxmaj thoracic xxmaj society consensus guidelines management community acquired pneumonia adults xxmaj clin xxmaj infect xxmaj dis s s xxmaj niederman xxup ms xxmaj mandell xxup la xxmaj anzueto a xxmaj bass xxup jb xxmaj broughton xxup wa xxmaj campbell xxup gd xxmaj dean n xxmaj file t xxmaj fine xxup mj xxmaj gross xxup pa et al xxmaj guidelines management adults community acquired pneumonia xxmaj am j xxmaj respir xxmaj crit xxmaj care xxmaj med xxmaj arnold xxup fw xxunk xxup as xxmaj brock xxup gn xxmaj xxunk p xxmaj xxunk j xxmaj menendez r xxmaj xxunk g xxmaj torres a xxmaj rossi p xxmaj ramirez xxup ja xxmaj improving outcomes elderly patients community acquired pneumonia adhering national guidelines community acquired pneumonia organization international cohort study results xxmaj arch xxmaj intern xxmaj med mccabe c xxmaj kirschner c xxmaj zhang h xxmaj xxunk j xxmaj fisman xxup dn xxmaj guidelineconcordant therapy reduced mortality length stay xxup american xxup journal xxup of xxup respiratory xxup and xxup critical xxup care xxup medicine xxup vol adults community acquired pneumonia playing rules xxmaj arch xxmaj intern xxmaj med xxmaj xxunk xxup pg xxmaj torres a xxmaj valles x xxmaj mensa j xxmaj xxunk xxup ma xxmaj xxunk g xxmaj xxunk m xxmaj estruch r xxmaj sanchez m xxmaj menendez r et al xxmaj adherence guidelines empirical antibiotic recommendations communityacquired pneumonia outcome xxmaj eur xxmaj respir j xxmaj mortensen xxup em xxmaj restrepo xxup mi xxmaj anzueto a xxmaj pugh xxup ja xxmaj antibiotic therapy hour mortality patients pneumonia xxmaj am j xxmaj med xxmaj xxunk xxup cr xxmaj restrepo xxup mi xxmaj mortensen xxup em xxmaj burgess xxup ds xxmaj impact guideline concordant empiric antibiotic therapy communityacquired pneumonia xxmaj am j xxmaj med xxmaj mortensen xxup em xxmaj restrepo m xxmaj anzueto a xxmaj pugh j xxmaj effects guidelineconcordant antimicrobial therapy mortality among patients community acquired pneumonia xxmaj am j xxmaj med xxmaj villari p xxmaj xxunk l xxmaj xxunk a xxmaj methodological quality studies patient age major sources variation efficacy estimates influenza vaccination healthy adults meta analysis xxmaj vaccine xxmaj jefferson xxup to xxmaj rivetti d xxmaj di xxmaj pietrantonj c xxmaj rivetti a xxmaj demicheli v xxmaj vaccines preventing influenza healthy adults xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj rivetti d xxmaj jefferson t xxmaj thomas r xxmaj rudin m xxmaj rivetti a xxmaj di xxmaj pietrantonj c xxmaj demicheli v xxmaj vaccines preventing influenza elderly xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj schunemann xxup hj xxmaj jaeschke r xxmaj cook xxup dj xxmaj xxunk xxup wf xxmaj el xxmaj xxunk xxup aa xxmaj ernst a xxmaj xxunk xxup bf xxmaj gould xxup mk xxmaj horan xxup kl xxmaj xxunk xxup ja xxmaj an official xxup ats statement grading quality evidence strength recommendations xxup ats guidelines recommendations xxmaj am j xxmaj respir xxmaj crit xxmaj care xxmaj med xxmaj metersky xxup ml xxmaj ma a xxmaj bratzler xxup dw xxmaj houck xxup pm xxmaj predicting bacteremia patients community acquired pneumonia xxmaj am j xxmaj respir xxmaj crit xxmaj care xxmaj med xxmaj campbell xxup sg xxmaj xxunk xxup tj xxmaj xxunk r xxmaj dickinson g xxmaj xxunk xxmaj xxunk s xxmaj the contribution blood cultures clinical management adult patients admitted hospital community acquired pneumonia prospective observational study xxmaj chest xxmaj atkins d xxmaj best d xxmaj xxunk xxup pa xxmaj eccles m xxmaj falck xxmaj ytter y xxmaj xxunk s xxmaj guyatt xxup gh xxmaj harbour xxup rt xxmaj haugh xxup mc xxmaj henry d et al xxmaj grading quality evidence strength recommendations xxup bmj xxmaj ward xxup ac xxmaj the role causal criteria causal inferences xxunk aspects association xxmaj epidemiol xxmaj perspect xxmaj xxunk xxmaj xxunk i xxmaj xxunk r xxmaj reyes n xxmaj munoz j xxmaj fernandez a xxmaj hernandez m xxmaj merino m xxmaj perez j xxmaj lima j xxmaj clinical efficacy anti pneumococcal vaccination patients xxup copd xxmaj thorax xxmaj austrian r xxmaj surveillance pneumococcal infection field trials polyvalent pneumococcal vaccines xxmaj bethesda xxup md xxmaj national xxmaj institute xxmaj allergy xxmaj infectious xxmaj diseases pp xxmaj austrian r xxmaj douglas xxup rm xxmaj schiffman g xxmaj coetzee xxup am xxmaj koornhof xxup hj xxmaj hayden xxmaj smith s xxmaj reid xxup rd xxmaj prevention pneumococcal pneumonia vaccination xxmaj trans xxmaj assoc xxmaj am xxmaj physicians xxmaj davis xxup al xxmaj aranda xxup cp xxmaj schiffman g xxmaj xxunk xxup lc xxmaj pneumococcal infection immunologic response pneumococcal vaccine chronic obstructive pulmonary disease pilot study xxmaj chest xxmaj french n xxmaj xxunk j xxmaj carpenter xxup lm xxmaj xxunk e xxmaj xxunk c xxmaj moi k xxmaj moore m xxmaj xxunk d xxmaj mulder d xxmaj xxunk xxup en et al valent pneumococcal polysaccharide vaccine xxup hiv infected xxmaj xxunk adults double blind randomised placebo controlled trial xxmaj lancet xxmaj gaillat j xxmaj xxunk d xxmaj xxunk xxup mr xxmaj xxunk d xxmaj xxunk xxup jp xxmaj stahl xxup jp xxmaj xxunk p xxmaj xxunk m xxmaj clinical trial xxunk vaccine elderly subjects living institutions xxmaj rev xxmaj epidemiol xxmaj sante xxmaj xxunk xxmaj honkanen xxup po xxmaj xxunk t xxmaj miettinen l xxmaj herva e xxmaj sankilampi u xxmaj laara e xxmaj leinonen m xxmaj kivela xxup sl xxmaj makela xxup ph xxmaj incremental effectiveness pneumococcal vaccine simultaneously administered influenza vaccine preventing pneumonia pneumococcal pneumonia among persons aged years older xxmaj vaccine xxmaj kaufman p xxmaj pneumonia old age active immunization pneumonia pneumococcal polysaccharide results six year study xxmaj arch xxmaj intern xxmaj med xxmaj klastersky j xxmaj xxunk p xxmaj xxunk f xxmaj xxunk a xxmaj placebo controlled pneumococcal immunization patients bronchogenic carcinoma xxmaj eur j xxmaj cancer xxmaj clin xxmaj oncol xxmaj xxunk i xxmaj xxunk m xxmaj leinonen m xxmaj makela xxup ph xxmaj clinical efficacy pneumococcal vaccine elderly randomized single blind population based trial xxmaj am j xxmaj med xxmaj leech xxup ja xxmaj xxunk a xxmaj ruben xxup fl xxmaj efficacy pneumococcal vaccine severe chronic obstructive pulmonary disease xxup cmaj xxmaj xxunk a xxmaj hedlund j xxmaj xxunk xxup la xxmaj xxunk e xxmaj hofer m xxmaj leinonen m xxmaj lindblad i xxmaj xxunk b xxmaj xxunk m xxmaj randomized trial valent pneumococcal xxunk polysaccharide vaccine prevention pneumonia middle aged elderly people xxmaj swedish xxmaj pneumococcal xxmaj vaccination xxmaj study xxmaj group xxmaj lancet xxmaj riley xxup id xxmaj xxunk xxup pi xxmaj andrews m xxmaj pfeiffer m xxmaj howard r xxmaj xxunk p xxmaj xxunk g xxmaj immunization polyvalent pneumococcal vaccine reduction adult respiratory mortality xxmaj new xxmaj guinea xxmaj highlands community xxmaj lancet xxmaj xxunk xxup ms xxmaj cross xxup ap xxmaj al xxmaj ibrahim m xxmaj xxunk xxup al xxmaj xxunk xxup ph xxmaj nadler j xxmaj richmond xxup as xxmaj smith xxup rp xxmaj schiffman g xxmaj shepard xxup ds et al xxmaj efficacy pneumococcal vaccine high risk patients results xxmaj veterans xxmaj administration xxmaj cooperative xxmaj study n xxmaj engl j xxmaj med xxmaj smit p xxmaj xxunk d xxmaj hayden xxmaj smith s xxmaj koornhof xxup hj xxmaj hilleman xxup mr xxmaj protective efficacy pneumococcal polysaccharide vaccines xxup jama xxmaj xxunk j xxmaj xxunk xxup hb xxmaj xxunk j xxmaj xxunk g xxmaj andersen xxup jr xxmaj response pneumococcal vaccine chronic obstructive lung xxunk effect ongoing systematic steroid treatment xxmaj vaccine xxmaj xxunk xxup sd xxmaj xxunk xxup vd xxmaj xxunk xxup va xxmaj mel xxunk xxup pi xxmaj xxunk xxup pi xxmaj efficacy pneumococcal vaccine military units xxmaj zh xxmaj xxunk xxmaj epidemiol xxmaj xxunk xxmaj xxunk c de xxmaj vries h van xxmaj breukelen g a minimal contact intervention cardiac inpatients long term effects smoking cessation xxmaj prev xxmaj med xxmaj chouinard xxup mc xxmaj xxunk xxmaj xxunk s xxmaj the effectiveness nursing inpatient smoking cessation program individuals cardiovascular disease xxmaj nurs xxmaj res xxmaj croghan xxup ga xxmaj croghan xxup it xxmaj frost xxup ma xxmaj sloan xxup ja xxmaj novotny xxup pj xxmaj nelson xxup ma xxmaj smoking cessation interventions post operative outcomes xxunk lung cancer patients xxmaj society xxmaj research xxmaj nicotine xxmaj tobacco th xxmaj annual xxmaj meeting xxmaj march xxmaj prague xxmaj czech xxmaj republic xxmaj xxunk p xxmaj taylor xxup tz xxmaj mills p xxmaj brief intervention hospital admission help patients give smoking myocardial infarction bypass surgery randomized controlled trial xxup bmj xxmaj xxunk xxup dj xxmaj xxunk xxup ha mccarty xxup mc xxmaj xxunk d xxmaj xxunk n xxmaj xxunk xxup ja xxmaj xxunk s xxmaj xxunk xxup pr xxmaj pine d xxmaj sullivan s et al xxmaj the xxup team project effectiveness smoking cessation intervention hospital patients xxmaj prev xxmaj med xxmaj molyneux a xxmaj lewis s xxmaj xxunk u xxmaj xxunk a xxmaj xxunk m xxmaj xxunk a xxmaj nilsson f xxunk a xxmaj west r xxmaj xxunk j et al xxmaj clinical trial comparing nicotine replacement therapy xxup xxunk plus brief counseling alone minimal intervention smoking cessation hospital patients xxmaj thorax xxmaj xxunk xxup al xxmaj hensley xxup mj xxmaj schofield xxup mj xxmaj xxunk xxup aj a randomized controlled trial evaluate efficacy nurse provided intervention hospitalized smokers xxmaj aust n z j xxmaj public xxmaj health xxmaj pelletier xxup jg xxmaj moisan xxup jt xxmaj smoking cessation hospitalized patients quasi experimental study xxmaj quebec xxmaj can j xxmaj public xxmaj health xxmaj pederson xxup ll xxmaj xxunk xxup jm xxmaj xxunk xxup nm xxmaj the effects counseling smoking cessation among patients hospitalized chronic obstructive pulmonary disease randomized clinical trial xxmaj int j xxmaj addict xxmaj xxunk b xxmaj xxunk xxup me xxmaj baker xxup ca xxmaj the effectiveness xxunk minimal smoking cessation intervention among hospitalized patients cancer xxmaj oncol xxmaj nurs xxmaj forum xxmaj bridges xxup cb xxmaj thompson xxup ww xxmaj meltzer xxup mi xxmaj reeve xxup gr xxmaj talamonti xxup wj xxmaj cox xxup nj xxmaj xxunk xxup ha xxmaj hall h xxmaj klimov a xxmaj xxunk k xxmaj effectiveness cost benefit influenza vaccination healthy working adults randomized controlled trial xxup jama xxmaj couch xxup rb xxmaj quarles xxup jm xxmaj cate xxup tr xxmaj zahradnik xxmaj clinical trials live cold xxunk influenza virus vaccines xxmaj in xxmaj kendal xxup ap xxmaj patriarca xxup pa editors xxmaj options control influenza xxmaj proceedings xxmaj viratek xxup ucla symposium xxmaj xxunk xxup co xxup ucla xxunk xxmaj perspective sia molecular cellular biology xxmaj new xxmaj york xxmaj alan r xxmaj liss pp xxmaj eddy xxup ts xxmaj davies xxup na xxmaj the effect vaccine close epidemic xxmaj hong xxmaj kong influenza s xxmaj afr xxmaj med j xxmaj edmondson xxup kw xxmaj graham xxup ds xxmaj warburton xxup mf a clinical trial influenza vaccine xxmaj canberra xxmaj med j xxmaj aust xxmaj edwards xxup km xxmaj dupont xxup wd xxmaj westrich xxup mk xxmaj plummer xxup wd xxmaj jr xxmaj palmer xxup ps xxmaj wright xxup pf a randomized controlled trial cold adapted inactivated vaccines prevention influenza a disease j xxmaj infect xxmaj dis xxmaj hammond xxup ml xxmaj ferris xxup aa xxmaj faine s mcavan t xxmaj effective protection influenza vaccination subunit vaccine xxmaj med j xxmaj aust xxmaj hoskins xxup tw xxmaj davies xxup jr xxmaj allchin a xxmaj miller xxup cl xxmaj pollock xxup tm xxmaj controlled trial inactivated influenza vaccine containing xxmaj hong xxmaj kong strain outbreak influenza due xxmaj england strain xxmaj lancet xxmaj keitel xxup wa xxmaj cate xxup tr xxmaj couch xxup rb xxmaj huggins xxup ll xxmaj hess xxup kr xxmaj efficacy repeated annual immunization inactivated influenza virus vaccines five year period xxmaj vaccine xxmaj leibovitz a xxmaj xxunk xxup rl xxmaj kilbourne xxup ed xxmaj xxunk xxup lj xxmaj smith xxup cd xxmaj chin j xxmaj schulman xxup jl xxmaj correlated studies recombinant influenza virus vaccine xxup iv xxmaj protection naturally occurring influenza military trainees j xxmaj infect xxmaj dis xxmaj mair xxup hj xxmaj xxunk xxup da xxmaj tillett xxup he a controlled trial inactivated monovalent influenza a vaccines general practice j xxmaj hyg xxmaj lond xxmaj maynard xxup je xxmaj dull xxup hb xxmaj hanson xxup ml xxmaj feltz xxup et xxmaj berger r xxmaj xxunk l xxmaj evaluation monovalent polyvalent influenza vaccines epidemic type a b influenza xxmaj am j xxmaj epidemiol xxmaj xxunk xxup ma xxmaj vespa xxup gn xxmaj forleo xxmaj neto e xxmaj xxunk xxmaj neto j xxmaj alves xxup pm xxmaj impact influenza vaccination civilian xxunk illness absenteeism xxmaj xxunk xxmaj space xxmaj environ xxmaj med xxmaj mogabgab xxup wj xxmaj leiderman e xxmaj immunogenicity polyvalent xxmaj hong xxmaj kong influenza vaccines xxup jama xxmaj monto xxup as xxmaj miller xxup fd xxmaj maassab xxup hf xxmaj evaluation attenuated coldrecombinant influenza b virus vaccine j xxmaj infect xxmaj dis xxmaj nichol xxup kl xxmaj lind a xxmaj margolis xxup kl xxmaj murdoch m mcfadden r xxmaj hauge m xxmaj xxunk s xxmaj drake m xxmaj the effectiveness vaccination influenza healthy working adults n xxmaj engl j xxmaj med xxmaj nichol xxup kl xxmaj mendelman xxup pm xxmaj mallon xxup kp xxmaj jackson xxup la xxmaj gorse xxup gj xxmaj belshe xxup rb xxmaj glezen xxup wp xxmaj wittes j xxmaj effectiveness live attenuated intranasal influenza virus vaccine healthy working adults randomized controlled trial xxup jama xxmaj powers xxup dc xxmaj smith xxup ge xxmaj anderson xxup el xxmaj kennedy xxup dj xxmaj hackett xxup cs xxmaj wilkinson xxup be xxmaj volvovitz f xxmaj belshe xxup rb xxmaj treanor xxup jj xxmaj influenza a virus vaccines containing purified recombinant h hemagglutinin well tolerated induce protective immune responses healthy adults j xxmaj infect xxmaj dis xxmaj rytel xxup mw xxmaj jackson xxup lj xxmaj niebojewski xxup ra xxmaj haagensen xxup jl xxmaj rosenkranz xxup ma xxmaj field trial live attenuated influenza a b xxmaj alice r vaccine xxmaj am j xxmaj epidemiol xxmaj slepuskin xxup an xxmaj bobyleva xxup tk xxmaj russina xxup ae xxmaj vitkina xxup bs xxmaj xxunk xxup ns xxmaj xxunk xxup vm xxmaj evaluation effectiveness large scale vaccination influenza xxup ussr xxmaj bull xxmaj world xxmaj health xxmaj organ xxmaj tannock xxup ga xxmaj bryce xxup da xxmaj hensley xxup mj xxmaj saunders xxup na xxmaj gillett xxup rs xxmaj kennedy xxup ws xxmaj responses one two deoxycholate subunit influenza vaccine primed population xxmaj vaccine xxmaj waldman xxup rh xxmaj coggins xxup wj xxmaj influenza immunization field trial university campus j xxmaj infect xxmaj dis xxmaj waldman xxup rh xxmaj bond xxup jo xxmaj levitt xxup lp xxmaj hartwig xxup ed xxmaj prather xxup ec xxmaj baratta xxup rl xxmaj neill xxup js xxmaj small xxup pa xxmaj jr xxmaj an evaluation influenza immunization influence route administration vaccine strain xxmaj bull xxmaj world xxmaj health xxmaj organ xxmaj waldman xxup rh xxmaj mann xxup jj xxmaj small xxup pa xxmaj jr xxmaj immunization influenza prevention illness man aerosolized inactivated vaccine xxup jama xxmaj weingarten s xxmaj staniloff h xxmaj ault m xxmaj miles p xxmaj bamberger m xxmaj xxunk xxup rd xxmaj do hospital employees benefit influenza vaccine a placebocontrolled clinical trial j xxmaj gen xxmaj intern xxmaj med xxmaj wilde xxup ja mcmillan xxup ja xxmaj serwint j xxmaj butta j o xxmaj riordan xxup ma xxmaj steinhoff xxup mc xxmaj effectiveness influenza vaccine health care professionals randomized trial xxup jama xxmaj williams xxup mc xxmaj xxunk l mcdonald xxup jc xxmaj xxunk xxup pv xxmaj xxunk a xxmaj clayton xxup aj xxmaj trials aqueous killed influenza vaccine xxmaj canada xxmaj bull xxmaj world xxmaj health xxmaj organ xxup american xxup journal xxup of xxup respiratory xxup and xxup critical xxup care xxup medicine xxup vol,xxbos xxmaj arch xxmaj gynecol xxmaj obstet xxup doi xxup reproductive xxup medicine xxmaj letrozole versus laparoscopic ovarian diathermy ovulation induction clomiphene resistant women polycystic ovary syndrome randomized controlled trial xxmaj hatem xxmaj abu xxmaj hashim xxmaj abdel xxmaj xxunk xxmaj xxunk xxmaj ahmed xxmaj badawy xxmaj received xxmaj february xxmaj accepted xxmaj june xxmaj published online xxmaj june xxmaj springer xxmaj verlag xxmaj abstract xxmaj purpose xxmaj to compare xxunk letrozole laparoscopic ovarian diathermy xxup lod ovulation induction clomiphene citrate xxup cc resistant women polycystic ovary syndrome xxup pcos xxmaj methods xxmaj two hundred sixty anovulatory women xxup cc resistant xxup pcos selected randomized controlled trial xxmaj group a n received mg letrozole daily days six cycles xxmaj group b n underwent xxup lod months follow xxmaj outcome measures ovulation rate midcycle endometrial thickness pregnancy miscarriage live birth rates xxmaj results xxmaj ovulation occurred cycles letrozole group cycles xxup lod group without xxunk xxunk groups xxmaj resumption regular menstruation similar treatment groups a xxunk increase midcycle endometrial thickness observed letrozole group mm vs mm p xxmaj pregnancy rate similar groups vs xxmaj there statistical xxunk xxunk regards miscarriage live birth rates groups xxmaj no multiple pregnancy ovarian hyperstimulation occurred either group xxmaj conclusion xxmaj letrozole xxup lod equally xxunk inducing ovulation achieving pregnancy xxup cc resistant xxup pcos patients xxmaj keywords xxmaj polycystic ovary syndrome xxmaj clomiphene resistance xxmaj laparoscopic ovarian diathermy xxmaj letrozole xxmaj ovulation induction xxmaj introduction xxmaj polycystic ovary syndrome xxup pcos common cause infertility associated chronic anovulation hyperandrogenemia xxmaj it xxunk reproductive age women xxmaj clomiphene citrate xxup cc still holding place xxmaj xxunk line therapy ovulation induction patients xxmaj however use xxup cc may associated poor cervical mucous endometrial xxunk patients due prolonged xxunk depletion endometrium possibly cervix xxmaj furthermore clomiphene resistance e failure ovulate receiving mg day common occurs approximately women xxup pcos xxmaj although treatment gonadotropins often successful patients yet expensive risk ovarian hyperstimulation xxup ohss multiple pregnancy xxmaj laparoscopic ovarian diathermy xxup lod currently accepted successful second line treatment ovulation induction xxup cc resistant xxup pcos xxmaj bayram et al randomized trial compared xxup lod recombinant xxup fsh xxup cc resistant xxup pcos women xxmaj they reported ovulation rate per cycle pregnancy live birth rates patients respectively following xxup lod xxup fsh therapy xxmaj nevertheless xxup lod costly requires hospital treatment general anesthesia carries risk post operative adhesions premature ovarian failure xxunk hands h xxmaj abu xxmaj hashim a xxmaj xxunk a xxmaj badawy xxmaj departments xxmaj obstetrics xxmaj gynecology xxmaj mansoura xxmaj faculty xxmaj medicine xxmaj mansoura xxmaj university xxmaj mansoura xxmaj egypt e mail hatem ah hotmail com xxmaj arch xxmaj gynecol xxmaj obstet xxmaj letrozole aromatase inhibitor xxup ai attracted attention long time oral ovulatory agent reported ovulation rate pregnancy rate per cycle xxmaj moreover use xxup cc resistant xxup pcos patients achieve ovulation patients xxmaj to knowledge studies yet compared xxunk letrozole therapy xxup lod xxup cc resistant xxup pcos patients xxmaj the aim prospective randomized trial compare xxunk letrozole administration six cycles xxup lod ovulation induction xxup cc resistant infertile xxup pcos women xxmaj materials methods xxmaj patient population xxmaj the study comprised women xxup cc resistant xxup pcos among attending xxmaj outpatient xxmaj clinic xxmaj mansoura xxmaj university xxmaj hospitals private practice setting period xxmaj august xxmaj march xxmaj diagnosis xxup pcos based revised consensus diagnostic criteria long term health risks related xxup pcos xxmaj all women previously treated mg xxup cc daily days per cycle least three cycles persistent anovulation e xxup cc resistant xxmaj they patent xxmaj fallopian tubes proved hysterosalpingography normal semen analysis partners according xxunk criteria xxmaj world xxmaj health xxmaj organization xxmaj at study entry patients basal hormonal assays day progesterone induced menstruation overnight fast consisting xxup fsh xxup lh thyroid stimulating hormone xxup tsh prolactin xxunk xxup xxunk total testosterone sex xxunk globulin xxup shbg xxmaj fasting serum insulin glucose levels also performed xxmaj all patients normal serum prolactin xxup tsh xxup xxunk xxmaj exclusion criteria causes infertility age years xxup bmi contraindication general anesthetic previous history xxup lod women received metformin gonadotrophin oral contraceptives hormonal drugs preceding months xxmaj women intended start diet xxunk program physical activity also excluded xxmaj all women instructed maintain usual lifestyle eating habits study xxmaj the study approved xxmaj mansoura xxmaj university xxmaj hospital xxmaj research xxmaj ethics xxmaj committee participants gave informed consent inclusion trial xxmaj randomization xxmaj women randomized according computer generated random numeric table prepared independent statistician concealment treatment allocation use sealed opaque envelopes given third party nurse assigned patients study arms group a letrozole b xxup lod xxmaj once allocated treatment revealed investigator patient xxmaj however radiologist performed transvaginal ultrasound follow assessment blinded treatment groups xxmaj protocol treatment xxmaj in letrozole group group a treatment continued six cycles xxmaj initially withdrawal bleeding achieved using mg dydrogesterone tablets days stimulation using mg letrozole oral tablets xxmaj xxunk xxmaj novartis xxmaj pharma xxmaj services xxmaj switzerland daily day menses days xxmaj all patients monitored transvaginal ultrasound mean follicular diameter endometrial thickness days cycle xxmaj serum p ng ml measured days cycle xxup ria using antibody coated tube method xxmaj coat a xxmaj count xxmaj diagnostic xxmaj product xxmaj corporation xxmaj los xxmaj angeles xxup ca xxup usa xxmaj actually ovulate following three successive cycles letrozole dose considered responsive counseled lines treatment hcg total xxup iu xxup im xxmaj choriomon xxup ibsa xxmaj switzerland given one follicle measured least mm found xxmaj patients advised intercourse h hcg injection xxmaj in xxup lod group group b laparoscopy performed using three puncture technique xxmaj each ovary cauterized four points w depth mm mixed current using monopolar electrosurgical needle xxmaj karl xxmaj storz xxup nd xxmaj germany xxmaj the pelvis irrigated using xxmaj ringer lactated solution xxmaj the total duration procedure recorded intra operative post operative complications reported xxmaj follow continued months procedure xxmaj if menstruation occurred within weeks surgery blood sample would taken day cycle measurement serum concentration progesterone xxmaj ovulation diagnosed xxmaj serum p level ng ml xxmaj subsequent cycles monitored ovulation transvaginal ultrasound mean follicular diameter endometrial thickness days cycle serum progesterone day cycle xxmaj all patients showed ovulation advised natural intercourse xxmaj on hand anovulation persisted xxup lod evidenced low progesterone levels lack menstruation patient became anovulatory counseled lines treatment xxmaj in either group biochemical pregnancy considered serum hcg miu ml absence menstruation meanwhile sonographic evidence xxmaj arch xxmaj gynecol xxmaj obstet intrauterine gestational sac weeks gestation considered criteria xxunk clinical pregnancy xxmaj all pregnant women followed obtain miscarriage live birth rates xxmaj clinical miscarriage xxunk xxunk clinical pregnancy subsequently lost weeks gestation meanwhile biochemical miscarriage considered xxunk biochemical pregnancy subsequently lost without evidence intrauterine pregnancy demonstrated ultrasound xxmaj sample size xxmaj the primary outcome measure ovulation rate xxmaj secondary outcome measures included midcycle endometrial thickness mm biochemical pregnancy miscarriage live birth rates xxmaj sample size calculated based fact expected rate ovulation xxup lod group needed women show absolute increase ovulation rate letrozole group power xxunk interval using two tailed chi square test xxunk level type error xxmaj statistical analysis xxmaj data obtained statistically analyzed using xxmaj statistical xxmaj package xxmaj social xxmaj sciences xxup spss xxmaj chicago xxup usa software version xxmaj windows xxmaj analysis performed intention treat basis xxmaj means compared using unpaired student test proportions compared using chi square test p value less considered statistically xxunk xxmaj results a total patients studied women cycles women cycles groups a b respectively xxmaj fig xxmaj there statistical xxunk xxunk two groups regards age duration infertility anthropometric variables clinical manifestations hormonal xxunk ultrasound xxmaj xxunk xxup pcos xxmaj table xxmaj the duration xxup lod min intra operative post operative complications occurred xxmaj clinical reproductive outcomes presented xxmaj table xxmaj ovulation occurred cycles group a cycles group b without xxunk xxunk groups xxmaj resumption regular menstruation similar two treatment groups xxmaj there statistically xxunk xxunk pretreatment endometrial thickness two groups a xxunk increase mid cycle endometrial thickness observed group a mm vs mm p xxmaj biochemical pregnancy occurred cycles group a cycles group b xxmaj fig xxmaj flow chart participants trial xxmaj assessed eligibility n xxmaj excluded n xxmaj not meeting inclusion criteria n xxmaj refused participate n xxmaj randomized n xxmaj allocated xxup lod n xxmaj received allocated intervention n xxmaj did receive allocated intervention give reasons n xxmaj lost follow n xxmaj discontinued intervention n xxmaj analysed n xxmaj excluded analysis n xxmaj allocated letrozole n xxmaj received allocated intervention n xxmaj did receive allocated intervention give reasons n xxmaj lost follow n xxmaj discontinued intervention n xxmaj analysed n xxmaj excluded analysis n xxmaj enrolment xxmaj allocation xxmaj follow xxmaj analysis xxmaj table xxmaj patients characteristics xxmaj variable xxmaj group a letrozole n xxmaj group b xxup lod n xxmaj age years xxmaj parity xxmaj nulliparous xxmaj multiparous xxmaj duration infertility years xxup bmi kg xxmaj waist hip ratio xxmaj menstrual cycle xxmaj oligomenorrhoea xxmaj amenorrhoea xxmaj hyperandrogenism xxup lh miu ml xxup fsh miu ml xxup lh xxup fsh ratio xxmaj fasting glucose mg dl xxmaj fasting insulin u ml xxmaj fasting glucose insulin ratio xxmaj ovarian volume ml xxmaj arch xxmaj gynecol xxmaj obstet xxunk statistically xxunk xxmaj there statistically xxunk xxunk regarding clinical pregnancy rate two groups vs group a b respectively xxmaj no twin higher order pregnancies cases xxup ohss occurred either group xxmaj miscarriage either biochemical clinical live birth rates similar groups xxmaj discussion xxmaj in randomized controlled trial xxmaj xxunk time evaluated xxunk letrozole administration six cycles method ovulation induction xxup cc resistant infertile xxup pcos women comparison xxup lod xxmaj letrozole third generation aromatase inhibitor xxmaj its early administration follicular phase induces ovulation releasing hypothalamic pituitary axis e negative feedback thus increasing xxup fsh secretion stimulating ovarian follicular development xxmaj in addition increases follicular sensitivity xxup fsh accumulation intraovarian androgens xxmaj in study ovulation occurred cycles group a comparable reported two recent randomized trials xxmaj bayer et al xxmaj badawy et al ovulatory rates letrozole cycles respectively xxmaj in trials xxmaj xxunk xxmaj casper ovulatory rate xxmaj al xxmaj xxunk et al ovulatory rate xxmaj xxunk et al reported ovulation rate xxmaj this may explained small sample size trials xxmaj pregnancy achieved cycles group a comparable reported xxmaj badawy et al however less reported others xxmaj the miscarriage live birth rates similar groups a recent large randomized trial xxmaj xxunk et al compared xxunk letrozole rfsh xxup cc rfsh ovarian stimulation xxup iui cycles xxup pcos women xxup cc failure xxmaj they reported ovulation rate letrozole group versus groups respectively pregnancy rate letrozole group versus groups respectively xxmaj however included xxup cc resistant xxup pcos patients also failed conceive mg day xxup cc six cycles despite ovulating showed poor endometrial development e endometrial thickness mm day hcg administration xxmaj monofollicular growth seen advantage xxup lod ais xxup lod resume physiological monofollicular ovulation reducing risk xxup ohss multiple pregnancy ais rapidly eliminated body due relatively shorter half life days xxup cc month xxmaj so contrast use xxup cc hypothalamus able respond estrogen mediated negative feedback mechanism xxmaj this modulate excessive xxup fsh discharge thus likely result monofollicular ovulation moderate estrogen concentrations xxmaj also view absence regulation hypothalamic pituitary estrogen receptors late follicular phase adverse xxunk peripheral organs endometrium cervix considerably less xxmaj in study xxunk increase mid cycle endometrial thickness observed letrozole group xxmaj xxunk xxmaj casper showed letrozole associated xxunk endometrium compared xxup cc xxmaj this might due improved xxunk reported recent xxmaj doppler study xxmaj the safety letrozole xxunk xxunk discussion xxmaj preliminary data xxmaj xxunk et al suggested increased risk congenital anomalies letrozole treated babies whereas recent data retrospective prospective trials xxunk initial xxmaj xxunk supported safety letrozole compared traditional ovulation induction treatment xxmaj the cost treatment another issue xxmaj the cost letrozole per cycle much lower compared hospital charges needed xxup lod vs xxmaj egyptian xxmaj table xxmaj clinical reproductive outcomes letrozole xxup lod groups xxmaj group a letrozole n xxmaj group b xxup lod n p value xxmaj number cycles xxmaj regular menstruation xxup ns xxmaj ovulation cycle xxup ns xxmaj pretreatment endometrial thickness mm xxup ns xxmaj mid cycle endometrial thickness mm xxmaj biochemical pregnancy cycle xxup ns xxmaj clinical pregnancy patient xxup ns xxmaj biochemical miscarriage patient xxup ns xxmaj clinical miscarriage patient xxup ns xxmaj live birth rate xxup ns xxup ns xxunk xxmaj statistically xxunk xxmaj arch xxmaj gynecol xxmaj obstet pounds respectively xxmaj on hand xxup lod may cost xxunk one treatment principle results several ovulatory cycles whereas one course letrozole therapy yields single ovulatory cycle xxmaj in conclusion trial suggested six cycles letrozole xxup lod month follow period equally xxunk inducing ovulation achieving pregnancy patients xxup cc resistant xxup pcos xxmaj in view invasiveness cost surgery seems plausible letrozole therapy tried xxmaj xxunk women shifting xxup lod xxmaj acknowledgments xxmaj the authors would like thank xxmaj dr m xxmaj el xxmaj xxunk senior lecturer consultant xxmaj diagnostic xxmaj radiology xxmaj mansoura xxmaj university xxmaj hospitals xxunk xxunk transvaginal ultrasound assessment follow patients enabling completion trial report xxunk interest statement xxmaj we declare xxunk interest xxmaj references xxmaj azziz r xxmaj woods xxup ks xxmaj xxunk r xxmaj key xxup tj xxmaj knochenhauer xxup es xxmaj yildiz xxup bo xxmaj the prevalence features polycystic ovary syndrome unselected population j xxmaj clin xxmaj endocrinol xxmaj metab doi jc xxmaj brown j xxmaj farquhar c xxmaj beck j xxmaj boothroyd c xxmaj hughes e xxmaj clomiphene anti oestrogens ovulation induction xxup pcos xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj thessaloniki xxup eshre xxup asrm xxmaj sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group xxmaj consensus infertility treatment related polycystic ovary syndrome xxmaj fertil xxmaj steril doi j fertnstert xxmaj randall xxup jm xxmaj templeton a xxmaj cervical mucus score vitro sperm mucus interaction spontaneous xxup cc citrate cycles xxmaj fertil xxmaj steril xxmaj xxunk xxup ms xxmaj robins xxup ed o xxmaj connor xxup dm xxmaj scott xxup rt xxmaj fritz xxup ma xxmaj characteristics gonadotropin response follicular development endometrial growth maturation across consecutive cycles clomiphene citrate treatment xxmaj fertil xxmaj steril xxmaj nakamura y xxmaj xxunk m xxmaj yoshida y xxmaj sugino n xxmaj ueda k xxmaj kato h xxunk xxup cc endometrial thickness xxunk pattern endometrium xxmaj fertil xxmaj steril doi s xxmaj national xxmaj collaborating xxmaj centre xxmaj women xxmaj children xxmaj health xxmaj national xxmaj institue xxmaj clinical xxmaj excellence xxmaj fertility assessment treatment people fertility problems xxmaj clinical xxmaj guideline xxmaj no xxup rcog xxmaj press xxmaj london http www nice org uk xxunk pdf xxup cg xxunk pdf xxmaj farquhar xxup cm xxmaj williamson k xxmaj gudex g xxmaj johnson xxup np xxmaj garland j xxmaj sadler l a randomized controlled trial laparoscopic ovarian diathermy versus gonadotropin therapy women clomiphene citrate resistant polycystic ovary syndrome xxmaj fertil xxmaj steril doi s xxmaj farquhar c xxmaj lilford xxup rj xxmaj marjoribanks j xxmaj vandekerckhove p xxmaj laparoscopic drilling diathermy laser ovulation induction anovulatory polycystic ovary syndrome xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj bayram n van xxmaj wely m xxmaj kaaijk xxup em xxmaj bossuyt xxup pm van der xxmaj veen f xxmaj using electrocautery strategy recombinant follicle stimulating hormone induce ovulation polycystic ovary syndrome randomised controlled trial xxup bmj doi bmj xxmaj felemban a xxmaj lin xxmaj tan s xxmaj tulandi t xxmaj laparoscopic treatment polycystic ovaries insulated needle cautery reappraisal xxmaj fertil xxmaj steril doi s xxmaj holzer h xxmaj casper r xxmaj tulandi t a new era ovulation induction xxmaj fertil xxmaj steril doi j fertnstert xxmaj xxunk a xxmaj fouad h xxmaj xxunk m xxmaj xxunk n xxmaj letrozole induction ovulation women clomiphene citrate resistant polycystic ovary syndrome may depend period infertility body mass index luteinizing hormone xxunk hormone ratio xxmaj fertil xxmaj steril doi j fertnstert xxmaj xxunk xxup fm xxmaj casper xxup rf xxmaj use aromatase inhibitor induction ovulation patients inadequate response clomiphene citrate xxmaj fertil xxmaj steril doi s xxmaj al xxmaj xxunk xxup wr xxmaj xxunk w xxmaj al xxmaj xxunk n xxmaj comparison two aromatase inhibitors women clomiphene resistant polycystic ovary syndrome xxmaj int j xxmaj gynaecol xxmaj obstet doi j ijgo xxmaj rotterdam xxup eshre xxup asrm xxmaj sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group xxmaj revised consensus diagnostic criteria long term health risks related polycystic ovary syndrome xxmaj fertil xxmaj steril doi j fertnstert xxmaj organization xxmaj world xxmaj health xxup who laboratory manual examination human semen sperm cervical mucus interactions th edn xxmaj cambridge xxmaj university xxmaj press xxmaj cambridge xxmaj casper xxup rf xxmaj xxunk xxup mf xxmaj review aromatase inhibitors ovulation induction j xxmaj clin xxmaj endocrinol xxmaj metab doi jc xxmaj homburg r xxmaj oral agents ovulation induction clomiphene citrate versus aromatase inhibitors xxmaj hum xxmaj fertil xxmaj camb doi xxmaj xxunk u xxmaj xxunk m xxmaj xxunk s xxmaj xxunk a xxmaj xxunk s xxmaj use aromatase inhibitor patients polycystic ovary syndrome prospective randomized trial xxmaj fertil xxmaj steril doi j fertnstert xxmaj badawy a xxmaj xxunk a xxmaj xxunk m xxmaj xxunk letrozole ovulation induction clomiphene resistant women polycystic ovarian syndrome prospective randomized trial xxmaj fertil xxmaj steril doi j fertnstert xxmaj xxunk a xxmaj goswami xxup sk xxmaj xxunk r xxmaj xxunk k xxmaj xxunk b xxmaj comparison letrozole continuous gonadotropins clomiphene gonadotropin combination ovulation induction xxup pcos women clomiphene citrate failure randomized prospective clinical trial j xxmaj assist xxmaj reprod xxmaj genet doi xxmaj baruah j xxmaj roy xxup kk xxmaj rahman xxup sm xxmaj kumar s xxmaj sharma xxup jb xxmaj xxunk d xxmaj endometrial xxunk letrozole clomiphene citrate women polycystic ovary syndrome using spiral artery xxmaj doppler xxmaj arch xxmaj gynecol xxmaj obstet doi xxmaj xxunk xxup mm xxmaj xxunk r xxmaj xxunk n xxmaj the outcome babies following treatment letrozole letrozole gonadotropins xxmaj fertil xxmaj steril xxmaj supplement doi j fertnstert xxmaj tulandi t xxmaj martin j xxmaj al xxmaj xxunk r xxmaj kabli n xxmaj forman r xxmaj xxunk j xxmaj xxunk c xxmaj greenblatt e xxmaj casper xxup rf xxmaj congenital malformations among newborns conceived infertility treatment letrozole clomiphene citrate xxmaj fertil xxmaj steril doi j fertnstert xxmaj badawy a xxmaj xxunk a xxmaj xxunk xxup af xxmaj xxunk h xxmaj pregnancy outcome ovulation induction aromatase inhibitors clomiphene citrate unexplained infertility xxmaj acta xxmaj obstet xxmaj gynecol xxmaj scand doi,xxbos xxmaj abstract a double blind randomized placebo controlled cross multi center study conducted evaluate efficacy safety gabapentin treatment neuropathic pain caused traumatic postsurgical peripheral nerve injury using doses mg day xxmaj the study comprised run period two weeks two treatment periods five weeks separated three weeks washout period xxmaj the primary efficacy variable change mean pain intensity score baseline last week treatment xxmaj other variables included pain relief health related quality life xxup sf interference sleep pain xxmaj clinician xxmaj patient xxmaj global xxmaj impression xxmaj change adverse effects xxmaj nine centers randomized total patients withdrew xxmaj there statistically significant difference treatments primary outcome efficacy variable xxmaj however gabapentin provided significantly better pain relief p compared placebo xxmaj more patients least pain reduction gabapentin compared placebo p pain interfered significantly less sleep gabapentin treatment compared placebo p xxmaj both xxmaj patient p xxmaj clinician p xxmaj global xxmaj impression xxmaj change indicated better response gabapentin compared placebo xxmaj gabapentin well tolerated xxmaj the common adverse effects dizziness tiredness,xxbos xxup clinical xxup article xxmaj metformin versus laparoscopic ovarian drilling clomiphene insulin resistant women polycystic ovary syndrome xxmaj hossam o xxmaj hamed xxmaj xxunk f xxmaj hasan b xxmaj xxunk g xxmaj ahmed b xxmaj xxunk a xxmaj ahmed b xxmaj women xxmaj health xxmaj university xxmaj center xxmaj department xxmaj obstetrics xxmaj gynecology xxmaj faculty xxmaj medicine xxmaj assiut xxmaj university xxmaj assiut xxmaj egypt b xxmaj department xxmaj physiology xxmaj faculty xxmaj medicine xxmaj assiut xxmaj university xxmaj assiut xxmaj egypt article info abstract xxmaj article history xxmaj received xxmaj may xxmaj received revised form xxmaj august xxmaj accepted xxmaj september xxmaj keywords xxmaj clomiphene resistance xxmaj insulin resistance xxmaj laparoscopic ovarian drilling xxmaj metformin xxmaj polycystic ovary syndrome xxmaj objective xxmaj to compare hormonal metabolic profiles reproductive outcomes clomiphene resistant patients polycystic ovary syndrome insulin resistance women receiving metformin undergoing laparoscopic ovarian drilling xxmaj methods a total eligible participants randomly allocated diagnostic laparoscopy plus metformin therapy group n laparoscopic ovarian drilling group n xxmaj the test used mean comparisons hormonal metabolic parameters xxup ogtt values treatment xxmaj the test used comparisons ovulation pregnancy abortion rates xxmaj results xxmaj groups showed significant decline testosterone insulin like growth factor xxmaj pb vs xxmaj pb luteinizing hormone xxmaj pb vs xxmaj pb glucose insulin ratio significantly increased xxmaj pb vs xxmaj pb compared baseline xxmaj group patients regular cycles higher rates ovulation pregnancy compared group vs xxmaj pb vs xxmaj pb vs xxmaj pb respectively xxmaj the difference early abortion rate groups statistically significant xxmaj conclusion xxmaj although metformin results better attenuation insulin resistance laparoscopic ovarian drilling associated higher rates ovulation pregnancy xxmaj international xxmaj federation xxmaj gynecology xxmaj obstetrics xxmaj published xxmaj elsevier xxmaj ireland xxmaj ltd xxmaj all rights reserved xxmaj introduction xxmaj polycystic ovary syndrome xxup pcos common endocrine metabolic disorder affecting women reproductive age xxmaj insulin resistance found approximately obese xxup pcos patients increased risk associated glucose intolerance development type diabetes xxmaj insulin resistance obesity result hyperinsulinemia considered key factor pathogenesis anovulation hyperandrogenism xxmaj weight reduction clomiphene citrate xxup cc considered first line medical approach improve fertility women xxup pcos xxmaj when xxup cc fails second line treatments attempted include laparoscopic ovarian drilling xxup lod gonadotropins xxup lod associated ovulation rate comparable gonadotropins advantages lower complications less need ongoing monitoring xxmaj in last years metformin used improve ovulation conflicting results xxmaj in previous studies metformin seen effective achieving ovulation improving clinical biochemical features xxup pcos xxmaj however recently xxmaj thessaloniki xxup eshre xxup asrm sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group recommended treatment metformin restricted women glucose intolerance xxmaj this recommendation based randomized trials concluded routine use metformin primary line treatment associated improvement rates ovulation live birth xxmaj two studies literature compared metformin xxup lod xxup cc resistant patients without considering insulin resistance prerequisite results conflicting xxmaj in first study significant difference found ovulation pregnancy rates patients received metformin xxup lod however second study reported higher pregnancy rate metformin group xxmaj with background mind hypothesized metformin used xxup pcos patients insulin resistance ovulation pregnancy rates might comparable obtained patients underwent xxup lod xxmaj the aim present study compare hormonal metabolic profile reproductive outcomes xxup cc resistant xxup pcos patients insulin resistance received metformin underwent xxup lod xxmaj materials methods xxmaj the study conducted xxmaj women xxmaj health xxmaj center cooperation xxmaj physiology xxmaj department xxmaj assiut xxmaj university xxmaj egypt xxmaj all xxup pcos patients attending infertility clinic previous xxup cc failure years age counseled xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics xxmaj corresponding author xxmaj tel fax e mail address xxmaj hossam omar yahoo com h o xxmaj hamed see front matter xxmaj international xxmaj federation xxmaj gynecology xxmaj obstetrics xxmaj published xxmaj elsevier xxmaj ireland xxmaj ltd xxmaj all rights reserved doi j ijgo xxmaj contents lists available sciencedirect xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics j u r n l h om e p g e www e l ev e r c om l c e j g participate study period xxmaj may xxmaj september xxmaj the study approved xxmaj assiut xxmaj medical xxmaj school xxmaj ethical xxmaj review board xxmaj written informed consent obtained participant information sheet provided xxmaj all women met criteria diagnosis xxup pcos according xxmaj rotterdam xxmaj consensus xxmaj group xxmaj the inclusion criteria included patients xxup cc resistance xxmaj the male partner couple normal result semen analysis patent tubes woman shown hysterosalpingography xxmaj all recruited patients insulin resistance based fasting glucose insulin ratio g i using cut less xxmaj this test done recruited patients randomization xxmaj exclusion criteria included women years patients received gonadotropins hormonal contraception months prior study xxmaj patients hyperprolactinemia morning plasma prolactin ng ml endocrine hepatic renal disorders also excluded patients organic pelvic mass previous abdominal surgery suggesting pelvic factor infertility xxmaj randomization performed using computer generated random numbers table xxmaj allocation concealment done using serially numbered opaque envelopes xxmaj the patient allocation changed opening envelope xxmaj group underwent diagnostic laparoscopy followed mg metformin orally twice daily beginning day laparoscopic procedure xxmaj group underwent xxup lod using punctures according size ovary seconds insulated needle monopolar diathermy adjusted watts xxmaj all laparoscopic procedures performed general anesthesia xxmaj at enrollment study eligible patients examined physically body mass index xxup bmi calculated weight kilograms divided height meters squared recorded a blood sample baseline biochemical assays taken day prior laparoscopy groups a standard oral glucose tolerance test xxup ogtt performed using xxunk enzymatic method xxunk quantitation xxmaj glucose xxup hk xxmaj assay xxmaj kit xxunk xxmaj st xxmaj louis xxup mo xxup usa assessed according international standards xxmaj the fasting blood samples used measuring total testosterone xxup elisa kit xxmaj biosource xxmaj europe xxmaj belgium luteinizing hormone xxup drg xxmaj diagnostics xxmaj marburg xxmaj germany insulin like growth factor xxup igf xxup elisa method xxmaj xxunk xxmaj systems xxmaj limited xxmaj xxunk xxup uk xxmaj serum samples separated stored c assayed a second blood sample taken first postoperative menstrual period excluding patients achieved pregnancy first cycle xxmaj all surgical interventions biochemical assays done early proliferative phase spontaneous menstrual cycle progestin withdrawal bleeding xxmaj the patients treated followed cycles weeks whichever occurred first xxmaj they asked report length menstrual cycles bleeding days xxmaj throughout study patients asked follow usual diet physical activity report adverse effects poor compliance metformin xxmaj patients returned month visits measure xxup bmi confirm ovulation xxmaj the baseline xxup bmi compared xxup bmi obtained last visit pregnancy end study xxmaj ovulation confirmed either presence mature ovarian follicle mm day serum progesterone ng ml xxmaj the couples advised sexual intercourse every day mature follicle seen vaginal ultrasound xxmaj the patients asked contact clinic evaluation soon missed period n week positive urinary pregnancy test xxmaj once clinical pregnancy proved appearance intrauterine gestational sac patients xxmaj fig xxmaj participant flow trial h o xxmaj hamed et al xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics group instructed stop taking metformin xxmaj the pregnancy followed weeks gestation xxmaj the primary outcome ovulation rate xxmaj the secondary outcomes clinical pregnancy first trimester b weeks abortion rates patients xxunk regular cycles g i ratio a patient considered menstruating regularly cycles follow days duration xxmaj the sample size calculated according ovulation rate primary outcome study xxmaj in multiple previous reports xxup lod associated average ovulation rate range xxmaj on assumption difference ovulation rate metformin would clinically relevant needed patients arm demonstrate difference statistical significance type i error probability type xxup ii error power xxmaj data analyzed using xxup spss version xxup spss xxmaj chicago xxup il xxup usa expressed mean xxup se percentages xxmaj the test used mean comparisons hormonal metabolic parameters xxup ogtt values treatment xxmaj the test used comparisons ovulation pregnancy abortion rates p considered statistically significant xxmaj results xxmaj of patients assessed eligibility met inclusion criteria randomly allocated either receive metformin diagnostic laparoscopy group n undergo xxup lod group n xxmaj participant flow trial shown xxmaj fig xxmaj the patients demographic data baseline shown xxmaj table xxmaj there significant differences groups age duration infertility previous pregnancies xxup bmi biochemical assays testosterone luteinizing hormone xxup igf xxmaj throughout study metformin generally well tolerated xxmaj in group women treated metformin reported dizziness nausea flatulence first month treatment symptoms self limiting affect treatment continuation xxmaj laparoscopies completed successfully without intraoperative postoperative complications xxmaj in groups laparoscopy revealed patent healthy tubes pelvic masses adhesions endometriosis xxmaj the postoperative biochemical assays performed mean period days starting metformin group compared days undergoing xxup lod group xxmaj one patient group two patients group achieved pregnancy within first month treatment consequently excluded biochemical assays xxmaj both groups significant decreases levels testosterone xxup igf luteinizing hormone treatment compared baseline xxmaj table xxmaj however obvious increase g i ratio group vs xxmaj pb compared group vs xxmaj pb xxup bmi significantly decreased group xxmaj regarding xxup ogtt total number patients impaired fasting glucose baseline vs mg dl groups respectively xxmaj fig shows treatment significant decrease blood glucose minutes compared baseline groups xxmaj pb vs b xxmaj the patients observed total cycles groups respectively xxmaj as shown xxmaj table ovulation rate per cycle significantly higher group compared group odds ratio xxup ci xxmaj pb xxmaj women group xxmaj table xxmaj comparison baseline clinical hormonal metabolic characteristics study groups xxmaj characteristics xxmaj metformin xxup lod p value group group n n xxmaj age xxmaj period infertility mo xxmaj previous pregnancy xxmaj live birth xxmaj abortions xxmaj regular cycles xxup bmi xxmaj fasting glucose insulin ratio xxmaj fasting blood glucose mg dl xxmaj total testosterone ng dl xxmaj luteinizing hormone xxup iu l xxmaj insulin like growth factor ug l xxmaj abbreviation xxup bmi body mass index calculated weight kilograms divided height meters squared xxup lod laparoscopic ovarian drilling xxmaj values given mean xxup se range number percentage xxmaj table xxmaj body mass index biochemical assay results treatment xxmaj metformin group xxup lod group xxmaj before xxmaj after b p value xxmaj before xxmaj after b p value xxwrep 4 n xxup bmi xxmaj fasting g i ratio xxmaj testosterone ng dl xxmaj luteinizing hormone xxup iu l xxup igf ug l xxmaj abbreviations g i glucose insulin ratio xxup igf insulin like growth factor xxup bmi body mass index calculated weight kilograms divided height meters squared xxmaj values given mean xxup se unless otherwise indicated b xxmaj one patient group two patients group excluded assays conceived first month treatment xxmaj fig xxmaj oral glucose tolerance test xxup ogtt results metformin group laparoscopic ovarian drilling xxup lod group groups treatment h o xxmaj hamed et al xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics significantly increased pregnancy rate per cycle xxup or xxup ci cumulative pregnancy rate xxup or xxup ci number regular cycles xxup or xxup ci compared women group xxmaj although first trimester abortion rate higher group compared group difference statistically significant p xxmaj discussion xxmaj insulin resistance diagnosed using g i ratio less equal measured randomization xxmaj obesity documented current study high xxup bmi exacerbate insulin resistance increase risk type diabetes proven impairment fasting blood glucose patients xxmaj both insulin resistance obesity lead development hyperinsulinemia stimulation ovarian theca cell androgen production either direct action ovary binding insulin xxup igf receptors stimulating release luteinizing hormone xxmaj hyperinsulinemia could enhance bioavailability androgen decreasing biosynthesis sex hormone binding xxunk xxup shbg xxmaj perhaps convincing evidence linking insulin resistance reproductive metabolic abnormalities data trials metformin women xxup pcos xxmaj in agreement reports metformin current study showed significant decrease levels luteinizing hormone testosterone xxup igf xxmaj metformin possibly exerts effects part increasing xxup shbg modulation adrenal androgen production decreasing intraovarian androgen production either generalized improvement insulin metabolism modulation ovarian steroidogenesis localized attenuation insulin sensitivity ovary xxmaj in present study patients treated xxup lod also showed significant decrease levels luteinizing hormone testosterone xxup igf agreement previous reports xxmaj these changes could explained reduction ovarian theca cell mass consequently androgen production xxmaj converting androgenic intrafollicular environment estrogenic one corrects disturbances ovarian pituitary feedback resulting decrease luteinizing hormone pulse xxunk recruitment ovarian follicles xxmaj the significant improvement g i ratio treatment groups agreement several studies xxmaj however effect obvious metformin group xxup lod group xxmaj this could explained metabolic actions metformin xxmaj it inhibits hepatic glucose output improves peripheral insulin sensitivity increase glucose utilization skeletal muscles xxmaj on hand underlying mechanism xxup lod affects g i ratio fully understood xxmaj the attenuation ovarian androgen production ovarian cautery suggested possible mechanism xxmaj the improvement g i ratio seen xxup lod present study xxunk studies reported little change insulin sensitivity xxup lod however studies distinguish women hyperinsulinemia normal xxunk xxmaj in present study although metformin resulted greater improvement insulin resistance metabolic effect translated higher reproductive outcomes compared xxup lod xxmaj this could explained ovarian theca cell mass destruction together greater reduction luteinizing hormone seen xxup lod important role xxunk normal intraovarian xxunk xxunk decreasing local androgen production xxmaj these could greater effect achieving ovulation general metabolic effect metformin reducing insulin resistance xxmaj the higher rates ovulation pregnancy seen xxup lod present study inconsistent two previous studies compared metformin xxup lod xxup cc resistant patients xxmaj the first study prospective included patients xxup cc added treatment groups spontaneous ovulation achieved within months laparoscopy performed metformin group a significant improvement regularity menstrual cycles noted significant difference found ovulation pregnancy rates vs vs respectively xxmaj the second study carried overweight xxup pcos patients double blind placebo controlled randomized trial xxmaj diagnostic laparoscopy carried metformin group xxmaj although ovulation rate significantly different treatment groups cycles vs cumulative pregnancy live birth rates higher metformin group vs vs respectively xxmaj although present study showed significantly higher rates ovulation pregnancy xxup lod possibility benefit metformin can not excluded xxmaj the ovulation cumulative pregnancy rates metformin seen present study respectively relatively higher obtained multicenter randomized trial patients randomized xxup cc metformin combination xxmaj the study reported ovulation pregnancy rates respectively metformin group xxmaj this difference could explained targeting selected population high xxup bmi insulin resistance glucose intolerance hence metformin optimal metabolic reproductive effects xxmaj another possible explanation substantial decrease xxup bmi noted metformin additional factor could affect fertility independently xxmaj in present study ovulation pregnancy rates patients managed xxup lod respectively agreement studies reported rates respectively depending follow period xxmaj this variation regarding reproductive outcomes mostly due heterogeneity samples studied different techniques used xxmaj the first trimester abortion rate present study comparable groups xxmaj these results inconsistent xxmaj palomba et al reported significantly lower abortion rates metformin compared xxup lod vs respectively xxmaj table xxmaj reproductive clinical outcomes study groups xxmaj clinical outcomes xxmaj metformin group xxup lod group xxmaj relative risk p value n n xxmaj odds ratio xxup ci xxmaj total ovulation rate per cycle b xxmaj first cycle xxmaj second cycle xxmaj third cycle xxmaj fourth cycle xxmaj fifth cycle xxmaj sixth cycle xxmaj never ovulating patients xxmaj pregnancy rate per cycle c xxmaj cumulative pregnancy rate xxmaj first trimester abortion rate e xxmaj regular cycles f xxmaj values given number percentages unless otherwise indicated b xxmaj calculated number ovulatory cycles divided number cycles c xxmaj calculated number pregnancies divided number cycles xxmaj calculated number pregnancies divided number patients e xxmaj calculated number abortions divided number pregnancies f xxmaj patient considered regularly menstruating observed cycles days duration h o xxmaj hamed et al xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics xxmaj however study adequately powered detect difference needs research xxmaj in conclusion although metformin better attenuated insulin resistance xxup lod associated greater regulation menstrual cycles higher rates ovulation pregnancy obese xxup pcos patients insulin resistance xxup cc failure xxmaj conflict interest xxmaj the authors conflicts interest xxmaj references xxmaj homburg r xxmaj polycystic ovary syndrome xxmaj best xxmaj pract xxmaj res xxmaj clin xxmaj obstet xxmaj gynaecol xxmaj hart r xxmaj norman r xxmaj polycystic ovarian syndrome prognosis outcomes xxmaj best xxmaj pract xxmaj res xxmaj clin xxmaj obstet xxmaj gynaecol xxmaj palomba s xxmaj orio f xxmaj zullo f xxmaj ovulation induction women polycystic ovary syndrome xxmaj fertil xxmaj steril xxmaj suppl s xxmaj seow xxup km xxmaj juan xxup cc xxmaj hwang xxup jl xxmaj ho xxup lt xxmaj laparoscopic surgery polycystic ovary syndrome reproductive metabolic effects xxmaj semin xxmaj reprod xxmaj med xxmaj xxunk xxup jm xxmaj flight xxup ih xxmaj norman xxup rj xxmaj insulin sensitizing drugs metformin xxunk xxunk xxunk d xxunk xxunk polycystic ovary syndrome xxmaj cochrane xxmaj database xxmaj syst xxmaj rev xxup cd xxmaj norman xxup rj xxmaj editorial xxmaj metformin comparison therapies ovulation induction polycystic ovary syndrome j xxmaj clin xxmaj endocrinol xxmaj metab xxmaj de xxmaj leo v xxmaj la xxmaj xxunk a xxmaj xxunk f xxmaj insulin lowering agents management polycystic ovary syndrome xxmaj endocr xxmaj rev xxmaj thessaloniki xxup eshre xxup asrm xxmaj sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group xxmaj consensus infertility treatment related polycystic ovary syndrome xxmaj hum xxmaj reprod xxmaj moll e xxmaj bossuyt xxup pm xxmaj xxunk xxup jc xxmaj lambalk xxup cb van der xxmaj veen f xxmaj effect clomifene citrate plus metformin clomifene citrate plus placebo induction ovulation women newly diagnosed polycystic ovary syndrome randomised double blind clinical trial xxup bmj xxmaj legro xxup rs xxmaj barnhart xxup xxunk xxmaj xxunk xxup wd xxmaj carr xxup br xxmaj diamond xxup mp xxmaj carson xxup sa et al xxmaj clomiphene metformin infertility polycystic ovary syndrome n xxmaj engl j xxmaj med xxmaj malkawi xxup hy xxmaj qublan xxup hs xxmaj hamaideh xxup ah xxmaj medical vs surgical treatment clomiphene citrate resistant women polycystic ovary syndrome j xxmaj obstet xxmaj gynaecol xxmaj palomba s xxmaj orio f xxmaj nardo xxup lg xxmaj falbo a xxmaj russo t xxmaj corea d et al xxmaj metformin xxmaj administration xxmaj versus xxmaj laparoscopic xxmaj ovarian xxmaj diathermy xxmaj clomiphene citrateresistant xxmaj women xxmaj polycystic xxmaj ovary xxmaj syndrome a xxmaj prospective xxmaj parallel xxmaj randomized xxmaj double xxmaj blind xxmaj placebo xxmaj controlled xxmaj trial j xxmaj clin xxmaj endocrinol xxmaj metab xxmaj rotterdam xxup eshre xxup asrm xxmaj sponsored xxup pcos xxmaj consensus xxmaj workshop xxmaj group xxmaj revised consensus diagnostic criteria long term health risks related polycystic ovary syndrome xxmaj fertil xxmaj steril xxmaj xxunk a xxmaj xxunk h xxmaj xxunk lane r xxmaj xxunk e xxmaj xxunk xxup fz xxmaj xxunk xxup rj xxmaj acute effects metformin therapy include improvement insulin resistance ovarian morphology xxmaj fertil xxmaj steril xxmaj tulandi t xxmaj saleh a xxmaj payne n xxmaj jacobs h xxmaj tan xxup sl xxmaj effects laparoscopic ovarian drilling serum vascular endothelial growth factor insulin responses oral glucose tolerance test women polycystic ovarian syndrome xxmaj fertil xxmaj steril xxmaj xxunk xxup mm xxmaj hanson xxup rl xxmaj xxunk d xxmaj xxunk g xxmaj xxunk j xxmaj bennett xxup ph et al xxmaj the xxmaj american xxmaj diabetes xxmaj association xxmaj world xxmaj health xxmaj organization criteria hyperglycemia diagnosis prediction diabetes xxmaj diabetes xxmaj care xxmaj tang t xxmaj xxunk j xxmaj hayden xxup cj xxmaj combined lifestyle modification metformin obese patients polycystic ovary syndrome a randomized placebo controlled double blind multicentre study xxmaj hum xxmaj reprod xxmaj tan s xxmaj hahn s xxmaj xxunk b xxmaj xxunk d xxmaj xxunk l xxmaj lars xxup cm et al xxmaj metformin improves polycystic ovary syndrome symptoms irrespective pre treatment insulin resistance xxmaj eur j xxmaj endocrinol xxmaj palomba s xxmaj orio f xxmaj falbo a xxmaj xxunk f xxmaj russo t xxmaj xxunk t et al xxmaj prospective parallel randomized double blind double dummy controlled clinical trial comparing clomiphene citrate metformin first line treatment ovulation induction nonobese anovulatory women polycystic ovary syndrome j xxmaj clin xxmaj endocrinol xxmaj metab xxmaj xxunk xxup ir xxmaj tulandi t xxmaj laparoscopic treatment polycystic ovaries time xxunk procedure xxmaj fertil xxmaj steril xxmaj xxunk xxup ir xxmaj yates xxup rw xxmaj cameron xxup it xxmaj fleming r xxmaj effects insulin sensitizing drug metformin ovarian function follicular growth ovulation rate obese women oligomenorrhoea xxmaj hum xxmaj reprod xxmaj youssef h xxmaj atallah xxup mm xxmaj unilateral ovarian drilling polycystic ovarian syndrome prospective randomized study xxmaj reprod xxmaj biomed xxmaj online xxmaj farquhar xxup cm xxmaj the role ovarian surgery polycystic ovary syndrome xxmaj best xxmaj pract xxmaj res xxmaj clin xxmaj obstet xxmaj gynaecol xxmaj saleh a xxmaj morris d xxmaj tan xxup ls xxmaj tulandi t xxmaj effects laparoscopic ovarian drilling adrenal steroids polycystic ovary syndrome patients without hyperinsulinemia xxmaj fertil xxmaj steril xxmaj api m xxmaj xxunk h xxmaj xxunk a xxmaj laparoscopic ovarian drilling polycystic ovary syndrome xxmaj eur j xxmaj obstet xxmaj gynecol xxmaj reprod xxmaj biol h o xxmaj hamed et al xxmaj international xxmaj journal xxmaj gynecology xxmaj obstetrics\n",
              "y: CategoryList\n",
              "P,Q,N,P,N\n",
              "Path: /content/gdrive/My Drive/covidnlp;\n",
              "\n",
              "Test: None, model=SequentialRNN(\n",
              "  (0): MultiBatchEncoder(\n",
              "    (module): AWD_LSTM(\n",
              "      (encoder): Embedding(31040, 400, padding_idx=1)\n",
              "      (encoder_dp): EmbeddingDropout(\n",
              "        (emb): Embedding(31040, 400, padding_idx=1)\n",
              "      )\n",
              "      (rnns): ModuleList(\n",
              "        (0): WeightDropout(\n",
              "          (module): LSTM(400, 1152, batch_first=True)\n",
              "        )\n",
              "        (1): WeightDropout(\n",
              "          (module): LSTM(1152, 1152, batch_first=True)\n",
              "        )\n",
              "        (2): WeightDropout(\n",
              "          (module): LSTM(1152, 400, batch_first=True)\n",
              "        )\n",
              "      )\n",
              "      (input_dp): RNNDropout()\n",
              "      (hidden_dps): ModuleList(\n",
              "        (0): RNNDropout()\n",
              "        (1): RNNDropout()\n",
              "        (2): RNNDropout()\n",
              "      )\n",
              "    )\n",
              "  )\n",
              "  (1): PoolingLinearClassifier(\n",
              "    (layers): Sequential(\n",
              "      (0): BatchNorm1d(1200, eps=1e-05, momentum=0.1, affine=True, track_running_stats=True)\n",
              "      (1): Dropout(p=0.27999999999999997, inplace=False)\n",
              "      (2): Linear(in_features=1200, out_features=50, bias=True)\n",
              "      (3): ReLU(inplace=True)\n",
              "      (4): BatchNorm1d(50, eps=1e-05, momentum=0.1, affine=True, track_running_stats=True)\n",
              "      (5): Dropout(p=0.1, inplace=False)\n",
              "      (6): Linear(in_features=50, out_features=3, bias=True)\n",
              "    )\n",
              "  )\n",
              "), opt_func=functools.partial(<class 'torch.optim.adam.Adam'>, betas=(0.9, 0.99)), loss_func=FlattenedLoss of CrossEntropyLoss(), metrics=[<function accuracy at 0x7f7d11556840>], true_wd=True, bn_wd=True, wd=0.01, train_bn=True, path=PosixPath('/content/gdrive/My Drive/covidnlp'), model_dir='models', callback_fns=[functools.partial(<class 'fastai.basic_train.Recorder'>, add_time=True, silent=False)], callbacks=[...], layer_groups=[Sequential(\n",
              "  (0): Embedding(31040, 400, padding_idx=1)\n",
              "  (1): EmbeddingDropout(\n",
              "    (emb): Embedding(31040, 400, padding_idx=1)\n",
              "  )\n",
              "), Sequential(\n",
              "  (0): WeightDropout(\n",
              "    (module): LSTM(400, 1152, batch_first=True)\n",
              "  )\n",
              "  (1): RNNDropout()\n",
              "), Sequential(\n",
              "  (0): WeightDropout(\n",
              "    (module): LSTM(1152, 1152, batch_first=True)\n",
              "  )\n",
              "  (1): RNNDropout()\n",
              "), Sequential(\n",
              "  (0): WeightDropout(\n",
              "    (module): LSTM(1152, 400, batch_first=True)\n",
              "  )\n",
              "  (1): RNNDropout()\n",
              "), Sequential(\n",
              "  (0): PoolingLinearClassifier(\n",
              "    (layers): Sequential(\n",
              "      (0): BatchNorm1d(1200, eps=1e-05, momentum=0.1, affine=True, track_running_stats=True)\n",
              "      (1): Dropout(p=0.27999999999999997, inplace=False)\n",
              "      (2): Linear(in_features=1200, out_features=50, bias=True)\n",
              "      (3): ReLU(inplace=True)\n",
              "      (4): BatchNorm1d(50, eps=1e-05, momentum=0.1, affine=True, track_running_stats=True)\n",
              "      (5): Dropout(p=0.1, inplace=False)\n",
              "      (6): Linear(in_features=50, out_features=3, bias=True)\n",
              "    )\n",
              "  )\n",
              ")], add_time=True, silent=False)\n",
              "alpha: 2.0\n",
              "beta: 1.0], layer_groups=[Sequential(\n",
              "  (0): Embedding(31040, 400, padding_idx=1)\n",
              "  (1): EmbeddingDropout(\n",
              "    (emb): Embedding(31040, 400, padding_idx=1)\n",
              "  )\n",
              "), Sequential(\n",
              "  (0): WeightDropout(\n",
              "    (module): LSTM(400, 1152, batch_first=True)\n",
              "  )\n",
              "  (1): RNNDropout()\n",
              "), Sequential(\n",
              "  (0): WeightDropout(\n",
              "    (module): LSTM(1152, 1152, batch_first=True)\n",
              "  )\n",
              "  (1): RNNDropout()\n",
              "), Sequential(\n",
              "  (0): WeightDropout(\n",
              "    (module): LSTM(1152, 400, batch_first=True)\n",
              "  )\n",
              "  (1): RNNDropout()\n",
              "), Sequential(\n",
              "  (0): PoolingLinearClassifier(\n",
              "    (layers): Sequential(\n",
              "      (0): BatchNorm1d(1200, eps=1e-05, momentum=0.1, affine=True, track_running_stats=True)\n",
              "      (1): Dropout(p=0.27999999999999997, inplace=False)\n",
              "      (2): Linear(in_features=1200, out_features=50, bias=True)\n",
              "      (3): ReLU(inplace=True)\n",
              "      (4): BatchNorm1d(50, eps=1e-05, momentum=0.1, affine=True, track_running_stats=True)\n",
              "      (5): Dropout(p=0.1, inplace=False)\n",
              "      (6): Linear(in_features=50, out_features=3, bias=True)\n",
              "    )\n",
              "  )\n",
              ")], add_time=True, silent=False)"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 22
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "3jlu_gTlThY4"
      },
      "source": [
        "#clas.lr_find()"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "HTCIORhvUXX7"
      },
      "source": [
        "#clas.recorder.plot(suggestion=True)"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "7e0WpMF-TUUy",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 77
        },
        "outputId": "d687a466-e09e-4cc0-8608-db5d5e66bdef"
      },
      "source": [
        "clas.fit_one_cycle(1)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: left;\">\n",
              "      <th>epoch</th>\n",
              "      <th>train_loss</th>\n",
              "      <th>valid_loss</th>\n",
              "      <th>accuracy</th>\n",
              "      <th>time</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <td>0</td>\n",
              "      <td>1.162545</td>\n",
              "      <td>1.054188</td>\n",
              "      <td>0.504000</td>\n",
              "      <td>01:08</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>"
            ],
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ]
          },
          "metadata": {
            "tags": []
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "ONKrCikMruh9"
      },
      "source": [
        "clas.unfreeze()"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "PxTZFW9nSC5c",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 343
        },
        "outputId": "1e9f8ff3-d2c3-4371-a629-3bf70535bb7f"
      },
      "source": [
        "clas.fit_one_cycle(10)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: left;\">\n",
              "      <th>epoch</th>\n",
              "      <th>train_loss</th>\n",
              "      <th>valid_loss</th>\n",
              "      <th>accuracy</th>\n",
              "      <th>time</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <td>0</td>\n",
              "      <td>1.012465</td>\n",
              "      <td>1.018925</td>\n",
              "      <td>0.528000</td>\n",
              "      <td>01:18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>1</td>\n",
              "      <td>1.010737</td>\n",
              "      <td>0.970368</td>\n",
              "      <td>0.560000</td>\n",
              "      <td>01:20</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>2</td>\n",
              "      <td>0.958278</td>\n",
              "      <td>0.915146</td>\n",
              "      <td>0.568000</td>\n",
              "      <td>01:17</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>3</td>\n",
              "      <td>0.916255</td>\n",
              "      <td>0.879932</td>\n",
              "      <td>0.544000</td>\n",
              "      <td>01:17</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>4</td>\n",
              "      <td>0.871967</td>\n",
              "      <td>0.863476</td>\n",
              "      <td>0.576000</td>\n",
              "      <td>01:18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>5</td>\n",
              "      <td>0.829018</td>\n",
              "      <td>0.924641</td>\n",
              "      <td>0.592000</td>\n",
              "      <td>01:19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>6</td>\n",
              "      <td>0.787010</td>\n",
              "      <td>0.950342</td>\n",
              "      <td>0.536000</td>\n",
              "      <td>01:19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>7</td>\n",
              "      <td>0.757835</td>\n",
              "      <td>0.945803</td>\n",
              "      <td>0.560000</td>\n",
              "      <td>01:20</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>8</td>\n",
              "      <td>0.734734</td>\n",
              "      <td>0.943507</td>\n",
              "      <td>0.544000</td>\n",
              "      <td>01:18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>9</td>\n",
              "      <td>0.711901</td>\n",
              "      <td>0.935932</td>\n",
              "      <td>0.560000</td>\n",
              "      <td>01:19</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>"
            ],
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ]
          },
          "metadata": {
            "tags": []
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "O9zJJCDMpOhR"
      },
      "source": [
        "df= pd.read_csv(path/'test.csv', encoding='utf-8')"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "FiQzWXwhqa3j",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "2b642c4b-176e-4114-b585-614ee92d5c00"
      },
      "source": [
        "import os\n",
        "for dirname, _, filenames in os.walk('/content/gdrive/My Drive/covidnlp'):\n",
        "    for filename in filenames:\n",
        "        print(os.path.join(dirname, filename))"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "/content/gdrive/My Drive/covidnlp/train.csv\n",
            "/content/gdrive/My Drive/covidnlp/test-sample.csv\n",
            "/content/gdrive/My Drive/covidnlp/databunch.pkl\n",
            "/content/gdrive/My Drive/covidnlp/filename.pth.pth\n",
            "/content/gdrive/My Drive/covidnlp/filename2.pth.pth\n",
            "/content/gdrive/My Drive/covidnlp/test.csv\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00068/00068-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00085/00085-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00067/00067-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00069/00069-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00070/00070-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00070/00070-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00070/00070-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00071/00071-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00071/00071-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00078/00078-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00063/00063-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00063/00063-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00063/00063-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00063/00063-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00081/00081-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00060/00060-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00086/00086-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00090/00090-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00099/00099-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00103/00103-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00103/00103-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00103/00103-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00103/00103-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00104/00104-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00089/00089-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00098/00098-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00097/00097-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00101/00101-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00107/00107-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00125/00125-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00132/00132-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00128/00128-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00128/00128-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00121/00121-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00126/00126-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00108/00108-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00122/00122-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00109/00109-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00109/00109-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00109/00109-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00127/00127-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00127/00127-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00127/00127-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-38.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-42.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-45.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-44.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00129/00129-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-55.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-54.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-69.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-42.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-82.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-96.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-97.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-83.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-81.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-68.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-80.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-90.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-93.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-137.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-51.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-108.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-45.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-50.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-95.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-87.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-130.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-109.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-118.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-57.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-133.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-125.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-52.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-53.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-121.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-132.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-91.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-136.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-85.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-84.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-47.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-43.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-92.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-131.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-134.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-46.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-94.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-123.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-135.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-119.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-127.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-122.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-120.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-86.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-44.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-124.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-111.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-114.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-128.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-116.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-103.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-63.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-61.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-102.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-98.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-74.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-49.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-73.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-101.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-89.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-100.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-59.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-104.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-99.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-110.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-129.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-117.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-88.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-66.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-112.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-62.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-67.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-48.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-115.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-113.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-107.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-105.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-72.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-106.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-70.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-71.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-64.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-58.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00168/00168-65.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00147/00147-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-51.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-80.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-42.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-78.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-43.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-83.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-50.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-82.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-68.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-57.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-45.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-69.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-54.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-55.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-81.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-44.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-52.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-47.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-90.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-85.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-38.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-86.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-79.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-53.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-84.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-61.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-65.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-72.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-75.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-77.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-74.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-59.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-76.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-62.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-70.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-58.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-89.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-48.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-67.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-88.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-73.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-71.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-60.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-66.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-63.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00185/00185-64.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00171/00171-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00186/00186-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00153/00153-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00136/00136-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00134/00134-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00135/00135-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00170/00170-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00455/00455-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00193/00193-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/train-data/00458/00458-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/models/tmp.pth\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-48.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-46.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-43.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-45.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-44.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-38.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-42.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00038/00038-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00010/00010-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00010/00010-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-38.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-43.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00021/00021-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-38.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00022/00022-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00025/00025-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00025/00025-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00025/00025-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00025/00025-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00025/00025-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00026/00026-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00037/00037-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00008/00008-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00008/00008-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00008/00008-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00008/00008-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00008/00008-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00008/00008-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00008/00008-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00008/00008-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00003/00003-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-60.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-58.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-61.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-59.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-47.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-48.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-50.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-51.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-52.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-53.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-55.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-56.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-54.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-57.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-45.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-43.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-44.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-37.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-38.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-40.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-41.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-42.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-39.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-46.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-33.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-31.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-35.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-32.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-34.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-36.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-28.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-30.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-27.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-10.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-13.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-03.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00005/00005-01.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-29.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-17.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-18.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-16.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-25.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-14.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-11.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-12.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-07.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-08.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-09.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-21.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-19.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-22.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-20.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-24.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-23.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-15.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-02.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-05.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-06.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-04.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-26.txt\n",
            "/content/gdrive/My Drive/covidnlp/test-data/test-data/00002/00002-28.txt\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "FN2McTxhqeZ5"
      },
      "source": [
        "texts = []\n",
        "for i in range(len(df['Id'])):\n",
        "    fn = df['Id'][i]\n",
        "    folder = fn.split(\"-\")[0]\n",
        "    f = open('/content/gdrive/My Drive/covidnlp/test-data/test-data/'+folder+'/'+fn, \"r\", encoding=\"utf8\", errors='ignore')\n",
        "    texts.append(f.read())\n",
        "\n",
        "df['text'] = texts"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "GotGiiMjqe4T",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 402
        },
        "outputId": "e5e6532e-9c09-43b5-bad9-34f1711c1bd0"
      },
      "source": [
        "df"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Id</th>\n",
              "      <th>Prediction</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00002-02.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>﻿Abstract\\nObjective: To assess the effect of ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00002-04.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>﻿Abstract\\nBACKGROUND: Steroid pre-treatments ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00002-06.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>﻿effect accross all trials. The pooled results...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00002-07.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>﻿Human Reproduction vol.11 no.5 pp. 1035-1037,...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00002-08.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>﻿576\\nProgestogen therapy during pituitary des...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>390</th>\n",
              "      <td>00053-26.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ORIGINAL ARTICLE\\nNottingham trial of faecal o...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>391</th>\n",
              "      <td>00053-27.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Baseline Findings of the Italian Multicenter\\n...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>392</th>\n",
              "      <td>00053-28.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>1310 Articles | JNCI Vol. 103, Issue 17 | Sept...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>393</th>\n",
              "      <td>00053-29.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Acceptability of flexible sigmoidoscopy screen...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>394</th>\n",
              "      <td>00053-30.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Population-Based Surveillance by Colonoscopy: ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>395 rows × 3 columns</p>\n",
              "</div>"
            ],
            "text/plain": [
              "               Id  ...                                               text\n",
              "0    00002-02.txt  ...  ﻿Abstract\\nObjective: To assess the effect of ...\n",
              "1    00002-04.txt  ...  ﻿Abstract\\nBACKGROUND: Steroid pre-treatments ...\n",
              "2    00002-06.txt  ...  ﻿effect accross all trials. The pooled results...\n",
              "3    00002-07.txt  ...  ﻿Human Reproduction vol.11 no.5 pp. 1035-1037,...\n",
              "4    00002-08.txt  ...  ﻿576\\nProgestogen therapy during pituitary des...\n",
              "..            ...  ...                                                ...\n",
              "390  00053-26.txt  ...  ORIGINAL ARTICLE\\nNottingham trial of faecal o...\n",
              "391  00053-27.txt  ...  Baseline Findings of the Italian Multicenter\\n...\n",
              "392  00053-28.txt  ...  1310 Articles | JNCI Vol. 103, Issue 17 | Sept...\n",
              "393  00053-29.txt  ...  Acceptability of flexible sigmoidoscopy screen...\n",
              "394  00053-30.txt  ...  Population-Based Surveillance by Colonoscopy: ...\n",
              "\n",
              "[395 rows x 3 columns]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 40
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "L0D6XFoSqluh",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 50
        },
        "outputId": "390d573c-168d-42de-c7e7-837a5712b2a6"
      },
      "source": [
        "from functools import partial\n",
        "import io\n",
        "import os\n",
        "\n",
        "df['text'] = df['text'].str.replace(\"[^a-zA-Z]\", \" \")\n",
        "import nltk\n",
        "nltk.download('stopwords')\n",
        "\n",
        "from nltk.corpus import stopwords \n",
        "stop_words = stopwords.words('english')\n",
        "# tokenization \n",
        "tokenized_doc = df['text'].apply(lambda x: x.split())\n",
        "\n",
        "# remove stop-words \n",
        "tokenized_doc = tokenized_doc.apply(lambda x: [item for item in x if item not in stop_words])\n",
        "\n",
        "# de-tokenization \n",
        "detokenized_doc = [] \n",
        "for i in range(len(df)): \n",
        "    t = ' '.join(tokenized_doc[i]) \n",
        "    detokenized_doc.append(t) \n",
        "\n",
        "df['text'] = detokenized_doc"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Package stopwords is already up-to-date!\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "FzqOQD-YsPqb",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 402
        },
        "outputId": "78fb8173-f976-4c30-a507-75b43f6de722"
      },
      "source": [
        "df"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Id</th>\n",
              "      <th>Prediction</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00002-02.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Abstract Objective To assess effect pretreatme...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00002-04.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Abstract BACKGROUND Steroid pre treatments may...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00002-06.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>effect accross trials The pooled results odds ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00002-07.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Human Reproduction vol pp A combination noreth...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00002-08.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Progestogen therapy pituitary desensitization ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>390</th>\n",
              "      <td>00053-26.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ORIGINAL ARTICLE Nottingham trial faecal occul...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>391</th>\n",
              "      <td>00053-27.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Baseline Findings Italian Multicenter Randomiz...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>392</th>\n",
              "      <td>00053-28.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Articles JNCI Vol Issue September DOI jnci djr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>393</th>\n",
              "      <td>00053-29.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Acceptability flexible sigmoidoscopy screening...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>394</th>\n",
              "      <td>00053-30.txt</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Population Based Surveillance Colonoscopy Effe...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>395 rows × 3 columns</p>\n",
              "</div>"
            ],
            "text/plain": [
              "               Id  ...                                               text\n",
              "0    00002-02.txt  ...  Abstract Objective To assess effect pretreatme...\n",
              "1    00002-04.txt  ...  Abstract BACKGROUND Steroid pre treatments may...\n",
              "2    00002-06.txt  ...  effect accross trials The pooled results odds ...\n",
              "3    00002-07.txt  ...  Human Reproduction vol pp A combination noreth...\n",
              "4    00002-08.txt  ...  Progestogen therapy pituitary desensitization ...\n",
              "..            ...  ...                                                ...\n",
              "390  00053-26.txt  ...  ORIGINAL ARTICLE Nottingham trial faecal occul...\n",
              "391  00053-27.txt  ...  Baseline Findings Italian Multicenter Randomiz...\n",
              "392  00053-28.txt  ...  Articles JNCI Vol Issue September DOI jnci djr...\n",
              "393  00053-29.txt  ...  Acceptability flexible sigmoidoscopy screening...\n",
              "394  00053-30.txt  ...  Population Based Surveillance Colonoscopy Effe...\n",
              "\n",
              "[395 rows x 3 columns]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 42
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "d8U_w7vBsReY"
      },
      "source": [
        "for i in df.text:\n",
        "  predicted = clas.predict(i)\n",
        "  df['Prediction'] = str(predicted[0])+str(predicted[0])\n"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "hYkMwPGtvEC3",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 402
        },
        "outputId": "3face32b-b3b5-4ef0-cae2-2dc3732d691b"
      },
      "source": [
        "df"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Id</th>\n",
              "      <th>Prediction</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00002-02.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>Abstract Objective To assess effect pretreatme...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00002-04.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>Abstract BACKGROUND Steroid pre treatments may...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00002-06.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>effect accross trials The pooled results odds ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00002-07.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>Human Reproduction vol pp A combination noreth...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00002-08.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>Progestogen therapy pituitary desensitization ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>390</th>\n",
              "      <td>00053-26.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>ORIGINAL ARTICLE Nottingham trial faecal occul...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>391</th>\n",
              "      <td>00053-27.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>Baseline Findings Italian Multicenter Randomiz...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>392</th>\n",
              "      <td>00053-28.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>Articles JNCI Vol Issue September DOI jnci djr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>393</th>\n",
              "      <td>00053-29.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>Acceptability flexible sigmoidoscopy screening...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>394</th>\n",
              "      <td>00053-30.txt</td>\n",
              "      <td>NN</td>\n",
              "      <td>Population Based Surveillance Colonoscopy Effe...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>395 rows × 3 columns</p>\n",
              "</div>"
            ],
            "text/plain": [
              "               Id Prediction                                               text\n",
              "0    00002-02.txt         NN  Abstract Objective To assess effect pretreatme...\n",
              "1    00002-04.txt         NN  Abstract BACKGROUND Steroid pre treatments may...\n",
              "2    00002-06.txt         NN  effect accross trials The pooled results odds ...\n",
              "3    00002-07.txt         NN  Human Reproduction vol pp A combination noreth...\n",
              "4    00002-08.txt         NN  Progestogen therapy pituitary desensitization ...\n",
              "..            ...        ...                                                ...\n",
              "390  00053-26.txt         NN  ORIGINAL ARTICLE Nottingham trial faecal occul...\n",
              "391  00053-27.txt         NN  Baseline Findings Italian Multicenter Randomiz...\n",
              "392  00053-28.txt         NN  Articles JNCI Vol Issue September DOI jnci djr...\n",
              "393  00053-29.txt         NN  Acceptability flexible sigmoidoscopy screening...\n",
              "394  00053-30.txt         NN  Population Based Surveillance Colonoscopy Effe...\n",
              "\n",
              "[395 rows x 3 columns]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 52
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "FGrvtWJmtL_G",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 402
        },
        "outputId": "aed59b4f-9fa0-4f6f-af1a-7a1a218d35a4"
      },
      "source": [
        "finalpredict = df[['Id', 'Prediction']]\n",
        "finalpredict"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Id</th>\n",
              "      <th>Prediction</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00002-02.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00002-04.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00002-06.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00002-07.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00002-08.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>390</th>\n",
              "      <td>00053-26.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>391</th>\n",
              "      <td>00053-27.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>392</th>\n",
              "      <td>00053-28.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>393</th>\n",
              "      <td>00053-29.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>394</th>\n",
              "      <td>00053-30.txt</td>\n",
              "      <td>NN</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>395 rows × 2 columns</p>\n",
              "</div>"
            ],
            "text/plain": [
              "               Id Prediction\n",
              "0    00002-02.txt         NN\n",
              "1    00002-04.txt         NN\n",
              "2    00002-06.txt         NN\n",
              "3    00002-07.txt         NN\n",
              "4    00002-08.txt         NN\n",
              "..            ...        ...\n",
              "390  00053-26.txt         NN\n",
              "391  00053-27.txt         NN\n",
              "392  00053-28.txt         NN\n",
              "393  00053-29.txt         NN\n",
              "394  00053-30.txt         NN\n",
              "\n",
              "[395 rows x 2 columns]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 56
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "nryH6FxFw7dt"
      },
      "source": [
        "finalpredict.to_csv('text.csv', index=False)"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "c1F0dluyxOcA"
      },
      "source": [
        ""
      ],
      "execution_count": null,
      "outputs": []
    }
  ]
}